Frontiers in Drug Design & Discovery Bentham Science Publishers Ltd. http://www.bentham.org/fddd
Volume 4, 2009
Contents In Vivo PK/PD and In Vitro ADME Techniques Editorial: Biopharmaceutical & Pharmacokinetic Considerations in Drug Design & Discovery G.W. Caldwell, Atta-ur-Rahman, Zhengyin Yan and M.I. Choudhary
i
Present and Future Mass Spectrometry-Based Approaches for Exploratory Drug Metabolism and Pharmacokinetic Studies Y. Hsieh
1
Glutathione Transferases in Drug Discovery and Development: Towards Safer and Efficacious Drugs K. Skopelitou, D. Platis, I. Axarli and N.E. Labrou
23
New Sampling Techniques for PharmacokineticPharmacodynamic Modeling C. Höcht, M. Mayer, J.A.W. Opezzo, G.F. Bramuglia and C.A. Taira
43
Role of Inflammatory Biomarkers in Establishing PK/PD Relationships and Target Organ Toxicity S. Pillarisetti and I. Khanna
81
Important Drug Interactions for Clinical Oncologists H. Ishiguro, I. Yano and M. Toi
97
Pharmacogenomic Considerations in Breast Cancer Management H. Ishiguro, I. Yano and M. Toi
122
More Than Skin Deep: The Human Skin Tissue Equivalent as an Advanced Drug Discovery Tool A.S. Bause, S.D. Lamore and G.T. Wondrak
135
Across Skin Barrier: Known Methods, New Performances K. Cal
162
The Tape Stripping Method as a Valuable Tool for Evaluating Topical Applied Compounds J.J. Escobar-Chávez, L.M. Melgoza-Contreras, M. López-Cervantes, D. Quintanar-Guerrero and A. Ganem-Quintanar
189
Methylphenidate Extended-Release Capsules: A New Formulation for Attention-Deficit Hyperactivity Disorder P. García-García, F. López-Muñoz, J.D. Molina, R. Fischer and C. Alamo
228
Osmotic-Controlled Release Oral Delivery System (OROS Technology) in Chronic Pain Management F. Coluzzi and C. Mattia
247
Drug Delivery Systems Prepared by Membrane Emulsification C. Charcosset and H. Fessi
273
In Silico ADME Approaches N.E. Campillo and J.A. Páez
291
Advances in ADMET Predictions and Modeling: Rapid Drug Discovery Efforts in 21st Centuries M.T.H. Khan
333
Computational Intelligence Methods for ADMET Prediction D. Hecht and G.B. Fogel
351
Data Modeling and Chemical Interpretation of ADME Properties Using Regression and Rule Mining Techniques K. Hasegawa and K. Funatsu
378
A Review on Virtual Reality and Haptics Approaches in Drug Design and Discovery S.K. Lai-Yuen
429
Contributors
454
Editorial
Frontiers in Drug Design & Discovery, 2009 Vol. 4 i
Editorial: Biopharmaceutical & Pharmacokinetic Considerations in Drug Design & Discovery The goal of all pharmaceutical scientists is to bring affordable, safe and effective drugs to patients globally. The Frontier in Drug Design and Discovery series is dedicated to contributed by leading researchers present comprehensive reviews with fresh new ideas on drug design and drug discovery. The first volume (2005) brought together experts to review and discuss the advantages and limitations of modern screening techniques used in the drug discovery process to identify potential drug candidates. The second volume (2006) discussed new technological and conceptual approaches to accelerate and to improve the predictability of the discoveries made in the laboratory into clinical testing. The third volume (2007) reviewed ways of applying structure-based design to identify potent lead drug candidates for a variety of diseases using techniques such as in-silico screening, peptidomimetics, fragment-based approaches, protein crystallography, and NMR spectroscopy. In the fourth volume of this series (2009), reviews and discussions are presented regarding biopharmaceutical and pharmacokinetic techniques to identify potent lead drug candidates. Pharmaceutical companies have embraced new technologies, such as analytical instrumentation, chemistry and biological screening robotic systems, computerized data handling systems, and computational and simulation software. While many successes have arisen from these changes, the cost to discover and market new drugs remains staggeringly high. There are many reasons why pharmaceutical drug development costs remain high. One reason is the continuing high attrition rates of drugs during costly phase II and III human clinical trials. One decision-making strategy used by pharmaceutical companies is to eliminate high-risk drug candidates as early as possible in the drug development process. By shifting the attrition of drug candidates to an earlier stage in development, pharmaceutical companies are aiming to cut the costs associated with developing and regulatory approval of a drug. The strategy used by most companies to identify unsuccessful likely drugs involves using biopharmaceutical and pharmacokinetic principles early in the discovery process to improve decision-making in drug selection. While biopharmaceutical principles are used to understand the physical properties of drug candidates, pharmacokinetic principles are used to quantitatively model the time course for drug concentration in the body and predict various parameters such as absorption, distribution, metabolism, and excretion (ADME) of the drug. Physical and ADME properties can be used to optimize drug design in relationship to pharmacological effects, such as efficacy and toxicity. Since efficacy and toxicity deficiencies are related in part to biopharmaceutical and pharmacokinetic properties, detecting problems in drug candidates as early as possible would be highly valuable in making go/no-go decisions. We have carefully selected authors to review biopharmaceutical, in-vitro ADME and pharmacokinetic applications in drug design. Hsieh has reviewed the current mass
ii Frontiers in Drug Design & Discovery, 2009, Vol. 4
Editorial
spectrometry-based approaches and their future potential in supporting exploratory invitro and in-vivo drug metabolism/pharmacokinetic studies, that include pharmacokinetic profiling, physical property, metabolite identification, and molecular imaging tests. The chapter by Labrou and colleagues gives a detailed description of several biotransformation reactions catalyzed by glutathione transferases (GSTs). This information is useful in the early phases of drug development to eliminate unsuitable drug candidates in the drug discovery process. Chapter by Höcht and colleagues gives an excellent review of sampling techniques, such as microdialysis and ultrafiltration. In addition, a review is presented on imaging techniques, such as positron emission topography and magnetic resonance spectroscopy. These techniques allow the measurement of drug concentration at the target site. The chapter by Pillarisetti and Khanna gives an overview of biomarkers, such as the tumor necrosis factor (TNF), interleukins (IL-1, IL-6, IL-8 and IL-18), vascular cell adhesion molecules, and markers of macrophage inflammation (e.g. MMPs). Their potential applications in monitoring inflammatory responses in normal animals and case histories linking these biomarkers to PK/PD correlation from preclinical and clinical studies are discussed. Ishiguro and colleagues give an overview of the importance of ADME properties in the understanding of antineoplastics drugs. Their second paper describes the important of pharmacogenomic factors associated with drugs for the treatment of breast cancer. Wondrak and colleagues wrote an excellent review of the development of in-vitro intact stratum corneum human skin reconstruct from matrixembedded dermal fibroblasts and epidermal primary keratinocytes. These human skin reconstructs, which closely resemble the complex architecture and functional complexity of skin, can be used to screen skin care products in a 96-well format. Cal contributed a well-balanced review of transdermal drug delivery principles. Escobar-Chávez and colleagues describe the applications of the tape stripping technique to evaluate drug penetration through the skin, as well as stratum corneum composition and physiology, underlining its versatile application in the area of topical and transdermal drugs. The chapter by López-Muñoz and colleagues describe the pharmacokinetics of new extended-release formulation of methylphenidate (Medikinet®) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). They compare of the characteristics of Medikinet® with those of other formulations used for treating. Coluzzi and Mattia review the osmoticcontrolled release oral delivery system (OROS®). This drug delivery technology, which employ osmotic pressure as the driving force to deliver pharmacotherapy, is demonstrated for hydromorphone. Chapter by Charcosset summarizes the progress made in drug delivery systems based on membrane emulsification. Campillo and Páez review the progress in ADME in-silico methods, focusing on oral absorption, blood-brain barrier, metabolism, and some aspects on excretion. Khan reviews in-silico ADMET predictions of the potential drug candidates based on Quantitative Structure-Activity Relationship (QSAR) modeling approaches. The chapter by Hecht and Fogel reviews the utility of some of the more popular applications of computational intelligence to Quantitative Structure-Property Relationship (QSPR) modeling approaches including: artificial neural
Editorial
Frontiers in Drug Design & Discovery, 2009 Vol. 4 iii
networks, fuzzy logic, and evolutionary computing. Hasegawa and Funatsu review ADME modeling techniques including regression, multiple linear regressions (MLR), partial least squares (PLS), artificial neural networks (ANN), and support vector machines (SVM). Finally, S.K. Lai-Yuen introduces the reader to virtual reality and haptics techniques for in-silico drug design. We are grateful to all contributors and also wish to express our gratitude of staff and editorial assistants for their untiring efforts in beinging this volume in good shape and in timely manner.
Atta-ur-Rahman M. Iqbal Choudhary
Gary W. Caldwell Zhengyin Yan
Editorial
Frontiers in Drug Design & Discovery, 2009 Vol. 4 i
Editorial: Biopharmaceutical & Pharmacokinetic Considerations in Drug Design & Discovery The goal of all pharmaceutical scientists is to bring affordable, safe and effective drugs to patients globally. The Frontier in Drug Design and Discovery series is dedicated to contributed by leading researchers present comprehensive reviews with fresh new ideas on drug design and drug discovery. The first volume (2005) brought together experts to review and discuss the advantages and limitations of modern screening techniques used in the drug discovery process to identify potential drug candidates. The second volume (2006) discussed new technological and conceptual approaches to accelerate and to improve the predictability of the discoveries made in the laboratory into clinical testing. The third volume (2007) reviewed ways of applying structure-based design to identify potent lead drug candidates for a variety of diseases using techniques such as in-silico screening, peptidomimetics, fragment-based approaches, protein crystallography, and NMR spectroscopy. In the fourth volume of this series (2009), reviews and discussions are presented regarding biopharmaceutical and pharmacokinetic techniques to identify potent lead drug candidates. Pharmaceutical companies have embraced new technologies, such as analytical instrumentation, chemistry and biological screening robotic systems, computerized data handling systems, and computational and simulation software. While many successes have arisen from these changes, the cost to discover and market new drugs remains staggeringly high. There are many reasons why pharmaceutical drug development costs remain high. One reason is the continuing high attrition rates of drugs during costly phase II and III human clinical trials. One decision-making strategy used by pharmaceutical companies is to eliminate high-risk drug candidates as early as possible in the drug development process. By shifting the attrition of drug candidates to an earlier stage in development, pharmaceutical companies are aiming to cut the costs associated with developing and regulatory approval of a drug. The strategy used by most companies to identify unsuccessful likely drugs involves using biopharmaceutical and pharmacokinetic principles early in the discovery process to improve decision-making in drug selection. While biopharmaceutical principles are used to understand the physical properties of drug candidates, pharmacokinetic principles are used to quantitatively model the time course for drug concentration in the body and predict various parameters such as absorption, distribution, metabolism, and excretion (ADME) of the drug. Physical and ADME properties can be used to optimize drug design in relationship to pharmacological effects, such as efficacy and toxicity. Since efficacy and toxicity deficiencies are related in part to biopharmaceutical and pharmacokinetic properties, detecting problems in drug candidates as early as possible would be highly valuable in making go/no-go decisions. We have carefully selected authors to review biopharmaceutical, in-vitro ADME and pharmacokinetic applications in drug design. Hsieh has reviewed the current mass
ii Frontiers in Drug Design & Discovery, 2009, Vol. 4
Editorial
spectrometry-based approaches and their future potential in supporting exploratory invitro and in-vivo drug metabolism/pharmacokinetic studies, that include pharmacokinetic profiling, physical property, metabolite identification, and molecular imaging tests. The chapter by Labrou and colleagues gives a detailed description of several biotransformation reactions catalyzed by glutathione transferases (GSTs). This information is useful in the early phases of drug development to eliminate unsuitable drug candidates in the drug discovery process. Chapter by Höcht and colleagues gives an excellent review of sampling techniques, such as microdialysis and ultrafiltration. In addition, a review is presented on imaging techniques, such as positron emission topography and magnetic resonance spectroscopy. These techniques allow the measurement of drug concentration at the target site. The chapter by Pillarisetti and Khanna gives an overview of biomarkers, such as the tumor necrosis factor (TNF), interleukins (IL-1, IL-6, IL-8 and IL-18), vascular cell adhesion molecules, and markers of macrophage inflammation (e.g. MMPs). Their potential applications in monitoring inflammatory responses in normal animals and case histories linking these biomarkers to PK/PD correlation from preclinical and clinical studies are discussed. Ishiguro and colleagues give an overview of the importance of ADME properties in the understanding of antineoplastics drugs. Their second paper describes the important of pharmacogenomic factors associated with drugs for the treatment of breast cancer. Wondrak and colleagues wrote an excellent review of the development of in-vitro intact stratum corneum human skin reconstruct from matrixembedded dermal fibroblasts and epidermal primary keratinocytes. These human skin reconstructs, which closely resemble the complex architecture and functional complexity of skin, can be used to screen skin care products in a 96-well format. Cal contributed a well-balanced review of transdermal drug delivery principles. Escobar-Chávez and colleagues describe the applications of the tape stripping technique to evaluate drug penetration through the skin, as well as stratum corneum composition and physiology, underlining its versatile application in the area of topical and transdermal drugs. The chapter by López-Muñoz and colleagues describe the pharmacokinetics of new extended-release formulation of methylphenidate (Medikinet®) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). They compare of the characteristics of Medikinet® with those of other formulations used for treating. Coluzzi and Mattia review the osmoticcontrolled release oral delivery system (OROS®). This drug delivery technology, which employ osmotic pressure as the driving force to deliver pharmacotherapy, is demonstrated for hydromorphone. Chapter by Charcosset summarizes the progress made in drug delivery systems based on membrane emulsification. Campillo and Páez review the progress in ADME in-silico methods, focusing on oral absorption, blood-brain barrier, metabolism, and some aspects on excretion. Khan reviews in-silico ADMET predictions of the potential drug candidates based on Quantitative Structure-Activity Relationship (QSAR) modeling approaches. The chapter by Hecht and Fogel reviews the utility of some of the more popular applications of computational intelligence to Quantitative Structure-Property Relationship (QSPR) modeling approaches including: artificial neural
Editorial
Frontiers in Drug Design & Discovery, 2009 Vol. 4 iii
networks, fuzzy logic, and evolutionary computing. Hasegawa and Funatsu review ADME modeling techniques including regression, multiple linear regressions (MLR), partial least squares (PLS), artificial neural networks (ANN), and support vector machines (SVM). Finally, S.K. Lai-Yuen introduces the reader to virtual reality and haptics techniques for in-silico drug design. We are grateful to all contributors and also wish to express our gratitude of staff and editorial assistants for their untiring efforts in beinging this volume in good shape and in timely manner.
Atta-ur-Rahman M. Iqbal Choudhary
Gary W. Caldwell Zhengyin Yan
Frontiers in Drug Design & Discovery, 2009, 4, 1-22
1
Present and Future Mass Spectrometry-Based Approaches for Exploratory Drug Metabolism and Pharmacokinetic Studies Yunsheng Hsieh* Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, 2015 Galloping Hill Road, K-15-3700, Kenilworth, NJ 07033, USA Abstract: For more than a decade, mass spectrometry (MS) has played an important role in absorption, distribution, metabolism, excretion and toxicology (ADMET) studies for drug discovery to help convert lead compounds into drug candidates. Drug discovery efforts have been focused on identifying drug metabolism and pharmacokinetic (DMPK) issues at the earliest possible stage to reduce attrition rate of drug candidates throughout the drug development process by applying cutting edge MS-based techniques. These emerging techniques have proven to be extremely valuable to accelerate the lead optimization and characterization processes by eliminating potentially unpromising candidates. In this article, the current MS-based approaches and their future perspectives in supporting exploratory DMPK studies including in vitro and in vivo pharmacokinetic profiling, physical property, metabolite identification and molecular imaging tests are reviewed.
INTRODUCTION Combinatorial chemistry is an efficient way of synthesizing and testing very large libraries for bioactivity to discover leads more quickly than was formerly possible. The selected leads with an appropriate in vitro potency are further screened to provide medicinal chemists relevant pharmacokinetic parameters such as tissue penetration, protein binding, intestinal absorption, drug-drug interaction potential, metabolic stability and pathway to embark on a lead optimization campaign. Drug design is a fast moving and iterative process for creating a chemical compound with drug-like properties suitable for development as a therapeutic agent (Fig. 1). The early evaluation of pharmacokinetics, pharmacodynamics and toxicological effects should lead drug candidates with optimum performance characteristics to proceed further into development. The major purposes of obtaining DMPK knowledge during the early drug discovery stage are to identify DMPK issues earlier to resolve problems arising from lead optimization, to ensure sufficient exposure multiples achievable in all toxicology test species and to reduce the attrition rate for drug development [1-10].
*Corresponding Author: E-mail:
[email protected]
Gary W. Caldwell / Atta-ur-Rahman / Z. Yan / M. Iqbal Choudhary (Eds.) All rights reserved – © 2009 Bentham Science Publishers.
2 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Yunsheng Hsieh
Modified drug discovery compounds Biological activity Protein binding Drug-drug interaction
Physical properties
Metabolite identification
In vitro screening
Permeability
Metabolic stability
In vivo pharmacokinetics / pharmacodynamics In vivo toxicology Nomination for preclinical development Fig. (1). Strategy for use of early ADME screens in the lead optimization and characterization processes.
Drug-drug interactions can occur when one drug inhibits the biotransformation of another if patients take more than one drug. Cytochrome (CYP) P450s are a family of enzymes primarily responsible for metabolizing xenobiotics [11-15]. For CYP enzyme inhibition screening, direct and metabolism/ mechanism-based inhibition potentials of CYP of new leads are frequently quantified in terms of 50% inhibitory concentration (IC50) values for prioritizing [11]. For direct CYP inhibition measurement, the individual compounds are incubated with human liver microsomes, probe substrate and NADPH. The IC50 is calculated using certain substrate assays by fitting the inhibition data to the following equation; y = 100/ [1+(x / IC50)S] where y is % of control, x is concentration of the inhibitor and S is a slope factor [12]. Metabolite production from each enzyme inhibition assay can also be quantified to reflect the ability of the probe compounds to
Present and Future Mass Spectrometry-Based
Frontiers in Drug Design & Discovery, 2009, Vol. 4 3
directly inhibit the activity of P450s. For metabolism/mechanism-based inhibition, the test compounds are generally pre-incubated first with liver microsomes in the presence of NADPH so that metabolites might be produced before the addition of the test compounds. Compounds with low IC50 values under the pre-incubation conditions compared with co-incubation conditions are suspected to be metabolism/mechanism-based inhibitors. Oral administration is the preferred drug-dosing route for the drug development in the pharmaceutical industry. Various in vitro assays such as Caco-2, a human intestinal epithelia cell line, as a rapid permeability screening tool have been developed to predict the extent of absorption of drug candidates after oral administration in early discovery [16-20]. As an example, the Caco-2 immortal cell line forming a monolayer presents a barrier to ion flow due to the tight junctions between cells. Compounds with sufficient rates of passive diffusion across membranes will demonstrate good permeability in the Caco-2 experiments. The analyte concentrations from both sides of the cell were used to calculate the permeability and recovery of the drug candidates as follows [16]: Permeability = (VR/(S*7200)) (CR,2 hr / CD,0 hr) % Recovery = [(CD,2 hr *VD *CR,2 hr *VR) / ( CD,0 hr *VD)]*100 where S is the membrane surface area; CD, 0hr and CD, 2hr are the donor concentration immediately after dosing and after two hours incubation, respectively; CR, 2hr is the receiver concentration after two hours incubation; VD and VR are the volume of donor and receiver compartments, respectively. In addition to oral absorption, first-pass metabolism, a process of converting a dosed compound to more water soluble metabolites to be easily eliminated from the human and animal body, is the other factor to contribute the bioavailability of a drug after oral administration. In general, drug metabolism is divided into phase I and phase II reactions. Phase I reactions involve oxidation reduction and hydrolysis reactions primarily catalyzed by CYP and flavin-containing monooxygenases. Phase II reactions known as conjugation reactions involve the interactions of the polar functional groups of phase I metabolites [21-27]. Metabolic stability refers to the susceptibility of compounds to biotransformation. In the context of drug discovery screens, intrinsic metabolic clearance (CLint), the proportionality constant between drug concentrations at the enzyme site (Ce) and rate of metabolism (vo), is often referred to as metabolic stability: CLint = vo / Ce [28]. The intrinsic half-life is determined by incubating a test compound with liver subcellular preparations for a certain period of time and plotting ln % remaining versus times as t1/2 = 0.693 / m where m is the slope of the plot. Integration of metabolic stability assessment with identification of the site (soft spot) of metabolism is valuable in leading toward a modified compound with an appropriate rate of metabolism to achieve an ideal pharmacokinetic profile. Meanwhile, characterization of reactive and pharmacologically active metabolites following incubation in microsomal systems for a predetermined period is also critical in designing new drug candidates with an improved toxicological profile and efficacy [29-37]. Detection of glutathione conjugates in both in vitro and in vivo suggests the production of potentially reactive intermediates. Acyl-glucuronides metabolites are susceptible to both hydrolysis and intramolecular acyl migration to form reactive intermediates for covalently binding to proteins which may implicate in various drug-induced toxicities [29, 38]. The other objectives of metabolite profiling in drug research settings are to characterize major me-
4 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Yunsheng Hsieh
tabolites across species and to identify human-specific metabolites to allow for assessment of potential human safety issue. Animal PK results are considered the most predictive of human PK parameters and used to select compounds with no potential PK deficiency such as poor bioavailability, short half-life, circulating reactive metabolites and so on for drug development [39-47]. A variety of in vivo PK parameters such as oral bioavailability, volume of distribution, clearance, and mean resident time calculated from the drug concentrations in animal plasma samples can sometimes be employed to predict human PK via allometric scaling. Animal studies can also be used to assess the single-dose and multiple-dose non-clinical toxicity liability in the final lead characterization of drug candidates. Also, to conduct an Animal Safety program to meet IND requirements for enabling Phases I clinical trials, it is important to achieve sufficient exposure multiples following drug administration to the rodent and non-rodent toxicological species. In all aforementioned cases, what have enabled these in vitro and in vivo experiments to drug discovery to be efficient are the development of compound-specific analytical methods. Among these methods, MS-based approaches as described in the following sections have evolved to become irreplaceable techniques in the analysis of drug- related molecules in biological samples (Table 1) [48-55]. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-MS/MS The combination of high performance liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) has rapidly matured to become a very powerful analytical tool applied in many DMPK areas for qualitative and quantitative determination of new chemical entities (NCEs) and the marketed pharmaceuticals (Fig. 2) [56-66]. Due to its inherent selectivity, the HPLC-MS/MS system normally requires neither labor-intensive sample preparation procedures nor extensive chromatographic run times to avoid matrix interference. This allows researcher to shorten chromatographic times and in turn to increase sample throughput. Micro-column [67-69], monolithic column [70-76], high temperature [77] and ultra high pressure [78-85] HPLC-MS/MS methods (Fig. 3) are four popular approaches to achieve faster HPLC cycle times for small molecule assays prior to tandem mass spectrometric detection. 200
100
0 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 Fig. (2). Swift growth of HPLC-MS/MS applications for drug assays in the PubMed database.
Present and Future Mass Spectrometry-Based
Table 1.
Frontiers in Drug Design & Discovery, 2009, Vol. 4 5
Representative MS-Based Methods Used for DMPK Studies
Study
Rationale
MS-Based Method
Reference
P450 enzyme inhibition
To evaluate direct and mechanism-based inhibition of CYP enzymes that are responsible for metabolism of most drugs to assess the potential for drug-drug interactions.
HPLC-MS/MS Direct-injection HPLC-MS/MS LDTD-MS/MS
[11, 188] [189]
P450 enzyme profiling
To determine which P450 is primarily responsible for metabolizing the compound to anticipate drug-drug interactions and polymorphisms.
HPLC-MS/MS
[190]
Caco-2 permeability and efflux substrate screening
To evaluate permeability in human intestinal cell line to project in vivo absorption potential.
HPLC-MS/MS Nano-ESI-MS/MS
[19] [16]
Plasma protein binding
To determine the magnitude of plasma protein binding in different species. The free drug concentration can be used to interpret PK/PD relationships.
HPLC-MS Affinity chromatography-MS AMS
[191] [144, 192]
To evaluate compound stability following incubation in plasma. Results can assist in understanding an in vivo clearance value that exceeds hepatic blood flow.
Direct-injection HPLC-MS/MS HPLC-MS/MS
[112]
Intrinsic clearance (hepatocyte stability)
To evaluate the magnitude of hepatic clearance to predict in vivo clearance and assess species differences.
HPLC-MS/MS SFC-MS/MS Pulsed ultrafiltration-MS
[195] [126] [151]
In vitro and in vivo metabolite identification
To examine the metabolic profile of a compound across species with particular emphasis on the identification of any human specific metabolites.
HPLC-MS/MS nano-ESI-MS
[119, 196, 197] [156]
Animal PK study
To access in vivo PK parameters and to support the safety pharmacology cardiovascular study.
HPLC-MS/MS SFC-MS/MS nano-ESI-MS
[198-200] [140] [157, 201]
Blood-Brain barrier
To access the potential of compounds to penetrate the blood-brain barrier.
HPLC-MS/MS
[202, 203]
Mass balance
To evaluate the amount of drug that is recovered over time via the different elimination routes of the body.
AMS
[179]
Tissue Distribution
To access the distribution of a drug and its metabolites in various tissues from laboratory animal experiments.
MALDI-IMS
[185, 187]
Plasma stability
[163]
[193]
[194]
6 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Yunsheng Hsieh
Higher-Throughput LC-MS Strategies in Drug Discovery Fast Chromatography Micro-column HPLC Monolithic column HPLC High-temperature HPLC Ultra performance liquid chromatography (UPLC) Parallel Instrumentation micro parallel liquid chromatography (uPLC) Staggered parallel liquid chromatography Multiple Ionization Sources APPI, ESI, APCI Ion-pairing HPLC Porous graphite carbon HPLC Mixed-mode HPLC Hydrophilic interaction chromatography (HILIC) Direct injection HPLC
Fig. (3). Strategies of higher throughput HPLC-MS approaches in drug discovery.
According to chromatographic concepts, one effective way to improve the HPLC column efficiency is to reduce the particle size of the packing materials that indicate better diffusion and mass transfer in the mobile and the stationary phases. Micro-column technique adopts a shorter (less than 5 cm length) narrow-bore (~ 2 mm i.d.) column packed with small particles and operated at higher than optimal flow rates to provide for fast chromatographic separations while still maintaining satisfactory chromatographic resolution. Monolithic silica columns made from a single piece of porous silica gel can be operated at higher flow-rates than conventional HPLC columns due to their lower back pressure. The low back pressure despite higher mobile phase flow rates is due to the higher permeability of monolithic silica versus particulate silica columns to make higher speed separation possible without a noticeable effect on chromatographic resolution. The viscosity of the mobile phases used in reverse-phase chromatography decreases as the temperature increases. Consequently, the column pressure drop, P, decreases significantly to allow higher flow rates within the normal HPLC pressure limits when elevated column temperature chromatography is employed. Ultra high-pressure liquid
Present and Future Mass Spectrometry-Based
Frontiers in Drug Design & Discovery, 2009, Vol. 4 7
chromatography (UHPLC) is another technical advance that allows the liquid handling system to handle the high backpressure resulting from the stationary phase with sub-2 m particles. UHPLC offers theoretical advantages in chromatographic resolution, speed and sensitivity over conventional HPLC systems. The concept of using supercritical porous silica packing through fused-core technology was further extended for the design of a novel stationary phase for separation of small molecules [79]. The columns packed with sub-2 m stationary phases require expensive ultra-pressure equipment to achieve optimum performance. The fused-core silica columns generate backpressure slightly higher than the columns normally packed with 3- and 5-m particles which are still compliable with most existing HPLC pumps (Fig. 4). 6 0.74
4.2e5
Intensity, cps
A 1
4 2
3
5 0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
6
Time, min
B
Intensity, cps
4.4e5
4 2
3
1 5 0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Time, min
Fig. (4). Fast separation of six pharmaceutical compounds using (A) a 2.7-m fused-core silica column (the first injection- (solid line) and the 250th injection- (dotted line)) and (B) 1.7-m porous silica column at 40 oC. Compounds 1 through 6 are ketoconazole, thioridazine, clofazimine, amiodarone, felodipine and rimonabant, respectively [79].
Due to its inherent selectivity and sensitivity, HPLC-MS/MS method allows the simultaneous determination of multiple components sharing the same retention times. An alternative approach for higher-throughput assay without sacrificing chromatographic integrity is the use of parallel HPLC where samples were injected alternately onto each of two analytical columns in parallel at specified intervals within a single chromatographic run time [86]. The parallel system makes use of unused chromatographic time windows and can be controlled by the computer where the analyst defines the acquisition
8 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Yunsheng Hsieh
windows placed into HPLC timetable to provide a boost in throughput. To further speed up assays, the concept of using a staggered sample injection technique has been extended to multiple parallel HPLC-MS/MS methods for quantitative applications [87, 88]. The exponential growth in HPLC-MS applications is mainly due to the introduction of the atmospheric pressure ionization (API) interfaces between HPLC and a mass spectrometer. Electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) sources are the major ionization interface designs for the HPLC-MS/MS systems for qualitative and quantitative analysis of small molecules over the last decade. However, there is no single ionization source for HPLC-MS/MS system to cover all target compounds. New instrumental developments have resulted in combined sources such as APCI/ESI and APPI/APCI sources for on-line HPLC-MS/MS [89-91]. For example, the ESI/APCI source allows alternate on-line ESI and APCI scans with polarity switching within a single analysis. The new combined sources have reduced the analysis time of sample plates by eliminating the need for a source hardware change and repeat analyses. One of the common goals in the exploratory PK area is to develop a generic HPLCMS/MS method to simultaneously monitor a wide range of drug candidates and their metabolites in biological fluids. Reversed-phase HPLC is the most widely employed technique in pharmaceutical analysis due to its extensive application to most small drug molecules which are separated by their degree of hydrophobic interaction with the stationary phase. However, it is very challenging to establish a reliable bioanalytical method for the determination of NCEs with lower octanol-water partition coefficient, log P, because these polar compounds show little or no retention on traditional reversed-phase columns prior to mass spectrometric detection. Ion-pairing chromatography was reported as an effective way for obtaining satisfactory retention of polar analytes under reversedphase conditions [92-95]. The ion-pairing reagents added into mobile phase are used to improve chromatographic retention on the lipophilic stationary phase through the formation of neutral ion pairs. It was proven that the porous graphic carbon (PGC) column was able to provide more efficient retention than other kinds of the reversed-phase columns designed to trap and separate very polar compounds [96, 97]. The overall retention on PGC columns involves two major mechanisms: (1) dispersive interaction between analyte-mobile phase and analyte-graphite surface and (2) dipolar and ionic interaction of a polar analyte with the polarizable graphite. The mixed-mode column with an embedded ion-pairing group in the reversed-phase stationary providing the capability for ionexchange and hydrophobic interactions requires no ion-pairing reagent in the mobile phase to retain and to separate ionizable polar compounds. The mixed-mode HPLC allows for retaining hydrophobic compounds by the reversed-phase mechanism and hydrophilic compounds by the ion exchange mechanism at higher organic contents in the mobile phase [98]. Hydrophilic interaction chromatography (HILIC) using low aqueous/high organic mobile phase is emerging as another valuable supplement to the reversed-phase HPLC–MS/MS for the retention of polar pharmaceuticals [99-105]. The solvents used for HILIC-MS/MS systems, such as methanol, provide low column backpressure but also are MS-favorable for greater ionization efficiency. A simplified sample preparation step using protein precipitation technique to remove proteins from biological samples is normally sufficient for small molecule determination when HPLC-MS/MS methods are employed. This single clean-up step is required to prevent the HPLC column from clogging in reversed-phase chromatography but also to
Present and Future Mass Spectrometry-Based
Frontiers in Drug Design & Discovery, 2009, Vol. 4 9
avoid ion source contamination to reduce matrix ionization suppression in the mass spectrometer. The working principle of on-line extraction phases is to isolate macromolecules from the targeted small molecules in biological fluids based upon their sizes. The large macromolecules such as proteins, which are unable to penetrate into the hydrophobic pores, are first eluted to waste. The small molecules such as drug compounds that penetrate the pores are retained through the hydrophobic forces [106-111]. The directinjection HPLC-MS/MS method had been applied for the automatic measurement of plasma stability of drug candidates to eliminate the traditional labor-intensive sample preparation procedures [112]. The procedure makes use of a thermostatic autosampler as an incubator combined with the direct-injection HPLC-MS/MS method (Fig. 5). The untreated plasma samples from several species containing the test compound was directly and sequentially injected into a mixed-function column for on-line protein removal and chromatography. The injection-to-injection time was set at a certain time period. The peak responses of the test article were repeatedly monitored after each injection cycle which can be related to a constant incubation time period for individual plasma samples. The stability results of the test compound in all plasma samples obtained by the direct-injection HPLC-MS/MS method was found to be consistent with those obtained by the traditional HPLC-MS/MS approach (Fig. 4). Mouse Rat
Human Monkey Dog
120
% Remaining
100 80 60 40 20 0
Direct-injection HPLC-MS/MS
0
30
60
90
120 150 180 210 240 270 300
Time (min)
Result Spiking + Autosampler Fig. (5). Schematic of a direct-injection HPLC-MS/MS system for semi-automatic plasma stability measurement.
Tandem mass spectrometry covering a variety of scanning techniques such as precursor ion, neutral-loss and product ion scanning provides complementary information on small molecular structures [113, 114]. Triple-quadrupole (QqQ) is a tandem mass spectrometer commonly used for conducting product ion scan (MS2), precursor ion scan, neutral loss scan modes for structure elucidation and selected reaction monitoring (SRM) for the quantitation of trace components. The QqQ mass spectrometer is the most popular instrument for both quantitative pharmacokinetic (PK) assays and qualitative DMPK studies [50-52]. Linear ion trap (LIT) mass spectrometers perform multiple MS/MS (MSn) with a much faster trap scan speed than the QqQ mass spectrometer to generate more detailed structure information. A hybrid quadrupole linear ion trap (QqLIT) combines the features of both QqQ and LIT mass spectrometers with improved performances for supporting DMPK studies under one system [115-125]. With the QqLIT technology, collision-induced dissociation (CID) occurs in a quadrupole collision
10 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Yunsheng Hsieh
cell and fragment ions are trapped and analyzed in the LIT mode to simultaneously perform multiple experiments without the need to repeat the runs on different MS platforms and substantial sensitivity loss. The hyphenation of HPLC and tandem mass spectrometry has widely become a powerful analytical tool for the characterization of metabolites of pharmaceuticals. SUPERCRITICAL FLUID CHROMATOGRAPHY-MS Supercritical fluid chromatography (SFC) is a hybrid of gas and liquid chromatography that eases the resolution of a mixture of compounds not conveniently resolved by either gas or liquid chromatography. The mobile phases for SFC have low viscosities and high diffusion coefficients properties compared to those for HPLC to allow for high efficiency separations. The commercial API sources used for HPLC-MS/MS system were proven to be applicable to the SFC-MS/MS system with no modification [126,127] (Fig. 6). According to the US Food and Drug Administration’s (FDA) policy statement for the development of new stereoisomeric drugs, in order to evaluate the pharmacokinetics of a single enantiomer or mixture of enantiomers, manufacturers should develop quantitative assays for individual enantiomers in in vivo samples early in drug development. SFC, offering higher resolution per unit of time and faster column re-equilibration, has been becoming the top choice among enantioselective chromatographic techniques such as capillary electrophoresis (CE) [128-130] and HPLC [131-135]. Although the MS/MS detection provides little selectivity for stereoisomeric drugs, it can provide complete resolution of the administered drugs from endogenous materials and their metabolites. By taking advantage of the inherent selectivity and sensitivity of MS/MS detection, implementing chiral SFC-MS/MS method together with sample pooling technology allows us to simultaneously monitor samples containing multiple pairs of enantiomers with different masses within the same chromatographic run to further increase assay productivity [136]. The coupling of chiral SFC to MS/MS detection was shown to be comparable for most bioanalytical attributes such as specificity, linearity, accuracy and ruggedness but advantageous for higher sample throughput and peak resolution power with respect to the HPLC-MS/MS approach [137-139]. Oven & analytical column Autosampler SFC
Tandem mass spectrometer
Fig. (6). Schematic of SFC-MS/MS system.
SFC best emulates normal-phase chromatography, but has the capability to separate a much broader range of analyte polarities amenable to SFC-MS if appropriate mobilephase modifiers, additives and columns are utilized [140-142]. As a general strategy,
Present and Future Mass Spectrometry-Based
Frontiers in Drug Design & Discovery, 2009, Vol. 4 11
CO2 combined with more polar solvents containing either acidic or basic additives as modifier to enhance the solvent strength of the mobile phase will allow for the elution of the analytes on packed column with high efficiency. SFC is not limited to relatively nonpolar compounds but could be extended to allow for the elution of polar and ionic compounds. In HPLC, the direct serial coupling of achiral and chiral columns for the simultaneous achiral/chiral separation of a range of components in a complex mixture was not feasible due to either the increased backpressure or the different mobile-phase requirement. However, this concept is not restricted for SFC because the supercritical fluid has a significantly lower viscosity than a liquid, but also is an effective eluent for both chiral and achiral stationary phases [140]. AFFINITY CHROMATOGRAPHY-MS Affinity chromatography makes use of affinity-based interactions for the analysis of specific analytes within a sample. One of the examples of these interactions includes the binding of a serum albumin with drugs where albumin is the major contribution to drugprotein binding in the plasma [143-147]. Such binding processes are performed by placing a serum albumin as a known ligand onto a solid support within a column to interact with the desired analyte. Immobilized serum albumin affinity chromatography coupled to tandem mass spectrometry has been applied for chiral separation and drug-protein binding determinations [146, 147]. In this approach, the test compounds are injected to immobilized serum albumin column and the expression of 100 [k’ / (k’+ 1)] is used to estimate the % protein binding of the analytes where k’ is the capacity factor. Good correlation between the protein binding results of the analytes obtained from the affinity chromatography-MS methodology and those obtained from ultrafiltration or dialysis methods were reported [144]. The compounds with the high non-specific binding to artificial membrane which are not applicable to ultrafiltration assay can be analyzed by this affinity chromatographic method. The immobilized serum albumin column-MS method enabled the simultaneous estimation of the individual protein-binding affinities of a mixture of compounds but also was proved to be reproducible to rank order a series of molecules according to their protein-binding affinities in less than an hour [147]. PULSED ULTRAFILTRATION-MS Ultrafiltration is a separation process using membranes with a variety of pore sizes to remove high molecular-weight substances. Pulsed ultrafiltration interfaced with MS was proved to be a powerful method with multiple uses for combinatorial libraries, metabolic stability and metabolites screening [148-151]. As an example, in the pulsed ultrafiltration (PU) experiment for metabolic stability screening, a pulse containing a library of compounds is loaded and pumped through a stirred ultrafiltration chamber fitted with an appropriate molecular weight cut-off ultrafiltration membrane (Fig. 7). Liver microsomes from various species are trapped in an ultrafiltration chamber. A continuous flow of a buffer is pumped through the chamber and into an API interface and a mass spectrometer. Substrates for cytochrome P450 together with cofactors are flow injected through the chamber and the targeted metabolites are then monitored on-line by using mass spectrometry [149]. Pulsed ultrafiltration in conjunction with LC-MS-MS can be extended to screen mixtures for compounds that might be activated metabolically by cytochrome P450. The pulsed ultrafiltration-MS method provides comparable qualitative results of a metabolic stability test with those obtained via a microsomer off-line incubation but has
12 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Yunsheng Hsieh
the potential for increasing the throughput of such an analysis by carrying out multiple ultrafiltration reaction chambers in parallel with a HPLC injector/autosample and a single mass spectrometer [149].
Fig. (7). Scheme for a parallel pulsed ultrafiltration mass spectrometry system to screen drug candidates for drug metabolism [149].
COLUMNLESS MS MS-based methods frequently demonstrate no chromatographic interference from endogenous components. The attempt to further increase sample throughput has led some bioanalytical laboratories to replace chromatographic separation with flow injection analysis (FIA) [152-154], nanoelectrospray infusion [155-162], laser diode thermal desorption (LDTD) techniques [163], or matrix-assisted laser desorption/ionization (MALDI) [164-166] that eliminate the HPLC component prior to mass spectrometric detection. Nano-electrospray (nanoESI) ionization refers to an electrospray emitter consists of a glass capillary with a tip pulled to a narrow internal diameter operated at a flowrate between 10 to 100 nL/min. NanoESI technology initiated by microfluidic devices offers the possibility of increased sensitivity over conventional ESI. NanoESI system using a robotic platform for sample handling can automatically infuse 96 samples in approximately an hour to microfabricated nanoESI nozzles for unattended quantitative and qualitative analysis [117, 167]. For each analytical run, a new tip and a new nozzle is used to eliminate the potential carry-over issue associated with HPLC autosamplers. LDTD-MS is a direct sample introduction technique combining thermal desorption and mass spectrometry. The sample plate is held in an X-Y stage that positions it in alignment with the laser. The flare-shaped portion of the nozzle abuts on the 96-well plate. Thermal desorption by an infrared laser diode at the back of each well without addition of any matrix generates the gaseous molecules to be introduced directly into the mass spectrometer.
Present and Future Mass Spectrometry-Based
Frontiers in Drug Design & Discovery, 2009, Vol. 4 13
Laser power and duration and the carrier gas flowrate are the major parameters for optimization of the vaporization efficiency of analytes from the target samples [163]. Matrix-assisted laser desorption/ionization (MALDI) involves mixing the analyte with a large molar excess of a matrix solution. Once the mixture is applied to a stainless steel target, the sample is allowed to air evaporate for co-crystallization. The sample plate is then inserted into the mass spectrometer for laser bombardment. These crystals containing matrix materials are subject to absorb energy of the laser resulting in desorption and ionization of the analytes. The coupling of MALDI to a mass spectrometer has extended its application for the direct analysis of pharmaceuticals [165, 166]. The major concerns for direct detection of low molecular weight compounds extracted from biological fluids using MALDI-MS are poor shot-to-shot reproducibility due to the inhomogeneous distribution of analytes within the sample spots and ionization suppression [165]. In addition to a higher-throughput potential, these “columnless” direct MS-based methods offer the additional advantages over the hyphenated-MS methods which are no carry-over between samples, low sample consumption and no chromatographic method development time. However, extensive optimization of the sample clean up process would be normally required to eliminate matrix ion suppression and interferences from endogenous interferences or the metabolites of the dosed compound when attempting to perform these “columnless” MS-based assays. ACCELERATOR MS Accelerator mass spectrometry (AMS) is a nuclear physic technique to allow the remarkably sensitive means for counting elemental isotopes at the individual atom level in less than 1 milligram samples [168-171]. AMS uses a particle accelerator in conjunction with ion sources, magnets, filters and mass spectrometers to separate out interferences and detect single atoms in the presence of stable atoms. Briefly, various negative elemental or molecular ions are first created through bombardment by a beam of Cs+ ions to sputter material from the sample. The ion source is then introduced to the gas phase and enters an electrostatic accelerator. In the middle of the accelerator, all molecular species are destroyed and the outer valency electrons are stripped. The resulting positively charged species continue their acceleration toward a magnetic quadrupole lens. The desired isotope ions are separated and counted by a mass spectrometer [172, 173]. For the direct measurement of 14C atoms, AMS is at least 1000 times more sensitive than radioactivity decay counting and any other methods. This makes it possible to use for a wide variety of tracing applications for drug compounds enriched with 14C in the DMPK, pharmacology and toxicology areas [174-176]. For microdosing and mass balance studies, animals and human are administrated with 14C-labelled drug components [173, 177, 178]. At certain post-dosing time intervals, blood, urine and other samples are collected for AMS analysis. The specimen for AMS experiment must be converted to a thermally and electrically conductive solid form. As an example, carbon samples are reduced to graphite prior to each AMS experiment. Ultilization of ultrasensitive AMS technique permits drug administration with dose at least 1000 times lower than that used in conventional radioactive studies to reduce radiation exposure. Although AMS is not able to provide chemical identity information, it can be used to access the extent of metabolism through HPLC-MS metabolite profiling [179].
14 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Yunsheng Hsieh
MALDI-IMAGING MASS SPECTROMETRY During the drug discovery and development stages, often the question is raised as to whether the drug can reach the site of action which helps researchers better assess the potential value of that compound as a pharmaceutical product and the potential for toxicological outcomes. Most MS-based approaches are not able to provide the answer to certain questions regarding the distribution of a drug in various organs or tissues from in vivo animal experiments. Whole body autoradiography (WBA) normally provides a standard way to answer this question on the time course of the drug candidates [180]. However, the major disadvantage in the autoradiographic technique is that it provides for visualization of total drug-related materials, and provides no discrimination of the administrated drugs vs. metabolites. In addition, the availability of radiolabeled compounds is another concern at the drug discovery stage. To overcome these issues, matrix-assisted laser desorption/ionization-mass spectrometric method (MALDI-MS) has been developed to directly and simultaneously determine the distribution of pharmaceuticals and their metabolites in tissue sections which might unravel their disposition or biotransformation pathway for new drug development [181-186]. The concept of MALDI-IMS was introduced to direct profiling of the analytes within a tissue section or an organ. In this process, matrix materials are uniformly deposited over various tissue sections to extract analytes into the surface of the tissue and to produce crystals. A raster of organ sections containing the compounds of interest from a small animal under a stationary laser beam is then performed over a predetermined twodimensional array to generate ion plumes directly from the tissue sections in a large (5 cm x 5 cm) sample plate sufficient to contain whole tissue slices. The movement of the sample stage is automatically accomplished in the x and y directions to locate the edges of the tissue sample and to define the exact region of interest. During an imaging mass spectrometric experiment, MALDI-MS signals of small molecules from tissue sections within a user-defined area are first obtained as a function of acquisition times which are associated with the location of an array of pixels. Thus, two-dimensional ion maps of biological tissues are reconstructed with drug signals of a given m/z value monitored in each spectrum from each pixel to provide specific molecular images. The reliability of using MALDI-IMS for direct intact analysis of pharmaceuticals in tissues had been cross-validated by autoradiographic techniques [187]. For a fair parallel comparison between these molecular imaging technologies to visualize the accumulation of a well-established drug in rat brains, the animals had been administrated by direct infusion with 3H-clozapine into rat brain to avoid any possible biotransformation. Rat brain was chosen as a tissue model due to its unique symmetry and well-defined anatomy. The optical image of a sagittal section of the brain defined the presence of the cortex, limbic system, cerebellum, brain stem, and ventricles (Fig. 8). Results from the auto-radiography suggest that clozapine is distributed throughout the brain, with the highest concentration found in the lateral ventricle. The result from MALDI-IMS was in a good agreement with that obtained from autoradiography with regard to the distribution of clozapine in rat brain after intracerebral ventricular injection. MALDI-IMS could also be beneficial as a diagnosis, screening or discovery tool where tissue sections can be explored without knowing in advance what specific molecules have changed in a comparative study. Image comparison between control tissues and study tissues from small molecules will allow researchers to identify differences in resulting changes induced by drug candidates or their metabolites that could yield important toxicological information.
Present and Future Mass Spectrometry-Based
Frontiers in Drug Design & Discovery, 2009, Vol. 4 15
(a)
(b)
(c)
Fig. (8). (A) Optical images, (B) radioautographic images and (C) MALDI-MS/MS images from the study rat brain tissue section.
FINAL REMARKS The role of the DMPK screens is to provide an efficient paradigm for improving the drug likeness of the NCEs by using various in-vitro and in-vivo experiments for lead optimization and characterization. Hyphenation of the high-resolving HPLC to a tandem mass spectrometer (MS/MS) provides straightforward method development capabilities with excellent analytical linearity, sensitivity and selectivity for monitoring drug-related
16 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Yunsheng Hsieh
compounds. HPLC-MS/MS techniques will continue to be the mainstream as a bioanalytical tool in DMPK screens for the next decade. The search for universal API interfaces to cover more NCEs and to look for strategies to ease the ever-increasing demand for faster sample turnaround time using HPLC-MS/MS are currently in progress. Any improvement in HPLC–MS/MS instrumentation should enhance not only throughput but also the chance of success in attempting the structural identification of metabolites in biological matrices. ABBREVIATIONS AMS
=
Accelerator Mass Spectrometry
APCI
=
Atmospheric Pressure Chemical Ionization
API
=
Atmospheric Pressure Ionization
CE
=
Capillary Electrophoresis
CLint
=
Intrinsic Metabolic Clearance
DMPK
=
Drug Metabolism and Pharmacokinetics
ESI
=
Electrospray Ionization
FDA
=
United State Food and Drug Administration
FIA
=
Flow Injection Analysis
HILIC
=
Hydrophilic Interaction Chromatography
HPLC
=
High Performance Liquid Chromatography
IMS
=
Imaging Mass Spectrometry
IND
=
Investigational New Drug
LDTD
=
Laser Diode Thermal Desorption
LIT
=
Linear Ion Trap
MALDI
=
Matrix-Assisted Laser Desorption/Ionization
MS
=
Mass Spectrometry
MS/MS
=
Tandem Mass Spectrometry
NCEs
=
New Chemical Entities
P450
=
Cytochrome P450
PGC
=
Porous Graphic Carbon
PU
=
Pulsed Ultrafiltration
QqLIT
=
Hybrid Quadrupole Linear Ion Trap
SFC
=
Supercritical Fluid Chromatography
UHPLC
=
Ultrahigh-Pressure Liquid Chromatography
WBA
=
Whole body autoradiography
Present and Future Mass Spectrometry-Based
Frontiers in Drug Design & Discovery, 2009, Vol. 4 17
REFERENCES [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39]
Kola, I.; Landis, J. Nat. Rev. Drug Discov., 2004, 3, 711. White, R.E. Annu. Rev. Pharmacol. Toxicol., 2000, 40, 133. Caldwell, G.W.; Ritchie, D.M.; Masucci, J.A.; Hageman, W.; Yan, Z. Curr. Top Med. Chem., 2001, 1, 353. Korfmacher, W.A. Curr. Opin. Drug Discov. Devel., 2003, 6, 481. Di, L.; Kerns, E.H. Curr. Opin. Drug Discov. Devel., 2005, 8, 495. Di, L.; Kerns, E.H. Curr. Opin. Chem. Biol., 2003, 7, 402. Thompson, T.N. Curr. Drug Metab., 2000, 1, 215. Ekins, S.; Ring, B.J.; Grace, J.; McRobie-Belle, D.J.; Wrighton, S.A. J. Pharmacol. Toxicol. Methods, 2000, 44, 313. Bertrand, M.; Jackson, P.; Walther, B. Eur. J. Pharm. Sci., 2000, 2, S61. Lin, J.; Sahakian, D.C.; de Morais, S.M.; Xu, J.J.; Polzer, R.J.; Winter, S.M. Curr. Top. Med. Chem., 2003, 3, 1125. Chu, I.; Favreau, L.; Soares, T.; Lin, C, Nomeir, A.A. Rapid Commun. Mass Spectrom., 2000, 14, 207. Nakamura, K.; Watanabe, A.; Okudaira, N.; Okazaki, O.; Sudo, K. Drug Metab. Pharmacokinet., 2007, 22, 113. Di, L.; Kerns, E.H.; Li, S.Q.; Carter, G.T. Int. J. Pharm., 2007, 335, 1. Bu, H.Z.; Magis, L.; Knuth, K.; Teitelbaum, P. Rapid Commun. Mass Spectrom., 2001, 15, 741. Li, X.; Chen, X.; Li, Q.; Wang, L.; Zhong, D. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 852, 128. Van Pelt, C.K.; Zhang, S.; Fung, E.; Chu, I.; Liu, T.; Li, C.; Korfmacher, W.A.; Henion, J. Rapid Commun. Mass Spectrom., 2003, 17, 1573. Smalley, J.; Marino, A.M.; Xin, B.; Olah, T.; Balimane, P.V. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 854, 260. van Breemen, R.B.; Li, Y. Expert Opin. Drug Metab. Toxicol., 2005, 1, 175. Fung, E.N.; Chu, I.; Li C.; Liu, T.; Soares, A.; Morrison, R.; Nomeir, A.A. Rapid Commun. Mass Spectrom., 2003, 17, 2147. Wang, Z.; Hop, C.E.; Leung, K.H.; Pang, J. J. Mass Spectrom., 2000, 35, 71. Baranczewski, P.; Stanczak, A.; Kautiainen, A.; Sandin, P.; Edlund, P.O. Pharmacol. Rep., 2006, 58, 341. Baranczewski, P.; Stanczak, A.; Sundberg, K.; Svensson, R.; Wallin, A.; Jansson, J.; Garberg, P.; Postlind, H. Pharmacol. Rep., 2006, 58, 453. Masimirembwa, C.M.; Bredberg, U.; Andersson, T.B. Clin. Pharmacokinet., 2003, 42, 515. Masimirembwa, C.M.; Thompson, R.; Andersson, T.B. Comb. Chem. High Throughput Screen., 2001, 4, 245. Singh, S.S. Curr. Drug Metab., 2006, 7, 165. Roberts, S.A. Xenobiotica, 2001, 31, 557. Kassel, D.B. Curr. Opin. Chem. Biol., 2004, 8, 339. Thompson, T.N. Using Mass Spectrometry for Drug Metabolism Studies, Chapter 2, Korfmacher, W.A. Ed.; CRC Press: Boca Raton, FL. 2005; pp. 35-81. Ma, S.; Subramanian, R. J. Mass Spectrom., 2006, 41, 1121. Ma, S.; Chowdhury, S.K.; Alton, K.B. Curr. Drug Metab., 2006, 7, 503. Prakash, C.; Shaffer, C.L.; Nedderman, A. Mass Spectrom. Rev., 2007, 26, 340. Hop, C.E.; Tiller, P.R.; Romanyshyn, L. Rapid Commun. Mass Spectrom., 2002, 16, 212. Baillie, T.A. Chem. Res. Toxicol., 2006, 19, 889. Doss, G.A.; Baillie, T.A. Drug Metab. Rev., 2006, 38, 641. Prueksaritanont, T.; Lin J.H.; Baillie, T.A. Toxicol. Appl. Pharmacol., 2006, 217, 143. Clarke, N.J.; Rindgen, D.; Korfmacher, W.A.; Cox, K.A. Anal. Chem., 2001, 73, 430A. Castro-Perez, J.M. Drug Discov. Today, 2007, 12, 249. Samuel, K.; Yin, W.; Stearns, R.A.; Tang, Y.S.; Chaudhary, A.G.; Jewell, J.P.; Lanza, T. Jr.; Lin, L.S.; Hagmann, W.K.; Evans, D.C.; Kumar, S. J. Mass Spectrom., 2003, 38, 211. Mei, H.; Korfmacher, W.; Morrison, R. AAPS J., 2006, 8, E493.
18 Frontiers in Drug Design & Discovery, 2009, Vol. 4 [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80]
Yunsheng Hsieh
Caldwell, G.W.; Masucci, J.A.; Yan, Z.; Hageman, W. Eur. J. Drug Metab. Pharmacokinet., 2004, 29, 133. Feng, M.R.; Lou, X.; Brown, R.R.; Hutchaleelaha, A. Pharm. Res., 2000, 17, 410. Mahmood, I.; Balian, J.D. Clin. Pharmacokinet., 1999, 36, 1. McGinnity, D.F.; Collington, J.; Austin, R.P.; Riley, R.J. Curr. Drug Metab., 2007, 8, 463. Kitamura, R.; Yamamoto, Y.; Nagayama, S.; Otagiri, M. Drug Metab. Dispos., 2007, 35, 1611. Kramer, J.A.; Sagartz, J.E.; Morris, D.L. Nat. Rev. Drug Discov., 2007, 6, 636. Pritchard, J.F.; Jurima-Romet, M.; Reimer, M.L.; Mortimer, E.; Rolfe, B.; Cayen, M.N. Nat. Rev. Drug Discov., 2003, 2, 542. Sadaghiani, A.M.; Verhelst, S.H.; Gocheva, V.; Hill, K.; Majerova, E.; Stinson, S.; Joyce, J.A.; Bogyo, M. Chem. Biol., 2007, 14, 499. Hopfgartner, G.; Bourgogne, E. Mass Spectrom. Rev., 2003, 22, 195. Rossi, D.T.; Sinz, M.W. Mass Spectrometry in Drug Discovery, Marcel Dekker, Inc., NY, 2002. Niessen, W.M.D. The Encyclopedia of Mass Spectrometry, Vol. 8, Elsevier, Oxford, UK, 2006. Lee, M. Integrated Strategies for Drug Discovery Using Mass Spectrometry, Marcel Dekker, Inc., NY, 2002. Korfmacher, W.A. Using Mass Spectrometry for Drug Metabolism Studies, John Wiley and Sons, Inc., Hoboken, NJ, 2005, pp. 1-34. Roddy, T.P.; Horvath, C.R.; Stout, S.J.; Kenney, K.L.; Ho, P.I.; Zhang, J.H.; Vickers, C.; Kaushik, V.; Hubbard, B.; Wang, Y.K. Anal. Chem., 2007, 79, 8207. Staack, R.F.; Hopfgartner, G. Anal. Bioanal. Chem., 2007, 388, 1365. Chu, I.; Nomeir, A.A. Curr. Drug Metab., 2006, 7, 467. Niessen, W.M. J. Chromatogr. A, 2003, 1000, 413. Lee, M.S.; Kerns, E.H. Mass Spectrom. Rev., 1999, 18, 187. Ackermann, B.L.; Berna, M.J.; Murphy, A.T. Curr. Top. Med. Chem., 2002, 2, 53. Ermer, J.; Vogel, M. Biomed. Chromatogr., 2000, 14, 373. Jemal, M. Biomed. Chromatogr., 2000, 14, 422. Lim, C.K.; Lord, G.; Biol. Pharm. Bull., 2002, 25, 547. Tiller, P.R.; Romanyshyn, L.A.; Neue, U.D. Anal. Bioanal. Chem., 2003, 377, 788. Kostiainen, R.; Kotiaho, T.; Kuuranne, T.; Auriola, S. Mass Spectrom., 2003, 38, 357. Hsieh, Y.; Fukuda, E.; Wingate, J.; Korfmacher, W.A. Comb. Chem. High Throughput Screen., 2006, 9, 3. Hsieh, Y.; Korfmacher, W.A. Curr. Drug Metab., 2006, 7, 479. Xu, R.N.; Fan, L.; Rieser, M.J.; El-Shourbagy, T.A. J. Pharm. Biomed. Anal., 2007, 44, 342. Hsieh, Y.; Brisson, J.M.; Wang, G.; Ng, K.; Korfmacher, W.A. J. Pharm. Biomed. Anal., 2003, 33, 251. Witters, E.; Laukens, K.; Deckers, P.; Van Dongen, W.; Esmans, E.; Van Onckelen, H. Rapid Commun. Mass Spectrom., 2003, 17, 2188. Hsieh, Y.; Chintala, M.; Mei, H.; Agans, J.; Brisson, J.M.; Ng, K.; Korfmacher, WA. Rapid Commun. Mass Spectrom., 2001, 15, 2481. Kirchherr, H.; Kuhn-Velten, W.N. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2006, 843, 100. Batycka, M.; Inglis, N.F.; Cook, K.; Adam, A.; Fraser-Pitt, D.; Smith, D.G.; Main, L.; Lubben, A.; Kessler, B.M. Rapid Commun. Mass Spectrom., 2006, 20, 2074. Huang, M.Q.; Mao, Y.; Jemal, M.; Arnold, M. Rapid Commun. Mass Spectrom., 2006, 20, 1709. van de Merbel, N.C.; Poelman, H. J. Pharm. Biomed. Anal., 2003, 33, 495. Peng, S.X.; Barbone, A.G.; Ritchie, D.M. Rapid Commun. Mass Spectrom., 2003, 17, 509. Hsieh, Y.; Wang, G.; Wang, Y.; Chackalamannil, S.; Brisson, J.; Ng, K.; Korfmacher, W.A. Rapid Commun. Mass Spectrom., 2002, 16, 944. Wu, J.T.; Zeng, H.; Deng, Y.; Unger, S.E. Rapid Commun. Mass Spectrom., 2001, 15, 1113. Hsieh, Y.; Merkle, K.; Wang, G. Rapid Commun. Mass Spectrom., 2003, 17, 1775. Wang, G.; Hsieh, Y.; Cheng, K.C.; Morrison, R.A.; Venkatraman, S.; Njoroge, F.G.; Heimark, L.; Korfmacher, W.A. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 852, 92. Hsieh, Y.; Duncan, C.J.; Brisson, J.M. Anal. Chem., 2007, 79, 5668. Hsieh, Y.; Duncan, C.J.; Lee, S.; Liu, M. J. Pharm. Biomed. Anal., 2007, 44, 492.
Present and Future Mass Spectrometry-Based [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120]
Frontiers in Drug Design & Discovery, 2009, Vol. 4 19
New, L.S.; Saha, S.; Ong, M.M.; Boelsterli, U.A.; Chan, E.C. Rapid Commun. Mass Spectrom., 2007, 21, 982. Ma, Y.; Qin, F.; Sun, X.; Lu, X.; Li, F. J. Pharm. Biomed. Anal., 2007, 43, 1540. Mensch, J.; Noppe, M.; Adriaensen, J.; Melis, A.; Mackie, C.; Augustijns, P.; Brewster, M.E. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 847, 182. Wang, G.; Hsieh, Y.; Cui, X.; Cheng, K.C.; Korfmacher, A. Rapid Commun. Mass Spectrom., 2006, 20, 2215. Kalovidouris, M.; Michalea, S.; Robola, N.; Koutsopoulou, M.; Panderi, I. Rapid Commun. Mass Spectrom., 2006, 20, 2939. Korfmacher, W.A.; Veals, J.; Dunn-Meynell, K.; Zhang, X.; Tucker, G.; Cox, K.A.; Lin, C.C. Rapid Commun. Mass Spectrom., 1999, 13, 1991. Jemal, M. Rapid Commun. Mass Spectrom., 2001, 15, 994. Briem, S.; Pettersson, B.; Skoglund, E. Anal. Chem., 2005, 77, 1905. Gallagher, R.T.; Balogh, M.P.; Davey, P.; Jackson, M.R.; Sinclair, I.; Southern, L.J. Anal. Chem., 2003, 75, 973. Short, L.C.; Hanold, K.A.; Cai, S.S.; Syage, J.A. Rapid Commun. Mass Spectrom., 2007, 21, 1561. Syage, J.A.; Hanold, K.A.; Lynn, T.C.; Horner, J.A.; Thakur, R.A. J. Chromatogr. A, 2004, 1050, 137. Hsieh, Y.; Duncan, C.J. Rapid Commun. Mass Spectrom., 2007, 21, 573. Fuh, M.R.; Haung, C.H.; Wu, T.Y.; Lin, S.L.; Pan, W.H. Rapid Commun. Mass Spectrom., 2004, 18, 1711. Quintana, J.B.; Reemtsma, T. Rapid Commun. Mass Spectrom., 2004, 18, 765. Gao, S.; Bhoopathy, S.; Zhang, Z.P.; Wright, D.S.; Jenkins, R.; Karnes, H.T. J. Pharm. Biomed. Anal., 2006, 40, 679. Hsieh, Y.; Duncan, C.J.; Brisson, J.M. Rapid Commun. Mass Spectrom., 2007, 21, 629. Xia, Y.Q.; Jemal, M.; Zheng, N.; Shen, X. Rapid Commun. Mass Spectrom., 2006, 20, 1831. Hsieh, Y.; Duncan, C.J.; Liu, M. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 854, 8. Hsieh, Y.; Chen, J. Rapid Commun. Mass Spectrom., 2005, 19, 3031. Chang, Y.W.; Yao, H.T.; Chao, Y.S.; Yeh, T.K. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 857, 195. Naidong, W.; Eerkes, A. Biomed. Chromatogr., 2004, 18, 28. Shou, W.Z.; Naidong, W. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2005, 825, 186. Li, W.; Li, Y.; Francisco, D.T.; Naidong, W. Biomed. Chromatogr., 2005, 19, 385. Naidong, W. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 796, 209. Deng, Y.; Zhang, H.; Wu, J.T.; Olah, T.V. Rapid Commun. Mass Spectrom., 2005, 19, 2929. Santos-Neto, A.J.; Markides, K.E.; Sjoberg, P.J.; Bergquist, J.; Lancas, F.M. Anal. Chem., 2007, 79, 6359. Mao, Y.; Huang, M.Q.; Xia, Y.Q.; Jemal, M. J. Pharm. Biomed. Anal., 2007, 43, 1808. Hsieh, Y.; Wang, G.; Wang, Y.; Chackalamannil, S.; Korfmacher, W.A. Anal. Chem., 2003, 75, 1812. Hsieh, Y.; Bryant, M.S.; Brisson, J.M.; Ng, K.; Korfmacher, W.A. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 767, 353. Hsieh, Y.; Brisson, J.M.; Ng, K.; White, R.E.; Korfmacher, W.A. Analyst, 2001, 126, 2139. Hsieh, Y.; Brisson, J.M.; Ng, K.; Korfmacher, W.A. J. Pharm. Biomed. Anal., 2002, 27, 285. Wang, G.; Hsieh, Y.; Lau, Y.; Cheng, K.C.; Ng, K.; Korfmacher, W.A.; White R.E. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 780, 451. Kamel, A.; Prakash, C. Curr. Drug Metab., 2006, 7, 837. Lee, M.S.; Yost, R.A. Biomed. Environ. Mass Spectrom., 1988, 15, 193. Hopfgartner, G.; Husser, C.; Zell, M. J. Mass Spectrom., 2003, 38, 138. Shou, W.Z.; Magis, L.; Li, A.C.; Naidong, W.; Bryant, M.S. J. Mass Spectrom., 2005, 40, 1347. Hopfgartner, G.; Varesio, E.; Tschappat, V.; Grivet, C.; Bourgogne, E.; Leuthold L.A. J. Mass Spectrom., 2004, 39, 845. Xia, Y.Q.; Miller, J.D.; Bakhtiar, R.; Franklin, R.B.; Liu, D.Q. Rapid Commun. Mass Spectrom., 2003, 17, 1137. Li, A.C.; Gohdes, M.A.; Shou, W.Z. Rapid Commun. Mass Spectrom., 2007, 21, 1421. Li, A.C.; Alton, D.; Bryant, M.S.; Shou, W.Z. Rapid Commun. Mass Spectrom., 2005, 19, 1943.
20 Frontiers in Drug Design & Discovery, 2009, Vol. 4 [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160]
Yunsheng Hsieh
Hager, J.W.; Yves, Le Blanc, J.C. Rapid Commun. Mass Spectrom., 2003, 17, 1056. Zhang, M.Y.; Pace N.; Kerns E.H.; Kleintop, T.; Kagan, N.; Sakuma, T. J. Mass Spectrom., 2005, 40, 1017. Zheng, J.; Ma, L.; Xin, B.; Olah, T.; Humphreys, W.G.; Zhu, M. Chem. Res. Toxicol., 2007, 20, 757. Hakala, K.S.; Kostiainen, R.; Ketola, R.A. Rapid Commun. Mass Spectrom., 2006, 20, 2081. Peterman, S.M.; Duczak, N. Jr.; Kalgutkar, A.S.; Lame, M.E.; Soglia, J.R. J. Am. Soc. Mass Spectrom., 2006, 17, 363. Hsieh, Y.; Favreau, L.; Schwerdt, J.; Cheng, K.C. J. Pharm. Biomed. Anal., 2006, 40, 799. Hsieh, Y.; Favreau, L.; Cheng, K.C.; Chen, J. Rapid Commun. Mass Spectrom., 2005, 19, 3037. Heinemann, U.; Blaschke, G.; Knebel, N. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 793, 389. Kindt, E.K.; Kurzyniec, S.; Wang, S.C.; Kilby, G.; Rossi, D.T. J. Pharm. Biomed. Anal., 2003, 31, 893. Iwata, Y.T.; Kanamori, T.; Ohmae, Y.; Tsujikawa, K.; Inoue, H.; Kishi, T. Electrophoresis, 2003, 24, 1770. Martens-Lobenhoffer, J.; Reiche, I.; Troger, U.; Monkemuller, K.; Malfertheiner, P.; Bode-Boger, S.M. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 857, 301. Wickremsinhe, E.R.; Tian, Y.; Ruterbories, K.J.; Verburg, E.M.; Weerakkody, G.J.; Kurihara, A.; Farid, N.A. Drug Metab. Dispos., 2007, 35, 917. Nobilis, M.; Jira, T.; Lisa, M.; Holcapek, M.; Szotakova, B.; Lamka, J.; Skalova, L. J. Chromatogr. A, 2007, 1149, 112. Nikolai, L.N.; McClure, E.L.; Macleod, S.L.; Wong, C.S. J. Chromatogr. A, 2006, 1131, 103. Lausecker, B.; Fischer, G. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2006, 835, 40. Wang, Z.; Li, S.; Jonca, M.; Lambros, T.; Ferguson, S.; Goodnow, R.; Ho, C. Biomed. Chromatogr. 2006, 20, 1206. Chen, J.; Hsieh, Y.; Cook, J.; Morrison, R.; Korfmacher, W.A. Anal. Chem., 2006, 78, 1212. Coe, R.A.; Rathe, J.O.; Lee, J.W. J. Pharm. Biomed. Anal., 2006, 42, 573. Hoke, S.H.; Pinkston, J.D.; Bailey, R.E.; Tanguay, S.L.; Eichhold, T.H. Anal. Chem., 2000, 72, 4235. Hsieh, Y.; Li, F.; Duncan, C.J. Anal. Chem., 2007, 79, 3856. Pinkston, J.D.; Wen, D.; Morand, K.L.; Tirey, D.A.; Stanton, D.T. Anal. Chem., 2006, 78, 7467. Zhao, Y.; Woo, G.; Thomas, S.; Semin, D.; Sandra, P. J. Chromatogr. A, 2003, 1003, 157. Buchholz, L.; Cai, C.H.; Andress, L.; Cleton, A.; Brodfuehrer, J.; Cohen, L. Eur. J. Pharm. Sci., 2002, 15, 209. Cheng, Y.; Ho, E.; Subramanyam, B.; Tseng, J.L. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2004, 809, 67. Hage, D.S. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 768, 3. Beaudry, F.; Coutu, M.; Brown, N.K. Biomed. Chromatogr., 1999, 13, 401. Tiller, P.R.; Mutton, I.M.; Lane, S.J.; Bevan, C.D. Rapid Commun. Mass Spectrom., 1995, 9, 261. Johnson, B.M.; Nikolic, D.; van Breemen, R.B. Mass Spectrom. Rev., 2002, 21, 76. van Breemen, R.B.; Nikolic, D.; Bolton, J.L. Drug Metab. Dispos., 1998, 26, 85. van Breemen, R.B.; Huang, C.R.; Nikolic, D.; Woodbury, C.P.; Zhao, Y.Z.; Venton D.L. Anal. Chem., 1997, 69, 2159. Geun Shin, Y.; Bolton, J.L.; van Breemen, R.B. Comb. Chem. High Throughput Screen., 2002, 5, 59. Carducci, C.; Santagata, S.; Leuzzi, V.; Carducci, C.; Artiola, C.; Giovanniello, T.; Battini, R.; Antonozzi, I. Clin. Chim. Acta, 2006, 364, 180. Weinmann, W.; Svoboda, M. J. Anal. Toxicol., 1998, 22, 319. Morand, K.L.; Burt, T.M.; Regg, B.T.; Chester, T.L. Anal. Chem., 2001, 73, 247. Trunzer, M.; Graf, D.; Kiffe, M. Rapid Commun. Mass Spectrom., 2007, 21, 937. Wickremsinhe, E.R.; Singh, G.; Ackermann, B.L.; Gillespie, T.A, Chaudhary, A.K. Curr. Drug Metab., 2006, 7, 913. Wickremsinhe, E.R.; Ackermann, B.L.; Chaudhary, A.K. Rapid Commun. Mass Spectrom., 2005, 19, 47. Kapron, J.T.; Pace, E.; Van Pelt, C.K.; Henion, J. Rapid Commun. Mass Spectrom., 2003, 17, 2019. Dethy, J.M.; Ackermann, B.L.; Delatour, C.; Henion, J.D. Schultz, G.A. Anal. Chem., 2003, 75, 805. Hop, C.E. Curr. Drug Metab., 2006, 7, 557.
Present and Future Mass Spectrometry-Based [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195]
[196] [197]
Frontiers in Drug Design & Discovery, 2009, Vol. 4 21
Corkery, L.J.; Pang, H.; Schneider, B.B.; Covey, T.R.; Siu, K.W. J. Am. Soc. Mass Spectrom., 2005, 16, 363. Qi, L.; Danielson, N.D. J. Pharm. Biomed. Anal., 2005, 37, 225. Wu, J.; Hughes, C.S.; Picard, P.; Letarte, S.; Gaudreault, M.; Lévesque, J.F.; Nicoll-Griffith, D.A.; Bateman, K.P. Anal. Chem., 2007, 79, 4657. Gobey, J.; Cole, M.; Janiszewski, J.; Covey, T.; Chau, T.; Kovarik, P.; Corr, J. Anal. Chem., 2005, 77, 5643. Sleno, L.; Volmer, D.A. Rapid Commun. Mass Spectrom., 2005, 19, 1928. Hatsis, P.; Brombacher, S.; Corr, J.; Kovarik, P.; Volmer, D.A. Rapid Commun. Mass Spectrom., 2003, 17, 2303. Van Pelt, C.K.; Zhang, S.; Kapron, J.; Huang, X.; Henion, J.D. Am. Lab., 2003, 6, 14. Brown, K.; Dingley, K.H.; Turteltaub, K.W. Meth. Enzymol., 2005, 402, 423. Vogel, J.S. Biotechniques, 2005, 6, 25. Budzikiewicz, H.; Grigsby, R.D. Mass Spectrom. Rev., 2006, 25, 146. Garner, R.C. Curr. Drug Metab., 2000, 1, 205. Fifield, L.K. Rep. Prog. Phys., 1999, 62, 1223. Lappin, G.; Garner, R.C. Nat. Rev. Drug Discov., 2003, 2, 233. Papac, D.I.; Shahrokh, Z. Pharm. Res., 2001, 18, 131. Turteltaub, K.W.; Vogel, J.S. Curr. Pharm. Des., 2000, 6, 991. Lappin, G.; Rowland, M.; Garner, R.C. Expert Opin. Drug Metab. Toxicol., 2006, 2, 419. Sandhu, P.; Vogel, J.S.; Rose, M.J.; Ubick, E.A.; Brunner, J.E.; Wallace, M.A.; Adelsberger, J.K.; Baker, M.P.; Henderson, P.T.; Pearson, P.G.; Baillie, T.A. Drug Metab. Dispos., 2004, 32, 1254. Beumer, J.H.; Garner, R.C.; Cohen, M.B.; Galbraith, S.; Duncan, G.F.; Griffin, T.; Beijnen, J.H.; Schellens, J.H. Invest. New Drugs, 2007, 25, 327. Garner, R.C.; Goris, I.; Laenen, A.A.; Vanhoutte, E.; Meuldermans, W.; Gregory, S.; Garner, J.V.; Leong, D.; Whattam, M.; Calam, A.; Snel, C.A. Drug Metab. Dispos., 2002, 30, 823. Solon, E.G.; Balani, S.K.; Lee, F.W. Curr. Drug Metab., 2002, 3, 451. Hsieh, Y.; Chen, J.; Korfmacher, W.A. J. Pharmacol. Toxicol. Methods, 2007, 55, 193. Drexler, D.M.; Garrett, T.J.; Cantone, J.L.; Diters, R.W.; Mitroka, J.G.; Prieto Conaway, M.C.; Adams, S.P.; Yost, R.A.; Sanders, M. J. Pharmacol. Toxicol. Methods, 2007, 55, 279. Signor, L.; Varesio, E.; Staack, R.F.; Starke, V.; Richter, W.F.; Hopfgartner, G. J. Mass Spectrom., 2007, 42, 900. Reyzer, M.L.; Caprioli, R.M. Curr. Opin. Chem. Biol., 2007, 11, 29. Reyzer, M.L.; Hsieh, Y.; Ng, K.; Korfmacher, W.A.; Caprioli, R.M. J. Mass Spectrom., 2003, 38, 1081. Khatib-Shahidi, S.; Andersson, M.; Herman, J.L.; Gillespie, T.A.; Caprioli, R.M. Anal. Chem., 2006, 78, 6448. Hsieh, Y.; Casale, R.; Fukuda, E.; Chen, J.; Knemeyer, I.; Wingate, J.; Morrison, R.; Korfmacher, W. Rapid Commun. Mass Spectrom., 2006, 20, 965. Yao, M.; Zhu, M.; Sinz, M.W.; Zhang, H.; Humphreys, W.G.; Rodrigues, A.D.; Dai, R. J. Pharm. Biomed. Anal., 2007, 44, 211. Bu, H.Z.; Knuth, K.; Magis, L.; Teitelbaum, P. Rapid Commun. Mass Spectrom., 2000, 14, 1943. Benetton, S.A.; Fang, C.; Yang, Y.O.; Alok, R.; Year, M.; Lin, C.C.; Yeh, L.T. Drug Metab. Pharmacokinet., 2007, 22, 78. Wan, H.; Rehngren, M. J. Chromatogr. A, 2006, 1102, 125. Wan, H.; Ostlund, A.; Jonsson, S.; Lindberg, W. Rapid Commun. Mass Spectrom., 2005, 19, 1603. Lappin, G.; Garner, R.C. Anal. Bioanal. Chem., 2004, 378, 356. Wang, M.; Miksa, I.R. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 856, 318. Drexler, D.M.; Belcastro, J.V.; Dickinson, K.E.; Edinger, K.J.; Hnatyshyn, S.Y.; Josephs, J.L.; Langish, R.A.; McNaney, C.A.; Santone, K.S.; Shipkova, P.A.; Tymiak, A.A.; Zvyaga, T.A.; Sanders, M. Assay Drug Dev. Technol., 2007, 5, 247. Shou, W.Z.; Magis, L.; Li, A.C.; Naidong, W.; Bryant, M.S. J. Mass Spectrom., 2005, 40, 1347. Liu, D.Q.; Hop, C.E. J. Pharm. Biomed. Anal., 2005, 37, 1.
22 Frontiers in Drug Design & Discovery, 2009, Vol. 4 [198] [199] [200] [201] [202] [203]
Yunsheng Hsieh
Korfmacher, W.A.; Cox, K.A.; Ng, K.J.; Veals, J.; Hsieh, Y.; Wainhaus, S.; Broske, L.; Prelusky, D.; Nomeir, A.; White, R.E. Rapid Commun. Mass Spectrom., 2001, 15, 335. Chang, Y.W.; Chen, W.C.; Lin, K.T.; Chang, L.; Yao, H.T.; Hsieh, H.P.; Lan, S.J.; Chen, C.T.; Chao, Y.S.; Yeh, T.K. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 846, 162. De Nardi, C.; Bonelli, F. Rapid Commun, Mass Spectrom., 2006, 20, 2709. Chen, J.; Yang, L.; Kapron, J.T.; Ma, L.; Pace, E.; Van Pelt, C.K.; Rudewicz, P.J. J. Chromatogr. B Analyt, Technol. Biomed, Life Sci., 2004, 809, 205. Chu, I.; Liu, F.; Soares, A.; Kumari, P.; Nomeir, A.A. Rapid Commun. Mass Spectrom., 2002, 16, 1501. Chen, Y.F.; Chang, C.H.; Wang, S.C.; Tsai, T.H. Biomed. Chromatogr., 2005, 19, 402.
Frontiers in Drug Design & Discovery, 2009, 4, 23-42
23
Glutathione Transferases in Drug Discovery and Development: Towards Safer and Efficacious Drugs Katholiki Skopelitou, Dimitris Platis, Irene Axarli and Nikolaos E. Labrou* Laboratory of Enzyme Technology, Department of Agricultural Biotechnology, Agricultural University of Athens, 75 Iera Odos Street, GR-11855-Athens, Greece Abstract: Glutathione transferases (GSTs) are enzymes involved in cellular detoxification by catalysing the nucleophilic attack of glutathione (GSH) on the electrophilic centre of a number of electrophilic compounds of both endogenous and exogenous origins. This conjugation reaction usually makes the electrophilic substrates more water soluble and, thereby, facilitates their excretion from the body. Determination of metabolic properties of a new chemical entity (NCE) is one of the most important steps during the drug discovery and development process. Nowadays, in vitro methods are used for early estimation and prediction of in vivo metabolism of NCEs. In this review detailed descriptions are given of several biotransformation reactions catalyzed by GSTs that can be used at very early phases of drug development, thereby enabling unsuitable candidates to be eliminated from consideration much earlier in the drug discovery process. Knowledge of the structure-function relationships in classes of compounds that are substrates for GSTs enables the design of molecules that can be stable, or labile which has potential applications in drug and prodrug design.
Key Words: Detoxification, enzyme-activated prodrug, glutathione transferase. 1. INTRODUCTION GSTs are a family of detoxification enzymes that catalyse the conjugation of GSH to a wide variety of endogenous and exogenous electrophilic compounds. The GST superfamily can be subdivided into a number of classes on the basis of their amino acid sequence [1]. Within mammals, the following classes have been defined: alpha, mu, pi, sigma, theta, zeta, kappa and omega [2]. Analysis of the GST gene family in the Human Genome Organization database showed 21 putatively functional genes [3]. Upon closer examination, however, GST-kappa 1 (GSTK1), prostaglandin E synthase (PTGES) and three microsomal GSTs (MGST1, MGST2, MGST3) were determined as encoding membrane-bound enzymes having GST-like activity, but these genes are not evolutionarily related to the GST gene family [3]. Therefore, the complete GST gene family comprises 16 genes in six subfamilies: alpha (GSTA), mu (GSTM), omega (GSTO), pi *Corresponding Author: Tel: +30 (210) 5294308; Fax: +30 (210) 5294308; E-mail:
[email protected] Gary W. Caldwell / Atta-ur-Rahman / Z. Yan / M. Iqbal Choudhary (Eds.) All rights reserved – © 2009 Bentham Science Publishers.
24 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Skopelitou et al.
(GSTP), theta (GSTT) and zeta (GSTZ). In other organisms additional soluble GST classes have been reported. For example, in insects: delta and epsilon [4]; in plants: phi, tau, lambda, dehydroascorbate reductase [5]; and in bacteria: beta [6] and chi [7]. In general the catalytic efficiency of GSTs towards xenobiotics is relatively low [17]. As in the case with other xenobiotic metabolizing enzymes (e.g., cytochrome P450, glucuronosyl transferases, etc.) low catalytic efficiency appears to be a trade off with regard to broad substrate specificity [8,9]. On the other hand, constitutive levels of GSTs are high (3-10% of total cytosolic protein) and therefore, although catalytic efficiency is relatively low, the overall capacity due to the high constitutive expression is important. The biological function of the GSTs is far from established [8,9]. Various electrophilic xenobiotics can be substrates for GSTs. Electrophilic centres for GSH conjugation are found in areneoxides, aliphatic and arylic halides, in carbonyls, organonitro-esters and organic thiocyanates. Industrial substrates for GST are haloalkanes, chlorobenzenes, thiocarbamates, diphenylethers, triazines, chloracetanilide. Acrolein, propenals, lipid hydroperoxides, chlorambucil and fosfomycin are additional substrates. Identification of the GST-mediated pathway for drug cleavage has been useful for elucidating the mechanism of metabolic biotransformation of compounds that have been brought forward for clinical studies [10,11]. Knowledge of the structure-function relationships in classes of compounds that are cleavage by GSTs enables design of molecules an be stable, or labile which has potential applications in drug and prodrug design. In the next sections of this chapter the different reactive groups and reaction types operating under catalysis by GSTs will be discussed. 2. STRUCTURE AND CATALYTIC MECHANISM OF CYTOSOLIC GSTs 2.1. Structure of Cytosolic GSTs Cytosolic GSTs are dimeric proteins as shown in Fig. (1). Each subunit is composed 200-250 amino acid residues with typical molecular masses ranging from 20–28 kDa. Each GST subunit adopts a canonical GST fold of seven to nine -helices and four sheets to produce two distinct domains, the N- and C-terminal domains [1,2,8,12]. The interface between the two subunits can be hydrophobic or hydrophilic, and interactions between residues in both subunits are essential for dimer stability. For example, the subunit interface for the alpha class GSTs is that of a ‘lock-and-key’ type joint with the Phe52 serving as the ‘key’ and the hydrophobic ‘lock’ residues residing between 4 and 5 helices of C-terminal [8]. All alpha, mu, phi, zeta, tau and pi class GSTs have such a ‘lock-and-key’ style interface. On the other hand, in theta class GSTs the main subunit interface lacks a ‘lock-and-key’ motif. Structurally it seems that the theta class GSTs are missing the loop feature that holds the Phe residue for interaction with the 4 and 5 helices and the hydrophobic pockets within the helices themselves [8]. In this case subunit interface rely mainly on electrostatic and hydrogen bond interactions. Incompatibility in interfacial residues prevents the formation of heterodimers between two GST subunits from different classes. However, within a class, the formation of heterodimers can expand the range of functional proteins formed. Each GST is known to contain a G-site capable of binding the GSH substrate and an H-site that has xenobiotic compound binding capabilities, (Fig. 1A). he G-site share a highly conserved amino acid sequence. The G-site is mainly composed of amino acids in
GSTs in Drug Discovery and Development
Frontiers in Drug Design & Discovery, 2009, Vol. 4 25
A
B
Fig. (1). A: Subunit structure of human GSTA1-1 in complex with an ethacrynic acid-GSH conjugate (PDB code 1GSE). The G- and H-site and the N- and C-terminal are labeled. B: Ribbon diagram of the dimeric GSTA1-1 structure.
the N-terminal, including the active site residue that interacts with and activates the sulfhydryl group of GSH to generate the catalytically active thiolate anion [2,8,12,13]. In the alpha, mu, pi, sigma the active site residue is a Tyr. In the delta, epsilon, theta, and zeta GSTs, the active site residue is a Ser, and in omega class GSTs, it is a Cys [14]. Several
26 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Skopelitou et al.
crystal structures have shown that this active site residue is in hydrogen bond with the sulfur atom of GSH and is located at a position that would allow it to stabilize the thiolate anion of GSH and enhance its nucleophilicity. In addition, this residue may also contribute to the correct orientation of the sulfhydryl group of GSH in catalysis. Ser 11 and Tyr 9, the active site residues of rat GSTT2-2 [15] and rat GSTA1-1 [16] respectively, have been reported to play important roles in efficient product release and in controlling the C-terminal dynamics. The xenobiotic hydrophobic H-site is mainly found in the C-terminal. The H-site is hydrophobic but much less specific for substrate types allowing numerous substrates to bind [8]. This is the reason why initial attempts to classify GSTs according to substrate types (e.g. aryl-, alkyl-transferases) failed. Interclass amino acid sequence identity is rarely greater than 35% in the H-site region. Besides catalytic binding sites, GSTs have frequently been shown to possess noncatalytic binding sites. Numerous hydrophobic compounds have been identified to bind to these pockets such as bilirubin, heme, steroids, hormones and bile salts. This function has led to the name ‘ligandins’ for several of the enzymes [17]. The precise functions of ligandin GST binding to non-substrate ligands remain unclear. One possibility is that binding of non-substrate ligands to GSTs prevents oxidation of the molecules in vivo [17]. Another possibility is that GSTs prevent cellular damage from cytotoxic and genotoxic compounds that can oxidize protein and intercalate into DNA [18]. The third possibility is that GSTs facilitate delivery of the ligands to specific receptors or cellular compartments [17,18]. Some general structural features, (Fig. 2), of the main mammalian GST classes (alpha, mu, pi, theta, zeta and omega) will be discussed in the next paragraphs. Compared to the pi and mu GSTs the C-terminal of the alpha class GSTs is longer by some 4 to 8 amino acid residues [19]. The longer alpha C-terminal also forms an -helix (9), which comprises a portion of the smaller H-site [20]. This helix is thought to be important to dimer stabilization and affects both the GSH-binding rate and ionization state of the catalytically essential residue Tyr 9 [21]. Thus the alpha class C-terminal has a positive effect on catalytic activity. A special recognizable feature of the mu class GSTs is the socalled mu loop, which is the result of an insertion in N-terminal domain. Another structural attribute, which is recognizable in both mu and pi classes of GST, is the C-terminal wall [21]. On average, the C-terminal end is 4 to 8 amino acid residues shorter than their alpha counterpart and forms a wall that results in a partially blocked access to the xenobiotic binding site [22]. In addition, the pi and mu classes share a larger H-site that is more accessible to solvent entry than the alpha class GSTs. The theta class enzymes are quite distinct from alpha, mu, or pi – GST classes. The G-site of the theta class GSTs is, in general, much deeper than that of alpha, mu, and pi GST classes [8,12]. Several features set omega GSTO1-1 apart from the other members of the GST superfamily. Its N-terminal region has a unique extension of approximately 19 residues when compared with other cytosolic GSTs. This contains a proline-rich segment that in conjunction with the C-terminus forms a distinct structural unit with an unknown function. Unlike other mammalian GSTs, GSTO1-1 appears to have an active site cysteine that can form a disulfide bond with GSH. There are many structural features of the zeta class enzymes found in other GST classes, although it does not appear that GSTZ resembles more closely any one class in
GSTs in Drug Discovery and Development
Frontiers in Drug Design & Discovery, 2009, Vol. 4 27
particular. GSTZ has a truncated C-terminus and lacks the typical V-shaped dimer interface and hence resembles the theta class in this regard. The large loop preceding helix 2 is reminiscent of the mu loop previously seen in the mu class structure.
Fig. (2). The common chain fold of the GST superfamily. Protein data bank codes for the structures used are: alpha, 1gse; theta, 1ljr; mu, 1hna; pi, 1glp; omega, 1eem and zeta, 1fw1. Images in this figure were drawn using the program PyMol.
2.2. Kinetic Mechanism Conjugation reactions with GSH have been reported for a vast number of compounds and the kinetic mechanism has been clarified [22-27]. In general, kinetic mechanism of the GST-catalyzed conjugation reaction is very complex and class dependent. For example, several catalytic mechanisms, including random, ping-pong, and sequential, have been proposed [13,22-25], but random binding order of substrates seems to prevail. For instance, the maize GST I-catalyzed conjugation reaction between GSH and CDNB follows a rapid equilibrium random sequential Bi Bi kinetic mechanism [13], whereas a steady state sequential rapid Bi Bi mechanism was proposed for octopus GST, rat GSTs M1-1, M1-2, and A3-3 [26,27]. From a physiological point of view GSH binding should occur first because of the availability of GSH in millimolar concentrations in the cells. This value is about three magnitudes larger than the dissociation constant between GSH and GSTs [28]. 3. CATALYTIC FUNCTION The different reaction types operating under catalysis by GSTs are:
28 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Skopelitou et al.
3.1. Nucleophilic Displacement of an Alkyl or Aryl Halogen or a Nitro-Group Nucleophilic displacement of an alkyl or aryl halogen or a nitro-group, (Fig. 3), seems to be the most frequently observed reactions. Halogens or nitrogroups of these molecules are soft electrophiles and react readily with the GSH. In fact, the standard enzyme assays for GST activity use 1-chloro-2,4-dinitrobenzene or l,2-dinitro-4chlorobenzene as substrates. These are nucleophilic aromatic substitution reactions that occurs via an addition-elimination sequence involving a short-lived -complex intermediate [8,9]. The reaction of GSH with nitroalkanes involves attack of an electrophilic carbon atom leading to the formation of a thioester and to the release of nitrite as shown in Fig. (3). A Cl
SG +
+ GSH O2N
NO2
O2N
HCl
NO2
B Cl
SG
Cl
NO2
GS NO2
NO-2
NO2 CDNB
NO2
-Cl -
GS -
NO2
-complex
C RCH2NO2 + GSH
RCH2SG + HNO2
Fig. (3). A: The reaction of 1-chloro-2,4-dinitrobenzene with GSH catalyzed by GSTs. B: The nucleophilic aromatic substitution reaction occurs via an addition-elimination sequence involving a short-lived -complex intermediate. C: The reaction of GSH with nitroalkanes catalyzed by GSTs.
Several GSTs catalyze the conjugation of the GSH with alkyl halides and related compounds [29]. For example, conjugation of the drug chlorobucil is an example for this type of reaction. Examples of the GSH conjugations catalyzed by GSTs are presented in Fig. (4). GSH conjugations of alkyl halides can be detoxication or bioactivation reactions. In the later case the substrate is activated leading to reactions with other nucleophiles, particularly DNA and proteins. The theta class GST enzymes are the most active [30], towards alkyl halides although other mammalian GSTs also have some activities. 3.2. Addition of GSH to Epoxides and Arene Oxides GSH transferases catalyze the addition of GSH to epoxide and arene oxide substrates, as illustrated (Fig. 5) [8]. Carcinogenic intermediates have been identified as both
GSTs in Drug Discovery and Development
Frontiers in Drug Design & Discovery, 2009, Vol. 4 29
bay- and fjord-region diol epoxides (DEs) [31,32]. GSTA1-1, an alpha class enzyme, has efficient catalytic activity towards stereoisomers of a series of bay region diol epoxides fjord region diol epoxides such as (±)-anti-B[]PDE, (±)-syn-B[]PDE and (±)-antiB[c]PhDE [33,34]. It is important to mention that the chemically more reactive syn diastereomers are better substrates for GSTA1-1 and this is propably due to differences in the lipophilicity of the compound. The activity and enantioselectivity of human GSTs towards diol epoxides depend on the absolute configuration and the geometry of the aromatic structure. Human mu class enzymes catalyse, in most cases, the conjugation of the stereoisomeric bay-region DEs, in particular, the syn-diastereomers [35]. OH GSH + RX
GS-R (+HX)
SG H2O
X GSH +
X
_
HX
X SG
_ -
X
+ SG
SG
GSH
SG Nucl
Nucl SG
Fig. (4). The conjugation of GSH with alkyl halides catalyzed by GSTs.
In contrast, human pi class enzyme, showed, in most cases, a noticeable activity towards bay-region anti-DEs and a high preference for conjugation of enantiomers with (R,S,S,R)-configuration [35-37]. Whereas the alpha class has no catalytic activity towards the optical isomers of benzo[c]phenanthrene DE B[c]PhDE, both the mu and the pi class, have a lower catalytic activity using as substrate these metabolites than the other bay-region DEs [35]. One relatively large, bulky substrate for certain GSTs is the epoxide of aflatoxin B1 (AFB), (Fig. 5C) [38]. AFB, one of a group of related mycotoxins produced by the common fungal mold Aspergillus flavus, is a well documented rat and human carcinogen [15,16]. AFB is activated to the highly reactive aflatoxin 8,9-exo-epoxide by certain cytochromes P450. AFBO then serves as a substrate for some, but not all, GST isoenzymes [39]. 3.3. Addition of GSH to Carbon-Carbon-Double Bonds Addition of the thiolate to carbon-carbon-double bonds is a special type of reactions on compounds with reactive carbon-carbon double bonds neighboured by an electronwithdrawing group [40]. The conjugation on these bonds is a so-called Michael addition reaction and leads to a labile conjugate that may be sensitive to pH changes. Other similar substrates include alkenals [4] and particularly the (E)-4-hydroxyalk-2-enals (4hydroxy-alkenals), illustrated in Fig. (6). 4-Hydroxy-2,3-trans-nonenal (4-HNE), a racemic lipid peroxidation product, is the most abundant hydroxyl-alkenal formed during the peroxidative breakdown of n-6 polyunsaturated fatty acid residues of membrane lipids, such as linoleate and arachidonate [41,42] and also the most cytotoxic and genotoxic product, involved in a various cellular pathologies [42,43]. GSTs are involved in the predominant mechanism for protection against 4-HNE toxicity in mammalian liver [44,45], however, despite the fact that hGSTA1-1 is the major human liver GST isoform
30 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Skopelitou et al.
A GSH + SG
O
OH
OH phenanthrene 9,10 - oxide
SG
(9S, 10S) - GSPhen
(9R, 10R) - GSPhen
B Bay-region PAH Diol Epoxides
Diol Epoxides O S S HO
OH
CH3
R
HO R
S R S R
CH3 H3C
OH chrysene O
HO
RS R S
O
CH3 O
CH3
S R CH3
HO
OH
CH3
R S
CH3
OH benzo[a]pyrene
O
C O
dibenzo[a,h]anthracene
O O
HO O Glutathione
S
Fig. (5). A: GSTs catalyze the addition of GSH to epoxide and arene oxide substrates, such as phenanthrene 9,10-oxide. B: Structures of bay-region polycyclic aromatic hydrocarbons (PAHs). The stereochemistry of the syn- and anti-diol epoxides are shown to the right and left, respectively. The prefix syn indicates that the oxirane ring and the benzylic hydroxyl group are located on the same face of the molecule, while anti indicates that these groups are located on opposite faces. C: The structure of aflatoxin B1-GSH conjugate.
GSTs in Drug Discovery and Development
Frontiers in Drug Design & Discovery, 2009, Vol. 4 31
O H2C G-SH +
HC
O
CH H2C
CH
OH H2C
CH G
OH
S
O
CH CH
CH R
4-hydroxy-alkenal
G
CH
S
CH R
CH
R
OH
cyclic hemimercaptal
glutahione conjugate
Fig. (6). Reaction between GSH and 4-hydroxy-alkenals catalyzed by GSTs. The primary product is further transformed to a cyclic derivative.
it is relatively inefficient at conjugating 4-HNE [46,47] as well as other alkenal substrates. GSTA4-4 comprises the basic detoxification pathway for the removal of 4-HNE in the human liver mitochondria [48-50], but its contribution in other tissues is unknown due to its relatively low expression in human tissues [51]. 3.4. Addition of GSH to Organic Isothiocyanates and Thiocyanates Organic isothiocyanates, which are abundant in edible plants, undergo conjugation with GSH enzymatic as well as non-enzymatic to form dithiocarbamates [52,53], as presented in Fig. (7A). These dithiocarbamates are degraded in vivo to the corresponding S(N-acetyl)cysteinyl conjugates (mercapturates), which undergo rapid renal excretion. A number of isothiocyanates have also been shown to be inducers of GSTs in animal tissues and to display pronounced anticarcinogenic activity. In general, GSTM1-1 appears to be the most efficient catalyst towards isothiocyanates, closely followed by GST P1-1, whereas GSTAl-1 is less active by one and GSTM4-4 by even two orders of magnitude [53]. All four enzymes exhibit higher catalytic rate with increasing aliphatic chain length, and, of all the aliphatic substrates with linear carbon chains tested, hexyl-NCS gives the highest rates for all of them. The aromatic substrates, benzyl-NCS and phenethyl-NCS, tend to be the best ones. Moreover, GSTM4-4 has a preference for allyl-NCS among the aliphatic compounds. GSTs also catalyze the attack of the GSH thiolate ion on the electrophilic sulfur atom of several organic thiocyanates, resulting in the formation of an asymmetric glutathionyl disulfide and cyanide as shown in Fig. (7B). A R
C N
B
S
S
RSCN + GSH
+ GSH
HN R
C S
G
RSSG + HCN
Fig. (7). A: Organic isothiocyanates undergo enymatic conjugation with GSH to form dithiocarbamates. B: GSTs catalyze the attack of the GSH on the electrophilic sulfur atom of organic thiocyanates.
32 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Skopelitou et al.
3.5. Sulfonamidase Activity The mechanism of sulfonamide cleavage by GST has been investigated using as a model substrate the PNU-109112, a potent HIV-1 protease inhibitor [10,11]. The mechanism of reaction, shown in Fig. (8), could involve initial GS- attack on either the sulfonyl S atom or the adjacent carbon atom in the cyanopyridine ring. The net result is either direct or indirect sulfonamide N-S bond cleavage. C
N
O RNH2
N
+
C
S
S O
G
GSH O S
H N
N C
O
R RNH2
+
SO2
+
G
S
Fig. (8). GST/GSH-mediated sulfonamide leavage of PNU-109112.
The GST activity toward sulfonamide bond cleavage has been characterized with respect to the molecular mechanism of the enzymatic reaction and substrate structureactivity relationships [10,11]. For example, studies of GST-mediated cleavage of PNU109112 and a wide variety of other sulfonamides reveal two striking structural features common to sulfonamide substrates [10,11]. Groups capable of withdrawing electron density from the carbon atom to the sulfonyl group are an absolute requirement. Such groups positioned ortho and/or para on aromatic or heteroaromatic rings were shown to activate the corresponding sulfonamides. The electrophilic substructure of the sulfonyl group is solely responsible for activation of the sulfonamide bond toward cleavage. On the other hand, the amine portion has little or no impact on the cleavability of sulfonamide substrates [10,11]. Recombinant forms of GSTA1–1, GSTM1–1, and GSTP1–1 were tested for sulfonamidase activity. Activity was observed for all three isoenzymes; the M1-1 isoenzyme was 5.4 and 16 times more active than the A1-1 and the P1-1 forms, respectively [10,11]. 3.6. Peroxidase Activity The release of oxygen radicals, such as O2-, H2O2, singlet oxygen (1O2) and hydroxyl radical (.OH) during oxidative stress conditions can initiate an autocatalytic chain of lipid peroxidation which can breach membrane integrity [54,55] or even cause DNA damage [56]. In fact, it has been reported that peroxidation of membrane lipids in cells and tissues is known to produce various aldehydic compounds [41,42], seriously suspected to cause a variety of chronic diseases, including atherosclerosis [57], Alzheimer's disease [58], cataractogenesis [59], Parkinson's disease [60] and cancer [42]. Glutathione peroxidase (GPx, EC.1.11.1.9) is a selenoenzyme that functions as an antioxidant by catalyzing the reduction of H2O2, lipid hydroperoxides and other organic
GSTs in Drug Discovery and Development
Frontiers in Drug Design & Discovery, 2009, Vol. 4 33
peroxides with GSH. The selenium atom in the enzyme catalytic site undergoes a redox cycle involving the selenolate anion as the active form which reduces hydrogen peroxides and organic peroxides. The selenolate, which is oxidized to selenenic acid (EnzSeOH), reacts with reduced GSH to form a selenosulfide adduct (Enz-SeSG). Finally, the nucleophilic attack of a second GSH to Enz-SeSG regenerates the active form of the enzyme by attacking the selenosulfide to form oxidized GSH (GSSG), as illustrated in Fig. (9) [61,62]. Regeneration of the reduced enzyme is accomplished via a two-step process involving reduced GSH as reductant. In the present of high concentrations of hydroperoxide, selenenic acid (Enz-SeOH) can be futher oxidized to a seleninic acid (Enz-SeO2H) [63].
Fig. (9). Scheme of the mechanism of the peroxidase activity.
Several GSTs were reported to display GPx activity towards organic hydroperoxide. The peroxidase activity associated with the GSTs is referred to as NonSe-GPx activity, which represents one of the important antioxidant mechanisms that exist in cells for protection against hydroperoxides [64,65]. In humans, the NonSe-GPx activity of GSTs towards lipid hydroperoxides is predominantly associated with alpha class [66, 67]. In addition, NonSe-GPx activity is a common characteristic of mammalian theta class and zeta class GSTs. GSTs belonging to the alpha class have been implicated in the detoxification of the produced peroxides and shown to exhibit high peroxidase activity towards these compounds [46,68]. In this case there is a nucleophilic attack of the GSH thiolate on an oxygen atom of the peroxy group and the unstable sulfenic acid derivative is subsequently reduced by a second GSH molecule as presented in Fig. (9). In the human liver, this Se-independent glutathione peroxidase activity is expressed primarily by isoenzymes hGSTA1-1 and hGSTA2-2 [56,69,70], and although their activity is much lower that the Se-dependent human GPx-I [71], the high amount of GSTs in the liver compared to other GPx activities [72] compensates for the low activity. Both hGSTA1-1 and hGSTA2-2 exhibit high peroxidase activity towards fatty acid hydroperoxides, phospholipid hydroperoxides, and cumene hydroperoxide [73]. Similar phospholipid hydroperoxide activities have been detected in
34 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Skopelitou et al.
the human lung [74]. In mammalian cells, besides cytosolic GSTs, microsomal GSTs also express peroxidase activity [75,76]. 3.7. Transthiolation GSTs are induced in conditions of oxidative stress where it is known that sulfhydryl groups of cellular proteins can form S-thiol adducts (protein-thiol mixed disulfides, protein-S-S-glutathione (PSSG) and protein-S-S-cysteine (PSSC)) [77,78] with cysteine and GSH, through a process called S-thiolation. This result to deactivation, changes in conformation of even aggregation of the proteins involved. S-glutathionylation is a reversible post-translational modification with critical roles in sulfhydryl homeostasis acting as a protection mechanism of the cysteine residues from irreversible oxidation during periods of oxidative stress or a transport/storage form of cysteines [79]. Transthiolation reactions are not uncommon to proceed in cells without the aid of enzymes, however, cells do possess specific enzymes that catalyse the reduction of protein disulphides. In many cases this role has been attributed and accomplished by glutaredoxin (Grx). Modification of cysteine residues with GSH has also been reported for many enzymes, such as carbonic anhydrase [80] and fatty acid synthetase [81]. The transthiolation reaction consists of two steps. The first step involves the formation of a mixed disulfide with GSH which is subsequently reduced further by GSH with the production of GSH disulfide followed by complete reduction of the previously conjugated thiol residues. It is interesting that this reaction cannot distinguish between catalysis of the glutathionylation step (R-SSG formation, characteristic of a GST-mediated conjugation) and the deglutathionylation step (R-SSG reduction, characteristic of a deglutathionylase-like GRx). GST-dependent thioltransferase activity is generally very uncommon among GSTs but has been reported in mu, omega and pi classes. For example, thioltransferase activity has been observed in mu class GST from bovine lens, in three omega class GSTs in Saccharomyces cerevisae [82,83], and in human omega class GST (GSTO1-1) [14]. In addition, a pi class member has been shown to mediate the reactivation 1CysPRx, a protein that protects cells against membrane oxidation through GSH-dependent reduction of phospholipid hydroperoxides to corresponding alcohols. 3.8. Isomerase Activity It is well known that GSTs catalyze several types of isomerization reactions, with the conversion of cis double bonds to the trans configuration being the most well-studied [84-86], as in the case of isomerization of diethyl maleate to diethyl fumarate. Interestingly, GST-dependent isomerization reaction can proceed in a GSH-independent manner, as in the case of the cis-trans conversion of retinoic acid catalyzed by hGSTP1-1 [87]. The available information suggests that the prementioned cis-trans isomerization reactions are thermodynamic driven by the stability of the trans isomer, proceeding via the addition of GSH to the double bond, rotation around the resulting single bond, and elimination of GSH [86]. Positional isomerization of double bonds by GST-dependent reactions has also been been reported. The most well-characterized example of positional isomerization is the reaction in which endogenous 5-3-ketosteroids are converted to 4-3-ketosteroids [88,85,86]. For these reactions, the driving force is the stability of the conjugated double bonds in the product. In fact, GSTs appear to play an important role in the biosynthesis
GSTs in Drug Discovery and Development
Frontiers in Drug Design & Discovery, 2009, Vol. 4 35
of steroid hormones. All steroid hormones in humans are derived from cholesterol and in recent years it has been shown that GSTs are involved in the biosynthetic path of testosterone and progesterone [89,90]. Benson and Talalay [91] have initially discovered a GSH-dependent ketosteroid activity in rat liver, which was later identified as a GST [88]. The spontaneous conversion of 5-3-ketosteroid androstene-3,17-dione to the 4isomer product proceeds at a slow rate, which is markedly raised by the addition of GSH along with GSTA1-1, the first human GST discovered that exhibited double bind isomerase activity [92]. Another member of the alpha class, GSTA3-3 was found to exhibit approximately 20 fold higher catalytic isomerase activity towards 5-ketosteroids in human tissues [89,90] and is selectively expressed in gonads, placenta and the adrenal gland. GSTA3-3 efficiently catalyzes double-bond isomerizations of 5-androstene3,17-dione (5-AD) and of 5-pregnene-3,20-dione, intermediates in the biosynthesis of the steroid hormones progesterone and testosterone [8]. GST-catalyzed isomerization has also been observed during the biosynthesis of prostaglandins. Prostaglandin (PG) D synthase (PGDS) is the enzyme responsible for the formation of PGD2 and the J series of PGs [93]. In addition, prostaglandin H2 (PGH2) is obtained from prostaglandin D2 (PGD2) in a reaction catalyzed by a sigma class GST in vivo and alpha class GSTs in vitro [94]. The sigma class GST, isomerizes PGH2 to PGD2 selectively, whereas other GST isoenzymes catalyze the conversion of PGH2 nonselectively to produce PGD2, PGE2, and PGF2 [95]. A zeta class GST has also been identified as a maleylacetate isomerase [96], catalyzing the penultimate step in tyrosine degradation pathway, a pathway that has been associated with many disorders. [97,98]. This enzyme converts maleylacetoacetate into fumarylacetacetate, and maleylacetone into fumarylacetone. 3.9. Ester and Ether Hydrolysis Aromatic carboxylic acid esters and nitrate esters serve as substrates for GSTs as shown in Fig. (10). In the case of nitrate esters, the attack is on the electrophilic nitrogen. Experimental evidence supports the GSH sulfenyl nitrite intermediate, which is attacked nonenzymatically by a second molecule of thiol. GSTs also catalyze ‘reverse’ reactions, such as the hydrolysis of GSH thiol esters [99-101]. Reverse reactions are of interest as potential tumor-directed pro-drug activation strategies and as mechanisms for tissue redistribution of carboxylate containing drugs. Examples of ‘reverse’ GST reactions have been limited to retro-Michael additions [101], and hydrolysis of activated carbamate thiol esters and thiocarbamate thiol esters formed from GSH conjugation with isocyanates and isothiocyanates, respectively [53]. The reverse reactions are of therapeutic and toxicological importance, because the generation of GSH and an electrophile from GSH conjugates represents a potential pathway for delivery of ‘latent’ toxins or drugs to tissues remote from the initial conjugation reaction, whether release of the conjugate is mediated by GSTs or by nonenzymatic processes. The GSH thiol esters of ethacrynic acid (E-SG) (Fig. 11) and several nonsteroidal anti-inflammatory agents such as, sulindac, flurbiprofen, and diclofenac, have been tested as substrates with human GSTs [99]. Because ethacrynic acid produced by hydrolysis of E-SG contains a reactive --unsaturated ketone, it could form adducts with
36 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Skopelitou et al.
protein nucleophiles, as is well established for Cys-47 of GSTP1-1. Adduction of Cys-47 by ethacrynic acid results in a slowly reversible inhibited complex. O
A
OH O
O +
+ GSH
C
GS
CH3 NO2
NO2
RCH2ONO2 + GSH
B C
RCH2OH + HNO2 + GSSG
RCH2OH + [GSNO2]
RCH2ONO2 + GSH [GSNO2] + GSH
GSSG + HNO2
Fig. (10). GSTs catalyze the attack of the GSH thiolate ion on the electrophilic carbon of carboxylic (A) and nitrate (B) esters. The later reaction takes place through a GSH sulfenyl nitrite intermediate (C), which is attacked nonenzymatically by a second molecule of thiol.
E-SG
EA
GS-EA + GSH
Cl Cl
O
Cl
O
Cl
SG O
O
O O
Cl Cl
OH
O O
OH
O
SG
Fig. (11). Reaction pathways of ethacrynic acid (EA) following its release from thiol ester (E-SG). The released EA may further react with GSH to form GS-EA.
Other example of S-ether hydrolysis involves the biotransformation of the prodrug azathioprine, to generate its active form 6-mercaptopurine as illustrated in Fig. (12) [102]. The mechanism of action of GSTs with azathioprine involves a nucleophilic attack of the deprotonated form of GSH on the electrophilic 50 carbon in the imidazole moiety of azathioprine. Thus, 5-mercaptopurine and a GSH–imidazole conjugate are released [103]. Among several human GSTs tested, the alpha class GSTA2-2 had the
GSTs in Drug Discovery and Development
Frontiers in Drug Design & Discovery, 2009, Vol. 4 37
highest specific activity, whereas a second alpha class enzyme GSTA1-1, as well as the mu class GSTM1-1, also demonstrated prominent catalytic activity. NO2
N
Electrophilic center N
S
H3C N
S
N
N
N H
Fig. (12). GST catalysis of S-ether hydrolysis of azathioprine, to generate its active form 6mercaptopurine.
3.10. GST-Activated Pro-Drugs Pro-drug development using the platform of GST has recently produced a number of lead compounds [104-106]. GSTs are frequently overexpressed in neoplastic tissues, with the GSTP1-1 isoform most commonly overexpressed in cancers resistant to drugs. Therefore GSTP1-1 proved to be an attractive molecular target for pro-drug activation. Two such agents that are in preclinical development will be discussed in the next section. High GST-expression levels in human cancers together with the knowledge that nitric oxide (NO) has therapeutic potential, provided the rationale for the design of the NO-releasing GST-activated pro-drug such as O2-arylated diazeniumdiolates derivatives (Fig. 13) [104,106]. The general mechanism of action of such prodrugs involves nucleophilic aromatic substitution by GSH, generating the nitric oxide-releasing diazeniumdiolate ion. Nitric oxide prodrugs of the ionic diazeniumdiolate class that spontaneously dissociate at definitive rates to form NO are useful as possible therapeutic agents in the treatment of several disease states, such as cancer. Due to the involvement of NO in diverse physiological processes, site-directed delivery of therapeutic nitric oxide is essential to avoid any undesirable side-effects. SG NR2
NR2 O
N+
O2N
NO2
N+ N
O GSH
O
NR2
N SG
N
O
O O2N
NO2
O2N
N+
H+ 2 NO
O
R2NH
NO2
Fig. (13). Structure of an NO-releasing GST-activated pro-drug, and its reaction with GSH.
38 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Skopelitou et al.
Another prodrug, illustrated in Fig. (14), activated by GSTP1-1 is TLK286 [105]. This drug is activated through a -elimination reaction that cleaves the drug into a phosphorodiamidate (the eventual alkylating moiety) and a GSH analogue. Drug design ensured that this reaction was preferentially catalyzed by the Tyr 7 in the active site of GSTP 1-1.
Tyr 7 Cl Cl O
O~
O
P
Cl
N
O
H
Cl
S O H N
O H2N
N
COOH
N H
COOH
O Cl Cl CH2
O
H N
O H2N COOH
N
O
S O
P
+ COOH
Cl
N
O
Cl
N H O
Cl N
O
P O
Cl
N Cl
Fig. (14). Structure of TLK286 and its activation by human GSTP1-1. Tyr 7 is the catalytic residue.
3.11. The Negative Side of the GST-Detoxification System Despite the fact that detoxification is generally considered a significant positive aspect of GST function, in certain cases, chemically reactive metabolites produced by GST can have potentially harmful effects. A characteristic example is the case of the drug
GSTs in Drug Discovery and Development
Frontiers in Drug Design & Discovery, 2009, Vol. 4 39
acetaminophen (paracetamol) where the reactive metabolite N-acetyl-p-benzoquinoneimine is formed when the drug is ingested in high doses. In this case, the action of GST results in hepatic failure [107]. In fact, Henderson et al. were able to show that complete absence of pi class GSTs in mice was sufficient to alleviate any signs of hepatotoxicity and significantly improve GSH recovery rates [108]. 4. CONCLUSIONS The development process of new drugs is constantly being improved by defining new strategies and implementing new techniques. The human body contains a variety of enzymes that are involved in the metabolism of several chemicals that comprise today’s pharmaceuticals. One of the most important classes of metabolic enzymes is GSTs which are directly involved in the clearance of drugs from the body. During this process, drug metabolites are generated, some of which are biologically inactive or active. GSTs catalyze a wide range of reactions that can be described as accompanying the many varieties of catalysis in which the GSH thiolate anion participates as a nucleophile. The substrates are rather diverse and include important endogenous modulators, as well as xenobiotic chemicals and the oxidation products of the transformation of xenobiotics by other enzymes. In addition, GST-activated pro-drugs provide viable platform for the development of novel cancer drugs. Investigation of these biotransformation reactions in vitro can be very useful at very early phases of drug development, thereby enabling unsuitable candidates to be eliminated from consideration much earlier in the drug discovery process. ABBREVIATIONS AFB
=
Aflatoxin B1
CDNB
=
1-Chloro-2,4-dinitrobenzene
DE
=
Diol epoxide
EA
=
Ethacrynic acid
GPx
=
Glutathione peroxidase
Grx
=
Glutaredoxin
GSH
=
Glutathione
G-site
=
Glutathione binding site
GSSG
=
Oxidised GSH
GST
=
Glutathione transferase
hGST
=
Human glutathione transferase
4-HNE
=
4-Hydroxy-2,3-trans-nonenal
H-site
=
Hydrophobic binding site
NCE
=
New chemical entity
PG
=
Prostaglandin
PGDS
=
Prostaglandin D synthase
ROS
=
Reactive oxygen species
40 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Skopelitou et al.
REFERENCES [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40]
Mannervik, B.; Danielson, U.H. CRC Crit. Rev. Biochem., 1988, 23, 283. Frova, C. Biomol. Eng., 2006, 23, 149. Nebert, D.W.; Vasiliou, V. Hum. Genomics, 2004, 1, 460. Alias, Z.; Clark, A.G. Proteomics, 2007, 7, 3618. Dixon, D.P.; Davis, B.G.; Edwards, R. J. Biol. Chem., 2002, 277, 30859. Allocati, N.; Favaloro, B.; Masulli, M.; Alexeyev, M.F.; Di Ilio, C. Biochem. J., 2003, 373, 305. Wiktelius, E.; Stenberg, G. Biochem. J., 2007, 406, 115. Armstrong, R.N. Chem. Res. Toxicol., 1997, 10, 2. Hayes, J.D.; Flanagan, J.U.; Jowsey, I.R. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 51. Koeplinger, K.A.; Zhao, Z.; Peterson, T.; Leone, J.W.; Schwende, F.S.; Heinrikson, R.L.; Tomasselli, A.G. Drug Metab. Dispos., 1999, 27, 986. Zhao, Z.; Koeplinger, K.A.; Peterson, T.; Conradi, R.A.; Burton, P.S.; Suarato, A.; Heinrikson, R.L.; Tomasselli, A.G. Drug Metab. Dispos., 1999, 27, 992. Oakley, A.J. Curr. Opin. Struct. Biol., 2005, 15, 716. Labrou, N.E.; Mello, L.V.; Clonis, Y.D. Biochem. J., 2001, 358, 101. Board, P.G.; Coggan, M.; Chelvanayagam, G.; Easteal, S.; Jermiin, L.S.; Schulte, G.K.; Danley, D.E.; Hoth, L.R.; Griffor, M.C.; Kamath, A.V.; Rosner, M.H.; Chrunyk, B.A.; Perregaux, D.E.; Gabel, C.A.; Geoghegan, K.F.; Pandit, J. J. Biol. Chem., 2000, 275, 24798. Nieslanik, B.S.; Atkins, W.M. J. Biol. Chem., 2000, 275, 17447. Jemth, P.; Mannervik, B. J. Biol. Chem., 2000, 275, 8618. Axarli, I.A.; Rigden, D.J.; Labrou, N.E. Biochem. J., 2004, 382, 885. Oakley, A.J.; Lo, B.M.; Nuccetelli, M.; Mazzetti, A.P.; Parker, M.W. J. Mol. Biol., 1999, 291, 913. Cameron, A.D.; Sinning, I.; L'Hermite, G.; Olin, B.; Board, P.G.; Mannervik, B.; Jones, T.A. Structure, 1995, 3, 717. Sinning, I.; Kleywegt, G.J.; Cowan, S.W.; Reinemer, P.; Dirr, H.W.; Huber, R.; Gilliland, G.L.; Armstrong, R.N.; Ji, X.; Board, P.G. J. Mol. Biol., 1993, 232, 192. Dirr, H.W.; Wallace, L.A. Biochemistry, 1999, 38, 15631. Salinas, A.E.; Wong, M.G. Curr. Med. Chem., 1999, 6, 279. Caccuri, A.M.; Ascenzi, P.; Antonini, G.; Parker, M.W.; Oakley, A.J.; Chiessi, E.; Nuccetelli, M.; Battistoni, A.; Bellizia, A.; Ricci, G. J. Biol. Chem., 1996, 271, 16193. Caccuri, A.M.; Antonini, G.; Nicotra, M.; Battistoni, A.; Lo, B.M.; Board, P.G.; Parker, M.W.; Ricci, G. J. Biol. Chem., 1997, 272, 29681. Caccuri, A.M.; Lo, B.M.; Nuccetelli, M.; Nicotra, M.; Rossi, P.; Antonini, G.; Federici, G.; Ricci, G. Biochemistry, 1998, 37, 3028. Ivanetich, K.M.; Goold, R.D.; Sikakana, C.N. Biochem. Pharmacol., 1990, 39, 1999. Jakobson, I.; Warholm, M.; Mannervik, B. Biochem. J., 1979, 177, 861. Wilce, M.C.; Parker, M.W. Biochim. Biophys. Acta, 1994, 1205, 1. Kurtovic, S.; Shokeer, A.; Mannervik, B. Protein Eng. Des. Sel., 2008, 21, 329. Meyer, D.J.; Coles, B.; Pemble, S.E.; Gilmore, K.S.; Fraser, G.M.; Ketterer, B. Biochem. J., 1991, 274(Pt 2), 409. Dipple, A. In Polycyclic Hydrocarbons and Carcinogenesis ACS Symposium Series 283; Harvey, R.G., Ed.; American Chemical Society: Washington, D.C, 1985, pp. 1-17. Jerina, D.M.; Chadha, A.; Cheh, A.M.; Schurdak, M.E.; Wood, A.W.; Sayer, J.M. Adv. Exp. Med. Biol., 1991, 283, 533-53. Dreij, K.; Sundberg, K.; Johansson, A.S.; Nordling, E.; Seidel, A.; Persson, B.; Mannervik, B.; Jernstrom, B. Chem. Res. Toxicol., 2002, 15, 825. Jernstrom, B.; Funk, M.; Frank, H.; Mannervik, B.; Seidel, A. Carcinogenesis, 1996, 17, 1491. Sundberg, K.; Widersten, M.; Seidel, A.; Mannervik, B.; Jernstrom, B. Chem. Res. Toxicol., 1997, 10, 1221. Sundberg, K.; Seidel, A.; Mannervik, B.; Jernstrom, B. FEBS Lett., 1998, 438, 206. Sundberg, K.; Johansson, A.S.; Stenberg, G.; Widersten, M.; Seidel, A.; Mannervik, B.; Jernstrom, B. Carcinogenesis, 1998, 19, 433. Van Ness, K.P.; McHugh, T.E.; Bammler, T.K.; Eaton, D.L. Toxicol. Appl. Pharmacol., 1998, 152, 166. Esaki, H.; Kumagai, S. Toxicon, 2002, 40, 941. Talalay, P.; De Long, M.J.; Prochaska, H.J. Proc. Natl. Acad. Sci. USA, 1988, 85, 8261.
GSTs in Drug Discovery and Development [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59]
[60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83]
Frontiers in Drug Design & Discovery, 2009, Vol. 4 41
Esterbauer, H.; Zollner, H.; Schaur, R.J. Membrane Lipid Oxidation; Vigo-Pelfery, E., Ed.; CRC Press: Boca Raton, 1990, pp. 239-268. Esterbauer, H.; Schaur, R.J.; Zollner, H. Free Radic. Biol. Med., 1991, 11, 81. Lovell, M.A.; Xie, C.; Markesbery, W.R. Neurology, 1998, 51, 1562. Gardner, J.L.; Doi, A.M.; Pham, R.T.; Huisden, C.M.; Gallagher, E.P. Toxicol. Appl. Pharmacol., 2003, 191, 95. Hartley, D.P.; Petersen, D.R. Alcohol. Clin. Exp. Res., 1997, 21, 298. Coles, B.F.; Kadlubar, F.F. Methods Enzymol., 2005, 401, 9. Hubatsch, I.; Ridderstrom, M.; Mannervik, B. Biochem. J., 1998, 330 (Pt 1), 175. Canuto, R.A.; Ferro, M.; Muzio, G.; Bassi, A.M.; Leonarduzzi, G.; Maggiora, M.; Adamo, D.; Poli, G.; Lindahl, R. Carcinogenesis, 1994, 15, 1359. Cheng, J.Z.; Singhal, S.S.; Sharma, A.; Saini, M.; Yang, Y.; Awasthi, S.; Zimniak, P.; Awasthi, Y.C. Arch. Biochem. Biophys., 2001, 392, 197. Zimniak, L.; Awasthi, S.; Srivastava, S.K.; Zimniak, P. Toxicol. Appl. Pharmacol., 1997, 143, 221. Gallagher, E.P.; Gardner, J.L. Biochem. Pharmacol., 2002, 63, 2025. Fenwick, G.R.; Heaney, R.K.; Mullin, W.J. Crit. Rev. Food Sci. Nutr., 1983, 18, 123. Kolm, R.H.; Danielson, U.H.; Zhang, Y.; Talalay, P.; Mannervik, B. Biochem. J., 1995, 311 (Pt 2), 453. Kagan, V.E. Lipid Peroxidation in Biomembranes, CRC Press: Boca Raton, 1988. Slater, T.F. Biochem. J., 1984, 222, 1. Hayes, J.D.; Pulford, D.J. Crit. Rev. Biochem. Mol. Biol., 1995, 30, 445. Uchida, K.; Toyokuni, S.; Nishikawa, K.; Kawakishi, S.; Oda, H.; Hiai, H.; Stadtman, E.R. Biochemistry, 1994, 33, 12487. Harris, M.E.; Hensley, K.; Butterfield, D.A.; Leedle, R.A.; Carney, J.M. Exp. Neurol., 1995, 131, 193. Garland, D.; Russell, P.; Zigler, J.S. The oxidative modification of lens proteins. In Oxygen Radicals in Biology and Medicine: M.G. Simic, K.S. Taylor, J.F. Ward and C. von Sonntag, Eds; Plenum Press: New York, 1998, pp. 347-353. Yoritaka, A.; Hattori, N.; Uchida, K.; Tanaka, M.; Stadtman, E.R.; Mizuno, Y. Proc. Natl. Acad. Sci. USA, 1996, 93, 2696. Epp, O.; Ladenstein, R.; Wendel, A. Eur. J. Biochem., 1983, 133, 51. Ursini, F.; Maiorino, M.; Valente, M.; Ferri, L.; Gregolin, C. Biochim. Biophys. Acta, 1982, 710, 197. Ren, B.; Huang, W.; Akesson, B.; Ladenstein, R. J. Mol. Biol., 1997, 268, 869. Eshdat, Y.; Holland, D.; Faltin, Z.; Ben-Hayim, G. Physiol. Plant, 2008, 100, 234. Mannervik, B. Methods Enzymol., 1985, 113, 490. Yang, Y.; Cheng, J.Z.; Singhal, S.S.; Saini, M.; Pandya, U.; Awasthi, S.; Awasthi, Y.C. J. Biol. Chem., 2001, 276, 19220. Prabhu, K.S.; Reddy, P.V.; Gumpricht, E.; Hildenbrandt, G.R.; Scholz, R.W.; Sordillo, L.M.; Reddy, C.C. Biochem. J., 2001, 360, 345. Hurst, R.; Bao, Y.; Jemth, P.; Mannervik, B.; Williamson, G. Biochem. J., 1998, 332, 97. Awasthi, Y.C.; Sharma, R.; Singhal, S.S. Int. J. Biochem., 1994, 26, 295. Gallagher, E.P.; Gardner, J.L.; Barber, D.S. Biochem. Pharmacol., 2006, 71, 1619. Awasthi, Y.C.; Beutler, E.; Srivastava, S.K. J. Biol. Chem., 1975, 250, 5144. Awasthi, Y.C.; Dao, D.D.; Saneto, R.P. Biochem. J., 1980, 191, 1. Zhao, T.; Singhal, S.S.; Piper, J.T.; Cheng, J.; Pandya, U.; Clark-Wronski, J.; Awasthi, S.; Awasthi, Y.C. Arch. Biochem. Biophys., 1999, 367, 216. Singhal, S.S.; Saxena, M.; Ahmad, H.; Awasthi, S.; Haque, A.K.; Awasthi, Y.C. Arch. Biochem. Biophys., 1992, 299, 232. Morgenstern, R.; DePierre, J.W. Eur. J. Biochem., 1983, 134, 591. Morgenstern, R.; Lundquist, G.; Mosialou, E.; Anderson, C. Glutathione S-Transferases and Drug resistance; Hayes, Pickett, and Mantle, Eds.; Taylor and Francis: New York, 1990, pp. 57-64. Hanson, S.R.; Chen, A.A.; Smith, J.B.; Lou, M.F. J. Biol. Chem., 1999, 274, 4735. Seres, T.; Ravichandran, V.; Moriguchi, T.; Rokutan, K.; Thomas, J.A.; Johnston, R.B., Jr. J. Immunol., 1996, 156, 1973. Kosower ,N.S.; Kosower, E.M. Int. Rev. Cytol., 1978, 54, 109. Chai, Y.C.; Jung, C.H.; Lii, C.K.; Ashraf, S.S.; Hendrich, S.; Wolf, B.; Sies, H.; Thomas, J.A. Arch. Biochem. Biophys., 1991, 284, 270. Walters, D.W.; Gilbert, H.F. J. Biol. Chem., 1986, 261, 13135. Garcera, A.; Barreto, L.; Piedrafita, L.; Tamarit, J.; Herrero, E. Biochem. J, 2006, 398, 187. Raghavachari, N.; Qiao, F.; Lou, M.F. Exp. Eye Res., 1999, 68, 715.
42 Frontiers in Drug Design & Discovery, 2009, Vol. 4 [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108]
Skopelitou et al.
Boyland, E.; Chasseaud, L.F. Biochem. J., 1967, 104, 95. Keen, J.H.; Habig, W.H.; Jakoby, W.B. J. Biol. Chem., 1976, 251, 6183. Kubal, G.; Meyer, D.J.; Norman, R.E.; Sadler, P.J. Chem. Res. Toxicol., 1995, 8, 780. Chen, H.; Juchau, M.R. Biochem. J.; 1998, 336 (Pt 1), 223. Benson, A.M.; Talalay, P.; Keen, J.H.; Jakoby, W.B. Proc. Natl. Acad. Sci. USA, 1977, 74, 158. Johansson, A.S.; Mannervik, B. J. Biol. Chem., 2001, 276, 33061. Johansson, A.S.; Mannervik, B. J. Biol. Chem., 2002, 277, 16648. Benson, A.M.; Talalay, P. Biochem. Biophys. Res. Commun., 1976, 69, 1073. Pettersson, P.L.; Mannervik, B. J. Biol. Chem., 2001, 276, 11698. Ito, S.; Narumiya, S.; Hayaishi, O. Prostaglandins Leukot. Essent. Fatty Acids, 1989, 37, 219. Atkins, W.M.; Wang, R.W.; Bird, A.W.; Newton, D.J.; Lu, A.Y. J. Biol. Chem., 1993, 268, 19188. Ujihara, M.; Tsuchida, S.; Satoh, K.; Sato, K.; Urade, Y. Arch. Biochem. Biophys., 1988, 264, 428. Fernandez-Canon, J.M.; Penalva, M.A. J. Biol. Chem., 1998, 273, 329. Blackburn, A.C.; Tzeng, H.F.; Anders, M.W.; Board, P.G. Pharmacogenetics, 2000, 10, 49. Blackburn, A.C.; Coggan, M.; Tzeng, H.F.; Lantum, H.; Polekhina, G.; Parker, M.W.; Anders, M.W.; Board, P.G. Pharmacogenetics, 2001, 11, 671. Dietze, E.C.; Grillo, M.P.; Kalhorn,T.; Nieslanik, B.S.; Jochheim, C.M.; Atkins, W.M. Biochemistry, 1998, 37, 14948. Hederos, S.; Broo, K.S.; Jakobsson, E.; Kleywegt, G.J.; Mannervik, B.; Baltzer, L. Proc. Natl. Acad. Sci. USA, 2004, 101, 13163. Ibarra, C.; Grillo, M.P.; Lo, B.M.; Nucettelli, M.; Bammler, T.K.; Atkins, W.M. Arch. Biochem. Biophys., 2003, 414, 303. Kurtovic, S.; Moden, O.; Shokeer, A.; Mannervik, B. J. Mol. Biol., 2008, 375, 1365. Kurtovic, S.; Grehn, L.; Karlsson, A.; Hellman, U.; Mannervik, B. Anal. Biochem., 2008, 375, 339. Saavedra, J.E.; Bohle, D.S.; Smith, K.N.; George, C.; Deschamps, J.R.; Parrish, D.; Ivanic, J.; Wang, Y.N.; Citro, M.L.; Keefer, L.K. J. Am. Chem. Soc.; 2004, 126, 12880. Morgan, A.S.; Ciaccio, P.J.; Tew, K.D.; Kauvar, L.M. Cancer Chemother. Pharmacol., 1996, 37, 363. Findlay, V.J.; Townsend, D.M.; Saavedra, J.E.; Buzard, G.S.; Citro, M.L.; Keefer, L. K.; Ji, X.; Tew, K.D. Mol. Pharmacol., 2004, 65, 1070. Gillam, E.M.J. Trends Pharmacol. Sci., 2001, 22, 11. Henderson, C.J.; Wolf, C.R.; Kitteringham, N.; Powell, H.; Otto, D.; Park, B.K. Proc. Natl. Acad. Sci. USA, 2000, 97, 12741.
Frontiers in Drug Design & Discovery, 2009, 4, 43-80
43
New Sampling Techniques for PharmacokineticPharmacodynamic Modeling Christian Höcht1,2,*, Marcos Mayer1,2, Javier A.W. Opezzo1,2, Guillermo F. Bramuglia1 and Carlos A. Taira1,2 1
Cátedra de Farmacología, 2Instituto de Fisiopatología y Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, (C1113AAD) Buenos Aires, Argentina Abstract: Considering that pharmacokinetic–pharmacodynamic (PK–PD) modeling describes the relationship between tissue concentrations of drugs and their corresponding pharmacological response, an important issue of PK-PD studies is the availability of powerful sampling techniques that allow measurement of tissue concentrations of drugs at multiple time points. Traditional sampling techniques, including biopsy, blood and saliva sampling, and skin blister sampling, have several limitations for drug monitoring during PK-PD studies, considering that these techniques did not allow the measurement of drug concentrations at the site of action. In the last decades, new sampling techniques, including membrane based techniques (microdialysis and ultrafiltration) and imaging techniques (positron emission tomography and magnetic resonance spectroscopy), have been available for measurement of drug concentration at the target site. The possibility of simultaneous monitoring of target site concentrations of drugs and their pharmacological effect with these new sampling techniques have significantly improves current knowledge of PK-PD modeling. In addition, membrane based techniques also allow simultaneous monitoring of endogenous compounds and therefore permit the study of the relationship between drug target site concentrations and their effect on biochemical markers, making these techniques highly useful for PK-PD modeling studies. The aim of this chapter is to describe the principles of membrane based techniques and imaging techniques, and their applicability for drug monitoring in PK-PD modeling.
INTRODUCTION The demand for efficacious pharmacological agents is increasing due to higher lifestyle expectations and changes in demographic profiles. The discovery of the existence of a large number of orphan receptors will increase the number of new therapeutic agents to be tested. The availability of new techniques, such as the Human –Genome Project and the High throughput screening and combinatorial chemistry, will also *Corresponding Author: Tel: +(54-11)-4964-8265; Fax: +(54-11)-4508-3645; E-mail:
[email protected]
Gary W. Caldwell / Atta-ur-Rahman / Z. Yan / M. Iqbal Choudhary (Eds.) All rights reserved – © 2009 Bentham Science Publishers.
44 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
identify an exploding number of new molecular targets as well as potential new therapeutic agents [1]. Therefore, a more rigorous selection process will be needed at early stages of drug development. Integration of pharmacokinetic-pharmacodynamic (PK-PD) concepts through PK-PD modeling is a potential tool to enhance the information gain and the efficiency of drug selection during drug development [2-4]. PK-PD modeling became as an important tool in clinical practice due to the possibility of an adequate dose regimen selection and the early detection of non-responders to the pharmacological therapy [2, 4]. Another important trend of drug properties to evaluate at early stages of drug development is its capability to reach the target site at sufficient amount to exert its therapeutic effect. It has been estimated that up to 40% of new chemical entities fail in the early phases of drug development because of inappropriate pharmacokinetic properties, such as inadequate drug distribution [5]. Target site distribution is also an important factor in the clinical use of pharmacological agents, especially antiinfective, antineoplastic and central acting drugs, to ensure success of pharmacological interventions. Although pharmacokinetic properties of drugs can be studied by means of traditional blood sampling, this technique is limited by the impossibility to evaluate variability in drug distribution at the target site. Therefore, in the last years, regulatory authorities have been emphasizing the evaluation of drug distribution at the target site during drug development (http://www.fda.gov/cder/guidance/2580dft.pdf). Although other traditional sampling techniques, such as biopsy and skin blister, allow measurement of tissue concentrations of drugs, the utility of these methodologies is strongly limited by the existence of serious limitations, including the inability of serial sampling for the study of the complete tissue pharmacokinetic profile of the drug [6]. In the last decades, new sampling techniques, including microdialysis and imaging techniques, have been available and validated for the study of drug distribution at the target site and PK-PD modeling [6]. Use of these techniques in preclinical and early clinical drug development might reduce failing rates of new chemical entity, also improving cost and the time required until a new chemical entities reaches the market. In addition, these new sampling techniques have also been used in clinical practice to ensure adequate tissue distribution of drugs and for the study of PK-PD models of drugs. Taking into account these antecedents, the aim of this chapter is to: i) describe the concepts of drug distribution at the target site and PK-PD modeling; ii) compare the available techniques for the study of tissue distribution of drugs and PK-PD modeling and iii) to comment the methodological and practical aspects of microdialysis and imaging techniques, and their application for the study of drug distribution and PK-PD modeling of drugs and new chemical entities during drug development and clinical practice. THE IMPORTANCE OF MEASURING TARGET SITE CONCENTRATIONS OF DRUGS The selection of the adequate dose and dosing timing is a fundamental step to achieve therapeutic success with any pharmacological treatment. Selection of the best drug and dosing regimen does not only increase the likelihood of therapeutic success but also reduces the appearance of adverse drug reactions. However, the selection of the most adequate drug and dosing interval of the same is not an easy issue. For most thera-
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 45
peutic agents, drug and dose regimen are empirically selected based on trial and error and by adjusting drug dosing taking into account patient weight. However, this strategy is subject to high clinical failure because of large interindividual variability in pharmacokinetic and pharmacodynamic properties of therapeutic agents in patient population [7, 8] (Fig. 1). Currently, therapeutic drug monitoring (TDM) (Fig. 1) is applicated for drugs with small therapeutic window, including antiepileptic drugs, antimicrobials, inmunesupressors, antiviral agents, teophylline and others, to individualize pharmacological interventions [9]. TDM guides patient dosing according to plasma concentrations of therapeutic agents. In other words, measurement of plasma concentrations has the objective to consider the relationship between dose and attained plasma concentrations in the large interindividual variability of drug response in a treated population [9]. Nevertheless, TDM has several limitations and its cost-benefit relationship is controversial [10]. It must be taken into account that most therapeutic agents exert their pharmacological effect in peripheral tissues rather than the blood compartment, and tissue and plasma pharmacokinetics may differ substantially in patients and healthy volunteers [11-13]. Large interindividual variability also exists between tissue concentrations and therapeutic response because of different receptor sensitivity along the patient population [7]. In conclusion, although TDM has been established as a valuable therapeutic tool for some drugs, measurement of plasma concentrations of drugs is a surrogate parameter with several drawbacks, since it does not exclude interindividual variability in drug distribution at the target site and pharmacodynamic variability.
Fig. (1). Sources of interindividual variability in drug response and methods available for their assessment.
Based on the assumption that unbound plasma concentrations and free tissue levels are equal at equilibrium, it is frequently considered that total plasma concentrations and plasma protein binding can be used to predict free tissue levels of therapeutic agents. However, many studies have shown lower tissue unbound levels than plasma concentrations [14-17]. Tissue distribution is also affected by anatomic barriers, such as blood-brain barrier (BBB), the presence of active transport systems, like P-glycoprotein, and tissue metabolism. For instance, BBB prevents water soluble xenobiotics from entering the brain [18]. BBB is mainly formed by brain capillary endothelial cells, pericytes, astrocytes, and
46 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
neuronal cells. Endothetial cells are different from peripheral cells because of the presence of tight junctions, which prevent paracellular transport of water-soluble compounds from blood to the brain [19]. It has also been discovered that many transport systems play an important role in determining tissue concentrations of drugs. These comprise carrier- and receptormediated transport systems, including cationic and anionic influx and efflux systems such as P-glycoprotein [20], multidrug-resistance (MDR) proteins [21], nucleoside transporters, organic anion transporters, organic cation transporters, large amino acid transporter and the scavenger receptors SB-AI and SB-BI [22]. These transporters modulate drug disposition process, with particular importance in terms of the clinical implications of transporters for drug-drug interactions, drug toxicity, interindividual variability in drug response, and disease [8]. Efflux transporters, such as P-glycoprotein, are expressed in several tissues, especially in the central nervous system, hepatocytes, kidney and the small intestine. At these sites, efflux transporters reduce drug bioavailability, tissue distribution and enhance drug elimination in order to reduce drug exposure in a given patient [23]. Moreover, an overexpression of efflux transporters exists in several pathologies affecting therapeutic success because of limited distribution of the drug at the target site [24]. For instance, reduction of central bioavailability of antiepileptic drugs by overexpression of efflux transporters has been established for several drugs in different models of experimental epilepsy as a mechanism of pharmacoresistance (for review see [25, 26]). The need to study antiepileptic drug distribution at the target site is emphasized by the fact that overexpression of efflux transporters seems only to affect drug distribution in the biophase and not in other central nuclei. The finding that resistant epileptic patients have similar central adverse effect to drug treatment than responders supports this conclusion [22]. Success of cancer treatment is also affected by the existence of an enhanced efflux transporter activity. In this case, efflux transporters reduce intracellular concentrations of cytotoxic drugs compromising the activity of chemotherapeutic agents [27]. Tissue metabolism also affects the relationship between plasma unbound concentrations of therapeutic agents and their levels at the biophase. Although most part of drug metabolism takes place in hepatocytes, other tissues present relative high metabolic activity, including small intestine, central nervous system and kidney [28]. Therefore, tissue biotransformation could also influence target site concentrations and pharmacological effects. Taking into account these antecedents, the Food and Drug Administration (FDA) encourages the study of tissue distribution of antimicrobial agents in unaffected and infected target sites and the relationship of unbound drug concentrations at the site of action to the in vitro susceptibility of the infecting microorganism (http://www.fda.gov/ cder/guidance/2580dft.pdf). In conclusion, the utility of therapeutic tools actually used for rational selection of the best drug and dosing regimen, such as TDM, is limited by the fact that this approach allows the determination of plasma drug concentrations rather than their levels at the target site. Several pharmacokinetic factors affect tissue distribution of drugs and their pharmacological effect. Therefore, an important fact in drug design and clinical practice
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 47
is the evaluation of the in vivo pharmacokinetics of new chemical entities and drugs at the biophase. In the following sections of the present chapter, available sampling techniques for the study of drug distribution at the target site, including imaging techniques and microdialysis, are discussed. Variability in drug response is also due to pharmacodynamic factors [7] (Fig. 1). Transporters activity, concentration of endogenous agonist and expression of receptors and their sensitivity to drug action vary among different patients and during the course of drug treatment on a single patient. Therefore, selection of the adequate dose of a therapeutic agent and its dose regimen also depends on pharmacodymanics of the drug at the target site. In the last years, PK-PD modeling have become an interestingly tool of pharmacological sciences for the study of factors influencing drug response [3] (Table 1). Table 1.
Information Obtained from Pharmacokinetic-Pharmacodynamic Modeling During Preclinical and Clinical Phases of Drug Development and Clinical Practice
Preclinical phase of drug development Precise definition of the dose–concentration–pharmacological effects and dose–concentration–toxicity relationship Determination of the appropriate dosing regimen for Phase I studies Identification of biomarkers and animal models for efficacy and toxicity Explore any dissociation between plasma concentration and duration and onset of pharmacological effect Provide information on drug effects that would be difficult to obtain in human subjects Provide insights regarding the mechanism of action of the new chemical entity Allows the study of the influence of the physiopathological state on PK-PD parameters Clinical phase of drug development Understanding the dose-concentration–pharmacological effects and dose–concentration–toxicity relationship in healthy volunteers. Characterization of pharmacokinetics and pharmacodynamics in special population Study of tolerance development Determination of the dosing regimens for Phase II studies. Confirms and explores the relationship between dose–concentration–effect in patients. Examination of a variety of therapeutic endpoints to understand the most adequate for further modeling. Determination of the dosing regimens for Phase III studies Prediction of the probability distribution of further clinical trial outcomes Clinical practice Early detection of poor responders or non-responders. Optimization of antihypertensive drug regimen, in terms of dose, sampling interval and time of dosing. Evaluation of the clinical impact of drug interactions.
UTILITY OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING IN DRUG DISCOVERY AND CLINICAL PRACTICE Two different approaches exist for characterizing the pharmacodynamics of a drug, namely the classical dose response trial and PK–PD modeling [4]. PK–PD modeling has
48 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
several advantages over classical dose–response studies. PK–PD modeling allows not only better pharmacodynamic characterization of drugs, but also permits screening and dosage–regimen selection [4]. More recently, the introduction of mechanism-based PKPD models have allowed the study of the influence of physiological parameters on PKPD properties of the drug. Information obtained from PK-PD modeling during drug development and clinical practice is resumed in Table 1. PK-PD relationships build a bridge between the time course of drug concentrations in the organism, as assessed by pharmacokinetics (PK), and the intensity of the observed pharmacological response, as quantified by pharmacodynamics (PD). The link between PK and PD of a drug is established by the use of mathematical models, allowing the estimation of parameters such as effective concentration to yield half-maximal response (EC50) and maximal efficacy (Emax). PK-PD modeling also provides information about the onset, magnitude and duration of the pharmacological effect [4]. A drawback of PK–PD modeling is the need of simultaneous measurement of drug tissue levels and their corresponding pharmacological effect at multiple time points [4]. Blood sampling, which has traditionally been used for this purpose, has the disadvantage that the removal of samples by themselves may interfere with PK and PD drug behavior, especially in preclinical studies with small animals [29]. Furthermore, traditional sampling techniques allow the measurement of plasma concentrations of pharmacological agents rather than their levels at the target tissue. These limitations could be resolved by the application of new sampling techniques, including in vivo microdialysis and imaging techniques. Accurate measurement of the intensity of the pharmacological effect of the active compounds is also necessary for a PK-PD modeling design. A drug effect could be considered as any change in physiological parameters induced by the administration of a drug, compared to respective baseline values. Measurement of the effect should meet validation parameters, such as continuity, sensitivity, objectivity and repeatability [30]. To obtain the greatest precision in estimating PK-PD relationships, the number of measurements of drug tissue levels and its corresponding effect must be as large as possible [30]. However, multiple time point sampling is not always possible in the clinical setting. To overcome this limitation, population PK and PK-PD modeling is increasingly being introduced [31, 32]. PK-PD relationships have been described using diverse mathematical models depending on the nature of drug administration, the magnitude of the pharmacological effect and the time dependency of pharmacodynamics of the tested drug [3, 31]. Relative simple PK-PD models are needed for describing PK-PD relationship after multiple doses or long-term infusion, because the system is kinetically at steady state [31]. The most common mathematical equations employed at steady state condition are the linear, log linear and the Emax model. Although the linear and log linear model allow easy parameter estimation, these models erroneously assume that the effect can increase with concentrations without limits [30]. Therefore, the Emax model is the most broadly applied to characterize a myriad of pharmacological effects. This model derives from the classical theory of drug-receptor interaction, relating the effect to drug concentrations as in the following equation:
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 49
E = E0 +
E max C EC 50 + C
where E0 is the baseline effect, Emax the maximal effect and EC50 the effective concentration yielding half maximal response. Conversely, more complex PK-PD models are needed for describing PK-PD relationship after single dose administration or when time dependency in the pharmacodynamics of the drug is present [31]. Plotting drug effects as a function of drug concentrations and connecting data in a chronological order allows the determination of possible delays between drug response and its tissue levels [4]. A hysteresis loop appears in the plotting when the magnitude of an effect corresponds to more than one drug concentration. Anticlockwise hysteresis loop could be explained by the disequilibrium between biophase and plasma compartment [33], appearance of active metabolites [34] or indirect mechanism of action [35]. On the other hand, tolerance to the pharmacological effect is suggested when a clockwise hysteresis loop is observed [36]. In theses cases, plasma concentrations can not be directly linked to drug effect, and more complex PK-PD models, such as an effect compartment model and a physiological indirect response model, are needed [31]. The effect compartment model considers a hypothetical effect compartment as an additional compartment of a pharmacokinetic compartment model, representing the drug concentration at the effect site. The time-dependent aspects of the equilibrium between plasma concentration and effect are characterized by the first-order rate constant ke0 that represents the irreversible disappearance of the drug from the effect compartment and is in equilibrium with the rate constant of entrance of the drug to the effect compartment. The time course of drug concentration in the effect compartment is described by the following equation:
dC e = k e 0 (C p C e ) dt where Ce and Cp represent the concentration in the effect compartment and plasma, respectively and ke0 the equilibration rate constant. This approach has been successfully applied to predict the PK-PD relationship of diverse drugs [37]. Physiologic indirect response models have been employed in a variety of studies regarding biological responses such as muscle relaxation, synthesis and secretion of endogenous compounds, mediator flux, cell trafficking, enzyme induction, or inactivation, among others [35]. The physiological indirect response can be described as an inhibitory or stimulatory function applying the following equations:
I (t ) = 1
C (t ) IC50 + C (t )
S (t ) = 1 +
E max C (t ) EC 50 + C (t )
where IC50 and EC50 are the concentrations eliciting 50% of inhibition or the maximal effect (Emax), respectively.
50 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
PK–PD modeling should cover the complete pharmacodynamic range of a drug after a single administration [4]. Often, in clinical pharmacology, it is not possible to determine the maximal effect of a drug because of the appearance of adverse drug reactions, in which case an alternative PK–PD model must be applied [38]. In this model, the authors replaced the parameter EC50 with S0 in the Emax equation, which represents the initial sensitivity to the drug. The following equation describes the relationship between drug concentration and its pharmacological effect for this PK-PD model:
E = E0 +
S 0 E max C E max + S 0 C
Considering that the selection of an inadequate PK–PD model according to the PK– PD study characteristics might lead to an erroneous interpretation, it is extremely important to determine which PK–PD model is going to be applied for the analysis of the data. When selecting the PK–PD model, the investigator must keep in mind experimental variables, including type of drug administration, type of pharmacological effect measured, the existence of time dependency in the pharmacological effect of a drug and the possibility to reach a maximal response in their experimental design. More recently, development of mechanism-based models has improved knowledge of the interaction between PK-PD properties of drugs and clinical response (for review see [39, 40]). Mechanism-based PK-PD modeling integrates parameters for describing drug-specific properties with biological system-specific properties, and therefore characterizes the causal path between drug exposure and drug response. By estimating drug target-site distribution, target binding and activation and transduction process, mechanism-based PK-PD models will also characterize the interaction of the drug effect with disease processes and disease progression [39, 40]. OVERVIEW OF AVAILABLE TECHNIQUES FOR THE STUDY OF DRUG DISTRIBUTION AND PK-PD MODELING Target site concentrations of drugs and new chemical entities can be evaluated by means of traditional techniques, including biopsies, skin blisters, or using more recently available methodologies, such as imaging techniques, ultrafiltration and microdialysis [6]. Biopsy consists of homogenized tissue samples those results in cellular lysis. Therefore, biopsy gives information about analyte concentrations in the homogenate without distinguishing between blood, intra- or extracellular drug levels. Moreover, it is an invasive method associated with the risk of infection due to cross-contamination and scarring. As tissue has to be removed, biopsy is not suitable for the study of the concentration–time course of a drug and, therefore, PK-PD modeling of drugs [41]. Advantages of biopsy are that no special equipment is needed, there is no limitation with the size of the drug and no calibration is necessary [41]. Suction blisters have been an established method for more than 30 years for the study of pharmacokinetics in the dermis [42]. The method principle relies on the separation of the epidermis from the dermis along the lamina lucida due to the application of prolonged suction to the skin surface (suction blister technique) or due to the adverse reaction effect of cantharidin (cantharides blister technique). The fluid drawn into the sepa-
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 51
rated epidermis can be sampled and analyzed for drug content [41]. Skin blister technique has been compared to other sampling techniques, such as microdialysis, concluding that skin blister seems to be only valid for the dermal study of low protein bound drugs. Other limitations of skin blister sampling is the production of a great discomfort in the patients and is only applicable for studies at a certain time point not allowing continuous monitoring of drug skin penetration to the same test area. Traditional techniques have several drawbacks that limit their applicability for the evaluation of tissue distribution and PK-PD modeling during drug development. These methodologies have largely been replaced by modern analytical techniques, including ultrafiltration, imaging techniques and microdialysis sampling (Table 2). Table 2.
New Sampling Techniques for Pharmacokinetic and PK-PD Studies
Technique
Advantages
Microdialysis Simultaneous determination of the bioactive concentration of drugs, metabolites and endogenous compounds in the biophase. Good temporal and spatial resolution. Online coupling of analytical determination Monitoring of drug concentrations in different tissues by multiprobe microdialysis. Monitoring of drug effect on endogenous compounds Possibility of local drug administration. Cheap technique.
Drawbacks Semi-invasiveness technique Diluting effect of the microdialysis procedure Need of highly sensitive analytical methods In vivo calibration of the microdialysis probe during the experiment Sticking of lipophilic drugs to tubing and probe components Low recovery of large molecules
PET
Non-invasive technique High spatial and time resolution No time consuming Allows estimation of in vivo drug-receptor interactions
Short physical half-life of the most used radioisotope. Did not discriminate between drugs and its metabolites. Determinates total tissue concentrations of drugs. Expensive technique.
MRS
Allows discrimination between drugs and its metabolites. Non-invasive technique No time consuming
Poor spatial resolution. Low sensitivity Expensive technique
Ultrafiltration is an alternative membrane sampling technique to microdialysis. This technique collects a sample by the application of negative pressure as driving force. The rate of fluid collection is determined by the amount of negative pressure applied, the membrane surface area and the hydraulic resistance [43]. The mayor advantage of ultrafiltration with regards to other membrane sampling techniques, such as microdialysis, is that in vivo calibration of the technique is not necessary because the in vivo recovery is greater than 95% for small molecules [43]. However, continuous tissue sampling with
52 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
ultrafiltration depends on rapid replacement of interstitial fluid by blood vessels. In tissues with limited flow rate and low replenishment of interstitial fluid, such as subcutaneous tissue, only low sampling rates are possible [43]. Brain is also unsuitable for ultrafiltration sampling because of the limited extracellular space. In addition, ultrafiltration does not allow the administration of a substance into the extracellular space through the probe. Although the applicability of ultrafiltration has been demonstrated for drug kinetic studies and glucose and lactate monitoring [43], the scope of application of ultrafiltration technique is limited in clinical pharmacology. Microdialysis is a membrane sampling technique that allows continuous monitoring of extracellular concentrations of new chemical entities and drugs withouth fluid loss [29]. As discussed later, microdialysis has several advantages compared to other sampling techniques, including the capability to monitor unbound tissue concentrations of drugs and their metabolites, the simultaneous study of drug concentrations in several tissues and the possibility of concomitant sampling of endogenous compounds or biochemical markers [37]. However, it must be pointed out that microdialysis is a semiinvasive methodology that often requires calibration during the experiment [29]. Alternatively, several imaging techniques such as planar -scintigraphy, single photon emission computed tomography (SPET), positron emission tomography (PET), and magnetic resonance spectroscopy (MRS) have been developed for the study of drug distribution in basic and clinical settings [13]. PET is a new nuclear imaging technique that employs molecules labeled with positron-emiting radioisotopes [44]. Advantages of this imaging technique reside in its non-invasive nature, high spatial resolution (1-5 mm) and time resolution (30 seg.). However, the physical half-life of the most used radioisotope 11 C (20.4 min) does not allow monitoring of tissue levels of radiolabeled drugs over several elimination half-lifes as desired in pharmacokinetic studies [13]. Another drawback of PET is that this methodology samples total tissue concentrations of drugs and their metabolites and, consequently, does not allow to differenciate them [13]. MRS utilizes nuclear magnetic resonance phenomenon, which consists in the emission of a radiosignal equal to the respective resonance frequency with amplitude proportionally to the number of nuclei present in the examinant objective [13]. MRS can be performed serially with a temporal resolution of minutes. Contrary to other imaging techniques, MRS is capable of identifying drug metabolites in tissues [13]. However, an important limitation of MRS is its low sensitivity, allowing only the evaluation of drug distribution of xenobiotics that are present in large concentrations. In addition, spatial resolution of this imaging methodology is low [13]. Although imaging techniques are non-invasive, they are only applicable for a small group of compounds with special functional groups. Moreover, imaging techniques are very expensive and labor-intensive and, therefore, not suitable for clinical routine settings [13]. In conclusion, to date, modern techniques exist for the evaluation of tissue distribution of drugs at the target site and simultaneous PK-PD modeling, providing information that has been inaccessible with previously available methods. In the next sections, the principles and applicability of microdialysis, PET and MRS for evaluation of pharmacokinetic and pharmacodynamic properties of drugs will be discussed.
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 53
PRINCIPLES OF MICRODIALYSIS SAMPLING In the past twenty years, the microdialysis technique has become a method of choice for the study of tissue concentrations of both endogenous and exogenous substances. Microdialysis is a powerful and versatile sampling technique based on the dialysis principle [45]. In this technique, a probe that is inserted into a tissue mimics the function of a capillary blood vessel (for review see [29]). The probe has a hollow fiber that is permeable to water and small molecules, and when the perfusate solution passes through the dialysis membrane, molecules diffuse into (recovery) or out of (delivery) the perfusion fluid depending on the concentration gradient. Thus, microdialysis can be used for both collecting a substance in the dialysate as well as delivering it into the periprobe fluid. The latter is referred to as reverse microdialysis [46]. Then, dialysate samples are analyzed using quantitative techniques like liquid chromatography (LC) or capillary electrophoresis (CE). The basic setup for a microdialysis experiment consists of a microdialysis probe, a perfusion pump, and an analytical method with the required sensitivity to quantify small concentrations of substances [29]. As microdialysis sampling is not performed under equilibrium conditions because the perfusate is constantly being pumped through the probe, concentrations of the drug in the sample are some fraction of that in the surrounding tissue. Therefore, limit of quantification of analytical methods should be extremely low [47]. On the other hand, to obtain true tissue concentrations the factor by which these concentrations are interrelated needs to be determined. This factor, which is obtained during an in vivo or an in vitro calibration procedure, is called relative recovery [29]. Microdialysis sampling offers several advantages over conventional methods and imaging methods of studying the pharmacokinetics and pharmacodynamics of drugs. Microdialysis technique allows continuous tissue sampling without removing liquid, achieving higher temporal resolution than traditional techniques, without interfering with the PK and PD behavior of the drug. An economical and ethical advantage is that 5-10 times fewer animal experiments have to be performed to determine the time profile of a drug [29]. Placement of multiple microdialysis probes in different tissues allows monitoring of the drug time course in different organs in the same animal, supplying information about the distribution process of xenobiotics. The fact that the microdialysis technique provides protein free samples permits the analysis of the sample without pretreatment and LC or CE on-line coupling. Conversely, traditional blood sampling requires clean up procedures prior to analysis with the possibility of analyte loss during protein precipitation and the need of an internal standard for an accurate determination of the drug. On the other hand, tissue enzymes are also excluded from the dialysate sample without further enzymatic degradation of the drug [29]. The microdialysis technique not only allows sampling of extracellular levels of drugs but also endogenous compounds such as neurotransmitters, metabolites, glucose, lactate and low molecular wheighing peptides [29]. Therefore, this technique is highly useful for the simultaneous study of the pharmacokinetic behavior of drugs and their effects on extracellular levels of endogenous compounds [37].
54 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
However, the microdialysis sampling technique has some disadvantages compared to traditional sampling methods. Drug tissue concentrations often are in the picomolar to micromolar range and the limit of detection of the analytical methods should be for some drugs extremely low. On the other hand, in vivo recovery of the microdialysis probe must be determined during the experiment to permit conversion of microdialysis concentration into extracellular levels if an absolute concentration is needed [29]. The calibration aspects of the microdialysis probe will be discussed in following sections. In addition, a minimal lesion of the tissue surrounding the probe is produced by implantation of the microdialysis probe, causing tissue responses such as a compromise of BBB [48, 49] and acute inflammation in different tissues [47, 50, 51]. Nevertheless, several studies have demonstrated that baseline conditions are reached following periods of 60 min after probe implantation [29]. Methodological Aspects of Microdialysis Sampling The microdialysis probe is perhaps the nucleus of the microdialysis experiment. Many types are described and they are used in different experiments. The different geometry of microdialysis probes enables their use in virtually any tissue and any fluid of the body [52]. Many laboratories have designed their own probe considering that its construction takes no longer than several minutes. To date, there are also many commercial approved probes for studies in soft tissues and brain of humans and animals. Probes will have a longitudinal, a semicircular or an I-shape design. Various designs have been described, including concentric cannula probe, linear probe, and shunt probe. In addition, several modified probe designs have been reported, such as spinal loop dialysis catheter, flexible intravenous probe, and shunt intraarterial microdialysis probe [29]. For soft peripheral tissues like muscle, skin, liver, tumor, and fluids like blood and bile, flexible probes can be used. Linear probes are useful for monitoring transdermal drug delivery. However, an increase in skin blood flow, erythema and skin thickness was demonstrated after insertion of a microdialysis probe [53]. Rigid microdialysis probes, such as the concentric cannula, are placed in hard tissues, including the brain. In this case, guide cannulas can also be implanted, opening up the possibility to insert the probe after surgical recovery, thereby decreasing negative effects of anesthesia [29]. The choice of the membrane type is an essential element to optimize the probe for a particular microdialysis protocol. Conventional microdialysis probes are constructed with 20 kDa molecular weight cut-off membranes enabling measurement of small molecules [29]. Recently, a 100 kDa molecular weight cut-off microdialysis catheter have been used to sample larger molecules such as cytokines [54]. These probes can be constructed with polyethylenesulphone [55]. A technical problems encountered with the 100 kDa microdialysis membrane is the issue of poor sample volume retrieval, considering that it enables passage of high molar mass molecules. One way of addressing this problem is to equalize the pressure differences between in-flowing and out-flowing perfusate at the membrane by increasing the colloidal pressure of the perfusate using dextran [56]. Molecular weight of the substance of interest must be taken into consideration for selection of the most adequate dialysis membrane. Only substances with a molecular weight lower than the membrane cut-off are able of passing the membrane. However, even if the molar mass falls below the molecular weight cutoff, an acceptable relative
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 55
recovery will only be attained with substances having a molar mass lower than approximately one-fourth of the membrane cutoff [41]. The size of the microdialysis membrane influences the relative recovery. According to Fick’s law, perfusion across a membrane is proportional to its area. Increasing the length of the microdialysis membrane will lead to an increase in relative recovery [41]. Increasing the outer diameter of the inner cannula may also enhance relative recovery of the probe [57, 58]. An important key is that the membrane does not interact with the surrounding tissue or with the perfusate. Low recoveries of acid aminoacids have been described due to the presence of surface charge [59]. Recovery of neuropeptides can vary as much as 20% with different dialysis membranes [60]. Different perfusion media have been used in microdialysis experiments and they vary widely in their composition and pH. Composition, ion strength, osmotic value and pH of the perfusion solution should be as close as possible to those of the extracellular fluid of the dialyzed tissue. In most experiments, the perfusate is an aqueous solution of sodium and potassium salts and other ions in a minor proportion, without proteins or a very small concentration of them. Addition of dextran to the perfusion solution prevents fluid loss. Rosdahl et al. [61] have demonstrated that the estimated concentrations of dextran in the perfusion solution at which no net loss of perfusion fluid occurred produces a colloid osmotic pressure similar to the reported values for plasma. This implies that the plasma colloid osmotic pressure contributes to a mass transfer of fluid from microdialysis catheter to capillaries. In some cases, proteins should be added to the perfusion medium to prevent sticking of drugs to the microdialysis probe and tubing connection [62]. When microdialysis probes are implanted into a tissue, it is necessary to keep asepsis in the area immediately around the site of the insertion. Huff et al. [63] reported a preliminary evaluation of several disinfection/sterilization techniques used with experimental microdialysis probes. These authors found that two disinfection methods, 70% ethanol and a commercial contact lens solution, and two sterilization methods, hydrogen peroxide plasma, and e-beam radiation, did not affect the functionallity of the probes. However, hydrogen peroxide plasma and contact lens solution groups reduced extraction efficiencies of microdialysis probes. Gamma irradiation has also been used for sterilization of microdialysis probes [64]. Probes were sterilized by gamma irradiation (32 kGy) prior to use. Subsequent in vitro experiments confirmed that the irradiated probes behaved identically to native probes from the supplier. In this work, no sign of infection at the implantation sites was found, probably due to the strict attention to sterility during the probe implantation as well as to prophylactic treatment with a broad-spectrum antibiotic [64]. However, one of the most popular methods to sterilize microdialysis probes is the gas sterilization method with ethylene oxide [65, 66]. An important aspect of microdialysis in pharmacokinetic studies is the selection of an adequate analytical method for drug concentration determination. Microdialysis generates small volume samples (1-10 l), because of the need of slow perfusion rates (0.12 l/min) to obtain high recoveries of the drug maintaining an adequate temporal resolution. In addition, microdialysis samples often contain the analyte at low concentration (pM-M range) needing of a high sensitive analytical method [29]. A wide range of analytical methods can be used for the analysis of microdialysis samples. Non-separation-based methods allow the detection of one analyte at a time, in
56 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
contrast to separation-based methods that can be used for the detection of multiple analytes (original drug and metabolites) in each sample. Therefore, its applicability for microdialysis studies is scarce [29]. Separation-based methods available for analysis of microdialysis samples include LC, microbore LC, capillary LC and CE. A wide range of different detectors can be coupled to the separation method. Immunoassay, ultraviolet absorbance, electrochemical detection, fluorescence and mass spectrometry (MS) are the most common detectors for LC analysis [29]. For CE, electrochemical and laser induced fluorescence detection have been most commonly employed [29]. The drawback of the separation-based methods is the dilution of the microdialysis sample. Nevertheless, LC with tandem MS/MS detection, due to its low limit of quantification, is a powerful analytical technique for quantification of drug concentrations in microdialysis samples. In comparison to the non-separation-based methods, these methods allow the detection of many compounds in each sample allowing simultaneous quantification of drug metabolites. The great diversity of detection methods provides to the researcher the chance to select the more adequate analytical system for the determination of the compound of interest [67]. The most important aspect of the analytical system is its sensitivity in order to improve the temporal resolution of a microdialysis protocol. Importance of Microdialysis Probe Calibration Use of microdialysis sampling for determination of target site concentrations of drugs needs accurate calibration of the microdialysis probe, considering that the desired information is the absolute drug concentration in the tissue. The relationship between concentration of the drug in the dialysate and its concentration in the sample matrix may be thought of as the recovery of the probe. Several factors influence recovery of the microdialysis probe, including temperature, perfusate flow rate, chemical and physical properties of the dialysis membrane, probe geometry, membrane surface area, chemical properties of the drug and the diffusion rate of the drug within the matrix [68]. All of these parameters remain constant during the experiment under normal conditions. Few parameters, such as membrane surface area and perfusate flow rate, can be modified by the researcher to improve recovery of the microdialysis probe. If high microdialysis probe recovery is needed to obtain concentrated samples, the researcher can opt among increasing the size of the surface area or decreasing the perfusate rate. However, increase of membrane surface area implies loss of spatial resolution and decrease of the perfusate rate implies loss of temporal resolution, because of prolongation of the sampling interval [29]. Recovery of the microdialysis probe can be determined by both in vitro and in vivo assays. The in vitro estimation of the probe recovery, serves only to prove if the microdialysis probe works, since in vitro recovery values are often an overestimation of the in vivo recovery [29]. In vivo recovery of the microdialysis probe can be determined through different methods, including flow-rate or stop- flow method [69], zero-net-flux method [45], retrodialysis method [70] and delivery method [71]. Because the zero-net-flux method and the flow rate method require that examination of the study subject under steady state conditions prior to the experiment, the total study time is extended. This limits the application of these methods for pharmacokinetics purposes [29].
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 57
Determination of the in vivo recovery with the retrodialysis or delivery method is more appropriately. Both methods are based on the principle that recovery is independent of the direction of analyte diffusion. Therefore, loss of the analyte from the perfusion media to the extracellular matrix should be equal to gain of the analyte from the tissue to the perfusate. This equality must be determined by the determination of in vitro recovery of the analyte both by loss and gain methods [29]. The retrodialysis method consists in the diffusive loss of molecules of a calibrator from the perfusate into the environment surrounding the probe. The dialysance or permeability-area product (PeA) of the calibrator must be similar to that of the compound of interest [29]. The in vivo recovery of the calibrator is calculated with the following equation: R= (Cin - Cdial)/ Cin where R is the calibrator in vivo recovery, Cin is the concentration of the calibrator in the perfusate and Cout is the concentration of the calibrator in the dialysate. Unbound concentrations of the compound of interest in the surrounding environment (C) are calculated using the following equation: C = Cout / R where Cout is the compound of interest concentration in the dialysate and R is the in vivo recovery of the microdialysis probe. The delivery method consists in the determination of the in vivo recovery of the compound of interest by retrodialysis before the actual experiment. In vivo recovery of the compound of interest is determined before drug administration by perfusing microdialysis probe with a solution of the compound of interest, taking the proportion of loss across the dialysis membrane as an estimate of the recovery [29]. Comparing the last two methods, a limitation of the retrodialysis is the necessity of an analyte with similar physico-chemical characteristic as the compound of interest. On the other hand, if the analyte is added to the perfusate at high concentrations, it could introduce unwanted perturbations in the surrounding tissue area [29]. The delivery method overcomes the uncertainty introduced by using a standard to mimic the compound of interest. The shortcoming of this approach is that recovery changes resulting from the experiment are not detected. However, recovery of the microdialysis probe generally remains constant in pharmacokinetic studies [29]. Another issue of microdialysis sampling in pharmacokinetic studies is the fact that microdialysis generates data that are the integral of the concentration surrounding the probe during the sampling interval, conversely to tissue samples, which provides a point measurement during the same interval. To estimate pharmacokinetic parameters, microdialysis data must to be transformed from a series of integrals to a series of points corresponding to the same time of tissue samples collection [72]. CURRENT APPLICATIONS OF MICRODIALYSIS SAMPLING FOR EVALUATION OF TISSUE DISTRIBUTION AND PK-PD MODELING OF DRUGS Microdialysis sampling has been extensively used for the study of target site distribution and PK-PD modeling of established drugs and new chemical entities in both pre-
58 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
clinical and clinical protocols (for review see [12, 29, 37, 41]). Although pharmacokinetic properties and PK-PD relationship of different therapeutic groups have been evaluated by means of microdialysis sampling, most of microdialysis studies addressed drug distribution and PK-PD modeling of antiinfective, antineoplastic and central acting drugs [12, 37]. Microdialysis sampling is also useful for PK-PD modeling of cardiovascular drugs in laboratory animals and for the evaluation of dermal pharmacokinetics of drugs after its topical application [12, 36]. In this section, most important microdialysis studies in this area are discussed. Antiinfective Drugs Traditionally, pharmacokinetic assessment of antimicrobial agents was largely based on the measurement of total plasma concentrations. Nevertheless, the use of plasma antibiotic levels is not ideal, because most infections occur in tissue sites, and therefore the ability of antibiotics to reach the target site is a key determinant of clinical outcome. It is considered that total plasma concentrations and plasma protein binding can be used to predict free tissue levels of antibiotics, based on the assumption that unbound plasma concentrations and free tissue levels are equal at equilibrium, considering that tissue distribution is generally mediated only by passive diffusion. However, many studies have shown lower tissue unbound levels than plasma concentrations [14-17]. As discussed above, tissue distribution is also affected by anatomic barriers, presence of active transport systems and tissue metabolism. On the other hand, time to reach equilibrium between plasma and tissue concentrations of antibiotics may range from minutes to days [73]. Therefore, measurement of unbound drug concentrations in the interstitial fluid of the target tissue should be considered a gold standard for improvement of antimicrobial therapy and dose adjustment. Microdialysis has been used to measure various antimicrobials agents in human and laboratory animal tissues, including aminoglucosides, penicillins, cephalosporines, fosfomycin, fluoroquinolones and antiviral agents (for review see [74-76]). These studies have served to evaluate drug distribution in several organs, including infective tissues, and to develop in vivo PK- in vitro PD models at the target site using the same parameters calculated in plasma: time (T) above the minimum inhibitory concentration (MIC) (T>MIC), the ratio of the maximum concentration of drug in serum (Cmax) to the MIC (Cmax/MIC), the area under the inhibitory curve or the area under the curve (AUC)/MIC ratio [76]. Using microdialysis sampling, the relevance of protein binding in therapeutic failure was demonstrated. A relationship was found between the failure in cefoperazone treatment in serious illness and the degree of drug bounded to proteins [77]. In addition, cefpodoxime, with lower protein binding than cefixime (25 vs 65%) showed higher peak concentration and tissue penetration than cefixime [78], suggesting a favorable efficacy of cefpodoxime, and this is supported by clinical trial data provided by a study in paediatric acute otitis media [79]. Microdialysis sampling was also used for the determination of antimicrobial agents in the interstitial fluid of non-infected soft tissues of healthy volunteers and rats. Several studies have demonstrated that tissue concentrations of different antibiotics, including ertapenem [80], gemifloxacin [81], telithromycin [82], and imipenem [83] among others, are similar in soft tissues with regards to unbound plasma concentrations, indicating a good distribution of antimicrobial in non-infected tissues.
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 59
In addition, drug distribution of antimicrobial drugs in infected tissues was also evaluated by means of microdialysis sampling both in basic research and clinical setting. Experiments conducted in rats showed that lung and peritoneal penetration of imipenem is not reduced in rats with pneumonia and peritonitis, respectively [84, 85]. In another study, lung penetration of meropenem was determined in patients with pneumonia and metapneumonic pleural emphysema by means of microdialysis [86]. Although meropenem rapidly penetrated infected lung tissue, interstitial lung fluid levels were lower than serum concentrations with target site drug concentrations above the MIC90 threshold for many clinically relevant pathogens for up to 6 hours [86]. In another clinical protocol, moxifloxacin exhibited similar penetration into the interstitial space fluid in normal subcutaneous tissue and infected decubitus ulcers in patients with spinal cord injury [87]. Conversely, penetration of the fluorquinolone levofloxacin into tissues appears to be unaffected by local inflammation. Bellman et al. [88] observed that administration of a standard dose of levofloxacin reached adequate levels at target site, although the extent of tissue penetration showed a high interindividual variability. Zeitlinger et al. [89] have also demonstrated a reduced distribution of levofloxacin in infected lung with regards to interstitial fluid of non-infected soft tissues obtained from healthy volunteers. Microdialysis sampling was also extensively employed for PK-PD modeling of antiinfective agents (for review see [75, 76]). A three step approach has been used for the in vivo PK- in vitro PD modeling by means of microdialysis. Firstly, interstitial fluid concentrations of the antibacterial drug at the target site are measured by means of microdialysis. Secondly, time versus drug concentration profile measured in vivo is simulated in an in vitro setting on bacterial cultures. Thirdly, unbound antibiotic concentrations are linked to bacterial kill rates by means of a PK-PD model [90]. Delacher et al. [90] have demonstrated a significant correlation between the maximal bactericidal effect and several pharmacokinetic surrogate parameters, such as AUC/MIC, Cmax/MIC and T>MIC. The authors concluded that the therapeutic success or failure in antibacterial therapy depends on the target site concentrations of the antimicrobial agent. Moreover, in vivo PK- in vitro PD modeling provides valuable guidance for drug and dose selection of antibacterial drugs [90]. In vivo PK – in vitro PD modeling of antimicrobial drugs was also studied in critical ill patients by means of microdialysis. Zeitlinger et al. [91] have applied an in-vivo pharmacokinetic/in-vitro pharmacodynamic method to simulate bacterial killing in plasma and the interstitium of skeletal muscle tissue after intravenous administration of cefpirome and fosfomycin alone and in combination to patients with sepsis. The in vitro simulation of in vivo plasma and tissue pharmacokinetics of cefpirome and fosfomycin has shown that both antimicrobial agents kill Staphylococcus aureus and Pseudomonas aeruginosa strains after single dose administration, observing a synergic antimicrobial effect by the combined use. Therefore, this data confirms antimicrobial strategies of simultaneous administration of cefpirome and fosfomycin in patients with severe soft tissue infection [91]. It must be pointed out that all PK–PD studies of antimicrobial drugs by means of microdialysis have used a combined in vivo PK–in vitro PD simulation without applying mathematical PK–PD models in their analysis. Recently, (Liu et al.) [92] demonstrated that a PK–PD model based on unbound antibiotic concentrations at the site of infection,
60 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
and a sigmoid Emax relationship, effectively described the antimicrobial efficacy of both cefpodoxime and cefixime. This approach offers a more detailed information than the MIC does about the time course of antibacterial efficacy of antibiotics [92]. In this way, (Huang et al.) [93] have evaluated the simultaneous estimation of amoxicillin influx/efflux in chinchilla middle ear fluid and its antibacterial effect. The authors found that the microdialysis procedure did not interfere with the bacterial growth-kill profile, thereby enabling pharmacokinetic and pharmacodynamic evaluation concomitantly. In summary, several microdialysis studies have demonstrated that anti-infective levels at the target site are sub-inhibitory, although effective concentrations are attained in plasma. Therefore, study of target site concentrations and PK-PD modeling of antiinfective agents in clinical drug development and in critically ill patients by means of microdialysis should enhance knowledge on adequate antibiotic drug dosing and improve patient's outcome. Preliminary studies demonstrated that microdialysis sampling did not interfere and therefore might be an interesting approach for the simultaneous estimation of target site concentrations of the antimicrobial agent and their in vivo antibacterial effect. Antineoplastic Drugs Tumor drug exposure, a marker linked to clinical outcome, may be dramatically reduced due to diffusion barriers in solid tumors [27]. Differences in tumor drug distribution do not allow to predict the antineoplastic response from plasma profiles [94], thus measurements of drug exposure into tumor interstitium by microdialysis may help to develop clinical PK-PD models with the aim of individualize drug therapy [95]. Microdialysis has been employed for the characterization of different antineoplastic drugs. Methotrexate, cisplatin, capecitabine, 5-fluorouracil, dacarbacine and melphalan have been measured into the tumor using clinical microdialysis in several types of malignancies such as breast cancer, melanoma, osteosarcoma and malignant fibrous histiocitoma (for review see [95, 96]). Measurements of plasma drug concentration have been employed during high-dose methotrexate treatment [97]. Although this practice has served to identify individuals with impaired renal function in order to avoid serious side effects, it assumed a relationship between pharmacological response and circulating levels of drug. Müller et al. [98] have studied interstitial tumor pharmacokinetics and plasma-to-tumor transfer rates of methotrexate in breast cancer patients by insertion of microdialysis probes into the primary tumor and the periumbilical subcutaneous adipose layer of previously chemotherapy-naive breast cancer patients. Absence of correlation between plasma AUC and the AUC in the interstitial space of tumor tissue was found, together with a high interindividual variability in transendothelial methotrexate transfer. Therefore, plasma levels of methotrexate were not predictive of intratumor levels. Similar results were obtained for 5-fluorouracil (5-FU), showing that plasma or subcutaneous levels of 5-FU failed to predict tumor response. Conversely, high interstitial tumor concentrations of 5-FU were associated with increased tumor response. This information may explain drug resistance in some patients and help to optimize dosing and administration schedules [99].
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 61
Microdialysis has also been used to assess the pharmacodynamics of chemotherapeutic agents [96]. Castejon et al. [66] have determined plasma concentrations of serotonin and 5-hydroxyindoleacetic acid during cisplatin treatment by means of microdialysis. Serotonin is involved in the production of emesis associated to antineoplastic treatment. Microdialysis has also been used for the monitoring of extracellular levels of growth factors, such as the vascular endothelial growth factor (VEGF), during treatment with tamoxifen in a mouse model of human breast cancer [100]. Although to date scarce PK-PD modeling studies applying microdialysis were made, integration of the pharmacological response with tumor PK profiles of the corresponding drug would help to define PK-PD relationship, which is essential for the rational design of drug administration regimens in cancer patients. Thompson et al. [101] studied the clinical and biochemical responses to the time course of melphalan in the subcutaneous interstitial space and in tumor tissue from patients with various limb malignancies. The authors showed a significant correlation between the melphalan mean concentration in subcutaneous microdialysate and tumour response [101]. In another PK-PD protocol, (Müller et al.) [102] have determined the unbound interstitial drug pharmacokinetics of 5-fluorouracil and methotrexate in solid tumour lesions of patients by means of in vivo microdialysis. The authors then made a pharmacodynamic simulation of the time versus drug concentration profile in an in vitro setting by exposing breast cancer cells to interstitial tumour concentration of the antineoplastic drugs. The authors concluded that in vivo PK–in vitro PD models might provide a rational approach for describing and predicting pharmacodynamics of cytotoxic drugs at the target site [102]. In summary, high interindividual variability in intratumoral drug distribution exists, indicating lack of correlation between plasma concentration of antineoplastic drugs and their interstitial tumoral levels. Plasma measurements do not serve as surrogates for intratumoral concentration and microdialysis may help to design optimal treatment schedules and to select appropriate drug, doses and dosing intervals for antineoplastic agents. Surprisingly, in the last three years, only few clinical microdialysis protocols were conducted for the study of intratumoral distribution of anticancer drugs. A possible explanation is that microdialysis experiments in cancer patients must be conducted in strict compliance with regulatory demands and need to be based on appropriate ethical conditions. In addition, there are other factors that limit the use of microdialysis in cancer research. Puncture of solid tumors by microdialysis catheter implantation may induce metastasis. However, the estimated incidence of metastasis by puncture ranged from 0.003% to 0.005 % and there is no evidence that puncture of tumor lesions affected the course or prognosis of the underlying disease [103]. Another limitation of the applicability of microdialysis sampling in oncology is the fact that the majority of the antineoplastic drugs act within cells. The relationship between extracellular drug concentrations and intracellular drug levels remains unknown. This drawback could be overcome by applying an attractive approach consisting in the simultaneous study of drug distribution with microdialysis and PET. PET measures total (intracellular, extracellular, and intravascular) concentrations of radiolabeled drugs in tissue, and microdialysis determines unbound drug concentrations in the extracellular space fluid of tissue. Therefore, combination of both techniques allows the description of the intracellular drug pharmacokinetics. Langer et al. [104], using 18F-labeled-cipro-
62 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
floxacin as a model drug, have found that in vivo intracellular ciprofloxacin pharmacokinetics was in accordance with previous in vitro data describing cellular ciprofloxacin uptake and retention. Therefore, PET/microdialysis combination might be useful during research and development of new drugs, for which knowledge of intracellular concentrations is of interest. Finally, some antineoplastic drugs, such as 5-fluorouracil, requires intracellular enzymatic conversion in order to exert their cytotoxic activity. In addition, other aspects like tumor location and accessibility for microdialysis probe implantation, and the possibility of variation in interstitial concentrations of cytotoxic drugs in different metastases in a patient restrict the utility of microdialysis for studies of antineoplastic drug distribution [12]. Central Acting Drugs Knowledge of brain uptake is an important issue for drugs acting in the central nervous system, such as anticonvulsivants, antidepressants, anaesthetics and anticancer drugs. Concentration-time profile of the drug in the central nervous system determines the intensity and duration of the effects of a central acting drug. As in the clinical setting, the measurement of brain concentrations of the drug is highly restricted; alternative determination of lumbar or ventricular cerebrospinal fluid is sometimes used. Nevertheless, drug concentrations in the cerebrospinal fluid provides only limited information with respect to drug distribution into the brain, because brain parenchyma distribution of a central acting agent is determined by multiple factors, including active biotransformation, active transport at the BBB and intracellular-extracellular exchange [105]. Intracerebral microdialysis would be a significant improvement, considering that it allows the study of the pharmacokinetic profile of the unbound drug fraction at a specific region within the brain. However, as discussed previously, microdialysis is a semi-invasive technique and may bear risks. Therefore, microdialysis sampling is restricted in the clinical setting for the study of brain drug distribution used in critical care patients subjected to surgery. Another drawback of microdialysis for the study of central acting drugs is the fact that this technique records the average drug concentration over a sampling interval of at least 5 min, being this sampling frequency not suitable to assess central pharmacokinetics of drugs that rapidly penetrate the brain (e.g. anesthetic induction agents) [106]. Nevertheless, microdialysis can be used in the early phase of clinical trials to establish brain penetration of drugs. A phase II trial of topiramate in severe traumatic brain injury demonstrated different free-drug concentrations in the extracellular space from that measured in cerebrospinal fluid (CSF) [107]. An interesting field of intracerebral microdialysis in the clinical setting is the study of brain distribution of anticonvulsivant agents. Despite the existence of a large variety of antiepileptic drugs, almost 30% of epileptic patients are resistant to treatment [108]. There is increasing evidence that over-expression of multidrug transporters such as Pglycoprotein is involved in the generation of pharmacoresistance to antiepileptic drugs because of a greater efflux from the brain of the central acting agent [24]. Therefore, monitoring of target site concentration of antiepileptic drugs by means of intracerebral microdialysis could elucidate the involvement of the efflux transport in the generation of the pharmacoresistance to antiepileptic drugs.
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 63
In the clinical setting, microdialysis protocols have demonstrated that intracerebral concentrations of valproic acid [109] and phenytoin [110] were slightly lower than plasma levels, suggesting that both anticonvulsivant drugs may be substrate for an energy-dependent carrier transport out of the central nervous system. Conversely, carbamazepine and carbamazepine-10,11-epoxide concentrations in the extracellular brain fluid closely mirror their unbound serum concentrations [111]. Intracerebral microdialysis was also used for measurement of brain concentration of other central acting drugs. Ederoth et al. [112] studied the BBB transport of morphine in patients with severe brain trauma by simultaneous microdialysis of morphine levels in "better" and "worse" brain tissue. The authors found that unbound brain morphine levels were lower than plasma concentrations suggesting the existence of an efflux transport system for morphine across the human BBB. In addition, the results suggested an increase of BBB permeability to morphine in the "worse" brain tissue. Brain penetration of anticancer drugs was also evaluated using microdialysis sampling in basic research. Zhuang et al. [113] have shown that P-glycoprotein and breast cancer resistance protein 1 (BCRP-1) limit topotecan distribution in brain parenchyma. Microdialysis sampling also allows the study of drug distribution to brain tumors. A significant increase in the penetration of methotrexate into the tumor tissue was found [114]. A hybrid physiologically-based pharmacokinetic model was used by the authors to characterize the mechanisms that may be responsible for the high methotrexate tumor concentration. Although microdialysis sampling is restricted in the clinical setting, this membranebased sampling technique is highly attractive for the preclinical evaluation of central acting drugs, considering the possibility of the simultaneously monitoring of brain drug concentrations and their effect on neurotransmission. Both traditional neurotransmitters and neuropeptides have a low molecular weight and diffused through the membrane of the probe, and therefore microdialysis allows the evaluation of drugs actions on biophase concentration of virtually all neurochemical substance [29]. Intracerebral microdialysis sampling has been extensively used for the study of antiepileptic drug concentrations at the target site in non-epileptic animals and experimental models of refractory epilepsy. Involvement of drug efflux transporters in brain parenchyma distribution of antiepileptic drugs was demonstrated in non-epileptic animals by enhancement of drug central levels by the application of drug efflux transporters inhibitors [24, 25]. Only few studies evaluated central pharmacokinetics of antiepileptic drugs in refractory epilepsy models with conflicting results. Whilst Rizzi et al. [115] using the Kainate model of epilepsy showed that overexpression of P-glycoprotein in the hippocampus is associated with reduced brain concentrations of phenytoin compared with control animals, Potschka and Löscher [116] did not find altered levels of phenytoin in hippocampus and amygdala of kindled when compared to non-kindled rats. Recently, we have demonstrated a critical role of P-gp overexpression in the development of pharmacoresistance to phenytoin in a model of epilepsy induced by 3-mercaptopropionic acid chronic administration, suggesting that administration of efflux transporters inhibitors could be an effective strategy to decrease pharmacoresistance to phenytoin antiepileptic treatment [117]. Comparing pharmacokinetics of anticancer agents in tumor and non-tumor extracellular fluid of brain might be an attractive approach to establish the therapeutic potential
64 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
of antineoplastic therapies. Apparaju et al. [118] have found, by means of intracerebral microdialysis, that gemcitabine levels in the tumor extracellular fluid was 2.2-fold greater than the corresponding value in the tumor-free extracellular fluid of the brain, suggesting that the greater tumoral distribution of gemcitabine region may facilitate selectively higher cytotoxicity against brain tumor cells. Pharmacodynamics and PK-PD modeling of antidepressant drugs have also been evaluated using intracerebral microdialysis. In an elegant study, (Bundgaard et al.) [119] validated an integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents, such as antidepressant drugs. Concomitant with brain microdialysis, serial blood sampling was conducted by means of an automated blood sampling device. Pharmacokinetics of escitalopram have been characterized simultaneously in plasma and the hippocampus of conscious, freely moving rats. Concomitantly, the modulatory and functional effects of escitalopram could be monitored as increases in brain 5-HT and plasma corticosterone levels following drug administration. Therefore, microdialysis sampling allows simultaneous monitoring of hippocampal escitalopram levels and their effect on serotonin extracellular concentrations and therefore the assessment of PK-PD modeling of neurochemical actions of antidepressant drugs [119]. Neurochemical effects of desvenlafaxine, a novel antidepressant drug, on cathecholamine hypothalamic levels were also studied in freely moving rats by microdialysis. Administration of desvenlafaxine induced an increase in noradrenaline levels in hypothalamic dialysate without any effect on dopamine and serotonin concentrations, suggesting its utility in a variety of central nervous system-related disorders [120]. In another report, using in vivo microdialysis, the protective effect of NGP1-01, a dual blocker of neuronal voltage- and ligand-operated calcium channels, was evaluated by monitoring choline release during N-methyl-D-aspartic acid (NMDA) infusion as a measure of excitotoxic membrane breakdown [121]. Intraperitoneal administration of NGP1-01 reduced NMDA-induced membrane breakdown demonstrating that NGP1-01 simultaneously blocks both major neuronal calcium channels and is sufficiently brainpermeable. Therefore, NGP1-01 is a promising lead structure for a new class of dualmechanism neuroprotective agents. Microdialysis was also used to describe, by means of PK–PD modeling, the effect of drug candidates on dopaminergic activity at different nuclei of the central nervous system (CNS) [122, 123]. The effect of benzatropine analogues on dopamine concentration in the nucleus accumbens after its intravenous administration was evaluated [123]. The authors fitted plasma concentration of the analogues and their effects on extracellular dopamine levels to two different PK–PD models, such as an effect compartment model and a model with indirect physiological response. The authors demonstrated that the indirect model is more suitable for PK–PD modeling of benzatropine analogues than the linked PK–PD model. These results are in accordance with the mechanism of action of the analogues because these drugs bind to the dopamine transporter inhibiting the dopamine re-uptake and consequently elevate dopamine extracellular levels. Brain microdialysis has also been used for PK-PD modeling of therapeutic agents at the central nervous system. PK–PD modeling allows the study of the mechanism responsible for the time delay of central actions of drugs. In an elegant study, (Bouw et al.) [124] have simultaneously determined blood and brain concentrations of morphine-6-
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 65
glucuronide and its antinociceptive effect by means of microdialysis sampling. By applying a PK–PD model with an effect compartment, the authors found a greater delay in the onset of the effect when antinociceptation was related to plasma morphine-6glucuronide concentrations with regard to brain levels. Therefore, it was concluded that half of the effect delay could be explained by transport across the blood–brain barrier, suggesting that the remaining delay is a result of drug distribution in the brain parenchyma [124]. Microdialysis was used to describe the relationship between norfloxacin concentrations in the CNS and its adverse reactions, such as convulsive effect [125]. Brain extracellular concentrations of norfloxacin by means of microdialysis and a quantitative electroencephalogram (EEG) were simultaneously determined. Blood samples were also collected to determine norfloxacin plasma levels. Although norfloxacin brain concentrations peaked early after its intravenous administration, the effect on the EEG measurement was delayed. By applying a PK–PD model with an effect compartment, the authors demonstrated that the delayed EEG effect of norfloxacin is not due to BBB transport [125]. In conclusion, microdialysis sampling is a promising technique for drug development of central acting drugs, especially in the preclinical phase. The most attractive application of brain microdialysis seems to be the evaluation of brain parenchyma distribution of developing antiepileptic drugs and its ability to overcome pharmacoresistance in chronic epileptic animal models. In addition, impact of therapeutic strategies to enhance brain penetration of antiepileptic, such as efflux transporters inhibitors, could also be evaluated during preclinical phase of drug development by means of microdialysis sampling. Antihypertensive Drugs A poor concentration-response relationship with regard to the blood pressure effect of antihypertensive drugs has been found. Taking into account the pharmacodynamic properties of antihypertensive drugs, the suggestion of absence of relationship between plasma levels of antihypertensive drugs and its blood pressure lowering effect could reflect an inadequacy or failure in the approaches designed to detect such correlation. A number of factors have hampered the possible identification of a correlation, including failure to study individual patients, inability to collect sufficient pharmacodynamic data, failure to identify and account for temporal delay in the onset of the pharmacological effect, the use of restricted concentration ranges and the use of dose rather than concentration [126, 127]. Using a ‘shunt’ intra-arterial microdialysis probe, a good relationship was found between metoprolol concentration in the effect compartment and its hypotensive and chronotropic effect [128-130]. Moreover, the maximal response was significantly greater in hypertensive animals, such as spontaneously hypertensive rats and animals with aortic coarctation, with regards to their respective control animals. Therefore, this data suggests that the proposed lack of relationship between plasma levels of -blockers and its antihypertensive effect is probably a consequence of an inadequate experimental design and data analysis. More recently, by using in vivo microdialysis, we have demonstrated that the modified Emax designed by Schoemaker et al. [38] allows an accurate and precise estimation
66 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
of diltiazem and verapamil sensitivity to the hypotensive effect in conditions when maximal pharmacological response can not be attained [131, 132]. In conclusion, microdialysis sampling is a powerful tool for PK–PD modeling of cardiovascular drugs in basic research, taking into account that it allows continuous and simultaneous determination of antihypertensive drugs plasma levels and their corresponding effect on blood pressure and heart rate in the same animal. Moreover, PK–PD modeling not only allows a better pharmacodynamic characterization of blood pressure lowering agents, but also permits the study of the physiopathological mechanisms of the hypertensive stage in different experimental models. APPLICABILITY OF PET FOR TISSUE DRUG DISTRIBUTION STUDIES AND PK-PD MODELING Principles of PET Imaging In the last years, several imaging techniques have been developed for the evaluation of the pharmacokinetic and pharmacodynamic properties of therapeutic agents. PET, SPECT and MRS are the most popular imaging techniques used for this purpose [6]. However, SPECT and MRS have limited applicability in drug distribution studies because of the existence of technical drawbacks, including low sensitivity, impressive quantification and low spatial resolution [133]. Conversely, the main problems inherent to SPECT and MRS are not important issues with PET, and therefore this imaging technique became the most applied method for non-invasive pharmacokinetic studies of drugs. Principles of PET have been recently reviewed in several works and therefore only a brief description will be included in the present chapter (for review see [133-135]). PET is based on the emission of positrons (positive electrons, b+) of radionuclides with low atomic number and relative proton excess. After positron emission, it rapidly loses kinetic energy and sometimes interacts with an electron, generating an annihilation event. In this event, a positron-electron pair is converted to energy, resulting in the generation of two photons that emitted in opposite directions. These photons are then sensed by detector pairs positioned at 180° to each other [133]. Measurement of tissue drug levels of drugs by means of PET imaging requires radiolabelling of the compound of interest with an isotope that emits radiation that can be detected by imaging. It is important to mention, that a strict condition of PET imaging is that radiolabelling of the drug does not modify the pharmacokinetic and pharmacodynamic properties of the pharmacological agent [133]. One strategy is the radiolabelling of atoms that form part of the native structure of the drug, such as carbon, hydrogen, nitrogen or oxygen. However, there are great limitations in the use of isotopes of these atoms for PET imaging of drugs. Firstly, drugs labeled with 14C or 3H generates negative electrons that only diffused few millimeters from their site of generation. Therefore, although these isotopes could be used for the evaluation of tissue distribution of drugs in small laboratory animals, their applicability in human studies is neglected [133]. Secondly, the half-life of the decay of 15O, 13N, 11C, is extremely short to perform pharmacokinetic studies of drugs using PET imaging. Conversely, 18F, 76Br and 124I have long half-life that allows their used for PET imaging of pharmacological agents. However, only few therapeutic agents contain one or more atoms of F, Br or I that could be subjected for radiolabelling [133].
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 67
Alternatively, positron emitting halogen isotopes could also be substituted for hydrogen of hydroxyl groups. Although these analogues are not guaranteed to retain pharmacological properties of the original drug, fluoride substitution are generally hlghly conservative and have shown to be useful probes in many situations [133]. It is important to take into account that radiolabelled compounds need to be synthesized, isolated, purified and formulated as a sterile, pyrogen-free solution within 2 halflife of the radionuclide. Therefore, drug precursors that can be labelled in a single step are needed for most therapeutic agents. In addition, PET imaging studies requires both a cyclotron and a PET scanner in close proximity [106]. Compared with traditional methods for tissue sampling of drug concentrations, PET imaging has several advantages, including its non-invasive nature, high sensitivity and its universal nature, considering that theoretically the availability of PET radionuclides of nitrogen, carbon and fluorides makes possible to prepare for almost any drug [133]. In addition, PET has a high spatial resolution, allowing determination of drug tissue distribution in small volumes of tissue and also permits differentiation of physiological alterations that occurs nanometers apart [106]. Nevertheless, PET imaging studies have some drawbacks that could limit its applicability for pharmacokinetic studies. As comment above, most radiolabelled drugs need to be prepared in close proximity to the imaging laboratory [106]. In addition, due to rapid decay of most radionuclides, the time interval of the pharmacokinetic study is limited. For instance, pharmacokinetic study needs to be completed in 40 min with tracers containing 13N, 80 min with 11C and 8 hours with 18F [133]. Another drawback of PET imaging is that this methodology did not discriminate within positron emission from the parent drug and their metabolites, and therefore quantification is only accurate if drug biotransformation is negligible [133]. Additionally, PET imaging monitors total drug tissue concentrations rather than extracellular levels. Although anatomical resolution of PET imaging is high, it is much lower than other imaging techniques, including computed tomography, MRI and ultrasound [133]. Applicability of PET Imaging for Pharmacokinetic Studies In the field of pharmacology, the most attractive application of PET is the noninvasive evaluation of tissue distribution of drugs, especially in the treatment of infection and cancer. For these studies, the drug is radiolabelled with a positron emitter, preferentially with 18F, and injected in the experimental subject. Thereafter, PET images are acquired at different time points and quantified by means of maps of radioactivity concentration in the tissue [133]. When negligible biotransformation of the drug occurs, regional levels of the parent drug could be obtained by simply dividing each pixel in the images by the specific activity of the radiotracer. Therefore, repeating this procedure at different time points after drug administration allows the estimation of classical pharmacokinetic parameters, including peak concentration, plateau concentration and area under the curve of the drug. In the following section, we reviewed the most relevant PET based pharmacokinetic studies of different therapeutic agents [133]. Antiinfective Agents PET imaging was firstly used to describe tissue distribution of erythromycin in infected tissues [136]. Radiolabelled erythromycin is obtained by reductive methylation of
68 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
N-demethyl-erythromycin with [11C]formaldehyde yielding a product with similar chromatographic properties. By using this radiotracer, (Wollmer et al.) [136] showed that drug distribution in infected lung tissue is similar to normal pulmonary tissue. Although radiolabelling of erythromycin with carbon isotopes allows a successfull estimation of eryhtromycin tissue distribution, it must be taken into account that most antimicrobial agents have a much slower tissue equilibration, requiring the design of radiolabelled agents with longer lived radionuclides than 11C [136]. For instance, the presence of fluorine atoms in the molecular structure of fluconazole made this drug an ideal candidate for PET imaging. PET imaging of fluconazole is also justified considering that the drug undergoes minimal hepatic biotransformation and therefore measurement of tissue radioactivity reflects levels of the parent drug [133]. In an interestingly preliminar study [137], 18F-labelled fluconazole was used to compare pharmacokinetic properties of a microdose of the agent with regard to a pharmacological dose. Coadministration of 18F-fluconazole with a pharmacological dose of the unlabelled parent drug shows a rapid equilibration and an uniform distribution in most organs of the rabbit [137]. Conversely, application of the labelled drug in a “carrier-free” solvent accumulation of fluconazole was decreased in the heart, spleen and muscle and increased in the liver. This study clearly demonstrates the limitation of microdosing in the human phase 0 of drug development [137]. Pharmacokinetic properties of fluconazole were also evaluated in healthy volunteers by means of PET imaging [138]. The administration of 18F-fluconazole with unlabelled parent drug showed a non-uniform tissue drug distribution with accumulation of the drug in the spleen and lower levels in the bone [138]. Therefore, PET imaging demonstrated that fluconazole, at a dose of 5 mg/kg, is effective in the treatment of candidiasis at the hepatoesplacnic and urinary tract, but required higher doses for treatment of infections of the bone and central nervous system [138]. Fluoroquinolones also contain fluorine atoms in their chemical structure, and therefore are candidates for radiolabelling and PET imaging for in vivo pharmacokinetic studies. Fischman et al. [139] studied fleroxacin pharmacokinetics after administration of [18F]fleroxacin in 12 healthy volunteers. The authors demonstrated that fleroxacin rapidly distributed in most tissues, including heart, liver, lung myocardium and spleen, achieving concentrations two-fold above the MIC for 90% of Enterobacteriaceae strains tested. Conversely, a limited distribution of distribution of [18F]fleroxacin into the brain was observed. Additionally, concentrations of fleroxacin in tissue were similar in males and females [139]. Langer et al. [140] also studied the pharmacokinetic properties of radiolabelled [18F]ciprofloxacin in patients with soft tissue infections. Distribution of [18F]ciprofloxacin increased in infected tissues with peak ratios between infected and uninfected tissue ranging from 1.8 to 5.5. Nevertheless, radioactivity was not retained in infected tissue withouth differences in the elimination half-life of [18F]ciprofloxacin when comparing infected and uninfected tissues. The authors concluded that pharmacokinetics of [18F]ciprofloxacin in infected tissue are governed by increased blood flow and vascular permeability due to local infection [140]. Previously, the same authors have shown, by using [18F]ciprofloxacin, high tissue levels of this fluoroquinolone in several tissues, including kidney, heart, spleen, liver, musclea and lung [141]. Whilst [18F]ciprofloxacin rapidly wash out from the kidney, heart and spleen, prolonged readiotracer retention was
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 69
observed in liver, muscle and lung. Brain radioactivity concentrations of [18F]ciprofloxacin were under the limit of quantification suggesting that ciprofloxacin is not suitable for the treatment of infection at the central nervous system [141]. Briefly, PET imaging was also used for the study of trovafloxacin pharmacokinetics, showing that this fluoroquinolone will be useful in the treatment of a broad range of infections at diverse anatomic sites [142]. Drugs Acting at the Central Nervous System PET imaging have also been used for the study of different pharmacokinetic and pharmacodynamic properties of central nervous system acting drugs. Applicability of PET can be divided in direct and indirect studies. In direct studies, dynamic imaging is performed after administration of the radiolabelled drug, obtaining as information the distribution of the drug into different nuclei of the central nervous system [133]. However, PET imaging is also a valuable tool for the estimation of parameters describing in vivo drug-receptor interactions. For these studies, PET protocols are much more complex than for the study of drug distribution. Experimental design depends on the pharmacodynamic properties of the drug under study. For instance, for drugs that interact with a single subtype of receptors, time-activity curves from a single or multiple administration of the drug can be analysed by compartmental modeling to estimate receptor density (Bmax), binding affinity (KD), or binding potential (Bmax/K D). Conversely, in the case of drugs that bind to multiple receptor subtypes, kinetic parameters for a specific receptor can be estimated by blocking other receptors with unlabelled ligands [133]. Central distribution of zolmitriptan has been studied by means of PET imaging, considering the lack of studies regarding central nervous system access of this drug [143]. The authors found that [11C]zolmitriptan rapidly reached therapeutic concentrations at the central nervous system after its intravenous application of the triptan. Therefore it could be concluded that zolmitriptan enters the brain parenchyma in humans, achieving an uptake rate and concentration compatible with a central mechanism of action [143]. Brain distribution of vinpocetine, a compound used in the prevention of cerebrovascular disease, was evaluated by means of PET imaging after intravenous administration of [11C]vinpocetine [144]. The drug rapidly reached the central nervous system and distributed heterogeneously in different brain nuclei, suggesting the presence of specific binding site. Additionally, the authors found that the brain regions which showed increased uptake in the human brain correspond to those in which vinpocetine has been shown to induce elevated metabolism and blood flow [144]. Nevertheless, the most attractive application of PET for drugs with an action on the central nervous system is the in vivo study of receptor binding interaction. In this regard, a large number of radiotracer with specific affinity for different subtypes of receptors have been developed and validated, allowing the evaluation of in vivo binding properties of different pharmacological agents, including antipsychotics, antidepressants, anxiolytics, antiepileptics, among others (for review see [145]). On the other hand, these radiotracers also allow the study of brain receptor distribution. Table 3 summarizes actually available radiotracers for the evaluation of in vivo binding of different therapeutic drugs.
70 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Table 3.
Höcht et al.
Radiotracers Designed for Study of Drug-Receptor and Drug-Transporters Binding Studies Radiotracer
[11C]NNC 112, [11C]SCH 23390
Target D1 dopamine receptor
11
D2 dopamine receptor
18
[ F]fallypride
D2/D3 dopamine receptor
[11C]CFT
Dopamine uptake trabsporter
[11C]carfentanil, [11 C]diprenorphine
Opiate receptor
[ C]racloporide
18
Opiate sigma-1 receptor
11
5-HT1A serotonin receptor
11
5-HT2A serotonin receptor
[ F]FPS [ C]WAY 100635, [18F]MPPF [ C]MDL 100907 11
[ C]DASB 11
Serotonin transporter 11
[ C]flumazenil, [ C]Ro15-4513 11
Benzodiazepine receptor
[ C]TMSX
A2A adenosine receptor
NCFHEB
Nicotinic acetylcholine receptors
18
[ F]MK-9470
CB1 cannabinoid receptor
11
Abreviattions: [ C]TMSX: [7-methyl-(11)C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine ([(11)C]TMSX); NCFHEB: Norchloro-fluoro-homoepibatidine; [11C]NNC 112: (+)-8-Chloro-5-(7-benzofuranyl)-7-hydroxy-3-[11C]methyl-2,3,4,5tetrahydro-1H-3-benzazepine; [11C]SCH 23390: ((R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7ol); [11C]CFT: 2ß-carbomethoxy-3ß-(4-fluorophenyl)tropane; [18F]FPS: 3-fluoropropyl-4-((4-cyanophenoxy)methyl)-. Piperidine; [11C]WAY 100635: N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- N-(2-pyridyl)cyclohexanecarboxamide trihydrochloride; [18F]MPPF: 2'-Methoxyphenyl-(N-2'-pyridinyl)-p-18F-fluoro-benzamidoethylpiperazine; [11C]MDL 100907: ((R)-(+)-4 -(l-hydroxy-1-(2,3-dimethoxyphenyl)methyl)-N-2-(4-fluorophenylethyl)piperidine; [18F]MPPF: 2'-methoxyphenyl-(N-2'-pyridinyl)-p-18F-fluoro-benzamidoethylpiperazine; [11C]MDL 100907: (R)-(+)-4 -(l-hydroxy-1-(2,3-dimethoxyphenyl)methyl)-N -2-(4-fluorophenylethyl)piperidine; [11C]DASB: [(11)C]-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile.
Antineoplastic Agents PET imaging of antineoplastic drugs provides information regarding tumor pharmacokinetics and treatment response, making this sampling technique highly attractive both in drug development and clinical use of anticancer drugs (for review see 146-150]). PET can provide information that is often difficult to measure in the intact animal or patient. Several antineoplastic drugs were radiolabelled with the intention to study their tissue distribution and pharmacological response, including 5-fluorouracil (5-FU), N-[2(dimethylamino)ethyl]acridine-4-carboxamide (DACA), temozolomide, docetaxel, ifosfamide, gemcitabine, carboplatin, among others [133]. An example of the applicability of PET in drug development is the evaluation of tissue distribution properties of DACA in a pre-phase I study, using a radiotracer dose equivalent to 1/1000 of the phase-I starting dose [151, 152]. Radioactivity was shown to accumulate in vertebra < brain < tumour < kidney < lung < myocardium < spleen < liver. Tissue accumulation profile of DACA suggested that myelotoxicity and neurotox-
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 71
icity were less likely to be dose-limiting, and probably cardiotoxicity limited dose escalation in the clinical practice. PET study also showed a variable tumor uptake of [11C]DACA that was moderately correlated with blood flow [151-153]. Saleem et al. [154] evaluated the tumor, normal tissue, and plasma pharmacokinetics of temozolomide in vivo, and also determined whether such pharmacokinetics resulted in tumor targeting. Considering the postulation that temozolomide undergoes decarboxylation and ring opening in the 3-4 position to produce the highly reactive methyldiazonium ion that alkylates DNA, the authors used a dual radiolabelling strategy, with [11C]temozolomide separately radiolabelled in the 3-N-methyl and 4-carbonyl positions, to establish the mechanism of action. Both radiolabelled forms of [11C]temozolomide undergo rapid systemic clearance. A decrease in tissue exposure to [11C]temozolomide was also observed with [4-11C-carbonyl] temozolomide compared with [3-N-11Cmethyl]temozolomide [154]. Another interesting result of this study was the higher [11C]radiotracer and [11C]temozolomide exposure (AUC(0-90 min)) in tumors compared with normal tissue. The significantly higher amounts of plasma and exhaled [11C]CO(2), in addition to the lower normal tissue and tumor [11C]temozolomide AUC(0-90 min) observed with [4-11C-carbonyl]temozolomide, confirmed the mechanism of metabolic activation of temozolomide postulated by the authors. Considering these results, the authors concluded that the higher tumor [11C]temozolomide exposure compared with normal tissue and the tissue-directed metabolic activation of temozolomide may confer potential therapeutic advantage in the activity of this agent [154]. The work of (Saleem et al.) clearly demonstrates that PET imaging not only allows the noninvasive study of tumor durg distribution, but also permits the elucidation of the mechanism of action of anticancer agents. PET imaging also allows comparing drug uptake of primary tumors with regard to metastatic lesions. Jayson et al. [155], using iodinated radiotracer of HuMV833, a humanized anti-VEGF antibody, showed that primary tumors exhibited clearance rates that were three 3 times faster compared to metastatic tumors. The authors suggested that the heterogeneous tumor accumulation might explain the lack of response to antitumoral therapy in some patients. In addition, the study also found discrepancies between plasma and tumoral pharmacokinetics, indicating that traditional plasma sampling cannot be used to predict intratumoral drug concentrations [155]. PET imaging is also useful for monitoring antitumoral response to antineoplastic drugs. Tumor response to therapy has been assessed by determining the glycolytic response of tumors to chemotherapy with 18F-fluorodeoxyglucose (FDG) [147]. This tracer allows obtaining a mapping of tumor glucose use, and therefore establishing activity of malignant tumors. It was found that changes in FDG uptake by tumors after the first chemotherapy cycle are highly correlated with patient survival, suggesting that FDGPET might become an early indicator for treatment efficacy in drug development and clinical studies [156]. More recently, 18F-3-deoxy-3-fluorothymidine (FLT), a marker of DNA replication and cell proliferation, was used as an early imaging biomarker to assess antitumoral response in patients with glioblastoma [157, 158]. It was found that patients with an adequate metabolic response to bevacizumab and irinotecan regimen, defined as a decrease of at least 25% in FLT uptake by the tumor, showed a significantly longer survival than patient without response. Moreover, responders were identified only 2 weeks after the start of the therapy [157, 158].
72 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Höcht et al.
Utility of PET in PK-PD Modeling Although PET imaging has been extensively used for the study of tissue pharmacokinetics (eg antiinfective, antineoplastic and central acting drugs) and for monitoring drug-receptor interactions and pharmacological response, to the best our knowledge, this sampling technique has not been applied with the intention to integrate pharmacokinetic and pharmacodynamic concepts. A possible explanation for the lack of PK-PD modeling studies with PET imaging is the uncertainty of tissue concentration of the parent drug, considering that PET imaging did not allow discriminating between the original drug and its metabolites. Another limitation of PET for PK-PD studies is the impossibility to study multiple PET tracers in a single experiment. Therefore, this technique only allows the estimation of the pharmacokinetic or the pharmacodynamic component of a PK-PD modeling study. PRINCIPLES AND APPLICABILITY OF MRS FOR PHARMACOKINETIC STUDIES MRS is an alternative imaging technique to PET that allows discrimination between parent drug and metabolites. However, a strong limitation of MRS is its low sensitivity [133]. MRS employs magnetic field gradients to produce images generated by the relaxation of nuclei with magnetic spins. Considering that individual atoms of all compounds have specific resonance frequencies, it is theoretically possible to obtain specific MR images of any drug and drug metabolites [133]. However, considering its low sensitivity, in most applications of MRS images cannot be recorded, and therefore field gradients are used to select a specific tissue site for a spectrum record. Nevertheless, with this approach, sensitivity of MRS is much lower than PET imaging. MRS measurements can be performed serially, giving the possibility of pharmacokinetic analysis with a high temporal resolution [133]. Another advantage of MRS over PET imaging is that the number of tracers available for MRS studies is potentially unlimited. Isotopes with non-zero are available for all atoms in drugs, including 1H, 13C, 15N, 17O, 19F and 31P. Majority of MRS studies have been performed with 19F isotope, considering its high intrinsic sensitivity and zero natural background [133]. The existence of high background represents a limitation for the use of 1H.In addition, 13C and 15N show lower intrinsic sensitivity. MRS tracers are stable compounds and therefore the time interval of pharmacokinetic studies is unlimited with MRS. In other words, matching half-life of the tracer to the time scale of the pharmacokinetic study is not an issue with MRS [133]. In the next section, examples of MRS applications for pharmacokinetic studies of drugs will be described. Tumor distribution of several antineoplastic drugs has been evaluated using MRS imaging. One of the most anticancer drugs studied with this methodology is 5-FU. Estimation of tumoral half-life of 5-FU is highly important in anticancer therapy, considering that trapping of 5-FU is a necessary condition for pharmacological response [159]. It was found that patients with larger tumoral half-life of 5-FU assessed by MRS showed a greater pharmacological response. Therefore, 19F-MRS might become a useful technique for early detection of non-responders to 5-FU therapy [159]. 19 F-MRS ahs also been used for the study of liver and muscle distribution of fleroxacin in healthy volunteers [160]. Compared with PET imaging, this study has demonstrated that spatial resolution of MRS was low requiring larger volumes of tissue for
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 73
quantification of fleroxacin tissue levels [160]. Nevertheless, combining PET and MRS imaging could be an attractive approach, considering that PET imaging provides precise measurement of total drug levels in small volumes of tissue, and MRS can additionally discriminates the contributions of different molecular species (parent drug and metabolites) and differentiates between intra and extracellular drug concentrations. Whole brain concentrations of psychotropic drugs have been also monitored by MRS imaging. In a pioneer study, by using 7Li-MRS, it was found that a relative slow lithium accumulation may explain the delay in therapeutic response to antimaniac therapy in some patients [161]. In another work, (Renshaw et al.) [162] demonstrated that brain concentrations of fluoxetine and its active metabolite, norfluoxetine, were 2.6-fold higher with regards to plasma levels, which may have implications for understanding therapeutic and toxic effects of fluoxetine. CONCLUSIONS The development of new sampling techniques greatly enhances our current knowledge regarding tissue drug distribution and PK-PD models. Membrane-based sampling and imaging sampling techniques monitor with high spatial and temporal resolution drug levels at the target site. Also, these methodologies allow the simultaneous assessment of drug-receptor interactions and the effect of drugs on endogenous compounds. Therefore, considering that microdialysis and imaging techniques, especially PET, provide information about tissue pharmacokinetics and pharmacodynamics, they could be considered as the reference techniques in PK-PD modeling studies. Table 4 shows the most attractive application of microdialysis and imaging techniques for pharmacokinetic, pharmacodynamic and PK-PD modeling studies. However, as pointed out in the above mentioning sections, these techniques have some drawbacks that could limit their applicability. Whilst intracerebral microdialysis is restricted to use in critical care patients in the clinical setting, PET imaging does not allow discriminating between concentration of the parent drug and its metabolites. Nevertheless, it is important to take into account that microdialysis sampling and PET imaging are complementary techniques and the combination of the same could greatly improve the information gained in PK-PD studies. For instance, as comment above, whilst microdialysis sampling assesses extracellular tissue drug concentrations, PET imaging gives information regarding total tissue levels. Therefore, simultaneous microdialysis/PET studies allow a precise estimation of intracellular drug levels that may be highly relevant for drugs acting within the cellule. Another example of the benefits of microdialysis/PET combination is the assessment of PK-PD properties of drugs that affect central neurotransmission. As shown by Schiffer and collaborators [163], whilst PET imaging allows the study of the dopamine receptorsbinding properties of 11C-raclopride, microdialysis assesses the effect of the drug on dopamine extracellular levels. In addition, combining microdialysis sampling with PET imaging could be attractive for the evaluation of the impact of metabolite generation in PET. As comment above, PET imaging does not discriminate between parent drug and metabolites. Simultaneous intravenous microdialysis may give insights regarding drug biotransformation by assessing circulating levels of the drug and its degradation products.
74 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Table 4.
Applications of New Sampling Techniques for Pharmacokinetic and PK-PD Studies
Technique
Therapeutic Group
Antimicrobial agents
Applications
Microdialysis
Central acting drugs
Cardiovascular drugs Antimicrobial agents
PET imaging
Comments
Antibiotic penetration in non-infected soft Highly attractive for PKtissues PD modeling of antimicroDistribution of antimicrobial agents in infected bial agents tissues In vivo PK- in vitro PD modeling of antibiotics In vivo evaluation of prodrugs
Anticancer drug distribution in solid tumors Compartmental distribution within a tumor Antineoplastic Pharmacodynamics of antineoplastic drugs on drugs biochemical markers In vivo PK-PD modeling of anticancer agents
MRS imaging
Höcht et al.
Limited by the fact that most antineoplastic drugs act within cells. Tumor distribution is not homogenous Ethical considerations
Brain penetration of anticonvulsant agents Distribution of anticonvulsivants at the epileptic focus Evaluation of central pharmacokinetics of developmental anticonvulsivant drugs Evaluation of efflux transporters inhibitors as a therapeutic strategy to overcome antiepileptic drug pharmacoresistance In vivo PK-PD modeling of antiepileptic drugs In vivo evaluation of neurochemical effects of antidepressants and antipsychotic agents
Use of clinical microdialysis limited to critical care patients. Highly attractive for preclinical drug evaluation
In vivo PK-PD modeling of antihypertensive agents
Limited to preclinical drug evaluation
Antibiotic penetration in non-infected soft Limited to specific antimitissues crobial agents Distribution of antimicrobial agents in infected tissues
Anticancer drug distribution in solid tumors Antineoplastic Pharmacodynamics of antineoplastic drugs on drugs biochemical markers
Allows evaluation of heterogeneous drug distribution in different tumors
Central acting drugs
Estimation of in vivo drug receptor interaction Allows simultaneous monitoring of drug accuCentral distribution of drugs mulation in different nuclei
Antimicrobial agents
Antibiotic penetration in non-infected soft Limited to specific antimitissues crobial agents Distribution of antimicrobial agents in infected tissues
New Sampling Techniques
Frontiers in Drug Design & Discovery, 2009, Vol. 4 75 (Table 4) contd....
Therapeutic Group
Technique
Applications
Comments
Anticancer drug distribution in solid tumors Antineoplastic Pharmacodynamics of antineoplastic drugs on drugs biochemical marker
Only allows estimation of tumor half-life
Central distribution of drugs
Only allows estimation of whole brain distribution Differentiates between parent drug and metabolites
MRS imaging Central acting drugs
These few examples strength out the potential of combined microdialysis/PET for PK-PD studies. To the best our knowledge, no studies have applied simultaneous microdialysis/PET for the evaluation and development of mechanism-based PK-PD model. Nevertheless, considering that the combination of these sampling methodologies allow the simultaneous assessment of target site drug distribution and receptor binding properties, simultaneous microdialysis/PET may became an attractive approach for mechanism-based PK-PD modeling. In conclusion, membrane-based and imaging techniques, both used alone or simultaneously, will became the standard methodology for PK-PD modeling, enhancing gain of information during both drug development and clinical practice. ABBREVIATIONS 5-FU
=
5-Fluorouracil
AUC
=
Area under the curve
BBB
=
Blood-brain barrier
CE
=
Capillary electrophoresis
Cmax
=
Maximum concentration of drug in serum
CNS
=
Central nervous system
DACA
=
Dimethylamino)ethyl]acridine-4-carboxamide
EC50
=
Effective concentration to yield half-maximal response
EEG
=
Electroencephalogram
Emax
=
Maximal efficacy
FDG
=
18
F-fluorodeoxyglucose
FLT
=
18
F-3-deoxy-3-fluorothymidine
LC
=
Liquid chromatography
MIC
=
Minimum inhibitory concentration
76 Frontiers in Drug Design & Discovery, 2009, Vol. 4
MRS
=
Magnetic resonance spectroscopy
MS
=
Mass spectrometry
NMDA
=
N-methyl-D-aspartic acid
PET
=
Photon emission tomography
PK-PD
=
Pharmacokinetic-pharmacodynamic
SPET
=
Single photon emission computed tomography
TDM
=
Therapeutic drug monitoring
Höcht et al.
REFERENCES [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38]
Debouck, C.; Metcalf, B. Ann. Rev. Pharmacol. Toxicol., 2000, 40, 193. Curtis, G.; Colburn, W.; Heath, G.; Lenehan, T.; Kotschwar, T. Appl. Clin. Trials, 2000, 9, 52. Derendorf, H.; Lesko, L.J.; Chaikin, P.; Colburn, W.A.; Lee, P.; Miller, R.; Powell, R.; Rhodes, G.; Stanski, D.; Venitz, J. J. Clin. Pharmacol., 2000, 40, 1399. Toutain, P.L. AAPS J., 2002, 4, 1. Prentis, R.A.; Lis, Y.; Walker, S.R. Br. J. Clin. Pharmacol., 1988, 25, 387. Brunner, M.; Langer, O. AAPS J., 2006, 8, E263. Levy, G. Clin. Pharmacokinet., 1998, 34, 323. Ho, R.H.; Kim, R.B. Clin. Pharmacol. Ther., 2005, 78, 260. Gogtay, N.J.; Kshirsagar, N.A.; Dalvi, S.S. Br. J. Clin. Pharmacol., 2001, 52, 103S. Schumacher, G.E.; Barr, J.T. Expert Rev. Pharmacoeconomics Outcomes Res., 2002, 2, 89. Schuck, E.L.; Derendorf, H. Expert Rev. Antiinfect. Ther., 2005, 3, 361. Höcht, C.; Opezzo, J.A.W.; Bramuglia, G.F.; Taira, C.A. Curr. Clin. Pharmacol., 2006, 1, 163. Langer, O.; Müller, M. Curr. Drug. Metab., 2004, 5, 463. Nordbring, F. Scand. J. Infect. Dis. Suppl., 1978, 14, 21. Fischman, A.J.; Babich, J.W.; Bonab, A.A.; Alpert, N.M.; Vincent, J.; Callahan, R.J.; Correia, J.A.; Rubin R.H. Antimicrob. Agents Chemother., 1998, 42, 2048. Jain, E.K. Nat. Med., 1994, 4, 655. Heikkinen, T.; Laine, K.; Neuvonen, P.J.; Ekblad, U. Br. J. Obstet. Gynaecol., 2000, 107, 770. Begley, D.J. Pharmacol. Ther., 2004, 104, 29. de Boer, A.G.; Gaillard, P.J. Annu. Rev. Pharmocol. Toxicol., 2007, 47, 323. Cordon-Cardo, C.J.; O’Brien, J.P.; Casals, D.; Rittman-Grauer, L.; Biedler, J.L.; Melamed, M.R.; Bertino, J.R. Proc. Natl. Acad. Sci. USA, 1989, 86, 695. de Boer, A.G.; van der Sandt, I.C.; Gaillard, P.J. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 629. Löscher, W.; Potschka, H. Nat. Rev. Neurosci., 2005, 6, 591. Fromm, M.F. Trends Pharmacol. Sci., 2004, 25, 423. Löscher, W.; Potschka, H. Prog. Neurobiol., 2005, 76, 22. Remy, S.; Beck, H. Brain, 2006, 129, 18. Lazarowski, A.; Czornyj, L.; Lubieniecki, L.; Vazquez, S.; D’Giano, C.; Sevlever, G.; Taratuto, A.L.; Brusco, A.; Girardi, E. Curr. Drug Ther., 2006, 1, 291. Lin, J.H. Curr. Drug Metab., 2006, 7, 39. Gibbs, M.A.; Hosea, N.A. Clin. Pharmacokinet., 2003, 42, 969. Höcht, C.; Opezzo, J.A.W.; Taira, C.A. Curr. Drug Discov. Technol., 2004, 1, 269. Perez-Urizar, J.; Granados-Soto, V.; Flores-Murrieta, F.J.; Castañeda-Hernandez, G. Arch. Med. Res., 2000, 31, 539. Csajka, C.; Verotta, D. J. Pharmacokinet. Pharmacodyn., 2006, 33, 227. Bauer, R.J.; Guzy, S.; Ng, C. AAPS J., 2007, 9, E60. Sheiner, L.B.; Stanski, D.R.; Vozeh, S.; Miller, R.D.; Ham, J. Clin. Pharmacol. Ther., 1979, 25, 358. Mandema, J.W.; Tuck, B.; van Stevenink, A.L.; Breimer, D.D.; Cohen, A.F.; Danhof, M. Clin. Pharmacol. Ther., 1992, 51, 715. Dayneka, N.L.; Garg, V.; Jusko, W. J. Pharmacokinet. Biopharm., 1993, 21, 457. Bauer, J.A.; Balthasar, J.P.; Fung, H.L. Pharm. Res., 1997, 14, 1140. Höcht, C.; Opezzo, J.A.W.; Bramuglia, G.F.; Taira, CA. Expert Opin. Drug Discov., 2006, 1, 289. Schoemaker, R.C.; van Gerven, J.M.A.; Cohen, A.F. J. Pharmacokinet. Biopharm., 1998, 26, 581.
New Sampling Techniques [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83]
Frontiers in Drug Design & Discovery, 2009, Vol. 4 77
Danhof, M.; de Lange, E.C.; Della Pasqua, O.E.; Ploeger, B.A.; Voskuyl, R.A. Trends Pharmacol. Sci., 2008, 29, 186. Danhof, M.; de Jongh, J.; De Lange, E.C.; Della Pasqua, O.; Ploeger, B.A.; Voskuyl, R.A. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 357. Plock, N.; Kloft, C. Eur. J. Pharm. Sci., 2005, 25, 1. Benfeldt, E.; Serup, J.; Menne, T. Acta Derm. Venérelo., 1999, 79, 338. Vogt, G.L.; Janle, E.; Ash, S.R.; Venema, K.; Korf, J. Life Sci., 2003, 73, 2005. Nutt, R. Mol. Imaging Biol., 2002, 4, 11. Lönnroth, P.; Jansson, P.A.; Smith, U. Am. J. Physiol., 1987, 253, E228. Höcht, C.; Opezzo, J.A.; Taira, C.A. J. Pharmacol. Toxicol. Methods, 2007, 55, 3. Davies, M.I.; Lunte, C.E. Drug Metab. Dispos., 1995, 23, 1072. Benveniste, H.; Hüttemeier, P.C. Prog. Neurobiol., 1990, 35, 195. de Lange, E.C.; Danhof, M.; de Boer, A.G.; Breimer, D.D. Brain Res. Rev., 1997, 25, 27. Ault, J.M.; Riley, C.M.; Meltzer, N.M.; Lunte, C.E. Pharm. Res., 1994, 11, 1631. Palsmeier, R.K.; Lunte, C.E. Life Sci., 1994, 55, 815. de Lange, E.; de Boer, A.G.; Breimer, D. Adv. Drug Deliv. Rev., 2000, 45, 125. Groth, L.; Serup, J. Acta Derm. Venereol. (Stockh), 1998, 78, 5. Hutchinson, P.J.; O’Connell, M.T.; Nortje, J.; Smith, P.; Al-Rawi, P.G.; Gupta, A.K.; Menon, D.K.; Pickard, J.D. Physiol. Meas., 2005, 26, 423. Sjögren, F.; Svensson, C.; Anderson, C. Br. J. Dermatol., 2002, 146, 375. Rosdahl, H.; Ungerstedt, U.; Henriksson, J. Acta Physiol. Scand., 1997, 159, 261. Wisniewski, N.; Torto, N. Analyst, 2002, 127, 1129. Torto, N.; Mikeladze, E.; Gorton, L.; Csoregi, E.; Laurell, T. Anal. Commun., 1999, 36, 171. Sandberg, M.; Lindström, S. J. Neurosci. Methods, 1983, 9, 65. Kendrick, K.M. Methods Enzymol., 1989, 168, 182. Rosdahl, H.; Ungerstedt, U.; Henriksson, J. Acta Physiol. Scand., 1997, 159, 261. Maidment, N.T.; Brumbaugh, D.R.; Rudolph, V.D.; Erdelyi, E.; Evans, CJ. Neuroscience, 1989, 33, 549. Huff, J.K.; Bresnahan, J.F.; Davies, M.I. Life Sci., 2003, 73, 275. Ekstrøm, P.O.; Andersen, A.; Saeter, G.; Giercksky, K.E.; Slørdal, L. Cancer Chemother. Pharmacol., 1997, 39, 267. Mantovani, V.; Kennergren, C.; Berglin, E.; Moratti, R.; Lonnroth, P.; Hamberger, A.; Vigano, M. Scand. Cardiovasc. J., 2002, 36, 308. Castejon, A.M.; Paez, X.; Hernandez, L.; Luigi, X.; Cubeddu, L.X. J. Pharmacol. Exp. Ther., 1999, 291, 960. Davies, M.I.; Cooper, J.D.; Desmond, S.S.; Lunte, C.E.; Lunte, S.M. Adv. Drug Deliv. Rev., 2002, 45, 169. Johnson, R.D.; Justice, J.B. Brain Res. Bull., 1983, 10, 567. Jacobson, I.; Sandberg, M.; Hamberg, A. J. Neurosci. Methods, 1985, 15, 263. Wang, Y.; Wong, S.L.; Sawchuk, R.J. Curr. Sep., 1991, 10, 87. Benveniste, H. J. Neurochem., 1989, 52, 1667. Ståhle, L. Eur. J. Clin. Pharmacol., 1992, 43, 289. Liu, P.; Derendorf, H. Infect. Dis. Clin. N. Am., 2003, 17, 599. Joukhadar, C.; Derendorf, H.; Müller, M. Eur. J. Clin. Pharmacol., 2001, 57, 211. Schuck, E.L.; Derendorf, H. Expert Rev. Antiinfect. Ther., 2005, 3, 361. Brunner, M.; Derendorf, H.; Müller, M. Curr. Opin. Pharmacol., 2005, 5, 495. Wise, R. Clin. Pharmacokinet., 1986, 11, 470. Liu, P.; Müller, M.; Grant, M.; Webb, A.; Obermann, B.; Derendorf, H. J. Antimicrob. Chemoter., 2000, 50, 19. Cohen, R.; de La Rocque, F.; Boucherat, M. Med. Mal. Infect., 1994, 24, 844. Burkhardt, O.; Brunner, M.; Schmidt, S.; Grant, M.; Tang, Y.; Derendorf, H. J. Antimicrob. Chemother., 2006, 58, 632. Islinger, F.; Bouw, R.; Stahl, M.; Lackner, E.; Zeleny, P.; Brunner, M.; Muller, M.; Eichler, H.G.; Joukhadar, C. Antimicrob. Agents Chemother., 2004, 48, 4246. Gattringer, R.; Urbauer, E.; Traunmuller, F.; Zeitlinger, M.; Dehghanyar, P.; Zeleny, P.; Graninger, W.; Muller, M.; Joukhadar, C. Antimicrob. Agents Chemother., 2004, 48, 4650. Marchand, S.; Dahyot, C.; Lamarche, I.; Mimoz, O.; Couet, W. Antimicrob. Agents Chemother., 2005, 49, 2356.
78 Frontiers in Drug Design & Discovery, 2009, Vol. 4 [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119]
Höcht et al.
Dahyot, C.; Marchand, S.; Pessini, G.L.; Pariat, C.; Debaene, B.; Couet, W.; Mimoz, O. Antimicrob Agents Chemother., 2006, 50, 2265. Lefeuvre, S.; Marchand, S.; Lamarche, I.; Mimoz, O.; Couet, W. Antimicrob. Agents Chemother., 2006, 50, 34. Tomaselli, F.; Maier, A.; Matzi, V.; Smolle-Jüttner, F.M.; Dittrich, P. Antimicrob. Agents Chemother., 2004, 48, 2228. Burkhardt, O.; Derendorf, H.; Jager, D.; Kumar, V.; Madabushi, R.; Rohl, K.; Barth, J. Scand. J. Infect. Dis., 2006, 38, 90. Bellmann, R.; Kuchling, G.; Dehghanyar, P.; Zeitlinger, M.; Minar, E.; Mayer, B.X.; Muller, M.; Joukhadar, C. Br. J. Clin. Pharmacol., 2004, 57, 563. Zeitlinger, M.A.; Traunmuller, F.; Abrahim, A.; Muller, M.R.; Erdogan, Z.; Muller, M.; Joukhadar, C. Int. J. Antimicrob. Agents, 2007, 29, 44. Delacher, S.; Derendorf, H.; Hollenstein, U.; Brunner, M.; Joukhadar, C.; Hofmann, S.; Georgopoulos, A.; Eichler, H.G.; Muller, M. J. Antimicrob. Chemother., 2000, 46, 733. Zeitlinger, M.A.; Marsik, C.; Georgopoulos, A.; Müller, M.; Heinz, G.; Joukhadar, C. Int. J. Antimicrob. Agents, 2003, 21, 562. Liu, P.; Rand, K.H.; Obermann, B.; Derendorf, H. Int. J. Antimicrob. Agents, 2005, 25, 120. Huang, Y.; Yang, Z.; Cartier, L.; Cheung, B.; Sawchuk, R.J. Antimicrob. Agents Chemother., 2007, 51, 4336. Presant, C.A.; Wolff, W.; Walush, V.; Wiseman, C.; Kennedy, P.; Blayney, D.; Brechner, R.R. Lancet, 1994, 343, 1184. Brunner, M.; Müller, M. Eur. J. Clin. Pharmacol., 2002, 58, 227. Zhouh, Q.; Gallo, J.M. AAPS J., 2005, 7, E659. Evans, W.E.; Relling, M.V.; Rodman, J.H.; Crom, W.R.; Boyett, J.M.; Pui, C.H. N. Engl. J. Med., 1998, 338, 499. Müller, M.; Brunner, M.; Schmid, R.; Mader, R.M.; Bockenheimer, J.; Steger, G.G.; Steiner, B.; Eichler, H.G.; Blochl-Daum, B. Cancer Res., 1998, 58, 2982. Müller, M.; Mader, R.M.; Steiner, B.; Steger, G.G.; Jansen, B.; Gnant, M.; Helbich, T.; Jakesz, R.; Eichler, H.G.; Blochl-Daum, B. Cancer Res., 1997, 57, 2598. Garvin, S.; Dabrosin, C. Cancer Res., 2003, 63, 8742. Thompson, J.F.; Siebert, G.A.; Anissimov, Y.G.; Smithers, B.M.; Doubrovsky, A.; Anderson, C.D.; Roberts, M.S. Br. J. Cancer, 2001, 85, 157. Müller, M.; Bockenheimer, J.; Zellenger, U.; Klein, N.; Steger, G.G.; Eichler, H.G.; Mader, R.M. Breast Cancer Res. Treat., 2000, 60, 211. Lundstedt, C.; Stridbeck, H.; Andersson, R.; Tranberg, K.G.; Andren-Sandberg, A. Acta Radiol., 1991, 32, 518. Langer, O.; Karch, R.; Muller, U.; Dobrozemsky, G.; Abrahim, A.; Zeitlinger, M.; Lackner, E.; Joukhadar, C.; Dudczak, R.; Kletter, K.; Muller, M.; Brunner, M. J. Nucl. Med., 2005, 46, 1835. de Lange, E.C.M.; Danhof, M. Clin. Pharmacokinet., 2002, 41, 691. Upton, R.N. Clin. Exp. Pharmacol. Physiol., 2008, 34, 695. Alves, O.L.; Doyle, A.J.; Clausen, T.; Gilman, C.; Bullock, R. Ann. N. Y. Acad. Sci., 2003, 993, 25. Regesta, G.; Tanganelli, P. Epilepsy Res., 1999, 34, 109. Lindberger, M.; Tomson, T.; Wallstedt, L.; Stahle L. Epilepsia, 2001, 42, 256. Scheyer, R.D.; During, M.J.; Hochholzer, J.M.; Spencer, D.D.; Cramer, J.A.; Mattson, R.H. Epilepsy Res., 1994, 18, 227. Scheyer, R.D.; During, M.J.; Spencer, D.D.; Cramer, J.A.; Mattson, R.H. Neurology, 1994, 44, 1469. Ederoth, P.; Tunblad, K.; Bouw, R.; Lundberg, C.J.; Ungerstedt, U.; Nordstrom, C.H.; HammarlundUdenaes, M. Br. J. Clin. Pharmacol., 2004, 57, 427. Zhuang, Y.; Fraga, C.H.; Hubbard, K.E.; Hagedorn, N.; Panetta, J.C.; Waters, C.M.; Stewart, C.F. Cancer Res., 2006, 66, 11305. Devineni, D.; Klein-Szanto, A.; Gallo, J.M. Cancer Chemother. Pharmacol., 1996, 38, 499. Rizzi, M.; Caccia, S.; Guiso, G.; Richichi, C.; Porter, J.A.; Aronica, E.; Aliprandi, M.; Bagnati, R.; Fanelli, R.; D´Incalci, M.; Maman, R.; Vezzani, A. J. Neurosci., 2002, 22, 5833. Potschka, H.; Löscher, W. Neuroreport, 2002, 13, 167. Höcht, C.; Lazarowski, A.; Gonzalez, N.N.; Auzmendi, J.; Opezzo, J.A.; Bramuglia, G.F.; Taira, C.A.; Girardi, E. Neurosci. Lett., 2007, 413, 168. Apparaju, S.K.; Gudelsky, G.A.; Desai, P.B. Cancer Chemother. Pharmacol., 2008, 61, 223. Bundgaard, C.; Jørgensen, M.; Mørk, A. J. Pharmacol. Toxicol. Methods, 2007, 55, 214.
New Sampling Techniques [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140]
[141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152]
[153] [154]
Frontiers in Drug Design & Discovery, 2009, Vol. 4 79
Deecher, D.C.; Beyer, C.E.; Johnston, G.; Bray, J.; Shah, S.; Abou-Gharbia, M.; Andree, T.H. J. Pharmacol. Exp. Ther., 2006, 318, 657. Kiewert, C.; Hartmann, J.; Stoll, J.; Thekkumkara, T.J.; Van der Schyf, C.J.; Klein, J. Neurochem. Res., 2006, 31, 395. Weikop, P.; Egestad, B.; Kehr, J. J. Neurosci. Methods, 2004, 140, 59. Raje, S.; Cornish, J.; Newman, A.H.; Cao, J.; Katz, J.; Eddington, N.D. Pharm. Res., 2005, 22, 603. Bouw, M.R.; Xie, R.; Tunblad, K.; Hammarlund-Udenaes, M. Br. J. Pharmacol., 2001, 134, 1796. Chenel, M.; Marchand, S.; Dupuis, A.; Lamarche, I.; Paquereau, J.; Pariat, C.; Couet, W. Br. J. Pharmacol., 2004, 142, 323. Meredith, P.A. J. Hypertens., 1997, 15, S27. Brynne, L.; Karlsson, M.O.; Paalzow, L.K. J. Pharmacol. Exp. Ther., 1998, 286, 1152. Höcht, C.; Di Verniero, C.; Opezzo, J.A.W.; Taira, CA. Naunyn-Schmiedeberg’s Arch. Pharmacol., 2004, 370, 1. Höcht, C.; Di Verniero, C.; Opezzo, J.A.W.; Taira, CA. J. Pharmacol. Toxicol. Methods, 2005, 52, 244. Höcht, C.; Di Vereniero, C.; Opezzo, J.A.W.; Bramuglia, G.F.; Taira, C.A. Naunyn-Schmiedeberg’s Arch. Pharmacol., 2006, 373, 310. Bertera, F.M.; Mayer, M.A.; Opezzo, J.A.W.; Taira, C.A.; Höcht, C. J. Pharmacol. Toxicol. Methods, 2008, 57, 213. Bertera, F.M.; Mayer, M.A.; Opezzo, J.A.W.; Taira, C.A.; Bramuglia, G.F.; Höcht, C. J. Pharmacol. Toxicol. Methods, 2007, 56, 290. Fischman, A.J.; Alpert, N.M.; Rubin, R.H. Clin. Pharmacokinet., 2002, 41, 481. van den Hoff, J. Amino Acids, 2005, 29, 341. Martínez, M.J.; Ziegler, S.I.; Beyer, T. Cancer Res., 2008, 170, 1. Wollmer, P.; Pride, N.B.; Rhodes, C.G.; Sanders, A.; Pike, V.W.; Palmer, A.J.; Silvester, D.J.; Liss, R.H. Lancet, 1982, 2, 1361. Fischman, A.J.; Alpert, N.M.; Livni, E.; Ray, S.; Sinclair, I.; Elmaleh, D.R.; Weiss, S.; Correia, J.A.; Webb, D.; Lissm R. J. Pharmacol. Exp. Ther., 1991, 259, 1351. Fischman, A.J.; Alpert, N.M.; Livni, E.; Ray, S.; Sinclair, I.; Callahan, R.J.; Correia, J.A.; Webb, D.; Strauss, H.W.; Rubin, R.H. Antimicrob Agents Chemother., 1993, 37, 1270. Fischman, A.J.; Livni, E.; Babich, J.; Alpert, N.M.; Liu, Y.Y.; Thom, E.; Cleeland, R.; Prosser, B.L.; Correia, J.A.; Strauss, H.W. Antimicrob. Agents Chemother., 1993, 37, 2144. Langer, O.; Brunner, M.; Zeitlinger, M.; Ziegler, S.; Müller, U.; Dobrozemsky, G.; Lackner, E.; Joukhadar, C.; Mitterhauser, M.; Wadsak, W.; Minar, E.; Dudczak, R.; Kletter, K.; Müller, M. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 143. Brunner, M.; Langer, O.; Dobrozemsky, G.; Müller, U.; Zeitlinger, M.; Mitterhauser, M.; Wadsak, W.; Dudczak, R.; Kletter, K.; Müller, M. Antimicrob. Agents Chemother., 2004, 48, 3850. Fischman, A.J.; Babich, J.W.; Bonab, A.A.; Alpert, N.M.; Vincent, J.;Callahan, R.J.; Correia, J.A.; Rubin, R.H. Antimicrob. Agents Chemother., 1998, 42, 2048. Wall, A.; Kågedal, M.; Bergström, M.; Jacobsson, E.; Nilsson, D.; Antoni, G.; Frändberg, P.; Gustavsson, S.A.; Långström, B.; Yates, R. Drugs R D, 2005, 6, 139. Gulyás, B.; Halldin, C.; Sandell, J.; Karlsson, P.; Sóvágó, J.; Kárpáti, E.; Kiss, B.; Vas, A.; Cselényi, Z.; Farde, L. Acta Neurol. Scand., 2002, 106, 325. Whitcher, B.; Matthews, P.M. Int. J. Pharm. Med., 2006, 20, 167. Aboagye, E.O.; Price, P.M. Invest. New Drugs, 2003, 21, 169. Weber, W.A.; Czernin, J.; Phelps, M.E.; Herschman, H.R. Nat. Clin. Pract. Oncol., 2008, 5, 44. Weber, W.A. J. Clin. Oncol., 2006, 24, 3282. Gupta, N.; Price, P.M.; Aboagye, E.O. Eur. J. Cancer, 2002, 38, 2094. Hutchinson, O.C.; Collingridge, D.R.; Barthel, H.; Price, P.M.; Aboagye, E.O. Curr. Pharm. Des., 2003, 9, 931. Saleem, A.; Harte, R.J.; Matthews, J.C.; Osman, S.; Brady, F.; Luthra, S.K.; Brown, G.D.; Bleehen, N.; Connors, T.; Jones, T.; Price, P.M.; Aboagye, E.O. J. Clin. Oncol., 2001, 19, 1421. Harte, R.J.A.; Tilsley, D.W.O.; O’Reilly, S.M.; Byrne, H.; Cunningham, V.; Osman, S.; Luthra, S.K.; Brown, G.; Brady, F.; Baguley, B.; Denny, W.; Connors, T.; Jones, T.; Price, P. Ann. Oncol., 1994, 5, 176. Meikle, S.R.; Matthews, J.C.; Brock, C.S.; Wells, P.; Harte, R.J.; Cunningham, V.J.; Jones, T.; Price, P. Cancer Chemother. Pharmacol., 1998, 42, 183. Saleem, A.; Brown, G.D.; Brady, F.; Aboagye, E.O.; Osman, S.; Luthra, S.K.; Ranicar, A.S.; Brock, C.S.; Stevens, M.F.; Newlands, E.; Jones, T.; Price, P. Cancer Res., 2003, 63, 2409.
80 Frontiers in Drug Design & Discovery, 2009, Vol. 4 [155]
[156] [157] [158] [159] [160] [161] [162] [163]
Höcht et al.
Jayson, G.C.; Zweit, J.; Jackson, A.; Mulatero, C.; Julyan, P.; Ranson, M.; Broughton, L.; Wagstaff, J.; Hakannson, L.; Groenewegen, G.; Bailey, J.; Smith, N.; Hastings, D.; Lawrance, J.; Haroon, H.; Ward, T.; McGown, A.T.; Tang, M.; Levitt, D.; Marreaud, S.; Lehmann, F.F.; Herold, M.; Zwierzina, H.; European Organisation for Research and Treatment of Cancer Biological Therapeutic Development Group. J. Natl. Cancer Inst., 2002, 94, 1484. Shankar, L.K.; Hoffman, J.M.; Bacharach, S.; Graham, M.M.; Karp, J.; Lammertsma, A.A.; Larson, S.; Mankoff, D.A.; Siegel, B.A.; Van den Abbeele, A.; Yap, J.; Sullivan, D.; National Cancer Institute. J. Nucl. Med., 2006, 47, 1059. Vesselle, H.; Grierson, J.; Muzi, M.; Pugsley, J.M.; Schmidt, R.A.; Rabinowitz, P.; Peterson, L.M.; Vallières, E.; Wood, D.E. Clin. Cancer Res., 2002, 8, 3315. Chen, W.; Cloughesy, T.; Kamdar, N.; Satyamurthy, N.; Bergsneider, M.; Liau, L.; Mischel, P.; Czernin, J.; Phelps, M.E.; Silverman, D.H. J. Nucl. Med., 2005, 46, 945. Wolf, W.; Presant, C.A.; Waluch, V. Adv. Drug Deliv. Rev., 2000, 41, 55. Jynge, P.; Skjetne, T.; Gribbestad, I. Clin. Pharmacol. Ther., 1990, 48, 481. Renshaw, P.F.; Wicklund, S. Biol. Psychiatry, 1988, 23, 465. Renshaw, P.F.; Guimaraes, A.R.; Fava, M. Am. J. Psychiatry, 1992, 149, 1592. Schiffer, W.K.; Alexoff, D.L.; Shea, C.; Logan, J.; Dewey, S.L. J. Neurosci. Methods, 2005, 144, 25.
Frontiers in Drug Design & Discovery, 2009, 4, 81-96
81
Role of Inflammatory Biomarkers in Establishing PK/PD Relationships and Target Organ Toxicity Sivaram Pillarisetti* and Ish Khanna* Reddy US Therapeutics Inc., 3065 Northwoods Circle, Norcross GA 30071, USA Abstract: High levels of inflammatory cytokines and adhesion molecules are associated with many inflammatory disorders [e.g. rheumatoid arthritis, inflammatory bowel disease and lupus] as well as metabolic and cardiovascular diseases including diabetes and obesity. Examples of such markers include tumor necrosis factor [TNF], interleukins [IL-1, IL-6, IL-8 and IL-18], vascular cell adhesion molecules and markers of macrophage inflammation [e.g. MMPs]. In many preclinical disease models, levels of these markers are significantly elevated relative to normal animals. Modulation of these biomarkers with pharmaceutical agents in preclinical and clinical studies can be effectively used for concept validation, effective dose selection, and establishing good pharmacokinetics/pharcodynamics correlation. On the other hand, elevation of these markers in normal animals, following treatment with an agent, could indicate safety concerns leading to potential tissue damage. Monitoring of inflammatory markers in normal animals can be diagnostic and of high value in evaluating safety or efficacy of new molecules. The levels of biomarkers can be monitored either by high throughput microarrays/proteomics or by specific ELISA based assays. Since many of the biomarkers appear in systemic circulation, these can be monitored in blood/plasma without interference with tissues. This makes the approach particularly attractive for clinical studies. An overview of the biomarkers, potential applications and case histories linking biomarkers to PK/PD correlation from preclinical and clinical studies are discussed.
1. INTRODUCTION Inflammation is normally a localized, protective response to harmful stimuli such as pathogens or irritants. The process usually starts with an injury/insult to blood vessel wall endothelium. Exposure to a variety of pathogens can cause endothelial activation resulting in secretion of chemoattractant signals (Fig. 1). Depending on the nature of signal, circulating monocytes and other leukocytes are attracted to the site of injury and interact/bind to endothelium through a variety of receptors [e.g. selectins and vascular adhesion molecules] [1, 2]. Bound leukocytes transmigrate to the subendothelial space where they become tissue resident macrophages. The recruitment, accumulation and
*Corresponding Author: Tel: 770-446 9500; Fax: 770-446 1950; E-mail:
[email protected] or
[email protected] Gary W. Caldwell / Atta-ur-Rahman / Z. Yan / M. Iqbal Choudhary (Eds.) All rights reserved – © 2009 Bentham Science Publishers.
82 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Pillarisetti and Khanna
subsequent activation of leukocytes are central events in the pathogenesis of most forms of inflammation [1, 2]. Host-mediated inflammatory response destroys, dilutes or wards off the injurious agent and the injured tissue. Commonly, inflammation occurs as a defensive response to invasion of the host by foreign, particularly microbial, agents. Responses to mechanical trauma, toxins and neoplasia can also cause inflammatory reactions. Circulating monocytes
Tethering and rolling of monocytes
Transmigration
Chemotactic signals Endothelium Activated/injured endothelium
Maturation to macrophages
Cytokines (TNF, IL-1) Effects on surrounding cells in tissue
Inflammatory diseases e.g. RA, IBD, OA
Organ toxicity
Fig. (1). Pathways leading to tissue inflammation (see text for details).
There are other forms of inflammation that often don’t involve infection and host defense. These include autoimmune responses and subclinical inflammation. In autoimmune inflammation body proteins are recognized as foreign and antibodies are produced against body’s own proteins. This is the underlying cause of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Subclinical inflammation can occur under normal physiological conditions and is often attributed to nutritional status and related oxidative stress. Excess plasma glucose [hyperglycemia] or plasma lipids [cholesterol or free fatty acids] or obesity can induce oxidative stress [reactive oxygen species or ROS] within cells via various mechanisms [3-6]. Excess oxidative stress activates ROS-sensitive transcription factors which drive the expression of inflammatory cytokines [7, 8]. Prolongation of the inflammatory process can damage tissue of origin or can lead to inflammatory diseases as diverse as diabetes, diabetic nephropathy, atherosclerosis, Alzheimer’s, fatty liver, pancreatitis and cancer [9-18]. Many cytokines and the high-sensitivity C-reactive protein [CRP] are considered markers of inflammation and have been studied in both disease progression as well as organ toxicity. This review
Role of Inflammatory Biomarkers
Frontiers in Drug Design & Discovery, 2009, Vol. 4 83
will focus on selective markers of inflammation that are useful in monitoring the efficacy and safety of pharmacological agents. 2. KEY INFLAMMATORY CYTOKINES AND THEIR ROLES Cytokines encompass a large number of glycoproteins involved in cell-to-cell signaling. Cytokines can be classified based on their mode of action [pro or antiinflammatory] or based on cell type of origin. e.g., T helper cell type I [Th1; for TNF and interleukin-2] and T helper cell type II [Th2; for interleukins -4, -5, -6, -10, and -13. Cytokines may also be identified based on their function such as those effecting chemoattraction [chemokines, including monocyte chemoattractant protein-1 [MCP-1]]. Although leukocytes/lymphocytes are the major sources of these cytokines, other cell types and tissues including vascular cells, liver and adipose express one or more of these cytokines and their receptors, making them targets of down stream signaling and toxicities. A brief discussion on inflammatory cytokines is outlined below. 2a. Tumor Necrosis Factor (TNF) Tumor necrosis factor-alpha [TNF] often described as the master cytokine is the major mediator of inflammation in many tissues [19-21]. It was originally described as a circulating factor that can cause necrosis of tumors, but has since been identified as a key regulator of the inflammatory response. It is also a major mediator of cell apoptosis and plays key role in immune defense against bacterial infections. Elevated levels of TNF or sustained activation of TNF signaling has been implicated in the pathogenesis of many autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and psoriasis. In addition more recent data suggest that TNF along with other cytokines contribute to the pathogenesis of diabetes and cardiovascular disease [atherosclerosis]. TNF binds to two specific receptors, TNF-receptor type I [TNF-R1 aka p55/60] and TNF-receptor type II [TNF-R2, aka p75/80]. Signaling through these receptors is extremely complex, leading to induction of other inflammatory mediators as well as cell death and survival signals. Although signaling involves many players, nuclear transcription factor NFB appears to be critical for regulation of both inflammatory as well as cell death genes [22]. Vascular endothelial cells are highly susceptible to TNF challenge and undergo a number of pro-inflammatory changes, which increase leukocyte adhesion, transendothelial migration and promote thrombosis [23]. Thus all vascularized tissues are prone to TNF-mediated toxicity. TNF-signaling in cells also leads to induction of other pro- and anti-inflammatory cytokines including interleukins-1, -4, -6, -8 and -10 and monocyte chemoattractant protein MCP-1. The relative levels of these cytokines may determine the extent of damage/toxicity to the tissue. The central role of TNF in inflammation has been demonstrated in clinic. A number of agents that block the action of TNF have proven highly beneficial to treat a range of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis [24-26]. 2b. Interleukins IL-1 The IL-1 family consists of four proteins that share considerable sequence homology IL-1, IL-1, IL-1 receptor antagonist [IL-1Ra], and IL-18 [27, 28]. Mature IL-1 is deri-
84 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Pillarisetti and Khanna
ved proteolytically from pro-IL-1 by intracellular IL-1-converting enzyme [ICE or caspase-1]. IL-1 binds and induces signaling through IL-1 receptor [IL-1R]. Minute amounts [1ng/kg] of IL-1 cause significant inflammatory response in humans. The signaling cascade results in activation of nuclear factor kappa B [NF-B] and activating protein-1 [AP-1] and the transcription of a variety of pro-inflammatory genes, including autocrine amplification of IL-1 [28-30]. In addition to the IL-1RI, IL-1 may also bind to the type II interleukin-1 receptor. Binding of IL-1 to this receptor does not result in cellular activation, and IL-1RII is therefore presumed to act as a decoy that negatively regulates IL-1 activity. IL-18 has been assigned to the IL-1 family on the grounds of sequence homology [26% with IL-1] and similarity of the IL-18 receptor to IL-1R [31]. Like IL-1, IL-18 is dependent on ICE for proteolytic processing, and on nuclear translocation of NFB for transcriptional activation. IL-1 like TNF induces vessel wall inflammation. IL-1 plays a major role in a wide range of inflammatory and autoimmune diseases. These include RA, OA, chronic obstructive pulmonary disease [COPD], asthma, inflammatory bowel disease [IBD] [[both Crohn's disease [CD] and ulcerative colitis [UC]], atherosclerosis and diseases of the central nervous system such as multiple sclerosis [MS], Alzheimer's disease and stroke [32]. IL-6 The IL-6-type cytokines IL-6, IL-11, LIF [leukemia inhibitory factor], OSM [oncostatin M], ciliary neurotrophic factor, cardiotrophin-1 and cardiotrophin-like cytokine are an important family of mediators involved in the regulation of the acute-phase response to injury and infection [33]. Besides their functions in inflammation and the immune response, these cytokines also play a crucial role in hematopoiesis, liver and neuronal regeneration, embryonic development and fertility. IL-6-type cytokines exert their action via the signal transducers gp [glycoprotein] 130, LIF receptor and OSM receptor leading to the activation of the JAK/STAT [Janus kinase/signal transducer and activator of transcription] and MAPK [mitogen-activated protein kinase] cascades [34]. Although gp130 is ubiquitously expressed, the number of cells that respond to IL-6 is limited, since the expression of the other receptor subunits especially of the -receptors, is more restricted and tightly regulated. The function of the -receptors to render cells sensitive to the respective cytokinecan also be taken over by the soluble form of the -receptors. This is one of the rare situations in which a complex of cytokine and soluble receptor can act agonistically instead of antagonistically. Soluble forms of cytokine receptors in vivo are formed either by limited proteolysis [shedding] of membrane-bound receptors or by translation from an alternatively spliced mRNA [4]. In the case of IL-6, the scenario is more complex, since soluble forms for IL-6R [sIL-6R] and gp130 [sgp130] are both present in human serum. It has been demonstrated that sIL-6R potentiates the antagonistic activity of sgp130. Thus the naturally occurring combination of sIL-6R and sgp130 might act as a kind of buffer to modulate systemic responses to circulating IL-6. Because IL-6 has a wide range of biological activities on various target cells, deregulated overproduction of IL-6 causes various clinical symptoms. IL-6 plays important roles in the regulation of immune response and inflammation, and overproduction of IL-6 is involved in the pathology of inflammatory diseases such as rheumatoid arthritis [RA], Castleman’s disease, juvenile idiopathic arthritis and Crohn’s disease [35].
Role of Inflammatory Biomarkers
Frontiers in Drug Design & Discovery, 2009, Vol. 4 85
2c. Other Inflammatory Cytokines/Markers MCP-1 MCP-1 is a chemoattractant protein that specifically attracts blood monocytes and tissue macrophages to its source, via interaction with CCR2, its cell surface receptor [36]. Many cells produce MCP-1 in response to a variety of pro-inflammatory stimuli, and predictably, its expression has been identified in diseases which involve significant macrophage inflammation. These include atherosclerosis, rheumatoid arthritis and kidney diseases such as diabetic nephropathy. CRP CRP is an acute phase reactant that was discovered over 70 years ago. CRP is a blood protein that binds to the C-polysaccharide of pneumococci. CRP is a pentamer of 23 kDa subunits and is mainly produced by liver. CRP levels are usually low in normal individuals but can rise 100- to 200-fold or higher with acute systemic inflammation. CRP levels are high in patients with rheumatoid arthritis [RA] and cardiovascular disease [CVD]. In patients with CVD levels of CRP predict future myocardial infarction, stroke and peripheral vascular disease. IL-1, IL-6, and TNF, all can stimulate liver production of CRP. It is not entirely clear if CRP is just a biomarker for inflammation or CRP could have a more direct pro-inflammatory role. Modulation of CRP levels by drugs appear to correlate with disease severity [37, 38]. 3. CYTOKINES IN DISEASE Although elevated cytokines are seen in almost all inflammatory diseases the causal relationship has been established in autoimmune diseases such as rheumatoid arthritis [RA], inflammatory bowel disease [IBD], and psoriasis. 3a. Cytokines and Autoimmune Diseases Rheumatoid arthritis [RA] is a chronic disease characterized by synovial inflammation that leads to the destruction of cartilage and bone. Proinflammatory cytokines such as TNF, IL-1 and IL-6 play important role in initiating and perpetuating inflammatory and destructive processes in the rheumatoid joint [20, 27, 31, 34]. These cytokines regulate many NFB inducible genes that control expression of other cytokines, cell adhesion molecules, immunoregulatory molecules, and proinflammatory mediators. The expression of cyclooxygenase-2 and inducible nitric oxide synthase [iNOS] and thereby production of prostaglandins [PG] and NO are regulated by these cytokines. The prostaglandin PGE2 and nitric oxide [NO] further promote inflammation and likely participate in destructive mechanisms in the rheumatoid joint. Although the actions of IL-1 and TNF-alpha show a large degree of overlap, some differences have been observed in animal models [45, 47]. As indicated in Table 1 [39], inflammatory cytokines [TNF-, IL-1, IL-6] are significantly elevated in synovial fluids of RA patients relative to OA [40-44]. This seems particularly relevant for IL-6 where high levels in synovial fluid and serum correlate with disease progression. The preclinical studies suggest that IL-1 expression occurs later in the disease relative to TNF- [45, 46]. The reported data suggests that IL-1 has significant effect on cartilage destruction where as TNF- influences joint swelling [46, 47]. In RA, the cytokines such as IL-4, IL-10 and IL-13, detected in synovial fluid of
86 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Pillarisetti and Khanna
patients, have protective, anti-inflammatory effects. In patients with active rheumatoid arthritis, blockade of TNF-, IL-1 or IL-6 results in improvement in clinical and radiographic scores. TNF-alpha antagonists are currently the most effective treatments for early and late RA. Use of these agents provides relief of RA symptoms and improvements in American College of Rheumatology [ACR] criteria. ACR criteria is indicated as ACR 20, ACR 50, or ACR 70 and measures improvement in tender or swollen joint counts and improvement in three of five parameters [acute phase reactant such as erythrocyte sedimentation rate, patient assessment, physician assessment, pain scale and disability questionnaire]. Table 1.
Cytokine Levels in Patients with RA and OA
Cytokine
Disease
Concentration [pg/ml]
Fold Change
Reference
TNF
RA OA
95 ± 25 39-69±6-32
2.4
[40, 41]
IL-1
RA OA
130±22 27±4.5
4.6
[42]
IL-6
RA OA
1610 89-398
18
[41, 43]
IL-1 antagonism also has additional benefits on cartilage and bone erosion [48]. In vitro studies suggest that IL-1 can cause cartilage destruction by stimulating the release of matrix metalloproteinases and other degradative products, and it can increase bone resorption by stimulating osteoclast differentiation and activation. In animal models of RA, blocking the effects of IL-1 with either IL-1 receptor antagonist [IL-1Ra; endogenous], anti-IL-1 monoclonal antibodies significantly reduced cartilage destruction and bone erosion. More recently, IL-6 antagonists have shown good efficacy in autoimmune diseases. Tocilizumab, a humanized antihuman IL-6 receptor antibody recognizes both the membrane-bound and the soluble form IL-6R and specifically blocks IL-6 actions [49]. Tocilizumab has been shown to be effective not only for improving signs and symptoms but also for preventing joint destruction of RA. Significantly elevated levels of TNF-, and other cytokines were observed in other autoimmune diseases such as Crohn’s disease, psoriasis and systemic lupus erythematosus and TNF antagonists are effective in relieving symptoms. In summary, these data strongly show that elevated cytokines not only serve as a biomarker to predict disease severity but blockingtheir function can effectively reduce disease severity in many autoimmune diseases. 3b. Cytokines and Cardiovascular Disease Cardiovascular disease is currently the leading cause of death in developed countries. Atherosclerosis - a progressive disease characterized by the accumulation of lipids in the
Role of Inflammatory Biomarkers
Frontiers in Drug Design & Discovery, 2009, Vol. 4 87
large arteries - constitutes the single most important contributor to this growing burden of cardiovascular disease [50, 51]. Macrophage-mediated inflammation plays an important role in the initiation and progression of atherosclerosis and the development of atherosclerotic events. The macrophages can avidly take up lipids within the lesion leading to lipid loaded foam cells. Inflammatory cytokines can weaken the protective fibrous cap of the atheroma by stimulating the expression degradative enzymes such as MMP-2 and -9. Loss of fibrous cap results in thrombosis and the occurrence of acute coronary syndromes such as unstable angina pectoris and myocardial infarction [MI]. Serum levels of cytokines are elevated in many cardiovascular pathologies including coronary heart disease, aortic aneurysm and acute MI [52-60]. Of these cytokines, IL-6 has been identified as an important marker of inflammation in coronary atherosclerotic plaques. Serum levels of IL-6 increase in response to acute MI, unstable angina, percutaneous coronary intervention, and late restenosis [58-60]. IL-6 levels, which were undetectable [i.e., <3 pg/mL] in healthy volunteers is elevated in majority of patients with unstable angina. Median levels of IL-6 were 5.25 pg/mL [range, 0 to 90 pg/dL] in patients with unstable angina and were below the detection limit [range, 0 to 7 pg/dL] in patients with stable angina [60]. The importance of IL-6 is also highlighted by the fact that CRP, one of many human acute-phase reactants, is produced in the liver mainly in response to IL-6. It activates the classic complement cascade, mediates phagocytosis, regulates inflammation, and is a nonspecific but sensitive marker of infection and tissue inflammation. CRP has been shown to predict future cardiovascular events in individuals with and without established cardiovascular disease. Although direct evidence for causal relationship between cytokines and CVD has not been established with specific antagonists, drugs such as statins which substantially reduce cardiovascular morbidity and mortality have been shown to lower inflammatory markers independent of their effects on plasma cholesterol [61, 62] 3c. Cytokines and Metabolic Syndrome The metabolic syndrome, also known as syndrome X, represents a collection of metabolic abnormalities that includes central obesity, insulin resistance, glucose intolerance, dyslipidemia, and hypertension. Each of these features is known to augment the risk of developing diabetes mellitus [DM] and cardiovascular disease. In addition to genetic and other exogenous factors [diet, sedentary life, and alcohol consumption] in the past decade the role of inflammation in the development of the metabolic syndrome has been clearly documented [63, 64]. Adipose tissue secretes inflammatory cytokines, TNF, MCP-1 and IL-6 which in turn contribute to impaired glucose tolerance, insulin resistance, and type 2 diabetes [65]. In animal models TNF impairs insulin action on peripheral glucose disposal and hepatic glucose output resulting in severe impairment of glucose tolerance and insulin sensitivity [66, 67] while these effects are absent in animals that lack TNFR [68, 69]. In human studies the correlation is better established between IL-6 and diabetes. The levels of circulating C-reactive protein and interleukin-6 [IL-6] independently predict the risk of developing diabetes [70, 71]. 4. CYTOKINES AND ORGAN TOXICITY Cytokines in addition to inducing inflammatory pathways enhance pro and antiapoptotic pathways. For example TNF-induced apoptosis-signaling receptors include death receptor 3 [DR3], DR4, and DR5, their ligand TRAIL [72]. Unresolved inflamma-
88 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Pillarisetti and Khanna
tion leads to sustained activation of signaling pathways leading to cell death, which will result in tissue [organ] damage and organ failure. 4a. Liver Toxicity The role of TNF in liver injury has been studied in several animal models [73-83]. By using neutralizing anti-TNF antibodies or knockout mice for TNF, TNF-R1, or TNF-R2, it has become evident that TNF triggers apoptosis and/or necrosis of hepatocytes in vivo. In different animal models of liver injury, TNF plays a central or an additive role in the pathogenesis of acute liver injury. In endotoxin/galactosamine induced model of liver injury an increase in TNF levels in the wild-type C3H mice precedes liver failure. A role for TNF was also established in concavalin A [ConA] model of liver toxicity. ConA binds with high affinity the hepatic sinusoidal endothelial cells and triggers an increased influx of circulating lymphocytes into the hepatic sinus. Cytokine levels increase before infiltration of lymphocytes occurrs, showing that the early increase in cytokine levels is pivotal in triggering liver cell damage. TNF has been shown to directly contribute to liver cell damage, since anti-TNF antibodies protect against liver cell damage in this model. Additionally, it has been demonstrated that TNF null mice are protected from ConA-induced liver cell damage, further supporting the role of TNF in the pathogenesis. IL-10 inhibits liver cell damage in this model by reducing the serum levels of TNF. In humans, attempts to use TNF as an anti-cancer therapy have failed due to side effects especially in liver. One of the side effects of TNF treatment was an elevation in serum levels of transaminases and bilirubin levels, indicating a direct cytotoxic role of TNF in human hepatocytes. TNF may also be involved in viral hepatitis, alcoholic liver disease, and fulminant hepatic failure. TNF serum levels are clearly elevated in patients with fulminant hepatitis. In addition, it was found that serum TNF levels were significantly higher in patients who died than in patients who survived. A role for TNF in the pathogenesis of chronic hepatitis B and C viral infection has been suggested. Both viruses induce TNF expression in human liver and human hepatoma cell lines. Patients with chronic hepatitis B have elevated plasma TNF levels, and their peripheral blood mononuclear cells show enhanced TNF production in vitro. Serum levels of soluble TNF-R1 and TNF-R2 are also significantly elevated in chronic hepatitis B infection. The serum levels of soluble TNF-R2 correlate closely with the extent of inflammation and hepatocyte death in the liver. During interferon therapy, the response and the increase in transaminases are associated with an increase in soluble TNF-R2 serum levels. TNF serum levels are increased in patients with alcoholic hepatitis, and the levels correlate inversely with patient survival. Monocytes isolated from patients with alcoholic hepatitis spontaneously produced higher amounts of TNF compared with healthy controls. Increased TNF- levels are also observed in the liver following exposure to hepatotoxic agents. This typically leads to simultaneous generation of other cytokines such as IL-6 and acute phase reactants worsening the liver inflammation. 4b. Kidney Toxicity Patients with chronic kidney disease [CKD] of all stages experience high mortality and chronic inflammation is one of the key triggers to the process [84-86]. Macrophages are known to infiltrate into tubulointersitium in animal models of CKD. Exposure of
Role of Inflammatory Biomarkers
Frontiers in Drug Design & Discovery, 2009, Vol. 4 89
kidney epithelial cells to TNF/IFN results in a marked sustained elevation of transepithelial electrical resistance as well as elevated paracellular permeability thus compromising barrier function [87]. Pharmacological inhibition of specific signaling enzymes blocked the deleterious effects of the proinflammatory cytokines on barrier function [86, 88]. The role of inflammation and inflammatory cytokines has also been documented in acute renal failure [ARF]. Chemotherapy [Cisplatin]-induced ARF has been shown to be associated with an increase in the cytokines IL-1 and IL-6, and neutrophil infiltration in the Kidney and inhibition of cytokines in cisplatin-induced ARF is consistently associated with a reduction in renal neutrophils [89, 90]. 4c. Brain [CNS] Toxicity Inflammation is major player in diseases of the brain, such as multiple sclerosis or meningitis [91, 92]. In these cases, immune cells invade the central nervous system compartments, accompanied by a massive breakdown of the blood-brain barrier inducing changes to the cerebrospinal fluid. In addition, inflammation within the central nervous system is a common phenomenon even in diseases such as Alzheimer disease, Parkinson disease, or stroke. In these cases, inflammation is a frequent occurrence but displays different, more subtle, patterns compared with, for example, multiple sclerosis. Brain levels of IL-1 and TNF increase dramatically in neuropathological states and increased levels of these cytokines are associated with breakdown of the blood–brain barrier and recruitment of neutrophils into the CNS. Neutralizing antibodies to the two cytokines reduce the CNS accumulation of leukocytes in neuropathology. Agents that specifically inhibit the IL-1 pathway [endogenous IL-1 receptor antagonist or neutralizing IL-1 antibodies] show considerable reduction in neuronal loss in the various rodent models. 5. METHODS TO MONITOR CYTOKINES While measurement of plasma cytokines by ELISA based methods is the most widely used especially in clinical setting, PCR based methods may be more sensitive when employing tissues or blood cells. Several companies offer ELISA kits to measure rodent, monkey and human cytokines, including TNF, IL-1, IL-8, IL-6 and MCP-1. Following drug treatment of animals, plasma or serum is collected at various time points for cytokine estimation. In disease models basal cytokine levels are generally elevated and effect of drug could be seen in matter of hours to a few days. A popular model to monitor efficacy of an anti-inflammatory drug is the lipopolysaccharide-induced inflammation in rodents. Injection of low doses of LPS produces a robust increase in plasma TNF. This effect could be seen within 1 h of treatment. Anti-inflammatory drug could be given either 30 min to 1 h prior to the administration of LPS or along with LPS. In other models e.g. antigen or antibody-induced arthritis models it may take 7-14 days to show a significant reduction in plasma cytokines. [see case examples below]. In addition to monitoring plasma cytokines [TNF, IL-1 and IL-6] it would also be useful to measure cytokines in the affected tissue [e.g. synovial fluid and joint tissue in RA models] Induction of cytokine expression in a normal animal following the administration of drug is a reflection of drug toxicity. This can be monitored in repeat dose safety studies. Oral administration of a test substance in rodents for 28 and 90 days is used to evaluate chronic toxic effects, effects on organs, and no –observed-adverse effect-level [NOAEL]. The liver is the primary site for the metabolism of many chemicals and drugs by the body, and is also the primary site of potential toxic injury [hepatotoxicity]. Like all
90 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Pillarisetti and Khanna
organs, the liver is composed of various cell types; predominately hepatocytes. Liver cells contain phase 1 and phase 2 drug metabolizing enzymes which convert many chemicals and drugs to other forms that can be readily used or excreted by the body [biotransformation]. In some cases, the biotransformed chemical is the one that causes the toxicity [to the liver or to another organ]. Initial studies can be performed in isolated primary cultures of livers cells to determine if the drug induces the expression of cytokines. However longer treatment times may be required for the drug effect to set in, thus may only be monitored under in-vivo animal studies. 6. CASE STUDIES OF MARKETED DRUGS THAT INHIBIT INFLAMMATORY MARKERS AND MODULATE DISEASE SEVERITY In this section we will review some case examples where modulation of cytokine activity in animal models translate into modification of disease activity in animals and humans Anti-TNF Agents: Currently there are three marketed products that inhibit TNF action. They are infliximab, etanercept andadalimumab. Infiximab and adalimumab are antibodies that bind TNF and prevent its interaction with receptor while enbrel is a soluble form of TNF receptor which can bind TNF but can not transducer signals Case 1 - Infliximab and Ulcerative Colitis Currently infliximab is the only approved anti-TNF agent for treatment of ulcerative colitis. Infliximab is a chimeric IgG1 monoclonal antibody with an approximate molecular weight of 149,100 daltons. It is composed of human constant and murine variable regions. Infliximab binds specifically to human TNF with an association constant of 10-10 M. Infliximab neutralizes the biological activity of TNF by binding with high affinity to the soluble and transmembrane forms of TNF and inhibits its binding to its receptors. In adults, single intravenous [IV] infusions of 3 mg/kg to 20 mg/kg showed a linear relationship between the dose administered and serum concentration. The volume of distribution at steady state was independent of dose and indicated that infliximab was distributed primarily within the vascular compartment. Pharmacokinetic results from single dose studies at 3 mg/kg to 10 mg/kg in rheumatoid arthritis, 5 mg/kg in Crohn's disease, and 3 mg/kg to 5 mg/kg in plaque psoriasis indicate that the median terminal half-life of infliximab is 7.7 to 9.5 Preclinical Studies -Infliximab in Rat Models Of Colitis To investigate the influence of infliximab on experimental colitis Triantafillidis et al. used 2,4,6,trinitrobenzene sulfonic acid [TNBS]-induced colitis model in rats [93]. Colitis was induced by intracolonic installation of 25 mg of TNBS dissolved in 0.25 mL of 50% ethanol and infliximab was subcutaneously administered at doses of 5 -15 mg/kg BW. Plasma and tissue levels of TNF were measured and disease activity was monitored by fixing colon in 10% buffered formalin and examined by light microscopy for the presence and activity of colitis and the extent of tissue damage. There was a significant reduction of the tissue levels of TNF-alpha in all groups of treated animals as compared with the untreated. Better reduction in tissue TNF was seen at the lowest dose [5 mg/kg]. Consistently 5 mg/kg BW dose achieved better histological results than a dose of 10 mg/kg BW.
Role of Inflammatory Biomarkers
Frontiers in Drug Design & Discovery, 2009, Vol. 4 91
Clinical Studies - Infliximab in Ulcerative Colitis Cytokines [TNF, IL-6], cytokine receptor [TNFR] and other inflammatory marker [CRP] levels are increased in patients with ulcerative colitis [94]. The effect of infliximab on circulating levels of these markers as well as disease activity has been assessed in many clinical trials [95]. Studies by Gustot et al. showed that infliximab induced a rapid decrease in CRP at one week [0.7 vs 4.3 mg/dl; p<0.01] and four weeks [2.9 mg/dl; p<0.05] Similarly, IL-6 plasma levels decreased significantly at one week [6.2 v 24.3 pg/ml; p<0.05] and four weeks [4.5 v 24.3 pg/ml; p<0.05] after infliximab administration. Soluble TNFRII levels were also decreased at one week [1924.4 v 2570 pg/ml; p<0.05] and four weeks [2055 v 2570 pg/ml; p<0.05] treatment. In larger randomized, double-blind, placebo-controlled clinical studies in patients with moderate to severe active ulcerative colitis, infliximab decreased disease severity within 4 weeks. At week 30, clinical response, clinical remission and mucosal healing for infliximab treatment group [5 mg/kg and 10 mg/kg] groups were significantly higher than in the placebo group [p < 0.01] regardless of disease duration. These effects were maintained through the end of each trial [week 54]. Thus these data correlate reduced inflammatory responses with disease severity and demonstrates efficacy of infliximab for patients with active ulcerative colitis. Case 2 - Etanercept and Rheumatoid Arthritis Collagen-induced arthritis in rat or mouse is the most widely used animal model for the evaluation of drugs targeted for rheumatoid arthritis [96]. The disease is induced by immunization of genetically susceptible strains of mice or rats with type II collagen in adjuvant. As in human rheumatoid arthritis, a number of inflammatory cytokines are expressed in the joints of mice with collagen-induced arthritis, including TNF, IL-1 and IL-6. Similar to human disease, histopathological assessment of the joints of animals with collagen-induced arthritis reveal a proliferative synovitis with infiltration of polymorphonuclear and mononuclear cells, the formation of an erosive pannus, cartilage degradation, and fibrosis. In addition to the arthritis model, animals owhen injected with LPS [bacterial lipopolysaccharide, with or without drug treatment], casuse robust induction of inflammatory cytokines [TNF, MCP-1 and IL-6] within 1-2 h. Drug efficacy can be monitored by ability to modulate plasma or tissue levels of cytokines, post LPS challenge. Etanercept is currently the most widely used anti-arthritic drug. It is a fusion protein human soluble TNF receptor fused to the Fc component of human immunoglobulin G1 [TNFR:Fc]. In animal models injection of soluble TNF receptor completely blocks induction of TNF from 19509 ± 4682 pg/ml to no detectible TNF levels wheninjected with LPS alone or with etanercept [97]. Consistent with this, treatment with TNFR:Fc also prevents disease onset [when injected along with collagen] or reduces disease severity in established disease models [98]. In human trials, anti-TNF therapy has been linked to reduced cytokine levels [TNF-, IL-1, IL-6] in joints and serum of RA patients [99]. In clinical trials in patients with active rheumatoid arthritis, etanercept [25 mg, subcutaneous, twice a week] as a monotherapy or in combinations with methotrexate [up to 20 mg per week, oral] showed marked improvement in ACR 20 [85% and 76%], ACR50 [69% and 48%] and ACR70 [43% and 24%] scores. Etanercept has also proven to be effective when given as once a week regimen [50 mg, sc].
92 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Pillarisetti and Khanna
Case 3 - Methotrexate and Rheumatoid Arthritis Methotrexate, USP [formerly Amethopterin] is an antimetabolite used in the treatment of rheumatoid arthritis and severe psoriasis. Chemically methotrexate is N-[4[[[2,4-diamino-6-pteridinyl] methyl]methylamino]benzoyl]-L-glutamic acid. Although the mechanism of anti-arthritic effects of methotrexate is not completely understood among other activities methotrexate also inhibits cytokine production by T-cells [100]. A recent study by Haroon et al. [101] showed that anti-arthritic activity of methotrexate in patients is strongly correlated with its ability to suppress T-cell cytokine production. The drug is widely used, particularly in combination with anti-TNF therapy such as etanercept, infliximab, for treatment of rheumatoid arthritis. These data suggest that monitoring plasma cytokines is a valuable tool in assessing the efficacy of anti-inflammatory agents. Several other approaches that target other inflammatory cytokines [such as IL-1 and IL-6] either as antibodies, synthesis inhibitors [such as p38, TACE, JNK-1/2, MEK] or receptor antagonist have or are being evaluated in clinic to treat arthritis. Improved understanding on the importance of cytokines in the disease process led to a paradigm shift in the treatment algorithm for RA (Table 2). Table 2.
Paradigm Shift in Rheumatoid Arthritis Treatment over 25 Years
1983
2008
Hydroxychloroquine
Infiximab
Sulfasalazine
Etanercept
Injectable gold salts
Adalimumab
Azathiopurine
Methotrexate
D-penicillamine
Leflunamide Anakinara
7. CASE STUDIES OF DRUGS THAT INDUCE INFLAMMATORY CYTOKINES AND CAUSE ORGAN TOXICITY In this section we will review examples where increased cytokine levels translated into organ toxicity in animals and humans Case 1 - Role of TNF in Cisplatin-Induced Nephrotoxicity: Cisplatin is an chemotherapeutic agent used in the treatment of a wide variety of cancers. Dose-dependent and cumulative nephrotoxicity is the major toxicity of this compound, sometimes requiring a reduction in dose or discontinuation of treatment [102]. Approximately 25–35% of patients develop evidence of nephrotoxicity following a single dose of cisplatin. Oxidant stress, caused by cisplatin-treatment is an activator of the NFB transcription factor, which, in turn, promotes the production of proinflammatory cytokines, including TNF. TNF mRNA levels are increased in cisplatin renal
Role of Inflammatory Biomarkers
Frontiers in Drug Design & Discovery, 2009, Vol. 4 93
injury [103, 104]. Injection of mice with cisplatin leads to upregulation of a number of cytokine transcripts [104], e.g., TNF-, RANTES, MCP-1. The upregulation was evident 24–48 hours after injection and sustained to 72 hours. In addition, serum and tissue level of TNF protein was induced by 8-10 fold. Urine TNF- was undetectable in salinetreated mice and was markedly increased in mice injected with cisplatin. Inhibitors of TNF- production [e.g. pentoxifylline] and TNF antibody reduced serum and kidney TNF protein levels and also blunted the cisplatin-induced increases in TNF-, MCP-1 and IL-1 [105]. In addition, the TNF inhibitors also ameliorated cisplatin-induced renal dysfunction and reduced cisplatin-induced structural damage. Likewise, TNF– deficient mice were resistant to cisplatin nephrotoxicity [106]. These results indicate cisplatin nephrotoxicity is characterized by activation of proinflammatory cytokines and chemokines. TNF appears to play a central role in the activation of this cytokine response and also in the pathogenesis of cisplatin renal injury. Case 2 - Role of Cytokines in Acetaminophen-Induced Liver Injury Acetaminophen, 4'-hydroxyacetanilide, is a non-opioid, non-salicylate analgesic and antipyretic. Intake of an overdose of acetaminophen frequently causes severe acute liver injury. Acetaminophen is metabolized by cytochrome P450 to generate a toxic metabolite, N-acetyl-p-benzoquinone imine [NAPQI], which can reduce glutathione [GSH] in the liver [107]. Thus, an overdose of acetaminophen depletes hepatic GSH, and NAPQI covalently binds to cysteine residues on proteins, resulting in the formation of 3-[cysteineS-yl] adducts, which lead to liver injury. Several lines of observations demonstrate that TNF is produced after acetaminophen challenge [108, 109]. When wild-type or TNFreceptor null mice were intraperitoneally injected with a lethal dose of acetaminophen [750 mg/kg], the mortality of TNF-receptor null mice was significantly reduced compared with WT mice. Upon treatment with a nonlethal dose [600 mg/kg] of acetminophen, WT mice exhibited an increase in serum transaminase levels. Histopathologically, centrilobular hepatic necrosis with leukocyte infiltration was evident at 10 and 24 h after acetaminophen challenge. On the contrary, serum transaminase elevation and histopathological changes were attenuated in TNF-receptor null mice injected with acetaminophen. Moreover, anti-TNF-alpha neutralizing antibodies alleviated liver injury when administered at 2 or 8 h after but not at 1 h before acetaminophen challenge to WT mice. Thus TNF mediates the pathogenic effects in acetaminophen-induced liver failure. 8. EMERGING TRENDS AND SUMMARY During the last two decades, there have been important advancements in defining role of inflammatory cytokines such as TNF, IL-1, IL-6 in disease manifestations. The methods to analyze and monitor cytokines from serum or tissues have gotten increasingly sophisticated. Pharmaceutical industry is adopting biomarker monitoring as an essential tool in pre-clinical research for target validation, proof of concept and efficacy assessment. The biomarkers are also being investigated early in clinical trials for dose selection prior to delving in long, expensive efficacy trials. The technology and advances made above have resulted in paradigm shift and identification of new treatments for inflammatory diseases such as rheumatoid arthritis. This is well illustrated in Table 2. Identification of TNF as the master cytokine in inflammatory conditions is emerging a desirable option to manage, curtail and potentially reverse disease progression. The research in areas continues to progress and emerging trends include identification of cyto-
94 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Pillarisetti and Khanna
kines or immune modulators to treat patients that do not respond to anti-TNF therapy. In addition combination of anti-TNF biologics with complementary mechanism [such as leflunamide, methotrexate, Cox-2 inhibitors] are being used aggressively to treat disease from multiple angles. Orally active TNF- modulators with better tissue penetration are areas of intense investigation. Increasing examples of applications of biomarkers, showing good PK/PD correlation across therapeutic areas are emerging. The impact of this technology in drug discovery and development is likely to generate new opportunities. REFERENCES [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41]
Springer, T.A. Cell, 1994, 76, 301. Pober, J.S. Arthritis Res., 2002, 4, 109 Lin, Y.; Berg, A.H.; Iyengar, P.; Lam, T.K.; Giacca, A.; Combs, T.P.; Rajala, M.W.; Du, X.; Rollman, B.; Li, W.; Hawkins, M.; Barzilai, N.; Rhodes, C.J.; Fantus, I.G.; Brownlee, M.; Scherer, P.E. J. Biol. Chem., 2005, 280, 4617. Kleemann, R.; Kooistra, T. Curr. Drug Targets Cardiovasc. Haematol. Disord., 2005, 5 441 Berg, A.H.; Scherer, P.E. Circ. Res., 2005, 96, 939 Natali, A.; Toschi, E.; Baldeweg, S.; Ciociaro, D.; Favilla, S.; Saccà, L.; Ferrannini, E. Diabetes, 2006, 55, 1133. Karin, M. Proc. Am. Thorac. Soc., 2005, 2, 386 Nakano, H.; Nakajima, A.; Sakon-Komazawa, S.; Piao, J.H.; Xue, X.; Okumura, K. Cell Death Differ., 2006, 13, 730. Lin, W.W.; Karin, M. J. Clin. Invest., 2007, 117, 1175. Alikunju, S.; Pillarisetti, S. Med. Chem., 2006, 6, 461. Dandona, P.; Aljada, A.; Chaudhuri, A.; Mohanty, P.; Garg, R. Circulation, 2005 111, 1448. Wellen, K.E.; Hotamisligil, G.S. J. Clin. Invest., 2005, 15, 1111. Libby, P. Nature, 2002, 420, 868. Pradhan, A.D.; Ridker, P.M. Eur. Heart J., 2002, 11, 831. Pillarisetti, S.; Saxena, U. Expert. Opin. Ther. Targets, 2004, 8, 401. Fornoni, A.; Ijaz, A.; Tejada, T.; Lenz, O. Curr. Diabetes Rev., 2008, 4, 10. Wyss-Coray, T. Nat. Med., 2006, 12, 1005. Weninger, S.C.; Yankner, B.A. Nat. Med., 2001, 7, 527. Locksley, R.M., Killeen, N.; Lenardo, M.J. Cell, 2001, 104, 487. McDermott, M.F. Cell. Mol. Biol., 2001, 47, 619. Popa, C.; Netea, M.G.; van Riel, P.L.; van der Meer, J.W., Stalenhoef, A.F. J. Lipid Res., 2007, 48, 751. Garg, A.K.; Aggarwal, B.B. Mol. Immunol., 2002, 39, 509. Madge, L.A.; Pober, JS. Exp. Mol. Pathol., 2001, 70, 317. Zink, A.; Strangfeld, A.; Schneider, M.; Herzer, P.; Hierse, F.; Stoyanova-Scholz, M.; Wassenberg, S.; Kapelle, A. Arthritis Rheum., 2006, 54, 3399. Akobeng, A.K.; Zachos, M. Cochrane Database Syst. Rev., 2004, CD003574. Cordoro, K.M.; Feldman, S.R. Skin Therapy Lett., 2007, 12, 4. Dinarello, C.A. Clin. Exp. Rheumatol., 2002, 20, S1. Ringwood, L.; Li, L. Cytokine, 2008, 42, 1. Solt, L.A.; Madge, L.A.; Orange, J.S.; May, M.J. J. Biol. Chem., 2007, 282, 8724. Brigelius-Flohé, R.; Banning, A.; Kny, M.; Böl, G.F. Arch. Biochem. Biophys., 2004, 423, 66. Sims, J.E. Curr. Opin. Immunol., 2002, 14, 117. Braddock, M.; Quinn, A. Nat. Rev. Drug Discov., 2004, 3, 330. Rose-John, S.; Scheller, J.; Elson, G.; Jones, S.A. J. Leukoc. Biol., 2006, 80, 227. Rose-John, S.; Waetzig, G.H.; Scheller, J.; Grötzinger, J.; Seegert, D. Expert. Opin. Ther. Targets., 2007, 11, 613. Nishimoto, N.; Kishimoto, T. Curr. Opin. Pharmacol., 2004, 4, 386. Daly, C.; Rollins, B.J. Microcirculation, 2003, 10, 247. Szalai, A.J. Clin. Dev. Immunol., 2004, 11, 221. Yeh, E.T. Circulation, 2004, 109, 1. Read, S.J.; Dray, A. Expert Opin. Investig. Drugs, 2008 17, 619. McNerney, T.; Baethge, B.A.; Cao, S. Clin. Exp. Immunol., 2004, 137, 621. Schumacher, R.H.; Meng, Z.; Sieck, M. J. Rheumatol., 1996, 23, 1774.
Role of Inflammatory Biomarkers [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83]
Frontiers in Drug Design & Discovery, 2009, Vol. 4 95
Westacott, C.I.; Whicher, J.T.; Barnes, I.C. Ann. Rheum. Dis., 1990, 49, 676. Bertazzolo, N.; Punzi, L.; Stefani, M.P. Agents Actions, 1994, 41, 90. Kutukculer, N.; Caglayan, S.; Aydogdu, F. Clin. Rheumatol., 1998, 17, 288. Marinova-Mutafchieva, L.; Williams, R.O.; Mason, L.J.; Mauri, C.; Feldmann, M.; Maini, R.N. Clin. Exp. Immunol., 1997, 107, 507. Zvezdanovi, L. Jugoslov Med. Biohem., 2006, 25, 363. Kagari, T.; Doi, H.; Shimozato, T. J. Immunol., 2002, 169, 1459. Abramson, S.B.; Amin, A. Rheumatology, 2002, 41, 972. Nishimoto, N.; Kishimoto, T. Handb. Exp. Pharmacol., 2008, 181, 151. Libby, P. Nature, 2002, 420, 868. Ross, R. N. Engl. J. Med., 1999, 340, 115. Pai, J.K.; Pischon, T.; Ma, J.; Manson, J.E.; Hankinson, S.E.; Joshipura, K.; Curhan, G.C.; Rifai, N.; Cannuscio, C.C.; Stampfer, M.J.; Rimm, E.B. N. Engl. J. Med., 2004, 351, 2599. Ridker, P.M.; Hennekens, C.H.; Buring, J.E.; Rifai, N. N. Engl. J. Med., 2000, 342, 836. Ridker, P.M.; Cushman, M.; Stampfer, M.J.; Tracy, R.P.; Hennekens, C.H. Circulation, 1998, 97, 425. Volpato, S.; Guralnik, J.M.; Ferrucci, L.; Balfour, J.; Chaves, P.; Fried, L.P.; Harris, T, B. Circulation, 2001, 103, 947. Ridker, P.M.; Rifai, N.; Stampfer, M.J.; Hennekens, C.H. Circulation, 2000, 101, 1767. Wang, Y.N.; Che, S.M.; Ma, A.Q. Chin. Med. Sci. J., 2004, 191, 20. Jones, K.G.; Brull, D.J.; Brown, L.C.; Sian, M.; Greenhalgh, R.M.; Humphries, S.E.; Powell, J.T. Circulation, 2001, 103, 2260. Ferroni, P.; Rosa, A.; Di Franco, M.; Palmirotta, R.; Guadagni, F.; Davì, G.; Bertazzoni, G.; Basili, S. Clin. Chim. Acta. 2007, 381, 151. Biasucci, L.M.; Liuzzo. G.; Fantuzzi, G.; Caligiuri, G.; Rebuzzi, A.G.; Ginnetti, F.; Dinarello, C.A.; Maseri, A. Circulation, 1999, 99, 2079. Luo, Y.; Jiang, D.; Wen, D.; Yang, J.; Li, L. Heart Vessels, 2004, 19, 257. Kinlay, S.; Schwartz, G.G.; Olsson, A.G.; Rifai, N.; Leslie, S.J.; Sasiela, W.J.; Szarek, M.; Libby, P.; Ganz, P. Circulation, 2003, 108, 1560. Pradhan, A. Nutr. Rev., 2007, 65, S152. Navab, M.; Gharavi, N.; Watson, A.D. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11, 459. Gustafson, B.; Hammarstedt, A.; Andersson, C.X.; Smith, U. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 2276. Pradhan, A.D.; Manson, J.E.; Rifai, N.; Buring, J.E.; Ridker, P.M. JAMA, 2001, 286, 327. Lang, C.H.; Dobrescu, C.; Bagby, G.J. Endocrinology, 1992, 130, 43. Uysal, K.T.; Wiesbrock, S.M.; Marino, M.W.; Hotamisligil, G.S. Nature, 1997, 389, 610. Liang, H.; Yin, B.; Zhang, H.; Zhang, S.; Zeng, Q.; Wang, J.; Jiang, X.; Yuan, L.; Wang, C.Y.; Li, Z. Endocrinology, 2008, 149, 2943. Haffner, S.M.; Greenberg. A.S.; Weston, W.M.; Chen, H.; Williams, K.; Freed, M.I. Circulation, 2002, 106, 679. Deepa, R.; Velmurugan. K.; Arvind, K.; Pillarisetti, S.; Sientay, C.; Uday, S.; Mohan, V. Metabolism, 2006, 55, 1232. Ding, W.X.; Yin, X.M. J. Cell. Mol. Med., 2004, 8, 445. Bradham, C.A.; Plümpe, J.; Manns, M.P.; Brenner. D.A.; Trautwein, C. Am. J. Physiol., 1998, 275, G387. Bird, G.L.A.N.; Sheron, J.; Goka, G.J.; Alexander, R.S. Ann. Intern. Med., 1990, 112, 917. Gantner, F.M.; Leist, A.W.; Lohse, P.G.; Germann, A. Hepatology, 1995, 21, 190. Gonzalez-Amaro, R.C.; Garcia-Monzon, L.; Garcia-Buey, R.; Moreno-Otero, J. L.; Lonso, E.; Yague, J.P.; Pivel, M.; Lopez-Cabrera, E.; Fernandez-Ruiz, F. J. Exp. Med., 1994, 179, 841. Iimuro, Y.; Gallucci, R.M.; Luster, M.I.; Kono, H.; Thurman, R.G. Hepatology, 1997, 26, 1530. Küsters, S.; Tiegs, G.; Alexopoulou, L.; Pasarakis, M.; Douni, E.; Künstle, G.; Blüthmann, H.; Wendel, A.; Pfizenmaier, K.; Kollias, G.; Grell, M. Eur. J. Immunol., 1997, 27, 2870. Leist, M.; Gantner, F.; Jilg, S.; Wendel, A. J. Immunol., 1995, 154, 1307. Muto, Y.; Nouri-Aria, K.T.; Meager, A.; Alexander, G.J.; Eddleston, A.L.; Williams, R. Lancet, 1998, 8602, 72. Barton, C.C.; Barton, E.X.; Ganey, P.E.; Kunkel, S.L.; Roth, R.A. Hepatology, 2001, 33, 66. Künstle, G.; Hentze, H.; Germann, P.G.; Tiegs, G.; Meergans, T.; Wendel, A. Hepatology, 1999, 30, 1241. Biburger, M.; Tiegs, G. J. Immunol., 2005, 175, 1540.
96 Frontiers in Drug Design & Discovery, 2009, Vol. 4 [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109]
Pillarisetti and Khanna
Stenvinkel, P. Kidney Int., 2005, 67, 1216. Avesani, C.M.; Carrero, J.J.; Axelsson, J.; Qureshi, A.R.; Lindholm, B.; Stenvinkel, P. Partners Crime Kidney Int., 2006, 70, S8. Baud, L.; Ardaillou, R. Miner. Electrolyte Metab., 1995, 21, 336. Mullin, J.M.; Snock, K.V. Cancer Res., 1990, 50, 2172. Marano, C.W.; Laughlin, K.V.; Russo, L.M.; Peralta Soler, A.; Mullin, J.M. J. Cell. Physiol., 1993, 157, 519. Liu, M.; Chien, C.C.; Burne-Taney, M.; Molls, R.R.; Racusen, L.C.; Colvin, R.B.; Rabb, H. J. Am. Soc. Nephrol., 2006, 177, 65. Faubel, S.; Lewis, E.C.; Reznikov, L.; Ljubanovic, D.; Hoke, T.S.; Somerset, H.; Oh, D.J.; Lu, L.; Klein, C.L.; Dinarello, C.A.; Edelstein, C.L. J. Pharmacol. Exp. Ther., 2007, 322, 8. Griffin, W.S. Am. J. Clin. Nutr., 2006, 83, 470S. Lucas, S.M.; Rothwell, N.J.; Gibson, R.M. Br. J. Pharmacol., 2006, 147, S232. Triantafillidis, J.K.; Papalois, A.E.; Parasi, A.; Anagnostakis, E.; Burnazos, S.; Gikas, A.; Merikas, E.G.; Douzinas, E.; Karagianni, M.; Sotiriou, H. World J. Gastroenterol., 2005, 11, 6843. Komatsu, M.; Kobayashi, D.; Saito, K.; Furuya, D.; Yagihashi, A.; Araake, H.; Tsuji, N.; Sakamaki, S.; Niitsu, Y.; Watanabe, N. Clin. Chem., 2001, 47, 1297. Wilhelm, S.M.; McKenney, K.A.; Rivait, K.N.; Kale-Pradhan, P.B. Clin. Ther., 2008, 30, 223. Holmdahl, R. Methods Mol. Med., 2007, 136, 185. Mohler, K.M.; Torrance, D.S.; Smith, C.A.; Goodwin, R.G.; Stremler, K.E.; Fung, V.P; Madani, H.; Widmer, M.B. J. Immunol., 1993, 151, 1548. McComb, J.; Gould, T.; Chlipala, E.; Sennelo, G.; Frazier, J.; Kieft, G.; Seely, J.; Edwards, C.K. 3rd.; Bendele, A. J. Rheumatol., 1999, 26, 1347. Feldmann, M. Nat. Rev. Immunol., 2002, 2, 364. Swierkot, J.; Szechiski, J. Pharmacol. Rep., 2006, 58, 473. Haroon, N.; Srivastava, R.; Misra, R.; Aggarwal, A. J. Rheumatol., 2008, 35, 975. Hanigan, M.H.; Devarajan, P. Cancer Ther., 2003, 1, 47. Dong, Z.; Atherton, S.S. Kidney Int., 2007, 72, 5. Ramesh, G.; Reeves, W.B. J. Clin. Invest., 2002, 110, 835. Kim, Y.K.; Choi, T.R.; Kwon, C.H.; Kim, J.H.; Woo, J.S.; Jung, J.S. Ren. Fail., 2003, 6, 909. Ramesh, G.; Reeves, W.B. Am. J. Physiol. Renal Physiol., 2003, 285, F610. Larson, A.M. Clin. Liver Dis., 2007, 11, 525. Jaeschke, H. Expert Opin. Drug Metab. Toxicol., 2005, 1, 389. Ishida, Y.; Kondo, T.; Tsuneyama, K.; Lu, P.; Takayasu, T.; Mukaida, N. J. Leukoc. Biol., 2004, 75, 59.
Frontiers in Drug Design & Discovery, 2009, 4, 97-121
97
Important Drug Interactions for Clinical Oncologists Hiroshi Ishiguro1,*, Ikuko Yano2 and Masakazu Toi3 1
Translational Research Center, Department of Clinical Trial Management / Outpatient Oncology Unit; 2Department of Pharmacy and 3Breast Surgery Department, Kyoto University Hospital, 54 Shogoinkawaharara-cho,Sakyo-ku, Kyoto-city, 606-8507, Japan Abstract: Drug interactions can cause severe side effects and lead to early termination of drug development, refusal of drug approval, prescribing restrictions or drug withdrawal from the market. Of drugs used to treat humans, cytotoxic anti-neoplastic drugs have a particularly strong action. Furthermore, they have a complex pharmacological profile, a narrow therapeutic window, and a steep dose-toxicity curve, and are associated with considerable inter- and intrapatient pharmacokinetic and pharmacodynamic differences. The recommended dose is usually close to the maximally tolerated dose in order to achieve the maximum therapeutic effect. Thus, some adverse effects are usually inevitable, so these drugs are approved for usage based on a clinical risk to benefit ratio. Therefore, drug interactions affecting the pharmacokinetics of anti-neoplastic drugs are of particular concern. Any physicians treating oncology patients must understand the pharmacokinetic behavior (absorption, distribution, metabolism, excretion, etc.) of a drug, as well as the factors affecting its pharmacokinetic behavior, for example the effects of concomitantly administered drugs, and hepatic and renal function. Medical oncologists must have expertise in achieving a good balance between safety and efficacy in medical treatment, with a proper knowledge of supportive care and an understanding of pharmacokinetics, pharmacodynamics and pharmacogenomics. We summarize the drug interactions that are important in day-to-day oncology practice. We cover pharmaceutical interactions as well as the interactions at the levels of absorption, distribution, metabolism and excretion. This review is the one of the most comprehensive to date in the field of clinical oncology, where the level of understanding of drug interactions can directly affect patient management.
INTRODUCTION Drug interactions can cause severe side effects and lead to the early termination of drug development, refusal of drug approval, severe prescribing restrictions or withdrawal of drugs from the market [1]. For example, in the 1980s, terfenadine was a widely used antihistamine, representing 60% of all antihistamine prescriptions written in the United States. After a case of fatal arrhythmia (Torsades de Point) in 1990, this drug was *Corresponding Author: Tel: +81-75-751-4770; Fax: +81-75-751-4772; E-mail:
[email protected] Gary W. Caldwell / Atta-ur-Rahman / Z. Yan / M. Iqbal Choudhary (Eds.) All rights reserved – © 2009 Bentham Science Publishers.
98 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
removed from the market worldwide [2]. This is despite terfenadine cardiotoxicity having been only reported for overdoses. The problem arose because this drug is nearly entirely bio-transformed by the CYP3A enzyme system before entering the systemic circulation. When the CYP3A enzyme system is inhibited (e.g. by the simultaneous administration of erythromycin or ketoconazole) or overwhelmed (e.g. because of an overdose), or when its activity is reduced by disease (e.g. cirrhosis), the concentration of unmetabolized terfenadine entering the systemic circulation increases markedly, resulting in considerable prolongation of the QT interval [3]. Cytotoxic anti-neoplastic drugs have some of the strongest actions of drugs used clinically. They have a complex pharmacological profile, a narrow therapeutic window (Fig. 1), a steep dose-toxicity curve, and there are considerable inter- and intra-patient pharmacokinetic and pharmacodynamic differences [4]. In fact, some adverse effects are usually inevitable; therefore, usage of these drugs is based on assessment of the clinical risk to benefit ratio. For example, arsenic trioxide, which has been approved for the treatment of recurrent or refractory acute promyelocytic leukemia in Japan, was associated with a prolongation of QT of grade 3 or greater in more than 10% of patients in the Japanese registration trial [5]. In light of this finding, the drug was approved with the condition that a post-marketing study be performed for of all cases for 6 years after approval [5]. The recommended dose of cytotoxic anti-neoplastic drugs is usually close to the maximally tolerated dose in order to achieve maximum therapeutic effect. Therefore, drug interactions affecting the pharmacokinetics of anti-neoplastic drugs are of particular concern. Physicians engaged in treating oncology patients, especially with treatments involving anti-neoplastic drugs, must understand their pharmacokinetic behavior (absorption, distribution, metabolism and excretion, etc.) as well as the factors affecting this behavior (e.g. concomitantly administered drugs and hepatic and renal function). Medical oncologists must have expertise in achieving a good balance between safety and efficacy, with proper knowledge of supportive care, as well as an understanding of pharmacokinetics, pharmacodynamics and pharmacogenomics. In this review, we summarize the drug interactions that are important in day-to-day oncology practice. We have also included some non-antineoplastic drug interactions that may be relevant for clinical oncologists. TYPES OF DRUG-INTERACTIONS Pharmaceutical Interactions Some drugs require specific diluents in order to prevent precipitation, so possible incompatibility must be checked before drug preparation. Ideally, these drugs would be prepared by pharmacists that have been specifically trained in the preparation of antineoplastic drugs. Amphotericin B should be diluted in a non-electrolyte containing solution such as sterile water or 5% glucose solution, since it is likely to precipitate in sodium chloride solution [6]. Some penicillins, including carbenicillin, ticarcillin and piperacillin, have been shown to inactivate aminoglycosides in vitro [7]. This has been observed to a great extent with tobramycin and gentamycin, while amikacin has proven more stable against inactivation [7]. Concurrent use of these agents may pose a risk of reduced antibacterial
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 99
efficacy in vivo, particularly in the setting of profound renal impairment [7]. If combined penicillin/aminoglycoside therapy is desired in a patient, especially one with renal dysfunction, the clinician should consider separation of doses and routine monitoring of aminoglycoside level and clinical response [7]. A
Adverse Event
Response
Effect
Therapeutic window
Dose
Response
Effect
Therapeutic window
B
Adverse Event
Dose Fig. (1). Schematic illustration of the sizes of the therapeutic windows for general (A) and antineoplastic (B) drugs. Figure modified from reference [69]. The therapeutic windows are delineated by the vertical dashed lines, and the widths of the windows are indicated by the double-headed arrows. Variations in response are also illustrated, with the bold line indicating the average response.
100 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
Cisplatin is known to be unstable in aqueous solution. The primary mode of decomposition involves displacement of the chloride ligand, and so increasing the chloride ion concentration improves the stability of the drug in solution. In a solution with low sodium chloride concentration (e.g. a 5% glucose solution), cisplatin decomposes rapidly for the first 3 h, then gradually reaches an equilibrium at about 80% of the initial concentration (Fig. 2A) [8, 9]. However, in a 0.9% sodium chloride solution, the cisplatin concentration decreases by no more than 3% over a 24-h period (Fig. 2A) [8, 9]. Cisplatin may also become inactivated in an amino acid solution in as little as 4 h [10].
A
Cisplatin concentration (%)
Mesna, which is used to reduce the incidence of hemorrhagic cystitis arising from the use of ifosfamide or cyclophosphamide, may bind to cisplatin cations, thus inhibiting cisplatin DNA binding and leading to a reduced anti-tumor effect [11]. When mitomycin is dissolved in 5% glucose infusion fluid (pH 4–5), it is rapidly degraded into inactive mitosenes (Fig. 2B) [4]. Mitomycin changes color from bluish violet to reddish violet when pH and activity decrease [12]. 100 95
NS D5W
90 85 80 0
1
2
3
4
6
B
Mitomycin C concentration (%)
Hours
100
NS D5W
95
90
85 0
1
3
6
24
48
Hours Fig. (2). Stability of cisplatin (A) [8, 9] and mitomycin C (B) [12] in different solutions in vitro. NS, normal saline; D5W, 5% glucose solution.
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 101
Even small modifications of the dose and schedule of two drugs can have a profound effect on the plasma disposition of the drugs [13]. In one clinical study, when a 24-h infusion of paclitaxel preceded a 48-h infusion of doxorubicin, the end-of-infusion plasma doxorubicin concentration (Cmax) was 70% higher and the doxorubicin clearance was 32% lower on average compared with the reverse sequence (Fig. 3A,B), which resulted in a higher incidence of grade 2 and 3 stomatitis and hematological toxicity [14]. In another study, even when doxorubicin was given first, if the doxorubicin bolus was immediately followed by the paclitaxel infusion, such that the two drugs were both present at high concentrations, paclitaxel caused prolongation of the distribution and elimination phases of doxorubicin and its active metabolite, doxorubicinol (Fig. 3C, D) [13]. Doxorubicin clearance and area under the curve (AUC) are also significantly altered in the presence of Cremophor EL (BASF Corp.), an emulsifying agent and aqueous solubilizer
A N=8 p = 0.0021
2000 1000 0
60 40 20 0
Dox ⇒ Pac
Pac ⇒ Dox
Dox ⇒ Pac
C
4000
D
p < 0.05
N=8 p < 0.05
24 hours 2000 0
15 minutes
Pac ⇒ Dox
N=8 Not significant
40
CL (L/h/m2)
AUC (mg/L/h)
6000
N=8 p = 0.0062
80
CL (L/h/m2)
3000
AUC (μg/L/h)
B
20
24 hours 15 minutes
0
Doxorubicin
Fig. (3). AUC (A,C) and clearance (B,D) for doxorubicin in patients with breast cancer, according to administration sequence (A,B) [14], and the interval between administration of doxorubicin and paclitaxel (C,D) [13]. Doxorubicinol, a metabolite of doxorubicin, is also shown in (C). (A,B) Doses used were: doxorubicin 60 mg/m2 and paclitaxel 125 mg/m2. (C,D) Doses used were: doxorubicin 48 mg/m2 and paclitaxel 125 mg/m2. CL, clearance; Pac, paclitaxel; Dox, doxorubicin. Error bars represent standard deviation.
102 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
for hydrophobic agents such as paclitaxel. In the presence of Cremophor EL, doxorubicin AUC has been found to be increased by about 30% and the doxorubicinol AUC to be elevated by more than 100% (Fig. 4) [15]. These findings have been postulated to explain the increased incidence of doxorubicin cardiotoxicity that has been observed in some studies [16]. Similarly, a significantly larger docetaxel AUC value has been observed when docetaxel follows doxorubicin than when docetaxel is administered alone [17].
A
Cremophor EL not received Cremophor EL received
AUC (ng/mL・h)
3000 p = 0.02
2000
N = 11 p = 0.02
1000
0 Doxorubicin
Doxorubicinol
B
CL (mL/min/m2)
1000
Cremophor EL not received N = 11 p = 0.02
Cremophor EL received
800 600 400 200 0 Doxorubicin
Fig. (4). AUC (A) and clearance (B) of doxorubicin and its metabolite doxorubicinol in patients with advanced cancer according to whether they had also received Cremophor EL [15]. Doses used were: doxorubicin 60 mg/m2 and Cremophor EL 30mL/m2. CL, clearance. Error bars represent standard deviation.
Paclitaxel has also been shown to alter the pharmacokinetic profile of epirubicin. Sequence-dependent pharmacokinetic interactions between paclitaxel and epirubicin
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 103
have been described for breast cancer patients receiving either paclitaxel (175 mg/m2) followed by epirubicin (90 mg/m2) or the reverse sequence. The treatment sequence with paclitaxel first was associated with a higher level of hematological toxicity and a 36% increase in the AUC of epirubicin relative to the reverse sequence (Fig. 5A, B), which might also have contributed to some extent to the higher risk of epirubicin cardiotoxicity [18]. Overall, the combination of taxanes and anthracyclines is associated with consistent elevation of anthracycline plasma level and enhanced toxicity when the taxane is administrated concurrently with or just prior to the anthracycline. Therefore, the minimum recommended interval between administration of the two agents is 24 h, and it is recommended that the anthracycline be administered first [16]. In a phase 1 study in which the effects of sequence and dose for combined paclitaxel and cisplatin treatment were investigated, myelosuppression was more pronounced when paclitaxel was given after cisplatin compared with the reverse sequence [19]. This finding was explained by a 25% lower paclitaxel clearance (Fig. 5C) when cisplatin preceded paclitaxel than vice versa, possibly because of the effect of cisplatin on paclitaxelmetabolizing CYP enzymes [4, 19]. Absorption Although oral administration of chemotherapeutic agents has a number of advantages over other methods, drug bioavailability is limited and variable when delivered orally. The actions of drug transporters and CYP isoenzymes (e.g. CYP3A4 and CYP3A5) in the intestinal epithelium seem to be major obstacles to efficient drug uptake [4]. Quinolones inhibit DNA gyrase (topoisomerase II) in susceptible organisms, thereby inhibiting the relaxation of supercoiled DNA and promoting the breakage of DNA strands. When present, metal cations (aluminum, calcium, iron, magnesium, and zinc) bind to quinolones in the gastrointestinal tract and inhibit their absorption. Concurrent administration of quinolones with most antacids, oral electrolyte supplements, quinapril and sucralfate should be avoided where possible [20]. If these agents are necessary, quinolones should be taken at least 2 h before or after these agents [20]. For levofloxacin in particular, the peak/minimum inhibitory concentration (MIC) ratio is a better predictor of clinical and microbiological outcome than the AUC/MIC ratio [21]. Therefore, both dose splitting, which is recommended in the package insert of Cravit (levofloxacin) in Japan [20], and inhibition of absorption by concomitantly administered drugs are likely to reduce the anti-biological activities of quinolones. Treatment with allopurinol can lead to an increased level of mercaptopurine via inhibition of xanthine oxidase-catalyzed metabolic breakdown of mercaptopurine in the intestine and liver. Therefore, when allopurinol and mercaptopurine are used concomitantly, the dose of mercaptopurine should be reduced by 75% [22]. Absorption of gefitinib is affected by gastric pH, and it has been reported that the AUC for gefitinib is reduced by 50% when gastric pH is higher than 5 [23]. Patients with achlorydia (which occurs in many elderly patients), those that have undergone stomach resection, and those taking H2 blockers or proton pump inhibitors may obtain suboptimal benefit from gefitinib treatment [23]. In order to achieve maximum benefit, gefitinib is usually taken after meal, which promotes gastric acid secretion, in turn increasing
104 Frontiers in Drug Design & Discovery, 2009, Vol. 4
A
Ishiguro et al.
N = 15 p = 0.02
AUC (μg/L/h)
4000 3000 2000 1000 0 Epi ⇒ Pac
Pac ⇒ Epi N = 15 p = 0.02
B
CL (L/h/㎡)
60
30
0 Epi ⇒ Pac
Pac ⇒ Epi
C N = 15 P < 0.001
CL (mL/min/㎡)
600
400
200
0
Pac ⇒ CDDP
CDDP ⇒ Pac
Fig. (5). AUC (A) and clearance (B) of epirubicin when concomitantly administered with paclitaxel to patients with early-stage breast cancer, according to administration sequence [18]. Doses used were: epirubicin 90 mg/m2 and paclitaxel 175mg/m2. Clearance (C) of paclitaxel when concomitantly administered with cisplatin to patients with solid tumors, according to administration sequence [19]. Doses used were: paclitaxel 110-200 mg/m2 and cisplatin 50-75mg/m2. CL, clearance; Pac, paclitaxel; Epi, epirubicin; CDDP, cisplatin; Error bars represent standard deviation.
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 105
AUC and maximum plasma concentration (Cmax) by 37% and 32%, respectively, compared with an empty stomach [23]. For erlotinib, however, the manufacturer of the product marketed in Japan (Tarceva; Chugai) recommends administration on an empty stomach (at least 1 h before or 2 h after the ingestion of food) [24], even though this reduces drug absorption by approximately half relative to the same dose taken after a meal [24]. Thus, administration of erlotinib after a meal results in a doubling of the AUC [24]. Absorption of erlotinib is also affected by gastric pH and concomitant administration of proton pump inhibitors, which reduce the AUC by about half [24]. Protein Binding Anticancer drugs can bind to several blood components, including albumin, 1 acid glycoprotein, lipoproteins, immunoglobulin, and erythrocytes. When a drug is displaced from its plasma protein as a result of drug-drug interactions or disease-drug interactions, the concentration of biologically active unbound drug in the blood increases, potentially causing an increase in effect and/or toxicity. The net pharmacodynamic effect, however, is difficult to predict because drug displacement causing an increase in the free fraction not only makes the drug more available for its target, but also assists with metabolic and renal elimination [4]. Therefore, a change in plasma protein binding will usually only transiently influence the clinical exposure of a patient to a drug [25]. The cases described below were originally thought to be caused by a change in plasma protein binding, but other factors, such as inhibition of hepatic clearance (which will be discussed later), may actually be more significant. In a patient being treated with warfarin, after administration of paclitaxel, there was an increase in the international normalization ratio (INR): on day 2 of the first cycle, a warfarin INR value of 5.2 was observed, relative to a pre-chemotherapy INR of 3.0 [26]. A post-treatment rise was observed after all subsequent cycles. Given that 95-98% of paclitaxel is bound to plasma proteins, paclitaxel could conceivably displace warfarin from plasma protein binding sites. In the patient described above, that the warfarin INR increase occurred so soon after paclitaxel administration suggested that displacement of warfarin was the primary mechanism, but more recent findings indicate that this may not be the case [26]. The present authors have also experienced a similar phenomenon in a patient treated with warfarin and paclitaxel (unpublished data). Clearly, in patients treated with warfarin and paclitaxel, the warfarin INR must be monitored closely. There have been several reports of cases where warfarin effect has been potentiated by an etoposide-containing regimen [27]. Like paclitaxel, a very high proportion of etoposide (97%) binds to plasma proteins [27], leading to suggestions that it may bring about an increased warfarin INR in a similar manner to paclitaxel. In one patient being treated with warfarin, the INR value was found to be elevated within 24 h of receiving etoposide therapy [27]. In that patient, the INR value returned to baseline in 3 days [27]. For ifosfamide, an analogue of cyclophosphamide, 12-24% of molecules are bound to plasma proteins, but the proportion is higher for its metabolites [28]. Hall et al. described three patients who experienced serious disturbance of warfarin INR values while receiving ifosfamide/mesna-containing chemotherapy. In their cases, a previously stable warfarin INR became elevated to 5.5, 7.5 and 8.4, respectively [28]. Since warfarin has a very low hepatic extraction ratio and a long equilibration time, these phenomena are unlikely to be due to a change in plasma protein binding alone.
106 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
Other factors, such as inhibition of hepatic clearance, might also contribute to the effect on pharmacodynamics of warfarin [25]. Metabolism The hepatic CYP system is the major machinery for drug metabolism, and most drug-drug interactions arise because of their impact on this system [29, 30] (Table 1). For orally administered drugs, gut wall CYP3A is probably of major importance in drugdrug and drug-xenobiotic interactions [4]. Many anticancer drugs are cleared by the CYP3A4 system. There exists, therefore, the potential for drug-drug interactions between drugs that share the same CYP machinery, whether they are cytotoxic or noncytotoxic drugs. Table 1.
Major Routes of Elimination for Selected Anti-Neoplastic Agents
Class
Drug
Major Activating Enzyme
Major Inactivating Enzyme
Alkylating agent
Cyclophosphamide
CYP2B6
CYP3A4
Ifosfamide
CYP3A4
Antimetabolite
Busulfan
CYP3A4
5-FU
DPD
Capecitabine
Carboxyesterase Cytidine deaminase
DPD
Methotrexate
Antibiotic agent
Renal
Gemcitabine
Cytidine deaminase
Mercaptopurine
Xanthine oxidase
Doxorubicin
CYP2D6, CYP3A4
Epirubicin
Unknown
Bleomycin Anti-microtubule agent
Topoisomerase inhibitor
Renal
Vincristine
CYP3A4
Vinorelbine
CYP3A4
Irinotecan
Other Method of Excretion
Carboxyesterase
UGTA1A, CYP3A4
Paclitaxel
CYP2C8, CYP3A4
Docetaxel
CYP3A4
Etoposide
CYP3A4
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 107 (Table 1) contd....
Major Activating Enzyme
Major Inactivating Enzyme
Other Method of Excretion
Class
Drug
Platinum agent
Carboplatin
Renal
Cisplatin
Renal
Molecular targeted agents
Hormonal agent
Imatinib
CYP3A4
Gefitinib
CYP3A4
Tretinoin
CYP3A4
Tamoxifen
CYP2D6, CYP3A4
Toremifene
CYP3A4
Anastrozole
CYP3A4
Letrozole
CYP2A6, CYP3A4
Exemestane
CYP3A4
Progesterone
CYP3A4
Flutamide
CYP3A4
Increased Toxicity The AUC of midazolam, which is metabolized by CYP3A4, can be elevated two to 16-fold by moderate to strong inhibitors of CYP3A4, such as anti-fungal medications (fluconazole, itraconazole), macrolide antibiotics (erythromycin, clarithromycin), nondihydropyridine calcium channel blockers (diltiazem, verapamil) and even grapefruit juice [1]. The magnitude of inhibition depends on the drug, its dose, and the duration of administration. The inhibitory activity of a concomitantly administered drug is generally classified as strong (>5), moderate (~5) or weak (<2) based on the fold increase in midazolam plasma AUC [1] (Table 2). Although classified as “weak”, a two-fold increase in AUC for anti-neoplastic drugs is often very undesirable, since many of these agents have very narrow therapeutic windows. Metabolism of the vinca alkaloids generally appears to be mediated by the CYP3A subfamily. There have been several cases of severe neurotoxicity or even death possibly resulting from drug interactions between intravenously administered vinca alkaloids and CYP inhibitors such as the antifungal agent itraconazole [31-33]. Irinotecan is converted into its pharmacologically active metabolite, SN-38, by carboxyesterase. SN-38 is then inactivated by conversion to SN-38G by uridine diphosphate-glucuronosyltransferase (UGT) 1A1. A specific genetic polymorphism of UGT1A1 is known to be related to a higher level of irinotecan toxicity, and a diagnostic tool for this polymorphism is now available [34]. Irinotecan is also inactivated by CYP3A4, so
108 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Table 2.
Ishiguro et al.
CYP3A4 Inhibitors and Degree of Inhibition [1]
Strength of CYP3A4 Inhibition
Dose
CYP3A4 Substrate AUC (Fold Increase Relative to Baseline Value)
200 mg daily for 4 days
8-11
100 mg daily for 4 days
6
Clarithromycin
1000 mg daily for 7 days
7
Fluconazole
400 mg
3
Clarithromycin
500 mg daily for 5 days
3.6
Erythromycin
1500 mg daily for 5 days
3.8
Diltiazem
180 mg daily for 2 days
3.7
Verapamil
240 mg daily for 2 days
2.9
Grapefruit juice
~250 mL daily for 4 days
2.4
Grapefruit juice
200 mL
1.5
Azithromycin
400 mg daily for 3 days
1.3
Cimetidine
800 mg
1.3
Drug
Itraconazole Strong
Moderate
Weak
co-administration of a strong CYP3A4 inhibitor, ketoconazole, leads to significantly increased (109%, p = 0.04) levels of SN-38 [35]. Docetaxel is extensively metabolized by CYP3A4, and co-administration of ketoconazole has been found to decrease docetaxel clearance by 50% and increase AUC by more than two-fold (Fig. 6A, B) [36]. The AUC of docetaxel is reportedly a significant predictor of severe neutropenia, with a 50% decrease in docetaxel clearance corresponding to a 4.3-fold increase in the risk of developing grade 4 neutropenia and a 3.0-fold increase in the risk of developing febrile neutropenia [37]. Although a single dose of cimetidine (800 mg orally) does not significantly affect the AUC of midazolam (producing only a 1.3-fold increase) [1], the results of a study involving a small number of patients showed that 5 days of cimetidine treatment (400 mg orally twice per day) increased the AUC of epirubicin (a 50% increase, which was statistically not significant due to a small sample size) and its active metabolite, epirubicinol (41% increase) (Fig. 7A) [38]. These changes in exposure could not be explained by reduced cytochrome P-450 activity alone [38]. Cimetidine also reportedly affects the pharmacokinetics of 5-fluorouracil (5-FU): pretreatment with cimetidine for 4 weeks led to increased plasma concentration and AUC of 5-FU [39]. For oral 5-FU, the peak plasma concentration was increased by 74% and the AUC was increased by 72% [39]. For intravenous 5-FU, the AUC was increased by 27% and total body clearance was decreased by 28% (Fig. 7B, C) [39]. Since H2 blockers such as cimetidine are likely to be coprescribed or self-administered with anti-neoplastic drugs, oncologists should be aware of this potential drug interaction [38]. 5-FU clearance has been found to be significantly
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 109
reduced (26.9%) by prior administration of metronidazole, which leads to increased toxicity without enhanced therapeutic efficacy [40]. The mechanisms underlying these apparent interactions are unknown [40].
A
N=7 p = 0.018
AUC/dose (ng・h/mL・mg)
120 100 80 60 40 20 Doc alone
Doc+Keto
N=7 p = 0.018
B 50
CL (L/h)
40 30 20 10 Doc alone
Doc+Keto
Fig. (6). AUC/dose (A) and clearance (B) for docetaxel in patients with cancer treated with docetaxel [36] when administered alone or concomitantly with ketoconazole. Doses used were: docetaxel 100mg/m2 or 10mg/m2 with three 200mg dose of ketokonazole. CL, clearance; Doc, docetaxel; Keto, ketoconazole. Error bars represent standard deviation.
Calcium channel blockers such as verapamil inhibit both P-gp and CY3A. When paclitaxel was administered in combination with r-verapamil, there was a near doubling of the AUC and peak concentration of paclitaxel [41]. In another study, doxorubicin AUC appeared to be higher and plasma drug clearance appeared to be lower when concomitantly administered with verapamil, although these differences were not statistically significant due to a small sample size (Fig. 8A, B) [42]. Another calcium channel blocker, nifedipine, also affects the pharmacokinetics of vincristine, a CYP3A-metabolized drug. When patients receiving vincristine were treated with nifedipine, there was a decrease in vincristine clearance from the body (Fig. 8C, D) [43].
110 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
A
AUC (μg/L/min)
without cimetidine
Not significant
1600
with cimetidine
1200 p < 0.05
N=7
800
400
0 Epirubicin
Epirubicinol
B N = 15 p < 0.01
AUC (μg/mL/min)
2000 1500 1000 500 0 without cimetidine
with cimetidine
C
CL (mL/min)
1500 N = 15 p < 0.01
1000
500 without cimetidine
with cimetidine
Fig. (7). AUC for epirubicin and epirubicinol (A) [38] and AUC (B) and clearance (C) for 5-FU [39] when administered alone or concomitantly with cimetidine to patients with advanced cancer. Doses used were: (A) epirubicin 100 mg/m2 and cimetidine 400mg twice daily, (B,C) 5-FU 15 mg/kg and cimetidine 1000mg once daily. Error bars represent standard deviation.
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 111
A
N=5 Not significant
AUC (ng mL-1h)
4000 3000 2000 1000 0 without verapamil
with verapamil N=5 Not significant
B 80
CL (l/h)
60 40 20 0 without verapamil
with verapamil N = 26 p < 0.05
C AUC (μgxmin/mL)
15
10
5
0 without nifedipine
with nifedipine N = 26 p < 0.01
D CL (ml/min/m2)
1500
1000
500
0 without nifedipine
with nifedipine
Fig. (8). AUC (A,C) and clearance (B,D) for doxorubicin (A,B) or vincristine (C,D) when administered alone or concomitantly with verapamil (A,B) [42] or nifedipine (C,D) [43] to patients with advanced cancer. Dose used were: (A,B) doxorubicin 40 mg/m2 and verapamil 240-480mg daily, (C,D) vincristine 2mg and nifedipine 10mg three times a day. CL, clearance. Error bars represent standard deviation.
112 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
Decreased Benefit Corticosteroid and anti-convulsant (AC) medications that are commonly used for patients with brain tumors, such as phenytoin, carbamazepine and phenobarbital, can affect the cytochrome P-450 system and may cause increased clearance of antineoplastic drugs, which are also metabolized by the cytochrome P-450 system, thus producing a need for larger doses [44]. In a phase I study of paclitaxel in patients with recurrent malignant glioma, peak plasma concentration and clearances were similar for patients receiving 240 mg/m2 paclitaxel with no ACs and patients receiving 360 mg/m2 paclitaxel with ACs, which supports the theory that administration of ACs increases the clearance of paclitaxel [44]. Vincristine is metabolized by CYP3A4 to some extent, and in one study systemic clearance was found to be 63% higher, elimination half-life 35% shorter and total AUC 43% smaller in patients who were receiving carbamazepine or phenytoin than in those who were not (Fig. 9A, B) [45]. Etoposide clearance is also affected by ACs: AC therapy is reportedly associated with a 1.5-fold to two-fold increase in etoposide clearance, resulting in a 33% to 50% reduction in systemic exposure, which may result in ineffective therapy (Fig. 9C) [46]. In patients with malignant glioma who were being treated with irinotecan, all of whom were receiving chronic dexamethasone, and >90% of whom were receiving enzyme-inducing ACs, irinotecan, SN-38 and SN38G AUC values were approximately 40%, 25% and 25%, respectively, of the corresponding values in patients with metastatic colorectal cancer who were not receiving chronic dexamethasone and enzyme-inducing ACs (Fig. 10) [47]. It has been recommended that the dose of irinotecan be increased by 50% in patients who are being treated concomitantly with enzyme-inducing ACs, in order to achieve adequate exposure to irinotecan and SN-38 [29]. Pretreatment of patients with barbiturates has been found to stimulate docetaxel metabolism to a significant extent [48]. In any case, the American Academy of Neurology’s position is that ACs are not effective in preventing first seizure in patients with newly diagnosed brain tumor, and should not be used routinely [49]. St John’s wort has become one of the world’s most popular herbal preparations, particularly among cancer patients, because of its putative activity against mild to moderate depression. However, in cancer patients treated with irinotecan, concomitant administration of St John’s wort reduced the AUC of its active metabolite, SN-38, by 42%, which may have a deleterious impact on treatment outcome (Fig. 11) [50]. Cigarette smoke contains several constituents that are known to interact with drugmetabolizing enzymes. Among patients receiving irinotecan, irinotecan clearance was about 18% faster among smokers than among non-smokers, and systemic exposure to SN-38 was almost 40% lower in smokers [51]. In the same study, hematological toxicity was considerably less prevalent among smokers, which may reflect a less favorable therapeutic outcome [51]. CYP3A4 is the major enzyme responsible for metabolism of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor [52]. Oral clearance of erlotinib has been shown to be 24% faster in smokers compared with nonsmokers [53], and this may affect overall survival in patients with non-small-cell lung cancer [51]. Tamoxifen is converted to the active metabolites 4-hydroxytamoxifen and 4-hydroxyN-desmethyltamoxifen (endoxifen), which is more than 100 times potent than tamoxifen with respect to its anti-estrogen effect [54, 55]. Plasma endoxifen steady-state concentrations are, on average, 6-10 times higher than corresponding 4-hydroxytamoxifen concen-
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 113
N = 15 p = 0.004
A AUC (ng・h/mL)
80
60
40
20 without AC
B
N = 15 p = 0.04
1200
CL (mL/min)
with AC
1000 800 600 400 200 0 without AC
with AC
C N = 14 p = 0.01
CL (mL/min/m2)
40 30 20 10 0 without AC
with AC
Fig. (9). AUC (A) and clearance (B) of vincristine [45] and clearance (C) of etoposide [46] when administered alone or concomitantly with various anticonvulsants to patients with advanced cancer. Dose used were: (A,B) vincristine 1.4mg/m2 (max 2mg), (C) etoposide 960-1500mg/m2. CL, clearance. Error bars represent standard deviation.
114 Frontiers in Drug Design & Discovery, 2009, Vol. 4
A
Ishiguro et al.
p < 0.0001
AUC (ng・h/mL)
30000
Glioma
(N = 32)
25000 20000
Non-CNS tumor (N = 163)
p < 0.0001
15000 p < 0.0001
10000 5000 0 CPT
SN-38 (x10)
SN-38G (x10)
p < 0.0001
B
20
CL
(L/h/m2)
40
0 Glioma (N = 32)
Non-CNS tumor (N = 163)
Fig. (10). AUC of irinotecan (CPT) and its metabolites (A) and clearance of CPT (B) in patients with glioma and non-central nervous system tumors [47]. Dose used were: irinotecan 125mg/m2 . CL, clearance; CNS, central nervous system. CL, clearance. Error bars represent standard deviation.
trations in women receiving 20 mg/day tamoxifen in the long term, and endoxifen has been shown to be the metabolite most responsible for tamoxifen activity [54, 55]. Plasma concentrations of endoxifen are lower in patients who are also taking paroxetine, a selective serotonin re-uptake inhibitor (SSRI) that is commonly prescribed for the nonhormonal treatment of hot flashes, than in patients who are not taking paroxetine (Fig. 12) [56]. Tamoxifen-treated patients with impaired CYP2D6 metabolism arising from the presence of one or two CYP2D6*4 alleles or the concomitant administration of a moderate or potent CYP2D6 inhibitor have a nearly two-fold higher risk of breast cancer recurrence, independent of standard prognostic factors [54].
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 115
A
AUC (μM・h)
80
without SJW with SJW
p = 0.14
60 p = 0.033
40
N=5
20 0 CPT
B
SN-38 (x10)
N=5 p = 0.11
80
CL (L/h)
60 40 20 0 without SJW
with SJW
Fig. (11). AUC (A) and clearance (B) of irinotecan (CPT) when administered alone or concomitantly with St John’s wort (SJW) in patients with cancer [50]. AUC data for SN-38 are also shown. Dose used were: irinotecan 350mg/m2, SJW 300mg three times a day. CL, clearance; SJW, St John’s wort. Error bars represent standard deviation.
Cyclophosphamide is a prodrug that requires bio-activation to become cytotoxic. The first step in this activation process is the cytochrome p450 isoenzyme-catalyzed hydroxylation of cyclophosphamide to 4-hydroxycyclophosphamide. ThioTEPA, an agent used in high-dose chemotherapy regimens, strongly inhibits the bio-activation of cyclophosphamide, resulting in AUC values that are decreased by 26%, presumably resulting in decreased efficacy [57]. Therefore, the sequence and scheduling of these two agents in high-dose chemotherapy regimens is likely to be extremely important [57]. Effect on Warfarin Pharmacokinetics Imatinib is a strong inhibitor of CYP2C9, which is the principal enzyme required for inactivation of warfarin [58]. In a phase 1 clinical trial of docetaxel/estramustin/imatinib
116 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
administered to prostate cancer patients who were also receiving warfarin prophylaxis, two out of thirteen patients experienced grade 3 prolongation of prothrombin time, which was attributed to the interaction between imatinib and warfarin [59]. 200
Endoxifen concentration (nM)
N = 34
N=6
N=3
150
100
50
0
None
Paroxetine
None
Wt/Wt
Wt/Wt
Null/Null
SSRI Genotype
Fig. (12). Plasma endoxifen concentrations in patients with breast cancer concurrently taking commonly used antidepressants, paroxetine and tamoxifen 20mg/day, according to CYP2D6 genotype [56]. Error bars represent standard deviation. SSRI, selective serotonin re-uptake inhibitor; Wt, wild type.
An adverse interaction between FU and warfarin has been reported, which may be due to FU impairing vitamin K absorption or interfering with warfarin absorption, vascular transport, degradation, or excretion, or FU interfering with metabolism in general [4]. Several studies have shown that a 1 mg/day (mini-dose) of warfarin reduces catheter-related thrombosis without causing an alteration in prothrombin time or activated partial thromboplastin time, or causing bleeding. However, Masci et al. reported that there was a warfarin INR elevation of more than 1.5 in 33% of patients receiving fluorouracil-based chemotherapy, with 19% having an INR value of more than 3.0 [60]. Eight percent of patients also experienced bleeding. These authors also observed an INR elevation in 28% of patients treated with a de Gramont regimen (FU and folinic acid), 26% treated with a FU, folinic acid and irinotecan (FOLFIRI) regimen and 49% treated with a FU, folinic acid and oxaliplatin (FOLFOX) regimen. There was a significantly higher incidence of INR elevation in the patients treated with FOLFOX regimen. Oxaliplatin is largely bound to plasma protein and especially to albumin (85%), therefore it was originally suggested that displacement of warfarin from plasma protein could explain the prolongation of INR in that study [60] but other factors are now thought to be more important.
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 117
There is a significant pharmacokinetic interaction between capecitabine and warfarin, resulting in exaggerated anticoagulant activity. During capecitabine treatment, the AUC for a single dose of warfarin increased by 57%, with a 51% longer elimination half-life and an INR that was increased 2.8-fold relative to warfarin without capecitabine [61]. Copur et al. described two patients who presented with bleeding most likely caused by an adverse interaction between capecitabine and warfarin after 6 weeks of concomitant therapy [62]. In both cases, there was a marked elevation in INR value (to >10), with subsequent gastrointestinal bleeding. Since the exact mechanism by which this interaction occurs is unknown, close monitoring of coagulation parameters is recommended for all patients receiving concomitant warfarin and capecitabine, with appropriate adjustment of warfarin dosage as necessary [62]. Excretion For approximately one-third of anticancer agents, 30% or more undergoes renal clearance as an active or toxic compound. For example, methotrexate and bleomycin are mostly excreted unaltered in the kidney. Thus, even a minor decrease in renal function in patients undergoing chemotherapy can have profound effect on renal clearance, leading to significant toxicity [29]. When the cumulative dose of cisplatin is greater than 300 mg/m2, the total plasma clearance of a renally excreted drug such as bleomycin is reportedly decreased by 50% [63]. Thus, close monitoring of renal function should be performed in patients receiving concurrent cisplatin, such as in the MVAC regimen for bladder cancer and the BEP regimen for germ cell tumors [29]. Since fatal pulmonary toxicity has been associated with delayed bleomycin elimination as a result of cisplatininduced renal failure, the dose of bleomycin should be reduced when creatinine clearance is less than 60 mL/min [64]. Methotrexate is not only filtered but is also actively secreted by the renal tubules [65]. Concurrent administration of certain non-steroidal anti-inflammatory drugs or penicillin may increase the serum concentration of methotrexate via competition in renal tubular secretion [65, 66]. Further, when urine becomes acidified, methotrexate may precipitate within the renal tubules, which delays its elimination, causing further toxicity. Therefore, medications that potentially acidify urine, such as furosemide and thiazide diuretics as well as high dose vitamin C, should be avoided in patients receiving methotrexate treatment [67, 68]. Patients being treated with high doses of methotrexate must be kept hydrated and with a urine pH above 7.0 by using acetazolamide [67, 68]. SUMMARY In the field of oncology, drug-drug interactions are a major concern in both day-today practice and drug development. The US Food and Drug Administration has issued guidelines detailing which in vitro and in vivo drug interaction studies should be conducted during drug development [1]. However, data arising from studies of this type are not available for many drugs that are already on the market, meaning that data must be garnered from case studies. Further compounding the problem is that data from clinical trials that are terminated due to unexpected toxicities are not always reported in full in the literature. Further, drug-drug interactions that result in a lower level of efficacy but no increase in toxicity have not been given much attention until recently. The interaction between tamoxifen and SSRIs such as paroxetine is one famous example.
118 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
For most anti-neoplastic drugs, especially cytotoxic drugs, the recommended dose is close to the maximum tolerated dose in order to achieve maximum clinical benefit. Although CYP3A4 inhibitory activity leading to a less than two-fold increase in AUC is classified as “weak” inhibition, for anti-neoplastic drugs even a minor increase in AUC (e.g. 30%) can result in severe dose-limiting toxicity. Conversely, in cancer patients a reduction in AUC because of drug interactions might result in a lower level of efficacy, potentially leading to disease recurrence or progression. This phenomenon is particularly important for adjuvant chemotherapy, when there is no evaluable disease that might be used to monitor drug efficacy. Therefore, knowledge of drug interactions is more important for clinical oncologists than for any other specialty. Medical oncologists must not only control patient compliance via education, but also take charge of controlling the many factors affecting the pharmacokinetic and pharmacodynamic variables controlling response to treatment (Fig. 13).
Fig. (13). Schematic diagram showing the factors affecting the pharmacokinetics and pharmacodynamics of drugs.
ABBREVIATIONS 5-FU
=
5-Fluorouracil
AUC
=
Area under the concentration-time curve
Cmax
=
Maximum plasma concentration
Important Drug Interactions
Frontiers in Drug Design & Discovery, 2009, Vol. 4 119
CYP
=
Cytochrome P450
INR
=
International normalization ratio
MIC
=
Minimum inhibitory concentration
UGT
=
Uridine diphosphate-glucuronosyltransferase
REFERENCES [1]
[2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18]
[19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34]
Bjornsson, T. D.; Callaghan, J. T.; Einolf, H. J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, S. P.; Miwa, G.; Ni, L.; Kumar, G.; McLeod, J.; Obach, S. R.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J. T.; Tweedie, D.; Vega, J. M.; Walsh, J.; Wrighton, S. A. J. Clin. Pharmacol., 2003, 43, 443-69. Monahan, B. P.; Ferguson, C. L.; Killeavy, E. S.; Lloyd, B. K.; Troy, J.; Cantilena, L. R. Jr. JAMA, 1990, 264, 2788-90. Roden, D. M. N. Engl. J. Med., 2004, 350, 1013-22. Beijnen, J. H.; Schellens, J. H. Lancet Oncol., 2004, 5, 489-96. Arsenic trioxide (Trisenox) Package Insert (Japanese). In Nippon Shinyaku CO., LTD.: 2007. Amphotericin B (Fangizone) Package Insert (Japanese). In Bristol-Myers Squibb Company: 2007. Tobramycin (Tobracin) Package Insert (Japanese). In J-DOLPH Pharmaceutical CO., LTD.: 2008. Cheung, Y. W.; Cradock, J. C.; Vishnuvajjala, B. R.; Flora, K. P. Am. J. Hosp. Pharm., 1987, 44, 12430. Pujol Cubells, M.; Prat Aixela, J.; Girona Brumos, V.; Duran Pou, S.; Villaronga Flaque, M. Pharm. World Sci., 1993, 15, 34-6. Cisplatin (Randa) Package Insert (Japanese). In Nippon Kayaku CO., LTD.: 2007. Mesna (Uromitexan) Package Insert (Japanese). In Shionogi & CO., LTD.: 2005. Mitomycin C (Mitomycin) Package Insert (Japanese). In Kyowa Hakko Kogyo CO., LTD.: 2006. Gianni, L.; Vigano, L.; Locatelli, A.; Capri, G.; Giani, A.; Tarenzi, E.; Bonadonna, G. J. Clin. Oncol., 1997, 15, 1906-15. Holmes, F. A.; Madden, T.; Newman, R. A.; Valero, V.; Theriault, R. L.; Fraschini, G.; Walters, R. S.; Booser, D. J.; Buzdar, A. U.; Willey, J.; Hortobagyi, G. N. J. Clin. Oncol., 1996, 14, 2713-21. Millward, M. J.; Webster, L. K.; Rischin, D.; Stokes, K. H.; Toner, G. C.; Bishop, J. F.; Olver, I. N.; Linahan, B. M.; Linsenmeyer, M. E.; Woodcock, D. M. Clin. Cancer Res., 1998, 4, 2321-9. Baker, A. F.; Dorr, R. T. Cancer Treat. Rev., 2001, 27, 221-33. D'Incalci, M.; Schuller, J.; Colombo, T.; Zucchetti, M.; Riva, A. Semin. Oncol., 1998, 25(6 Suppl 13), 16-20. Venturini, M.; Lunardi, G.; Del Mastro, L.; Vannozzi, M. O.; Tolino, G.; Numico, G.; Viale, M.; Pastrone, I.; Angiolini, C.; Bertelli, G.; Straneo, M.; Rosso, R.; Esposito, M. J. Clin. Oncol., 2000, 18, 2116-25. Rowinsky, E. K.; Gilbert, M. R.; McGuire, W. P.; Noe, D. A.; Grochow, L. B.; Forastiere, A. A.; Ettinger, D. S.; Lubejko, B. G.; Clark, B.; Sartorius, S. E. J. Clin. Oncol., 1991, 9, 1692-703. Levofloxacin (Clavit) Package Insert (Japanese). In Daiichi Sankyo & CO., LTD.: 2008. Preston, S. L.; Drusano, G. L.; Berman, A. L.; Fowler, C. L.; Chow, A. T.; Dornseif, B.; Reichl, V.; Natarajan, J.; Corrado, M. JAMA, 1998, 279, 125-9. Mercaptopurin (Leukerin) Package Insert (Japanese). In Ohara Pharmaceutical CO., LTD.: 2007. Gefitinib (Iressa) Package Insert (Japanese). In AstraZeneca: 2006. Erlotinib (Tarceva) Package Insert (Japanese). In Chugai Pharmaceutical CO., LTD.: 2007. Benet, L. Z.; Hoener, B. A. Clin. Pharmacol. Ther., 2002, 71, 115-21. Thompson, M. E.; Highley, M. S. Ann. Oncol., 2003, 14, 500. Le, A. T.; Hasson, N. K.; Lum, B. L. Ann. Pharmacother., 1997, 31, 1006-8. Hall, G.; Lind, M. J.; Huang, M.; Moore, A.; Gane, A.; Roberts, J. T.; Cantwell, B. M. Postgrad. Med. J., 1990, 66, 860-1. Lam, M. S.; Ignoffo, R. J. J. Oncol. Pharma. Pract., 2003, 9, 45. Fujita, K. Curr. Drug Metab., 2006, 7, 23-37. Bosque, E. Ann. Intern. Med., 2001, 134, 427. Bohme, A.; Ganser, A.; Hoelzer, D. Ann. Hematol., 1995, 71, 311-2. Gillies, J.; Hung, K. A.; Fitzsimons, E.; Soutar, R. Clin. Lab. Haematol., 1998, 20, 123-4. United States Food and Drug Administration: Campostar label.
120 Frontiers in Drug Design & Discovery, 2009, Vol. 4 [35] [36] [37]
[38] [39] [40] [41] [42] [43] [44]
[45] [46] [47]
[48] [49] [50] [51] [52] [53] [54]
[55] [56] [57] [58] [59] [60] [61]
Ishiguro et al.
Kehrer, D. F.; Mathijssen, R. H.; Verweij, J.; de Bruijn, P.; Sparreboom, A. J. Clin. Oncol., 2002, 20, 3122-9. Engels, F. K.; Ten Tije, A. J.; Baker, S. D.; Lee, C. K.; Loos, W. J.; Vulto, A. G.; Verweij, J.; Sparreboom, A. Clin. Pharmacol. Ther., 2004, 75, 448-54. Bruno, R.; Hille, D.; Riva, A.; Vivier, N.; ten Bokkel Huinnink, W. W.; van Oosterom, A. T.; Kaye, S. B.; Verweij, J.; Fossella, F. V.; Valero, V.; Rigas, J. R.; Seidman, A. D.; Chevallier, B.; Fumoleau, P.; Burris, H. A.; Ravdin, P. M.; Sheiner, L. B. J. Clin. Oncol., 1998, 16, 187-96. Murray, L. S.; Jodrell, D. I.; Morrison, J. G.; Cook, A.; Kerr, D. J.; Whiting, B.; Kaye, S. B.; Cassidy, J. Clin. Oncol., (R Coll. Radiol.), 1998, 10, 35-8. Harvey, V. J.; Slevin, M. L.; Dilloway, M. R.; Clark, P. I.; Johnston, A.; Lant, A. F. Br. J. Clin. Pharmacol., 1984, 18, 421-30. Bardakji, Z.; Jolivet, J.; Langelier, Y.; Besner, J. G.; Ayoub, J. Cancer Chemother. Pharmacol., 1986, 18, 140-4. Tolcher, A. W.; Cowan, K. H.; Solomon, D.; Ognibene, F.; Goldspiel, B.; Chang, R.; Noone, M. H.; Denicoff, A. M.; Barnes, C. S.; Gossard, M. R.; Fetsch, P. A.; Berg, S. L.; Balis, F. M.; Venzon, D. J.; O'Shaughnessy, J. A. J. Clin. Oncol., 1996, 14, 1173-84. Kerr, D. J.; Graham, J.; Cummings, J.; Morrison, J. G.; Thompson, G. G.; Brodie, M. J.; Kaye, S. B. Cancer Chemother. Pharmacol., 1986, 18, 239-42. Fedeli, L.; Colozza, M.; Boschetti, E.; Sabalich, I.; Aristei, C.; Guerciolini, R.; Del Favero, A.; Rossetti, R.; Tonato, M.; Rambotti, P. Cancer, 1989, 64, 1805-11. Chang, S. M.; Kuhn, J. G.; Rizzo, J.; Robins, H. I.; Schold, S. C., Jr.; Spence, A. M.; Berger, M. S.; Mehta, M. P.; Bozik, M. E.; Pollack, I.; Gilbert, M.; Fulton, D.; Rankin, C.; Malec, M.; Prados, M. D. J. Clin. Oncol., 1998, 16, 2188-94. Villikka, K.; Kivisto, K. T.; Maenpaa, H.; Joensuu, H.; Neuvonen, P. J. Clin. Pharmacol. Ther., 1999, 66, 589-93. Rodman, J. H.; Murry, D. J.; Madden, T.; Santana, V. M. J. Clin. Oncol., 1994, 12, 2390-7. Friedman, H. S.; Petros, W. P.; Friedman, A. H.; Schaaf, L. J.; Kerby, T.; Lawyer, J.; Parry, M.; Houghton, P. J.; Lovell, S.; Rasheed, K.; Cloughsey, T.; Stewart, E. S.; Colvin, O. M.; Provenzale, J. M.; McLendon, R. E.; Bigner, D. D.; Cokgor, I.; Haglund, M.; Rich, J.; Ashley, D.; Malczyn, J.; Elfring, G. L.; Miller, L. L. J. Clin. Oncol., 1999, 17, 1516-25. Royer, I.; Monsarrat, B.; Sonnier, M.; Wright, M.; Cresteil, T. Cancer Res., 1996, 56, 58-65. Glantz, M. J.; Cole, B. F.; Forsyth, P. A.; Recht, L. D.; Wen, P. Y.; Chamberlain, M. C.; Grossman, S. A.; Cairncross, J. G. Neurology, 2000, 54, 1886-93. Mathijssen, R. H.; Verweij, J.; de Bruijn, P.; Loos, W. J.; Sparreboom, A. J. Natl. Cancer Inst., 2002, 94, 1247-9. van der Bol, J. M.; Mathijssen, R. H.; Loos, W. J.; Friberg, L. E.; van Schaik, R. H.; de Jonge, M. J.; Planting, A. S.; Verweij, J.; Sparreboom, A.; de Jong, F. A. J. Clin. Oncol., 2007, 25, 2719-26. Ling, J.; Johnson, K. A.; Miao, Z.; Rakhit, A.; Pantze, M. P.; Hamilton, M.; Lum, B. L.; Prakash, C. Drug Metab. Dispos., 2006, 34, 420-6. Lu, J. F.; Eppler, S. M.; Wolf, J.; Hamilton, M.; Rakhit, A.; Bruno, R.; Lum, B. L. Clin. Pharmacol.. Ther., 2006, 80, 136-45. Goetz, M. P.; Knox, S. K.; Suman, V. J.; Rae, J. M.; Safgren, S. L.; Ames, M. M.; Visscher, D. W.; Reynolds, C.; Couch, F. J.; Lingle, W. L.; Weinshilboum, R. M.; Fritcher, E. G.; Nibbe, A. M.; Desta, Z.; Nguyen, A.; Flockhart, D. A.; Perez, E. A.; Ingle, J. N. Breast Cancer Res. Treat., 2007, 101, 11321. Lim, H. S.; Ju Lee, H.; Seok Lee, K.; Sook Lee, E.; Jang, I. J.; Ro, J. J. Clin. Oncol., 2007, 25, 383745. Jin, Y.; Desta, Z.; Stearns, V.; Ward, B.; Ho, H.; Lee, K. H.; Skaar, T.; Storniolo, A. M.; Li, L.; Araba, A.; Blanchard, R.; Nguyen, A.; Ullmer, L.; Hayden, J.; Lemler, S.; Weinshilboum, R. M.; Rae, J. M.; Hayes, D. F.; Flockhart, D. A. J. Natl. Cancer Inst., 2005, 97, 30-9. Huitema, A. D.; Kerbusch, T.; Tibben, M. M.; Rodenhuis, S.; Beijnen, J. H. Cancer Chemother. Pharmacol., 2000, 46, 119-27. Imatinib (Glivec) Package Insert (Japanese). In Novartis: 2008. Lin, A. M.; Rini, B. I.; Derynck, M. K.; Weinberg, V.; Park, M.; Ryan, C. J.; Rosenberg, J. E.; Bubley, G.; Small, E. J. Clin. Genitourin. Cancer, 2007, 5, 323-8. Masci, G.; Magagnoli, M.; Zucali, P. A.; Castagna, L.; Carnaghi, C.; Sarina, B.; Pedicini, V.; Fallini, M.; Santoro, A. J. Clin. Oncol., 2003, 21, 736-9. Camidge, R.; Reigner, B.; Cassidy, J.; Grange, S.; Abt, M.; Weidekamm, E.; Jodrell, D. J. Clin. Oncol., 2005, 23, 4719-25.
Important Drug Interactions [62] [63] [64] [65] [66] [67] [68] [69]
Frontiers in Drug Design & Discovery, 2009, Vol. 4 121
Copur, M. S.; Ledakis, P.; Bolton, M.; Morse, A. K.; Werner, T.; Norvell, M.; Muhvic, J.; Chu, E. Clin. Colorectal Cancer, 2001, 1, 182-4. Yee, G. C.; Crom, W. R.; Champion, J. E.; Brodeur, G. M.; Evans, W. E. Cancer Treat. Rep., 1983, 67, 587-9. Kintzel, P. E.; Dorr, R. T. Cancer Treat. Rev., 1995, 21, 33-64. Liegler, D. G.; Henderson, E. S.; Hahn, M. A.; Oliverio, V. T. Clin. Pharmacol. Ther., 1969, 10, 84957. Ronchera, C. L.; Hernandez, T.; Peris, J. E.; Torres, F.; Granero, L.; Jimenez, N. V.; Pla, J. M. Ther. Drug Monit., 1993, 15, 375-9. Methotrexate (Methotrexate) Package Insert (Japanese). In Wyeth: 2006. Sketris, I. S.; Farmer, P. S.; Fraser, A. Cancer Treat. Rep., 1984, 68, 446-7. Minami, H. In Clinical Oncology Update - Essentials for Medical Oncologist (Japanese). Nankodo: Tokyo, Japan, 2006, pp. 240-6.
122
Frontiers in Drug Design & Discovery, 2009, 4, 122-134
Pharmacogenomic Considerations in Breast Cancer Management Hiroshi Ishiguro1,*, Ikuko Yano2 and Masakazu Toi3 1
Translational Research Center, Department of Clinical Trial Management / Outpatient Oncology Unit; 2Department of Pharmacy and 3Breast Surgery Department, Kyoto University Hospital, 54 Shogoinkawaharara-cho,Sakyo-ku, Kyoto-city, 606-8507, Japan Abstract: Many factors affect an individual’s response to a drug, and large inter-ethnic, intra-ethnic, and even intra-individual variations exist. These variations may affect both the therapeutic response to a drug, or the side effects that the patient experiences. Since anti-neoplastic drugs often have a very narrow therapeutic range, it is very desirable to be able to predict these variations in response or to ensure that these variations are as small as possible. It has recently become possible to predict some extreme responses, such as severe side effects, using pharmacogenomic approaches; for example, the uridine diphosphate-glucuronosyltransferase (UGT) 1A1 genetic polymorphism is a predictor of irinotecan toxicity. Further, adding pharmacokinetic and pharmacodynamic information may increase the accuracy of response prediction. Both severe toxicity and clinical benefit can be predicted using a combination of pharmacogenomic and pharmacokinetic information. For example, the clinical benefit obtained from adjuvant treatment with tamoxifen is reduced in patients who have either a particular Cytochrome P450 (CYP) 2D6 genetic polymorphism or who are taking paroxetine, a strong inhibitor of CYP2D6. It is possible to monitor pharmacodynamic parameters, such as serum estrogen levels, as a measure of the therapeutic effect of aromatase inhibitors. In this review, we summarize current knowledge in the field of pharmacogenomics as it relates to breast cancer, focusing particularly on clinical data.
INTRODUCTION Pharmacogenomics, the intersection of pharmacology and genomics, is an approach often used in drug development to assess the genetic determinants of drug response on a genome-wide basis. Pharmacogenetics, a subset of pharmacogenomics, is slightly more narrowly defined as the study of the genetic basis for variation in drug response [1]. Pharmacogenomics is an important field of research because the activity of drugmetabolizing enzymes often varies widely, even among healthy people, making drug metabolism highly variable between individuals (e.g. drug elimination rates can vary up to 40-fold [2]). Genetic factors and aging appear to account for most of these variations in healthy individuals [2]. Pharmacogenetic variations can have significant clinical con*Corresponding Author: Tel: +81-75-751-4770; Fax: +81-75-751-4772; E-mail:
[email protected] Gary W. Caldwell / Atta-ur-Rahman / Z. Yan / M. Iqbal Choudhary (Eds.) All rights reserved – © 2009 Bentham Science Publishers.
Pharmacogenomic Considerations
Frontiers in Drug Design & Discovery, 2009, Vol. 4 123
sequences; for example, patients who metabolize certain drugs rapidly may require higher and/or more frequent doses to achieve therapeutic concentrations. In contrast, patients who metabolize certain drugs slowly may need lower and/or less frequent doses to avoid toxicity, particularly for drugs with a narrow margin of safety, such as antineoplastic drugs. However, most genetically determined differences in drug metabolism cannot currently be predicted before drug administration. Also, many environmental and developmental factors, such as concomitantly administered drugs, can interact with each other and with genetic factors to affect drug response [2]. DRUG SAFETY AND PHARMACOGENOMICS Anti-neoplastic drugs, especially cytotoxic anti-neoplastic drugs, have a very narrow therapeutic window, so pharmacogenomics has become an important research topic in this context. Irinotecan, a key agent used in the treatment of colorectal and lung cancer, is also often used for advanced breast cancer. Irinotecan is in fact a prodrug, which is converted to its active but toxic metabolite, SN-38, by carboxyesterase in vivo (Fig. 1) [3]. Irinotecan is also metabolized by CYP3A4 to the inactive metabolites 7-ethyl-10-[4N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycampothecin (APC) and 7-ethyl10-(4-amino-1-piperidino] carbonyloxycampothecin (NPC). Over time, SN-38 is metabolized to an inactive form, SN-38G, by uridine diphosphate-glucuronosyltransferase (UGT) 1A1 glucuronidation. The area under the concentration-time curve (AUC) of SN38G is ~7-fold larger than for SN-38, suggesting extensive conversion of SN-38 into SN-38G in vivo, but high levels of inter-patient variability have also been found [3]. Recently, a series of studies have provided evidence that the UGT1A1*28 genetic polymorphism may have an important influence on irinotecan toxicity [4]. It has been shown that there is a significant reduction in SN-38 glucuronidation activity in individuals with the *28 variant, and that this haplotype is significantly associated with a reduced SN38G/SN-38 AUC ratio [5]. In 2005, the US Food and Drug Administration required that a warning to this effect be added to the irinotecan package insert [6], which now states: “Patients homozygous/heterozygous for the UGT1A1*28 allele: Patients homozygous for the UGT1A1*28 allele are at increased risk of neutropenia; initial one-level dose reduction should be considered for both single-agent and combination regimens. Heterozygous carriers of the UGT1A1*28 allele may also be at increased risk; however, most patients have tolerated normal starting doses.” Trastuzumab, a humanized anti-HER-2/neu immunoglobulin G (IgG) 1 monoclonal antibody (mAb), is a drug that has significant benefit in terms of breast cancer prognosis, but has also been associated with cardiotoxicity. Trastuzumab binds to the extracellular domain of HER2, which is encoded by the proto-oncogene HER2 (erbB-2, neu), and is a transmembrane protein with tyrosine kinase activity but no identified physiological ligand. The HER2 gene is amplified in 30% of cases of invasive breast cancer and HER2 gene amplification is correlated with poor prognosis. The most thoroughly investigated germinal HER2 polymorphism at a clinical level occurs at codon 655 (ATC/isoleucine to GTC/valine), which encodes a residue in the transmembrane domain of the HER2 protein. In a group of 61 patients with advanced breast cancer studied by Beauclair et al., although no cardiac toxicity was found in 36 patients with the Ile/Ile genotype, 24% (5/21) of patients with the Ile/Val genotype experienced a greater than 20% reduction of their left ventricular ejection fraction (LVEF). Only a few patients carried the Val/Val genotype, and none of them developed any symptoms of cardiotoxicity [7].
124 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
O APC HN
OH
CH2CH3 N N
O
O
Irinotecan O
CH2CH3 N
O
N
A4 P3 Y C
O N
O
N
O CH2CH3
N
OH O
CH2CH3
OH O
A4 P3 CY
Carboxyesterase
O
NH2
CH2CH3 OH
NPC
O
CH2CH3
N
N
O
O
N O
Carboxyesterase
SN-38
N O
OH O CH2CH3
UGT1A1
CH2CH3
O
N
O OH
OH O
CH2CH3 O
O
O N
OH
OH
N
OH
O SN-38G
CH2CH3
OH O
Fig. (1). Metabolic pathways of irinotecan. (Modified figure from reference [3]).
DRUG EFFICACY AND PHARMACOGENOMICS In the human genome, inter-individual differences occur approximately every 300 to 1000 nucleotides, with each individual harboring a an estimated total of 3.2 million single nucleotide polymorphisms [1]. There are thus likely to be many genetic polymorphisms within genes encoding pharmacokinetic- and pharmacodynamic-related proteins (e.g. metabolizing enzymes, transporters and receptors), and therefore variations in drug responses due to these polymorphisms are unlikely to be rare phenomena.
Pharmacogenomic Considerations
Frontiers in Drug Design & Discovery, 2009, Vol. 4 125
Cyclophosphamide is a drug that is commonly used to treat breast cancer. It is a prodrug that must be metabolized to 4-hydroxycyclophosphamide to become cytotoxic. After administration, 75-80% of the dose is bioactivated by several CYP enzymes, including (amongst others) CYP2B6, CYP3A4 and CYP3A5, of which CYP2B6 has the highest activity. 4-Hydroxycyclophosphamide and its ring-open tautomer aldophosphamide are detoxified by glutathione S-transferase (GST) and aldehyde dehydrogenase (Fig. 2) [8]. In cyclophosphamide-treated breast cancer patients with an unfavorable CYP3A/GST genotype, cyclophosphamide metabolism is affected, such that activation is slow and detoxification is rapid, leading to worse overall survival compared with patients with other genotypes (Fig. 3) [9, 10]. OO
ClH2CH2C N ClH2CH2C
N
OO
ClH2CH2C T GS
ClH2CH2C N
P
ClH2CH2C
HN SG
4-Glutathionylcyclophosphamide
OO
ClH2CH2C
CYP3A4?
P
N ClH2CH2C
HN OH
GS T
4-Hydroxycyclophosphamide
N ClH2CH2C
P NH2 O
O N
Decomposition
Aldophosphamide Cl
OH
P NH2
GS
GS T
Monochloromonoglutathionylphosphoramide mustard
O
ClH2CH2C N ClH2CH2C
O-
P
O
+
H2C
CH C
NH2
Phosphoramide mustard
HN
4-Ketocyclophosphamide
OO
ClH2CH2C
P
O
Equilibrium
OO
HN
Dechloromethylcyclophosphamide
CYP2B6 others
Cyclophosphamide
N
P
H
HN
ClH2CH2C
OO
ClH2CH2C
CYP3A4
P
H Acrolein
Fig. (2). Metabolic pathways of cyclophosphamide. (Modified figure from reference [7]).
126 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
Even though trastuzumab is usually only administered to patients with HER-2/neupositive breast cancer, only 25 to 30% of these patients will respond to this mAb. The mechanism by which it exerts an anti-tumor effect is not well understood, but antibodydependent cell-mediated cytotoxicity (ADCC) is thought to be involved [11]. In ADCC, the antibody binds to tumor cells and is then engaged by effecter cells via their receptors for IgG. FcR is an activating IgG fragment C receptor (FcR) that is expressed on monocytes/macrophages and natural killer cells. A polymorphism encoding valine (V) at amino acid 158 of FcR rather than phenylalanine (F) greatly increases the affinity of IgG1 to the Fc receptor, leading to a higher level of ADCC activity. The FcR158 V/V genotype is significantly correlated with a higher objective response rate and better progression-free survival in trastuzumab-treated breast cancer patients (Fig. 4) [11].
Overall survival (%)
100
Other CYP3A/GST genotype N = 86
p < 0.05
50 N=4 Unfavorable CYP3A/GST genotype
2
4
6
8
10
Years Fig. (3). Cyclophosphamide CYP3A/GST metabolic enzyme genotype versus overall survival for breast cancer patients treated with a cyclophosphamide-containing regimen. (Modified figure from references [9,10]).
TAMOXIFEN-METABOLIZING ENZYMES Tamoxifen is widely used as the standard treatment for recurrent or metastatic breast cancer, as well as in an adjuvant setting. Tamoxifen is a prodrug that requires CYP2D6catalyzed metabolic activation to 4-hydroxytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen) for therapeutic pharmacological activity (Fig. 5). Compared with the parent drug, these two metabolites have 100-fold greater affinity to estrogen receptor and 30- to 100-fold greater potency in suppressing estrogen-dependent cell proliferation [12]. Steady-state plasma endoxifen concentrations have been found to be 5- to 10-fold higher than those of 4-hydroxytamoxifen [13]. Therefore, the relationships between endoxifen concentration and CYP2D6 activity, and endoxifen concentration and tamoxifen treatment efficacy and adverse events have been studied.
Pharmacogenomic Considerations
Frontiers in Drug Design & Discovery, 2009, Vol. 4 127
Progression-free survival (%)
100 V/V genotype N = 11
50
p = 0.0035
Other genotype
1
N = 43
2
3
4
5
Years Fig. (4). Progression-free survival of trastuzumab-treated breast cancer patients according to FcRIII genotype. (Modified figure from reference [11]).
N O
CH3 O
CH3
CYP2D6
H3C
N
H3C
CYP3A4
CYP3A4
4-hydroxy-tamoxifen
O
N H
CH3 O
CYP2D6 H3C
OH N-desmethyl-tamoxifen
CH3
OH
Tamoxifen
H3C
CH3
Endoxifen
Fig. (5). Metabolic pathways of tamoxifen. (Modified figure from reference [13]).
N H
CH3
128 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
CYP2D6 GENE POLYMORPHISM AND ENDOXIFEN CONCENTRATION The plasma concentration of endoxifen appears to be influenced by a patient’s CYP2D6 genotype. The CYP2D6*4 allele results in a splicing defect, the CYP2D6*3 and *6 alleles lead to translation frameshifts, and in the CYP2D6*5 allele the entire CYP2D6 gene is deleted. None of these alleles yields a functional CYP2D6 enzyme [14]. In one study, more than 20% of a German Caucasian population had one of these four polymorphisms, compared with about 7% of the Japanese population (Fig. 6) [15]. In another study, tamoxifen-treated breast cancer patients who were heterozygous or homozygous for the null genotype had mean plasma endoxifen concentrations that were 55% and 26%, respectively, of those who were homozygous for the wild-type CYP2D6 genotype (Fig. 7A) [14]. The CYP2D6*10 allele, which produces an unstable enzyme that is associated with decreased CYP2D6 activity, is a major variant in individuals of Japanese, Korean and Chinese ethnic background [16]. This allele is seen in 40 to 50% of these populations (Fig. 6) [15]. Although the steady-state plasma concentrations of endoxifen were comparable in wild type and CYP2D6*10 heterozygotes, the concentration in CYP2D6*10 homozygotes was about 40% that of wild type (Fig. 7B) [16]. Wild
Null
Low
Others
Japanese
Caucasian
0%
20%
40%
60%
80%
100%
Percentage of population Fig. (6). Differences between German Caucasian and Japanese populations in terms of CYP2D6 gene polymorphism [15].
CONCOMITANTLY ADMINISTERED DRUGS AND ENDOXIFEN CONCENTRATION In one study of tamoxifen-treated breast cancer patients, plasma endoxifen concentrations in wild-type CYP2D6 homozygotes were found to be highly variable. However, those who were using CYP2D6 inhibitors such as paroxetine, fluoxetine, sertraline, citalopram, amiodarone and metoclopramide had plasma endoxifen concentrations that were 58% lower than concentrations in those who were not using CYP2D6 inhibitors (Fig. 7C) [14]. The plasma endoxifen concentration in subjects taking paroxetine was
Pharmacogenomic Considerations
Frontiers in Drug Design & Discovery, 2009, Vol. 4 129
p = 0.002
Endoxifen concentration (nM)
100
A 80 60 40 20 0 Wild/Wild
Wild/Null
Null/Null
(N = 48)
(N = 29)
(N = 3)
Endoxifen concentration (ng/mL)
CYP2D6 genotype p < 0.001
25
B
20 15 10 5 0 Wild/Wild (N = 64)
Wild/Low
Low/Low
(N = 89)
(N = 49)
CYP2D6 genotype
Endoxifen concentration (nM)
p = 0.0025 100
C
80
p = 0.08
60 40 20 0 -
+ Wild/Wild
(N = 34)
(N = 13)
-
+ Wild/Null
(N = 17)
(N = 11)
-
CYP2D6 inhibitor
Null/Null
CYP2D6 genotype
(N = 3)
Fig. (7). Endoxifen concentrations in breast cancer patients treated with tamoxifen, according to CYP2D6 genotype. (A) Wild-type versus null genotype [14]. (B) Wild-type versus low genotype [16]. (C) Wild-type versus null genotype with or without CYP2D6 inhibitor [14].
130 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
similar to that for subjects with the CYP2D6 null genotype who were not taking a CYP2D6 inhibitor [14]. Thus, not only genetic factors, but also environmental factors, including concomitantly administered drugs, can have a significant effect on a drug’s pharmacokinetics. CYP2D6 ACTIVITY AND ADVERSE EVENTS The most common request from breast cancer survivors regarding additional treatment or treatment modification is relief from hot flashes [17]. Hot flashes are the subjective sensation of heat that is thought to be related to a narrowing of the thermoneutral zone. The onset of symptoms is generally thought to occur as a result of decreased estrogen or increased gonadotropin concentrations. However, other reported precipitators include psychological stress, hot weather, alcohol and caffeine, although the physiological mechanism underlying this phenomenon is not well understood [17]. In a study conducted by Goetz et al., moderate to severe [National Cancer Institute Common Toxicity Criteria (version 1) grade 2-3] hot flashes were experienced by 20% of tamoxifen-treated breast cancer patients with either wt/wt or *4/wt CYP2D6 genotypes, but no patients with a *4/*4 genotype experienced hot flashes (Fig. 8A) [13]. Similarly, in a recent presentation, Rae et al. described how the presence of active CYP2D6 alleles predicts a higher likelihood of tamoxifen discontinuation in breast cancer patients due to treatment-related side effects* (Fig. 8B). These findings raise the question of whether the alleviation of the hot flashes is related to a reduced concentration of active metabolites. ADVERSE EVENTS AND TREATMENT EFFICACY Among breast cancer patients who took tamoxifen for adjuvant endocrine treatment, those who reported hot flashes were found to be less likely to develop recurrent breast cancer than those who did not develop hot flashes (Fig. 9A). In that study, hot flashes were a stronger predictor of breast cancer-specific outcome than age, hormone receptor status, or even disease stage [17]. These findings suggest an association between side effects, efficacy, and tamoxifen metabolism. Cuzick et al. recently reported the results of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) randomized, doubleblinded, multicenter trial, in which patients with early-stage breast cancer received treatment with anastrozole alone, tamoxifen alone or the two agents in combination*. The occurrence of hot flashes was an indicator of treatment efficacy for both tamoxifen and anastrozole, with similar differences in treatment efficacy between patients with and without hot flashes for both drugs (Fig. 9B). It is likely that the occurrence of hot flashes is an indirect measurement of estrogen suppression by anastrozole and tamoxifen. CYP2D6 ACTIVITY AND TREATMENT EFFICACY In the ATAC trial, using the annual hazard rate, the benefit of anastrozole over tamoxifen was seen throughout the follow-up period, and the early recurrence (less than 3 years) rate was significantly higher for the tamoxifen group (Fig. 10A) [18]. Among patients treated with adjuvant tamoxifen, an immediate broad peak in the hazard rate was seen in patients with decreased CYP2D6 activity (Fig. 10B) [19]. In contrast, the hazard rate in patients with extensive CYP2D6 activity was reduced and did not peak until _____________________ *2007 San Antonio Breast Cancer Symposium.
Pharmacogenomic Considerations
Frontiers in Drug Design & Discovery, 2009, Vol. 4 131
Incidence of hot flashes (%)
40
A p = 0.06
20
0 Null/Null (N = 13)
Wild/Null (N = 40)
Wild/Wild (N = 137)
CYP2D6 genotype
CYP2D6 genotype
B
High (N = 170)
Intermediate (N = 87)
Low (N = 10)
0
10
20
Treatment discontinuation (%)
Fig. (8). Relationship between CYP2D6 genotype and hot flashes [13] (A) and between CYP2D6 phenotype and treatment discontinuation (B) in breast cancer patients treated with tamoxifen*. *2007 San Antonio Breast Cancer Symposium.
nearly the fourth year after treatment. These findings suggest that the peak in the hazard rate for recurrence that was seen following the initiation of tamoxifen in the ATAC trial may be due to there being a subset of patients in which tamoxifen is not fully activated. Several other randomized trials have demonstrated that administration of an aromatase inhibitor following either 2-3 or 5 years of tamoxifen treatment (switching or extension) significantly prolongs disease-free survival and overall survival compared with tamoxifen treatment for 5 years. Further research is needed to determine whether prior assessment of CYP2D6 metabolism can be used to identify which patients are most suitable for these strategies without a risk of early recurrence [19]. SUMMARY There are many factors involved in drug response, and large variations in response can occur between patients with different ethnic backgrounds, between patients with the
132 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
Hot flashes
100 Disease free survival (%)
N = 674
A
p = 0.01 No hot flashes
50
N = 190
2
4
6
8
10
Years
100 Hot flashes Recurrence rate (%)
B
Tamoxifen Anastrozole
No hot flashes
(N = 1091)
(N = 963)
(N = 1614)
(N = 1738)
p < 0.05
50
2
4
6
8
10
Years
Fig. (9). Relationship between hot flashes and disease-free survival in tamoxifen-treated breast cancer patients [17] (A) and hot flashes and recurrence in breast cancer patients who participated in the ATAC trial* (B). Modified figure from reference [16] and a presentation by Cuzick J. et al.* *2007 San Antonio Breast Cancer Symposium.
same ethnic background, and even for single individual at different times. Pharmacogenomics is one approach that can be used to understand these variations. Ideally, for antineoplastic drugs, we would want to refer to pharmacodynamic or pharmacokinetic data such as the international normalized ratio for warfarin or the measures of drug concentration in the blood (pharmacokinetics) that exist for anti-convulsant and immunosuppressive drugs. These will be very useful in reducing variations in drug response in the field of oncology.
Pharmacogenomic Considerations
Frontiers in Drug Design & Discovery, 2009, Vol. 4 133
A
Smoothed hazard rate
Tamoxifen Anastrozole
Poor/Intermediate metabolizer
B
Extensive metabolizer
2
4
6
8
10
Years
Fig. (10). Hazard rates for recurrence in patients treated with tamoxifen or anastrozole [18] (A) and in breast cancer patients treated with tamoxifen according to CYP2D6 activity [19] (B). Modified figure from references [18,19].
ABBREVIATIONS ADCC
=
Antibody-dependent cell-mediated cytotoxicity
APC
=
7-Ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycampothecin
ATAC trial =
Arimidex, Tamoxifen, Alone or in Combination trial
AUC
=
Area under the concentration-time curve: AUC
CYP
=
Cytochrome P450
FcR
=
Fragment C receptor
GST
=
Glutathione S-transferase
IgG
=
Immunoglobulin G
LVEF
=
Left ventricular ejection fraction
mAb
=
Monoclonal antibody
NPC
=
7-Ethyl-10-(4-amino-1-piperidino] carbonyloxycampothecinecine
UGT
=
Uridine diphosphate-glucuronosyltransferase
134 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Ishiguro et al.
REFERENCES [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14]
[15] [16] [17] [18] [19]
Relling, V.M.; Giacomini, MK. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. eleventh ed.; McGRAW-HILL: New York, 2006, pp. 93-115. Cafiero, A.; Hussar, D.; Tarloff, B.J.; Vivian, M.E. In The Merck Manual of Diagnosis and Therapy. Eighteenth ed.; Merck Research Laboratories: Whitehouse Station, NJ, 2006, pp. 2513-44. Mathijssen, R. H.; van Alphen, R. J.; Verweij, J.; Loos, W. J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clin. Cancer Res., 2001, 7, 2182-94. O'Dwyer, P. J.; Catalano, R. B. J. Clin. Oncol., 2006, 24, 4534-8. Sai, K.; Saeki, M.; Saito, Y.; Ozawa, S.; Katori, N.; Jinno, H.; Hasegawa, R.; Kaniwa, N.; Sawada, J.; Komamura, K.; Ueno, K.; Kamakura, S.; Kitakaze, M.; Kitamura, Y.; Kamatani, N.; Minami, H.; Ohtsu, A.; Shirao, K.; Yoshida, T.; Saijo, N. Clin. Pharmacol. Ther., 2004, 75(6), 501-15. United States Food and Drug Administration: Campostar label. Beauclair, S.; Formento, P.; Fischel, J. L.; Lescaut, W.; Largillier, R.; Chamorey, E.; Hofman, P.; Ferrero, J. M.; Pages, G.; Milano, G. Ann. Oncol., 2007, 18(8), 1335-41. Nakajima, M.; Komagata, S.; Fujiki, Y.; Kanada, Y.; Ebi, H.; Itoh, K.; Mukai, H.; Yokoi, T.; Minami, H. Pharmacogenet. Genomics, 2007, 17(6), 431-45. DeMichele, A.; Aplenc, R.; Botbyl, J.; Colligan, T.; Wray, L.; Klein-Cabral, M.; Foulkes, A.; Gimotty, P.; Glick, J.; Weber, B.; Stadtmauer, E.; Rebbeck, T. R. J. Clin. Oncol., 2005, 23(24), 5552-9. DeMichele, A.; Gimotty, P.; Botbyl, J.; Aplenc, R.; Colligon, T.; Foulkes, A. S.; Rebbeck, T. R. J. Clin. Oncol., 2007, 25(35), 5675-7. Musolino, A.; Naldi, N.; Bortesi, B.; Pezzuolo, D.; Capelletti, M.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Bisagni, G.; Maria Neri, T.; Ardizzoni, A. J. Clin. Oncol., 2008, 26(11), 1789-96. Kiyotani, K.; Mushiroda, T.; Sasa, M.; Bando, Y.; Sumitomo, I.; Hosono, N.; Kubo, M.; Nakamura, Y.; Zembutsu, H. Cancer Sci., 2008, 99(5), 995-99. Goetz, M. P.; Rae, J. M.; Suman, V. J.; Safgren, S. L.; Ames, M. M.; Visscher, D. W.; Reynolds, C.; Couch, F. J.; Lingle, W. L.; Flockhart, D. A.; Desta, Z.; Perez, E. A.; Ingle, J. N. J. Clin. Oncol., 2005, 23(36), 9312-8. Jin, Y.; Desta, Z.; Stearns, V.; Ward, B.; Ho, H.; Lee, K. H.; Skaar, T.; Storniolo, A. M.; Li, L.; Araba, A.; Blanchard, R.; Nguyen, A.; Ullmer, L.; Hayden, J.; Lemler, S.; Weinshilboum, R. M.; Rae, J. M.; Hayes, D. F.; Flockhart, D.A. J. Natl. Cancer Inst., 2005, 97(1), 30-9. Fujita, K. Curr. Drug Metab., 2006, 7(1), 23-37. Lim, H.-S.; Ju, Lee, H.; Seok Lee, K.; Sook Lee, E.; Jang, I.-J.; Ro, J. J. Clin. Oncol., 2007, 25(25), 3837-45. Mortimer, J. E.; Flatt, S. W.; Parker, B. A.; Gold, E. B.; Wasserman, L.; Natarajan, L.; Pierce, J. P. Breast Cancer Res. Treat., 2008, 108(3), 421-426. Buzdar, A. U.; Cuzick, J. Clin. Cancer Res., 2006, 12(3 Pt 2), 1037s-1048s. Goetz, M. P.; Knox, S. K.; Suman, V. J.; Rae, J. M.; Safgren, S. L.; Ames, M. M.; Visscher, D. W.; Reynolds, C.; Couch, F. J.; Lingle, W. L.; Weinshilboum, R. M.; Fritcher, E. G.; Nibbe, A. M.; Desta, Z.; Nguyen, A.; Flockhart, D. A.; Perez, E. A.; Ingle, J. N. Breast Cancer Res. Treat., 2007, 101(1), 113-21.
Frontiers in Drug Design & Discovery, 2009, 4, 135-161
135
More Than Skin Deep: The Human Skin Tissue Equivalent as an Advanced Drug Discovery Tool Alexandra S. Bause, Sarah D. Lamore and Georg T. Wondrak* University of Arizona, College of Pharmacy, Arizona Cancer Center, Tucson, AZ, USA Abstract: Advanced human tissue equivalents are an emerging drug discovery tool that aims at minimizing costly candidate attrition in later stages of preclinical and clinical development. 3-D cellular tissue models amenable to screening in 96-well plate format and drug monitoring in real time provide more accurate compound screening in a physiologically relevant context, not achievable in traditional two dimensional, single cell type-based assays. Currently, equivalents that represent the healthy or pathological physiology of human tissues including skin, vasculature, lung, prostate, and various malignant tumors are used for rapid activity screening, toxicity profiling, and pharmacokinetic characterization of compound libraries. Human skin equivalents with intact stratum corneum reconstructed in vitro from matrix-embedded dermal fibroblasts and epidermal primary keratinocytes closely resemble the complex architecture and functional complexity of skin. Using human skin equivalents, delivery of novel topical agents for photoprotection has been studied, and toxicity and activity profiling of skin care products and FDA-approved drugs including sunscreens has been performed. Importantly, human skin equivalents are better predictors of drug activity than available animal models as mouse and guinea pig skin do not reflect the architecture of human skin in terms of physico-optical properties such as light reflectance and scattering, epidermal thickness, cellularity, and biochemical composition. Recently, cellular composition of advanced commercial skin reconstructs has been further optimized by incorporation of melanogenic melanocytes and immunomodulatory dendritic (Langerhans) cells in order to assess drug modulation of cutaneous pigmentation, inflammation, photo-immunosuppression, and photo-carcinogenesis. Continuous progress in skin equivalent engineering will ensure the expanding role of skin equivalents in disease model-based assays for rapid identification and development of novel cutaneous therapeutics.
1. INTRODUCTION. ENHANCING THE DRUG DISCOVERY PROCESS USING THREE-DIMENSIONAL RECONSTRUCTED TISSUE MODELS The paradigm of modern drug discovery is aptly represented by a complex funneling process that begins with initial identification and validation of a molecular target which
*Corresponding Author: Tel: 520-626-9017; Fax: 520-626-3797; E-mail:
[email protected] Gary W. Caldwell / Atta-ur-Rahman / Z. Yan / M. Iqbal Choudhary (Eds.) All rights reserved – © 2009 Bentham Science Publishers.
136 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Bause et al.
is causatively involved in a disease process and therefore selected for future pharmacological intervention as shown in Fig. (1). Further activities should then ultimately lead to market introduction of a novel drug that provides superior therapeutic benefit. In a time of ever increasing biological understanding of the molecular pathology underlying human disease states, no dearth of promising drug targets exists. However, it seems that many academic and industrial drug development projects have proven fruitful by further increasing our biological understanding of the disease process (target discovery), but fail to deliver a novel therapeutic agent that could enter the marketing phase [1-4].
target target identification & validation assay development & screening
lead identification
lead
• potency • selectivity • druglikeness • toxicological profile
lead optimization
preclinical development costliness of candidate attrition
clinical trials
drug Fig. (1). The obligatory funneling process underlying modern drug discovery. The use of human skin reconstructs as a versatile drug discovery tool throughout all developmental stages from target identification to preclinical development of cutaneous therapeutics may significantly reduce costly candidate attrition at late stages.
The reasons underlying the discrepancy between success rates of pharmaceutical target versus drug discovery are manifold and may be connected to the very nature of pharmaceutical discovery. The process of iterative selection and optimization of drug candidates that must outperform earlier therapeutic agents is intrinsically associated with high candidate attrition rates. Apart from limitations associated with high throughput screening of compound libraries with insufficient molecular diversity and inadequate coverage of chemical space, an inadequate quality of cell-based screening systems has been invoked to rationalize the high failure rate correlated with generation of promising
More Than Skin Deep
Frontiers in Drug Design & Discovery, 2009, Vol. 4 137
preclinical candidates. Indeed, it has been argued that cell-based screening methodologies and even advanced animal models such as mouse xenograft tumor models that are dependent on single-cell type cell culture insufficiently represent the biological complexity of the molecular target in a meaningful tissue context. After target identification and validation, development of screening assays aims at the identification of promising lead compounds that then can undergo iterative lead optimization based on preclinical efficacy, toxicity, and pharmacokinetic profiling. These efforts will then lead to the identification of clinical candidates that can be advanced through the obligatory phases of clinical testing. Obviously, a major determinant of the success rate of this funneling process is the validity and predictive power of the assay systems that are used for efficacy and toxicology screening. Advanced human tissue equivalents that mimic the exact physiology of the human target tissue to a great extent are an emerging drug discovery tool that aims at minimizing costly candidate attrition in later stages of preclinical and clinical development. Three dimensional cellular tissue models amenable to screening in 96-well plate format and drug monitoring in real time provide more accurate compound screening in a physiologically relevant context, not achievable in traditional two dimensional, single cell type-based assays [5]. Currently, equivalents that represent the healthy or pathological physiology of human tissues including skin, vasculature, lung, prostate, and various malignant tumors are used for rapid activity screening, toxicity profiling, and pharmacokinetic characterization of compound libraries and selected lead compounds during preclinical development [6,7]. As discussed in this review, the use of human skin reconstructs is now firmly established as a versatile drug discovery tool throughout all developmental stages from target identification to preclinical development of cutaneous therapeutics. Due to technological accessibility, commercial availability, and biological validity of skin tissue reconstructs, skin pharmacology is now fundamentally impacted by this technology that rapidly emerges as the novel gold standard of preclinical skin models. Skin reconstructs of variable complexity have been generated ranging from human differentiated epidermal equivalents with stratum corneum reconstructed to full thickness reconstructs that include extracellular matrix-embedded dermal fibroblasts and other skin cells of particular interest including melanocytes and Langerhans cells [8,9]. All of these closely resemble the complex architecture and functional complexity of skin. Obviously, cellular and acellular composition of skin reconstructs is highly adjustable and can be customtailored in order to provide a relevant model of a specific pathological condition. For example, photoaged skin can be reconstructed by incorporation of photo-crosslinked collagen and senescent fibroblasts during dermal reconstruction, and psoriatic skin can be reconstructed by incorporation of patient derived keratinocytes cultured from psoriatic lesions [10]. Using human skin equivalents delivery of novel topical agents for skin photoprotection and anti-psoriatic intervention has been studied, and pharmacodynamic profiling of FDA-approved drugs including sunscreens has been performed [11]. Importantly, human skin equivalents are superior predictors of drug photoprotective activity compared to available animal models, since mouse and guinea pig skin do not reflect the architecture of human skin in terms of physico-optical properties such as light reflectance and scattering, epidermal thickness, cellularity, permeability, and biochemical composition. Moreover animal models of specific skin conditions are often completely unavailable or poorly represent the human disease. For example, transgenic melanoma mo-
138 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Bause et al.
dels in mice are of debatable relevance to the human disease, and drug candidates that display anti-melanoma activity in these transgenic mice may be completely inactive against human melanoma. Therefore, the commercial availability of human melanoma reconstructed skin that mimics the successive progressional stages of the disease may provide a stringent and powerful screening tool for the identification of promising chemopreventive and chemotherapeutic anti-melanoma agents as discussed below [12]. In addition to high costs associated with animal experimentation and poor representation of human skin physiology in animal models, ethical concerns and regulatory guidelines limit or completely ban the extensive use of animal models particularly in the earlier stages of the drug discovery process that would require screening in high or moderate throughput. In the European Union (EU), animal testing for cosmetic ingredients is completely banned by 2009, and ethical and legal guidelines in other countries equally create an urgent need for alternative in vitro methods that allow the cost effective and highly predictive toxicity and efficacy assessment of topical consumer products and pharmaceutical agents. In summary, the emerging role of human skin reconstructs as superior drug discovery tool is based on the following characteristics: I. adequate representation of human skin; II. high model-to-human predictability of drug action; (i.e., drug effects in the model are predictive of therapeutic efficacy in humans; III. adaptability to screening in high throughput; IV. commercial availability and cost competitiveness; V. inter-laboratory reproducibility and standardization; VI. adjustable degree of tissue complexity (e.g. simple epidermal reconstruct versus skin-type specific pigmented skin reconstructs); VII. validated tissue biomarkers that specify test compound action and can easily be measured (e.g. toxicity markers for corrosion and irritation studies). VIII. superiority over animal experimentation based on ethical, legal, economical, and operational considerations; IX. superior predictive power and biological validity over cell-based and animal-based screening methods Three major applications of reconstructed human skin can be distinguished: First, skin reconstructs serve as basic research tools for skin biology. Second, skin reconstructs serve as drug discovery tools that allow drug target identification and validation. Moreover, compound screening for efficacy, toxicity, and pharmacokinetic profiling can be performed. Thirdly, skin reconstructs are used therapeutically in the area of skin tissue replacement and reconstructive surgery, for example in burn victims. 2. THE BIOLOGICAL COMPLEXITY OF HUMAN SKIN Human skin is a complex organ composed of a variety of specialized cells, organized into three highly differentiated principal layers: the epidermis, the outermost layer, followed by the dermis (jointly referred to as cutis and separated by a basement membrane), and the deeper localized subcutis, mainly composed of adipose tissue [13]. The epidermis is a squamous epithelium derived from terminal differentiation of keratinocytes with associated hair follicles and glandular structures (sebaceous glands and sweat glands). Keratinocytes constitute approximately 80% of epidermal cells forming the multilayered differentiated epidermis comprising (-from inside out-) the stratum germinativum/basale, the stratum spinosum, the stratum granulosum, the stratum lucidum, and the stratum corneum. The avascular epidermis is characterized by self-renewal with undifferentiated basal cells proliferating and differentiating into a stratified multilayered tissue, where complete turnover of the interfollicular epidermis occurs every
More Than Skin Deep
Frontiers in Drug Design & Discovery, 2009, Vol. 4 139
four weeks. Multipotent stem cells within the epidermis produce daughter cells that differentiate along multiple lineages. Remarkably, hair follicle lineages, sebocytes and interfollicular epidermis originate from stem cells within the hair follicle bulge. The differentiated epidermis acts as an effective barrier against physical (UV radiation), chemical (xenobiotics), and biological (microbial) insults. The outermost acellular stratum corneum consists of dead corneocytes (cornified keratinocytes), the endproduct of epidermal terminal differentiation. Cornification involves changes in expression patterns of keratins, where basal layers express keratins 5 and 14, while the suprabasal keratinocytes produce keratins 1 and 10. Furthermore, cornification involves synthesis of involucrin, loricrin, and small proline rich proteins as structural constituents of the cornified envelope that is crosslinked through transglutaminase enzymatic activity. As another essential part of the human skin barrier, proteolysis of the structural protein filaggrin during terminal differentiation produces a specific mixture of amino acids (serine, glycine, arginine, ornithine, citrulline, alanine, histidine) and their derivatives (pyrrolidone-5-carboxylic acid, urocanic acid) called the natural moisturizing factor (NMF). Components of the NMF are crucially involved in skin hydration, pH control, antimicrobial defense, immunomodulation, and UV-photoprotection [14]. Keratinocytes produce a multitude of molecules involved in barrier formation (structural proteins including keratins, filaggrin, loricrin, and involucrin, and lipids such as ceramides and cholesterol), melanogenesis (-MSH), mitogenesis (CCL5), host defense (defensins), inflammatory signaling (IL, TNF-), angiogenesis (VEGF), and cellular differentiation and calcium homeostasis (vitamin D3 and calcitriol). In addition to keratinocytes, the pigment-producing melanocytes at the epidermal– dermal junction are interspersed among every 5–10 basal keratinocytes, forming the ‘epidermal–melanin unit’. It is thought that one melanocyte synthesizes and transports melanin-containing melanosomes to the surrounding keratinocytes for phagocytotic uptake and formation of supranuclear melanin caps, protecting keratinocyte DNA from the genotoxic effects of ultraviolet light [15]. Another important cellular constituent of human epidermis are Langerhans cells (LC), bone marrow derived dendritic cells, which circulate in the peripheral blood as progenitors, and then migrate into the suprabasal epidermis. These cells play a major role in the skin immune defense system. After exposure to exogenous antigens, LC migrate to the regional lymph nodes to present them to naive T cells. Recently, LC have emerged as crucial epidermal targets of UV-photodamage involved in induction of photo-immunosupression thought to contribute to solar photocarcinogenesis [16]. The dermis with its mesenchymal components, i.e. fibroblasts and blood vessels embedded in fibroblast-derived extracellular matrix containing collagen, elastin and glycosaminoglycans, provides mechanical and nutritional support and rigidity to the skin. At least three subpopulations of dermal fibroblasts have been identified which occupy unique niches in the dermis: papillary dermal fibroblasts (superficial dermis), reticular fibroblasts (deep dermis), and hair follicle-associated fibroblasts [17]. Importantly, keratinocytes and fibroblasts interact with each other to maintain skin integrity through paracrine cytokine loops. For example, fibroblasts modulate epidermal homeostasis and reepithelialization after epidermal damage with production of keratinocyte growth factor and TGF-1, and fibroblast–keratinocyte interactions are involved in the formation of the basement membrane [18].
140 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Bause et al.
In addition to these basic skin constituents other specialized cells including sebocytes, mast cells, sensory Merkel cells, and adipocytes contribute to the fascinating functional and structural complexity of human skin. Remarkably, simple skin models can be generated from single cellular constituents using keratinocytes (epidermal reconstruct) or fibroblasts (dermal reconstruct). More advanced skin reconstructs that better represent the functional complexity of skin are characterized by incorporation of multiple skin cell types including keratinocytes, melanocytes, Langerhans cells, and fibroblasts and their genetically engineered or malignant counterparts. 3. BASICS OF HUMAN SKIN RECONSTRUCTION Historically, the development of skin reconstructs as a drug discovery tool occurred in three stages based on fundamental advances in (I) skin cell culture technology, (II) the generation of complex skin tissue models for biological studies, and (III) the optimization and validation of skin models for toxicological and pharmacological studies. (I)
Cell culture. All tissue reconstruction is based on developing the fundamental technology of culturing cells in monolayers. For human skin keratinocytes, this was achieved through serial cultivation of strains of human epidermal keratinocytes with the formation of keratinizing colonies from single cells using serum containing culture medium and a feeder-layer of pre-irradiated quiescent fibroblasts [19]. The inclusion of serum became dispensable when calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture was reported [20], followed by cultivation of other human skin cell types including melanocytes and Langerhans cells [21,22].
(II)
Tissue reconstructs. Cellular monolayers obviously do not represent the functional complexity of differentiated skin in vivo and are therefore poor models for molecular studies of skin biology and pathophysiology. Moreover, drug discovery targeting complex alterations of skin structure and function (barrier impairment, immunological and inflammatory dysregulation, altered epidermal differentiation and melanogenesis, carcinogenesis, photodamage, and chronological aging) depends on model systems that adequately represent the target tissue. A fully differentiated epidermal reconstruct was first generated by Pruniéras et al. who described methods for cultivation of keratinocytes at the air–liquid interface [23], and many skin reconstructs of diverse complexity have been created as discussed below. Interestingly, the differences between gene expression profiles of reconstructed human epidermis and classical cultures of keratinocytes based on cDNA expression arrays comprising 505 genes related to cutaneous biology have been examined. A comparison of gene expression between keratinocytes grown as cultures on plastic dishes or in a three-dimensional reconstruct identified six genes with considerably higher expression in the reconstruct. All of these genes (keratin 1, corneodesmosin, filaggrin, loricrin, calmodulin-like skin protein, and caspase 14) are related to keratinocyte terminal differentiation as expected in a model that adequately represents human epidermis [5]. Importantly, a major driving force behind technological advances in full thickness skin reconstruction is the use of reconstructed skin for therapeutic applications as skin substitutes [24,25]. Currently, skin replacement based on epidermal, dermal, or full-thickness skin substitutes is in clinical use to treat different types of difficult-to-heal wounds including
More Than Skin Deep
Frontiers in Drug Design & Discovery, 2009, Vol. 4 141
large and deep burns, trauma-induced wounds, and ulcers resistant to conventional therapies. (III)
Skin reconstruction as a pharmacological tool. Moreover, skin reconstructs have become the focus of increased research activities since it has been demonstrated that they may excellently reproduce certain aspects of the pathology of various skin diseases including skin carcinogenesis and solar photodamage. For example, various studies demonstrated the usefulness of reconstituted three-dimensional human skin as a novel in vitro model of skin carcinogenesis using established carcinogens including benzo[a]pyrene, ultraviolet B (UVB) radiation, UVA, and psoralen-UVA [11,26]. Molecular consequences of carcinogen exposure (upregulation of c-fos and p53 expression, DNA adduct formation) were similar to those reported previously in human and murine skin after carcinogenic insult demonstrating that skin reconstructs can be used as a discovery tool for assessing genotoxicity and mechanism of action of mutagens/carcinogens in human skin [26]. Recently, melanoma skin reconstruction has been achieved representing the progressional stages of the disease and a commercial model is now available as discussed below [12,15]. Remarkably, it is now possible to reconstruct human skin containing the major cellular targets for skin photodamage: keratinocytes (UVB-induced nonmelanoma skin cancer), Langerhans cells (photo-immunosuppression), melanocytes (melanoma), and fibroblasts (UVA-induced photoaging). Inclusion of human skin color- and phototype-specific melanocytes allows the reconstruction of human skin with differential inducible and constitutive pigmentation and photosensitivity [27,28]. Further progress may be facilitated by inclusion of optimized biomaterials (e.g. epidermal reconstruction on fibrin scaffolds) and genetically modified cellular components.
A representative full thickness reconstruct that has been generated according to the following standard procedure closely resembles the anatomy of human skin as shown in Fig. (2): First, dermal equivalents are prepared by mixing human dermal fibroblasts and native bovine type I collagen in a Petri dish. After lattice contraction for three days at
A
B
Fig. (2). Human reconstructed skin closely resembles the architecture of skin in situ. Human skin reconstructed in vitro (B) closely resembles normal human skin (A) displaying a well-stratified epithelium covered by a dense stratum corneum on top of a fibroblast populated dermis. However, the absence of interpapillary ridges, functionally significant extensions of the epithelium into the connective tissue, and the somewhat less pronounced thickness of the stratum corneum are apparent in reconstructed skin. (reproduced with permission from reference [64], Elsevier Ireland Ltd.).
142 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Bause et al.
37°C, 5% CO2, adult human epidermal keratinocytes grown in primary culture are seeded on this support using stainless rings. The rings are then removed and the cultures are kept submerged for seven days, allowing the cells to form a monolayer. The medium used is composed of minimum essential Eagle’s medium supplemented with 10% fetal calf serum, 10 ng/mL epidermal growth factor, 8.4 ng/mL cholera toxin, 0.4 g/mL hydrocortisone. The cultures are then raised at the air–liquid interface on grids and kept one week to allow keratinocytes to stratify and differentiate completely during which time the reconstruct is fed by capillarity [11]. 4. SKIN RECONSTRUCTS AS A DRUG DISCOVERY TOOL The broad availability of reconstructs that correctly represent the complex biology of healthy human skin facilitated research that aimed at defining the toxicological effects of chemical and physical insult on human skin. Indeed, established biomarker profiles indicative of exposure-induced toxicity in human skin can easily be studied in reconstructs with high reproducibility. Reconstructed skin has therefore become an indispensable screening tool for toxicological profiling of test compounds intended for future topical application [29]. Moreover, screening of compounds that exert protective effects against environmentally relevant insults such as solar UV-radiation has rapidly become a major application of skin reconstructs [8]. Since pathological key mechanisms involved in complex diseases affecting human skin such as chronic inflammation, psoriasis and cancer are adequately reproduced in skin reconstructs, pharmaceutical screening of compound libraries with high throughput and predictive power for drug efficacy seems feasible. Usefulness of these models has been established for activity screening of topical retinoids and glucocorticoids as discussed below. In particular, reconstructed human skin has rapidly emerged as a superior experimental model for the identification of novel pharmacological and cosmeceutical agents designed to interfere with skin photodamage and chronological aging including sunscreens and topical antioxidants as discussed below. Various human epidermal reconstructs are now commercially available and have been used successfully as pharmaceutical screening tools. For example, EpiDerm™ (MatTek,Ashland, MA, USA; http://www.mattek.com) consists of normal, human epidermal keratinocytes that form a multilayered, highly differentiated model of the human epidermis on cell culture inserts. Recently, EpiDermFT, a full thickness skin model comprising normal human epidermal keratinocytes and dermal fibroblasts has been created enabling in vitro studies on fibroblast-keratinocyte cell interactions. Moreover, specialized models representing pigmented human skin (MelanoDermTM), human melanoma skin (MLNM-FT-A375), and oral epithelium (EpiOralTM and EpiGingivalTM) are available. Another common model, EPISKIN TM (SkinEthic, Nice, France; http://www. skinethic.com), consists of adult human keratinocytes cultured on a base of bovine collagen type I and III, coated with a thin layer of human collagen IV, and forming a fully differentiated epidermis with a functional horny layer. From the same manufacturer, another in vitro reconstructed human epidermis comprising normal human keratinocytes cultured in chemically defined medium on inert polycarbonate filters at the air-liquid interface can be obtained (RHE by SkinEthic). Again, more specialized models that represent pigmented epidermis (RHPE) and oral (HOE) and gingival epithelium (HGE) are available.
More Than Skin Deep
Frontiers in Drug Design & Discovery, 2009, Vol. 4 143
5. SKIN RECONSTRUCTS AS A TOXICITY SCREENING TOOL Skin toxicity as a result of compound exposure comprises a variety of adverse effects ranging from acute corrosive tissue damage to inflammatory irritation, and many parameters including speed of onset, persistence, and reversibility define the severity of these reactions [29]. Animal skin toxicity testing is compromised both for its limited predictive capacity for human toxicity, as well as for ethical and legal restrictions associated with animal experimentation. Reconstructed human epidermis allows topical application of test compounds and identification of agents that (I) corrode the skin (‘corrosion’), (II) irritate the skin or the eyes (‘irritation’), (III) sensitize the skin (‘sensitization’), or (IV) elicit toxic responses in combination with UV-light (‘phototoxicity’) as summarized in Fig. (3) [29-33].
NH O
O O
OH
S
O O
N
N
F Na+
HO O2N
NO2
F O
O N
OH
N
Cl CnH2n+1
n=8, 10, 12, 14, 16, 18 Corrosives
Irritants
N O
N
O O
Sensitizers
Cl
S Photosensitizers
IL-1α IL-8 TNFα PGE2 Hsp27 cell death
skin damage, pain, edema, erythema, itching Fig. (3). Biomarkers of skin toxicity validated in human skin reconstructs. For abbreviations see text. Skin toxicity inducing compounds by category (from top to bottom): acrylic acid, 2-tertbutylphenol (corrosion); SDS, benzalkonium chloride (irritation); 1-fluoro-2,4-dinitrobenzene, oxazolone (sensitization); ciprofloxacine, chlorpromazine (phototoxicity).
Current international regulations require assessment of skin corrosion for all chemicals placed on the market [34]. Predictive test methods must define the toxicity profile of consumer products, single ingredients (e.g. detergents), experimental drugs, cosmeceuticals, and other agents leading to classification as irritant/slightly irritant/non-irritant or
144 Frontiers in Drug Design & Discovery, 2009, Vol. 4
Bause et al.
severely corrosive/ corrosive/ non-corrosive. In recent years, skin reconstructs have replaced more traditional animal-based test methods including the long established Draize test based on rabbit eye exposure as discussed in [29]. In the EU, the use of human skin reconstructs as predictive test models for corrosion testing of dangerous substances are now regulated through the OECD 431 guideline [35]. A common irritation protocol based on the use of human skin reconstructs has been established by the ECVAM (European Centre for the Validation of Alternative Methods) and is the subject of further validation studies [33,36,37]. 5.1. Corrosion Corrosive materials are identified by their ability to reduce cell viability below defined threshold levels at specified exposure periods [38]. Corrosive agents penetrate or erode the stratum corneum and cause cell death in the underlying cell layers. Skin damage from corrosion occurs within minutes after chemical exposure and results in irreversible tissue necrosis by physicochemical processes that occur independent of a biological damage response. An inflammatory response of the surrounding tissue is commonly a consequence of the skin corrosion process [38]. In an example test protocol and prediction model using reconstructed human epidermis, corrosion potential of test material is predicted from the mean tissue viabilities assessed after exposure times as short as 3 min [33]. Test materials are applied directly to the stratum corneum and exposure to the chemical is terminated by rinsing with phosphate buffered saline. Tissue viability is then assessed using the MTT assay with formazan solvent extraction followed by photometric analysis compared to untreated control tissue. A chemical is classified as ‘corrosive’ if the relative tissue viability is decreased below 50% after 3 min of exposure to a test material. In addition, test materials classified ‘non-corrosive’ after 3 min (viability > 50%) are classified ‘corrosive’ if the relative tissue viability is decreased below 15% after exposure for 1 h. Similar protocols have been implemented and used successfully according to ECVAM guidelines using various commercial and academic skin reconstruct models [33]. 5.2. Irritation During early development of novel cosmetic and pharmaceutical formulations designed for topical delivery, the potential for the induction of a